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resumo 
 
 
A Doença de Alzheimer (DA) é uma das doenças neurodegenerativas mais 
comuns, e apresenta uma incidência mundial de 2-7% em indivíduos com mais 
de 65 anos e de cerca de 15% em indivíduos acima dos 85 anos de idade.  
Apesar da sua etiologia multifactorial, há uma correlação bem descrita entre 
esta patologia e um peptídeo neurotóxico denominado Abeta. Este peptídeo 
deriva fisiológica e proteoliticamente de uma glicoproteína transmembranar 
com características de receptor: a Proteína Percursora de Amilóide de 
Alzheimer (PPA). As possíveis funções fisiológicas da proteína PPA, o seu 
destino e vias de processamento celulares, conjuntamente com possíveis 
proteínas celulares que com ela interajam, são assim tópicos de interesse e 
objectos de investigação científica mundial. Neste contexto tem sido 
amplamente descrito o envolvimento do processo de fosforilação de proteínas, 
uma importante modificação pós-transducional que regula muitos e variados 
acontecimentos intracelulares, na regulação do processamento da PPA. 
Apesar do exposto, muito pouco é conhecido acerca da fosforilação directa da 
própria PPA. Esta proteína possui na sua estrutura primária sequências 
consenso para fosforilação, quer no seu ectodomínio quer no seu domínio 
intracelular, já descritas como sofrendo fosforilação “in vitro” e “in vivo”. O 
resíduo Serina 655 pertence a um motivo funcional da APP, 653YTSI656, que 
forma um sinal de internalização e/ou de “sorting” basolateral. Este domínio é 
também o local de ligação para a APPBP2, uma proteína que interage com os 
microtubulos da célula. Embora ainda mal elucidados, os mecanismos pelos 
quais a fosforilação proteica regula o processamento da PPA parecem incluir 
uma alteração no tráfego desta proteína, sugerindo que o domínio fosforilável 
653YTSI656 desempenha um papel importante nesse processo.  
Esta dissertação visou assim contribuir para elucidar o papel da fosforilação 
directa da molécula de APP, mais especificamente no seu resíduo Serina 655, 
na regulação do direcionamento e tráfego subcelular da proteína, e nas suas 
possíveis clivagens proteolíticas. De forma a respondermos a essas questões 
desenvolvemos um modelo experimental para seguir o tráfego intracelular, que 
usa uma combinação de biologia molecular, técnicas de microscopia de 
epifluorescência e técnicas de cultura celular. Os resultados obtidos implicam 
este resíduo como um sinal de direcionamento subcelular da proteína APP, e 
revelam como o redireccionamento desta proteína por fosforilação favorece um 
tipo de processamento não amiloidogénico desta. Adicionalmente, a 
fosforilação do resíduo Serina 655 parece possuir um papel regulador da 
actividade da PPA como molécula de transdução de sinais. As implicações 
destas observações na DA e em novas aplicações terapêuticas para a doença 
são subsequentemente discutidas. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
abstract 
 
Alzheimer’s Disease (AD) is a common neurodegenerative disease affecting 
individuals worldwide with an incidence of 2-7% of post-65 and 15% of post-85 
years old. This disease is multifactorial in its etiology but central to its pathology 
is a neurotoxic peptide termed Abeta. This peptide is physiologically derived by 
a proteolytic process on the transmembranar Alzheimer’s Amyloid Precursor 
Protein (APP). Protein phosphorylation-dependent APP processing has been 
widely described and although the mechanisms involved remain far from 
clarified, alterations in APP trafficking seem to occur as part of the answer. 
Furthermore, the occurrence of consensus phosphorylation sites in the APP 
intracellular domain has been known for long, but little was known regarding 
the direct phosphorylation of APP. Efforts in unravelling the role of these 
domains are finally being successful in placing them as key control points in 
APP targeting and processing. Among these consensus sequences, the less 
studied 653YTSI656 motif forms a characteristic internalisation and/or basolateral 
sorting signal sequence, and is known to be the binding site for a microtubule-
interacting protein (APPBP2). Phosphorylation of this motif was thus suggested 
to be involved in APP targeting regulation, hitherto all attempts failed to confirm 
it or even to reveal substantial evidences.  
In this project, the role of the 653YTSI656 idomain, and in particular the 
phosphorylatable serine 655, in APP trafficking and proteolytic processing was 
studied. In order to address this question a new experimental methodology was 
developed, which coupled molecular biology, fluorescence imaging, and cell 
culture techniques. APP point mutants, mimicking serine 655 phosphorylated- 
and dephosphorylated-status, and tagged with the green-fluorescent protein, 
were used to study protein trafficking dynamics and processing. Results 
obtained place serine 655 phosphorylation as a key signal in APP sorting and 
targeting to specific subcellular locations. Also of high relevance was the 
observed implication of serine 655 phosphorylation as a regulatory mechanism 
that maybe involved in controlling APP function as a signal transducer. The 
implications of these observations in AD pathogenesis and therapeutic 
approaches are discussed.  
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CHAPTER I – GENERAL INTRODUCTION 
 
 
I. 1 – ALZHEIMER’S DISEASE 
I. 1. 1 – CHARACTERIZATION OF THE DISEASE 
Alzheimer's disease (AD) is a neurodegenerative disorder affecting a large percentage 
of the world's elderly population, being the most common form of senile dementia. The 
disease was first diagnosed by Alois Alzheimer in 1907, as a neuropathological syndrome 
characterized by progressive dementia and deterioration of cognitive function (Alzheimer, 
1907). This German neurologist demonstrated for the first time a relationship between 
specific cognitive changes, neurological lesions revealed by autopsy and a clinical history of 
dementia. His patient (a 56-year-old woman) had her cognitive capacities and behaviour 
affected due to the direct physiological effects of her disease condition. 
At the cerebral level, AD patients have a characteristic brain atrophy and mass loss, 
due to extensive neuronal damage and death (Fig. I.1). There is an overall shrinkage of brain 
tissue, with the most affected areas being the hippocampus and the cerebral cortex.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.1. AD patients exhibit shrinkage of the overall brain volume. Brains from a healthy person (left) 
and an Alzheimer’s patient (right), showing AD-induced depthnening of brain sulci and loss of grey matter. 
From: http://www.life-enhancement.com/article_template.asp?ID=912. 
AD Normal 
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The grooves or furrows in the brain, called sulci, are noticeably widened and there is 
shrinkage of the gyri, the well-developed folds of the brain's outer layer. In addition, the 
ventricles, or chambers within the brain that contain cerebrospinal fluid, are noticeably 
enlarged (Fig. I.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.2. Image representing a brain coronal section, as seen from the front. The left 
side represents a brain from a normal individual and the the right side represents a brain with 
Alzheimer's disease. From: http://www.ahaf.org/alzdis/about/BrainAlzheimer.htm. 
 
 
As a dementia, clinical symptoms in AD are characterized by the development of 
multiple cognitive deficits, including memory impairment, and altered behaviour. Reduced 
overall activity is also observed (Fig. I.3). In the early stages of AD, short-term memory begins 
to decline when the cells in the hippocampus, which is part of the limbic system, degenerate. 
The ability to perform routine tasks also declines. As the cerebral cortex (the outer layer of the 
brain) becomes affected, judgment declines, emotional outbursts may occur, and language is 
impaired. Progression of the disease leads to the death of more nerve cells and subsequent 
behavioural changes, such as wandering and agitation. The ability to recognize faces and to 
communicate is completely lost in the final stages of the disease. Patients lose bowel and 
bladder control, and eventually need constant care. This stage of complete dependency may 
last for years before the patient dies. The average length of time from diagnosis to death is 4 
to 8 years, although it can take 20 years or more for the disease to run its course.  
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Figure I.3. Brain imaging (PET) scans 
of an Alzheimer disease brain showing 
brain shrinkage and reduced activity 
(right) and normal brain (left). From: 
http://www.pfizer.com/brain/etour5.html 
(photo credit - National Institute on 
Aging). 
 
 
The extreme relevance of the scientific research involving AD ethiologies and the 
finding of therapeutic targets is well underlined in a transcript of the U.S. Pharmacist 
Continuing Education (ACPE Program No. 430-000-01-028-H01): “When Dr. Alzheimer first 
reported his cases, individuals over the age of 65 years represented only 3% of the U.S.A. 
population. The average life expectancy at that time was 47 years. It is estimated that by the 
year 2020, one fifth of the United States population, or more than 55 million people, will be 
65 years old or older. Of these, about 10% will develop AD. Both the prevalence and 
incidence of AD increase with age, so it is estimated that by age 85, up to 50% of individuals 
will be affected”. In the U.S., AD is the fourth-leading cause of death, and the third most 
expensive disease following heart disease and cancer. The total U.S. national cost of caring for 
AD patients is estimated to be over $90 billion annually.” The importance of this disease is 
also highlighted by the projects on AD and associated disorders (ADAD) funded by the 
European Union in several € million (Sykes et al., 2001). For example, between 2000 and 2003 
the V Framework Programme funded with € 2 million projects aiming to diagnose, prevent, 
delay the onset or treat AD (from: http://europa.eu.int/comm/research/ress/2000/pr2109-
alz-en.html).  
 
I. 1. 2 – AD HISTOPATHOLOGICAL CHARACTERISTICS 
Post-mortem histological analysis of Dr. Alzheimer's patient’s brain revealed dense 
bundles of unusual fibrils within nerve cells and numerous focal lesions within the cerebral 
cortex (Alzheimer, 1911). The dense fiber-like tangles were later called neurofibrillary tangles 
(NFTs) and the darkly staining focal lesions are now known as amyloid or senile plaques (AP) 
(Fig. I.4), as they had been previously observed in several other aged brain samples (reviewed 
in Brandt et al., 2005). The plaques may then occur in the absence of dementia, while the 
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tangles are seen in illnesses other than AD. The coexistence of both lesions, along with 
cerebral atrophy and neuronal degeneration, are the conclusive hallmarks of the disease. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.4. Microphotographs of an AD patient sectioned brain tissue exhibiting high density of: Panel A: 
Amyloid plaques (full arrow) with the amyloid core (dashed arrow) indicated; Panel B: Neurofibrillary tangles. 
From: http://www.neuropat.dote.hu/alzheim.htm. 
 
 
Neurofibrillary tangles are intraneuronal bundles of paired helical filaments (PHF) 
consisting predominantly of the protein Tau (Goedert et al., 1996), that occur at dystrophic 
neurites, and are mainly found in the pyramidal regions of the amygdala, hippocampus and 
neocortex (Williams, 2001). Tau protein is an axonal protein in neurons where it supports 
neurite outgrowth and stabilizes neuronal microtubules by acting on tubulin polymerization 
and stabilization (Smith, 1996). It was discovered that Tau can also function as a regulator of 
intracellular vesicles and organelle traffic (Drewes et al., 1998). Pathologically aggregated Tau 
is a hallmark of several dementias, in some cases caused by mutations in the tau gene (as in the 
frontotemporal dementia FTDP-17), but this not the case in AD (Poorkaj et al., 1998; 
Spillantini et al., 1998). 
Amyloid plaques are extracellular lesions containing 7-10 nm thick intermixed amyloid 
fibrils of the 40 - 42 amino acid peptide Abeta (Allsop et al., 1983) and non-fibrillar forms of 
Abeta, though in its constitution more than 30 other proteins/peptides have also been found. 
The underlying protein component of these fibrils invariably adopts a predominant antiparallel 
β-pleated sheet configuration, from which the name Abeta (amyloid β) arose. Figure I.5 shows 
that the Abeta core of the AP consists of large numbers of closely-packed, radiating fibrils, 
similar in appearance to those seen in other forms of amyloidosis (Kidd, 1964; Terry et al., 
1964). The amyloid plaques can be diffuse or neuritic (the latter containing dystrophic neurites 
with aggregated Tau), and are found diffusely throughout the brain, but notably in the cerebral 
cortex and hippocampus of AD patients (El Khoury et al., 1996; Dickson, 1997).    
A. B. 
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Figure I.5. Panel A: Microphotograph of an AD patient sectioned brain tissue (cerebral cortex) 
showing amyloid plaques (arrow) (from: http://w3.uokhsc.edu/pathology/deptlabs/Alzheimer/ 
alzheimer_neuritic.htm). Panel B: Atomic force microscopy image of AP amyloid fibrils formed 
by Abeta “in vitro” aggregation (from: Harper et al., 1997). 
 
 
The majority of Abeta peptides are 40 amino acids long (Abeta 1-40), soluble and 
apparently less neurotoxic, whereas the more hydrophobic peptides (less soluble) are 42 amino 
acids long (Abeta 1-42) and although they are less prevalent, overall they predominate in the 
protein core of plaques (Jarret and Lansbury, 1992; Jarret et al., 1993). Diffuse plaques, which 
are focal diffuse deposits of amyloid without accompanying dystrophic neurites, and that may 
represent an early stage of AD plaques, contain predominantly Abeta 1-42 and small levels of 
Abeta 1-43 rather than Abeta 1-40 (Gowing et al., 1994; Iwatsubo et al., 1994; Iizuka et al., 
1995; Iwatsubo et al., 1995; Lemere et al., 1996). 
Amyloid vs NFTs. Evidence points to amyloid deposition preceding and 
precipitating the formation of NFTs in some patients, with Abeta preceding Tau aggregation. 
In agreement with this, Tau deposition in transgenic mice is influenced by Abeta (Stalder et al., 
1999; Lewis et al., 2001). In young Down’s syndrome patients, Abeta deposits exist in the 
absence of NFTs, notably in areas of the brain most affected by AD (Iwatsubo et al., 1995; 
Leverenz and Raskind, 1998; Gouras et al., 2000). Typically, these two aggregates (APs and 
NFTs) constitute the neuropathologic criteria confirming AD. Post-mortem brain autopsy is 
still the most accurate and definitive mean of AD diagnosis (Crimson and Eggert, 1999), but 
the patient’s death often occurs long after the onset of the dementia. Consequently, the 
relationship between the pathology and the actual mechanism of the disease remains unclear. 
“In vivo” Diagnosis. Until recently, AD was diagnosed by ruling out other disorders 
known to cause similar symptoms (“diagnosis of exclusion”), such as cerebrovascular diseases, 
Parkinson disease, brain tumour, etc. (First, 1994). Nowadays physicians can use brain imaging 
A B 
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such as MRI (magnetic resonance imaging) techniques, alongside recently developed cognitive 
tests in order to identify and document specific changes in the brain as early as possible. 
Recently, an Alzheimer's-predicting FDG-PET scan has been developed where the metabolic 
activity in the hippocampus is measured to try to predict future AD development (Mosconi et 
al., 2005). In addition, a molecular-based diagnosis is presently the subject of particular 
interest. The aim is to identify alterations in molecular markers at an early stage of the disease, 
and to use these in the accurate clinical screening by means of recently developed microarray 
technology. Thus it is fundamental to understand the underlying molecular aspects of AD.   
 
I. 1. 3 – AD RISK FACTORS AND GENETIC LINKAGE 
Many theories exist as to the precise causes of AD, but the exact pathophysiological 
mechanisms remain unknown. It is a syndrome in which multiple molecular etiologies can 
trigger a varied but largely stereotyped pathogenic cascade. Whatever the causes that induce a 
variety of neurotoxic events they result in vast neuronal degeneration, which manifests as a 
progressive cognitive impairment with widespread neurological and neuropsychiatric 
disturbances (Emilien et al., 2000). From this perspective, AD resembles other common, 
multigenic degenerative pathologies of late life, such as atherosclerosis. Both AD prevalence 
and incidence estimates consistently follow an exponential pattern, both roughly doubling 
every 5 years after age of 65, when prevalence is about 5-10%. The prevalence of inherited 
forms of the disease ranges from 1% to 30%. A familial history of dementia is a risk factor in 
AD and several determinants may influence the development of the disease (Richard and 
Amouyel, 2001). 
I. 1. 3. 1 – AD genetic risk factors 
Late-onset AD. AD is typically a late-onset dementia, and in many cases sporadic in 
nature. The presence of the apolipoprotein E type 4 (Apoε4) allele on chromosome 19 is 
considered the major risk factor for the development of common late-onset AD. This risk 
factor is allelic dose-dependent, as the presence of one ε4 allele increases the risk of 
developing late-onset AD by 2-4 times, while a double allele increases that risk 4-8 times 
(Mayeux et al., 1998). Other genetic susceptibility factors have been proposed. Polymorphisms 
on genes encoding several proteins, including α2-macroglobulin, angiotensin I converting 
enzyme, Fe65 and Presenilin 1, are associated with the disease (Chapman et al., 1998; Alvarez 
et al., 1999; Rodriguez et al., 2000; Lambert et al., 2000). The situation may be further 
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complicated as some mitochondrial genetic polymorphisms have been recently proposed to be 
associated with AD (reviewed in Zhu et al., 2004). 
Early-onset AD. Approximately 5-10% (Richard and Amouyel, 2001) of AD cases are 
inherited as a fully penetrant autossomal dominant trait, related to mutations on chromosomes 
1, 14, and 21, and triggering early-onset AD (Schellenberg, 1995; Sandbrink et al., 1996b). 
These mutations contribute to the pathologic basis of the majority of AD Familial cases 
(FAD). Nonetheless, molecular and genetic studies of these forms have enormously increased 
our knowledge of the aetiology of the much more abundant sporadic form. The three genes 
identified with those chromosomal mutations code for the Amyloid Precursor Protein (APP) 
and for Presenilin 1 and 2 (PS1 and PS2) (Czech et al., 2000). Mutations in the app or ps genes 
are highly predictive for the disease, the prevalence of the AD phenotype being higher than 
95% (St. George-Hyslop, 1999). The phenotype in the majority of FAD early-onset cases is 
indistinguishable from that in sporadic late-onset AD. These mutations lead to abnormal 
processing of the APP protein, resulting in increased accumulation of amyloidogenic peptides 
Abeta 1-40 and Abeta 1-42. This is a common theme in inherited forms of amyloidosis, where 
a mutant protein or peptide is particularly “amyloidogenic”, i.e., it has an increased tendency 
to form antiparallel β-pleated sheet fibrillar structures. 
APP as a risk factor. The Abeta peptide is part of a much larger precursor protein - 
the Alzheimer’s amyloid precursor protein (Kang et al., 1987). The first of the 20 known 
mutations (Kowalska, 2004) to be discovered in the app gene (chromosome 21) was Glu22 to 
Gln (“Dutch” mutation) within the Abeta sequence (Hardy and Allsop, 1991). Subsequently, 
some families with early onset AD were found to have pathogenic mutations at APP Val642, 
resulting in a change from Val642 to Ile, Gly or Phe (Chartier-Harlin et al., 1991; Goate et al., 
1991; Murrell et al., 1991). All these mutations result in an increase in the relative amounts 
produced of the more amyloidogenic Abeta 1-42 compared with Abeta 1-40, i.e. a longer 
Abeta form with increased propensity to aggregate (Wisniewski et al., 1991; Burdick et al., 
1992; Clements et al., 1993). The “Swedish” double mutation (Lys595/Met596 to Asn/Leu, on 
the immediate Abeta N-terminus) results in secretion of larger amounts of total Abeta (Citron 
et al., 1992; Cai et al., 1993). The APP “Arctic” mutation (Glu693 to Gly) leads to decreased 
Abeta 1-40/1-42 levels in plasma and in cells conditioned media, but as a consequence of a 
higher Abeta tendency to aggregate. In fact, Abeta with the Arctic mutation forms protofibrils 
at a much higher rate and in larger quantities than wild-type Abeta (Nilsberth et al., 2001). 
Several APP mutations are listed in http://www.alzheimer-adna.com/Gb/APP/ 
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APPsequence.html. Further, the levels of APP being expressed also appear to be highly 
significant. For example individuals who have Down’s syndrome have at the same time an 
extra copy of chromosome 21 and a higher likelihood of developing AD by age of 50 (Esler 
and Wolfe, 2001). 
Presenilins 1 and 2 as risk factors. The genes responsible for the majority of FAD 
cases were found to be ps1 on chromosome 14 (Sherrington et al., 1995; Walter et al., 1996) 
and ps2 on chromosome 1 (Scheuner et al., 1996), and not on app itself. Nonetheless, 
pathological mutations on either APP or Presenilins lead to a similar phenotype, diverting 
APP processing towards the production of long Abeta 1-42 compared to short Abeta 1-40 
(Borchelt et al., 1996; Mehta et al., 1998). In fact, plasma and media samples from cultured 
skin fibroblast of subjects carrying these mutations exhibited a doubling in the levels of Abeta 
1-42 when compared to controls (Scheuner et al., 1996). Additionally, PS1 mutant mice 
exhibit up-regulated intracellular calcium release from the endoplasmic reticulum (ER), which 
is being associated with greatly increased vulnerability to Abeta-induced apoptosis (Chan et al., 
2002). There are at least 132 mutations reported to occur in Presenilins, with the majority 
being missense point mutations (for review see Kowalska, 2004). 
I. 1. 3. 2 – AD non-genetic risk factors 
Several environmental and non-genetic factors can contribute to the AD etiology. 
Some well-established risk factors for AD include age, female gender, low educational status, 
vascular changes, and decreased levels of acetylcholine (Amaducci et al., 1992; Rogers, 1998). 
More recently, head injury, elevated serum cholesterol, and high levels of aluminum in 
drinking water have been added to the list of potential risk factors (Guo et al., 2000; Rondeau 
et al., 2000; Wolozin et al., 2000). Cellular stresses, such as oxidative stress, have also been 
implicated as possible triggers for AD onset, along with their roles in its development, by 
interfering with signalling cascades (Farooqui et al., 2004; Maiese and Chong, 2004; Moreira et 
al., 2006). Moreover, a common phenotype observed in AD patients’ brains is altered protein 
phosphorylation, which can potentially lead to altered cellular signalling (da Cruz e Silva et al., 
2004a). The importance of this regulatory mechanism in AD and its possible implications on 
the disease onset will be further discussed and underlies the central theme of this thesis. 
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I. 1. 4 – THE “AMYLOID CASCADE” HYPOTHESIS OF AD ETIOLOGY 
Advances in AD research, especially in molecular genetic analysis of early onset FAD, 
led to the formulation of the “Amyloid Cascade” hypothesis. This hypothesis states that 
overproduction of Abeta and its aggregation into amyloid plaques is the root cause of AD 
(Hardy and Allsop, 1991). Almost all cases of FAD are linked by highly penetrant mutations 
to genes that affect the release of Abeta from APP, leading to higher overall Abeta production 
or to higher formation of its amyloidogenic forms, namely Abeta 1-42. Genetic polymorphism 
in the ApoE gene, a molecular chaperone involved in Abeta aggregation, may contribute 
differently in the aggregation of the latter into amyloid fibrils (Folin et al., 2006). The “amyloid 
cascade hypothesis” (Fig. I.6) is now widely accepted, with Abeta having a central role in 
neurotoxicity and AD, and has been extensively reviewed (e.g. Selkoe, 1994; Iversen et al., 
1995; Forloni, 1996; Mattson, 1997; Selkoe, 2001).  
 
 
 
Figure I.6. “Amyloid cascade hypothesis” underlying the central role of Abeta aggregation.  
 
 
At the molecular cascade level diffuse neurocentric amyloid deposits would evolve 
over time and eventually become neuritic APs. One hypothesis is that deposition of Abeta 1-
42 may form a “precipitation core” to which soluble Abeta 1-40 could aggregate, in an AD-
specific process. The “in vivo” aggregation of Abeta may precipitate a chronic and destructive 
inflammatory process in the brain, occurring in the immediate vicinity of APs in AD patient 
brains (Eikelenboom et al., 1994). Some of the proinflammatory molecules thereby produced 
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may be locally toxic to neuronal processes in the vicinity of AP, such as complement, 
cytokines, reactive oxygen and nitrogen intermediates. They also produce factors, such as 
Interleukin-1 (IL-1), which stimulate APP synthesis, leading to a vicious cycle of reciprocal 
activation and growth, which potentiates a local inflammatory cascade. These would culminate 
in the neurodegenerative process possibly via free radical production by microglia cells and/or 
complement lysis of neuronal membranes (Allsop, 2000). Although it is not clear if Abeta 
accumulation is a cause or effect in AD, its production nonetheless plays a central role. 
 
 
I. 2 – THE ALZHEIMER’S AMYLOID PRECURSOR PROTEIN 
I. 2. 1 – APP ISOFORMS AND GENE FAMILY  
APP is a glycoprotein with a single transmembrane domain towards its carboxyl-
terminus. The mammalian APP superfamily comprises three members: APP and APP-like 
proteins APLP1 and APLP2 (Sprecher et al., 1993; Wasco et al., 1993), of which APLP2 is the 
nearest relative (50% of homology). These three related proteins are well-conserved in 
evolution, functionally and structurally related, and share similar functions (Bayer et al., 1999; 
Coulson et al., 2000). The mammalian APP family members are type I integral membrane 
proteins that have relatively large extracellular domains and short intracellular domains. Of 
note is that APLP1 and APLP2 share homology at the amino acid sequence, domain structure 
and protein organization with APP, but lack the Abeta domain. Other known members of the 
APP superfamily are non-mammalian and include APPL in Drosophila (Rosen et al., 1989; Luo 
et al., 1992), APL-1 in C. elegans (Daigle and Li, 1993) and an APP homologue protein in 
Xenopus (Okado and Okamoto, 1992). 
APP isoforms. The APP gene is located on human chromosome 21 (21q21.2-3) and 
contains 18 exons (GenBank A.N. D87675), with the Abeta sequence divided between exons 
16 and 17 (Fig. I.7). The sequence of the Abeta peptide starts at residue 597 (except when 
otherwise indicated, numbering is according to the APP695 isoform) and spans the 
extracellular and membrane domains. At least eight isoforms of APP have been described, 
numbered according to their length in amino acids: L-677, 695, L-696, 714, L-733, 751, L-752, 
770 (Kitaguchi et al., 1988; Ponte et al., 1988). These isoforms arise from alternative splicing 
of exons 7, 8 and 15 of the APP mRNA (Kosik, 1993) and differ in size extracellularly, but 
share the same cytoplasmic, transmembranar and Abeta peptide sequences.  
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Figure I.7. Exon structure of the full length APP transcript and the final eight isoform products. The 
alternatively spliced exons are indicated in colour: blue, exon 7; grey, exon 8; green, exon 15. The Abeta sequence is 
indicated in red.  
 
 
Analysis of APP mRNA expression levels revealed that APP can be detected in 
almost all tissues examined, as well as in cultured cells. It is ubiquitously expressed in 
mammalian cells (Tanzi et al 1987; Neve et al., 1988; Tanzi et al., 1988; Weidemann et al., 
1989; Golde et al., 1990; Sisodia and Price, 1995) with a broad tissue distribution. The tissue-
specific pattern of APP mRNA splicing was studied by RT-PCR analysis (Sandbrink et al., 
1994a). The less abundant L-APP isoforms, lacking exon 15, are mainly expressed in 
leukocyte cells, such as T-lymphocytes, macrophages and microglial cells. They are also 
ubiquitously expressed in rat tissues, including brain, but not in neurons (Ohgami et al., 1993; 
Sandbrink et al., 1994a). The three major APP isoforms were found to be the 695, 751 and 
770 (Fig. I.7). Of these, APP695 is the only one lacking exon 7. The exon 7-containing APP 
mRNA isoforms (751 and 770) are predominantly expressed in peripheral tissues. Brain tissue 
expresses little APP770 and, depending on the animal species and brain region analysed, low, 
intermediate or high levels of APP751 (Neve et al., 1988 ; König et al., 1989; Tanaka et al., 
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1989; Kang and Muller-Hill, 1990). However, the exon 7-containing isoforms predominate in 
cultured astrocytes (Gray and Patel, 1993a,b; Rohan de Silva et al., 1997), with the 
695:751:770 ratio being 1:4:2 (Gray and Patel, 1993a,b). A number of studies have indicated 
that alternative splicing of exons 7 and 8 changes in brain during aging and with AD, but 
results obtained are still inconsistent and controversial to consider altered alternative splicing 
as an AD risk factor (Sandbrink et al., 1994b; Rockenstein et al., 1995; Moir et al., 1998; 
Panegyres et al., 2000). Conversely to the 751 and 770 isoforms, the 695 is the APP isoform 
predominantly produced in the mammalian brain, with the 695:751:770 mRNA ratios being 
approximately 20:10:1 (Tanaka et al., 1989). Furthermore, APP695 is most highly expressed in 
neurons, representing 95% of total neuronal APP (Tanzi et al., 1987; Weidemann, 1989; 
LeBlanc et al., 1991), and is therefore often referred to as the “cerebral” or “neuronal” 
isoform. In conclusion, as APP695 is the isoform predominantly produced in the brain, and 
predominates within the CNS (Neve et al., 1988; Tanzi et al., 1993), this isoform has received 
the most attention in AD research.                      
 
I. 2. 2 – APP FUNCTIONAL DOMAINS 
APP exon 7 encodes a 56-amino acid (aa) stretch with homologies to the Kunitz-type 
protease inhibitors (KPI) that inhibits proteases, such as trypsin or plasmin, and blood 
coagulation factors (Van Nostrand and Cunningham, 1987; Kitaguchi et al., 1988; Ponte et al., 
1988; Wagner et al., 1992). Exon 8 encodes a 19-aa domain with homologies to the MRC OX-
2 antigen found on the surface of neurons and certain immune cells such as thymocytes (Clark 
et al., 1985; Kitaguchi et al., 1988; Tanzi et al., 1988). In adition to KPI and OX-2, several 
other structural features have been identified within the APP ectodomain (Fig. I.8).  
 
 
Figure I.8. APP functional subdomains (APP770 numbering). Pink, signal peptide (1-17); light blue, heparin-
binding domains (28-123; 174-185; 391-412); violet, cupper-binding domain (135-155); green, zinc-binding domain 
(181-188); dark blue, KPI domain; grey, OX-2 domain; “RERMS”, putative growth-promoting motif (403-407); 
orange, gelateinase A (matrix metalloproteinase) inhibitor (407-417); lavander, collagen-binding site (523-540); red, 
Abeta; “RHDS”, integrin-binding motif (aa 5-8 of Abeta); “VHHQK”, heparin-binding motif (aa 12-16 of 
Abeta). APP exons boundaries are marked with arrowheads. M, cell membrane. 
“RHDS” 
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Two subdomains (328-332 and 444-612) were deduced to have a neuroprotective 
function, including the “RERMS” sequence with putative growth-promoting properties 
(Ninomiya et al., 1993). Several heparin-binding domains (Small et al., 1994), the stronger at 
316-337 (exon 9 and beginning of 10), a collagen-binding site (Beher et al., 1993), an integrin-
binding motif (amino acid sequence RHDS at residues 5-8 of Abeta) (Ghiso et al., 1992) and 
N-linked carbohydrate attachment sites (Weidemann et al., 1989) were also found in this 
region. Indeed, APP has been shown to bind laminin, collagen, and heparin sulphate 
proteoglycans (Breen et al., 1991; Kibbey et al., 1993). The ectodomain also contains two 
binding-sites for metals such as zinc (Bush et al., 1993; Bush et al., 1994) and copper (Hesse et 
al., 1994; Multhaup et al., 1996).  
 
I. 2. 3 – PUTATIVE FUNCTION OF APP AND APP FRAGMENTS  
Several putative roles have been postulated for APP, including participation in cell-cell 
and cell-matrix adhesion, heparin-binding, growth promoting activities, proteinase inhibition 
and receptor activity. Other suggestions include regulation of neurite outgrowth, promotion of 
cell survival, protection against a variety of neurotoxic insults, stimulation of synaptogenesis, 
modulation of synaptic plasticity, and involvement in learning and memory processes (for 
reviews: Mattson, 1997; De Strooper and Annaert, 2000; Dodart et al., 2000; Turner et al., 
2003). The first clues to APP function derived from sequence analysis and studies that 
identified different functional APP subdomains on the extracellular portion of the molecule. 
Presently, many putative functions of APP result from studies on the APP subcellular protein 
binding partners (as discussed further on) or transgenic animal models (Higgins et al., 1994; 
Mucke et al., 1994; von Koch et al., 1997; Rassoulzadegan et al., 1998; Heber et al., 2000). 
Additionally, APP can be processed (section I.2.4) and various physiological functions have 
also been attributed to the resulting cleavage products.  
Memory. There is evidence for a specific role of APP in long term memory (Doyle et 
al., 1990; Flood et al., 1991; Huber et al., 1993). APP knockout mice show impaired behavioral 
performance (Muller et al., 1994; Zheng et al., 1996). Additionally, blocking the extracellular 
domain of APP by intracerebral and intracerebroventricular administration of anti-APP 
antibodies targeted against various isoforms of APP differentially impairs behaviour and 
memory in rats (Doyle et al., 1990; Huber et al., 1993; Chan et al., 2002; Turner et al., 2003). 
Conversely, exposure of hippocampal slices to the secreted APP (sAPP) fragment αsAPP (see 
below section I.2.4) results in altered frequency of LTD and an increase in LTP (Ishida et al., 
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1994), strengthening a role for APP in learning and memory processes. Indeed, infusion of 
αsAPP and the RERMS sequence enhances memory formation (Meziane et al., 1998) and 
prevent APP anti-sense-induced memory loss (Mileusnic et al., 2000). 
Brain development. It has been suggested that the APP protein family has a role in 
the reelin signalling pathway, and may participate in neuronal migration and positioning during 
brain development (Ishida et al., 1994; Bothwell and Giniger, 2000). Supporting the hypothesis 
for APP involvement in cell differentiation and synaptogenesis, APP isoform levels were 
found to reach their maximum peak during the second postnatal week of the rat, the time of 
brain maturation and completion of synaptic connections (Loffler and Hubert, 1992). Also of 
note is the finding that APP can be regulated by cholinergic mechanisms (Bayer et al., 2001).  
CAM- (cell adhesion molecule) and SAM- (substrate adhesion molecule) 
functions. CAM or SAM molecules are known to play important roles in synaptic remodeling 
in development and during regeneration of neurites after injury (Chan et al., 2002). All APP 
isoforms possess two heparin-binding domains responsible for APP binding to the glycan 
moieties of proteoglycans, such as glypican (Small et al., 1996; Williamson et al., 1996), heparin 
and heparin-based glycosaminoglycans, such as heparin sulphate, in a time-dependent and 
saturatable manner (Multhaup et al., 1994; Multhaup et al., 1995). Heparin is a well known 
extracellular matrix component, and the APP strong heparin-binding site was found to be 
conserved in human APP, APLP1 and APLP2, and to occurr at residues 316-337 of APP695 
(Multhaup, 1994) (see above Fig. I.8). Other studies (Breen et al., 1991; Robakis et al., 1993; 
Coulson et al., 1997; Fossgreen et al., 1998; Storey et al., 1999; Soba et al., 2005) provided 
additional evidence for APP functioning as a CAM and SAM molecule. L-APP isoforms were 
observed to function as core proteins of the strong CAM apican proteoglycans (Pangalos et 
al., 1996). L-APP and L-APLP2 isoforms have an additional xylosylransferase recognition site 
for xylosylation (chondroitin-sulfate-glycosaminoglycans attachment) (Thinakaran et al., 1995; 
Gotting et al., 1998) (Fig. I.9). This post-translational modification confers more adhesiveness 
properties and less sensitivity to β-secretase cleavage (Sandbrink et al., 1996a). Fibroblasts 
from FAD patients that were observed to have down-regulated APP mRNA levels had at the 
same time decreased cellular adhesiveness (Ueda et al., 1989). Hep-1 cells expressing an APP 
FAD mutant cDNA also exhibited decreased comparative cell adhesion properties (Kusiak et 
al., 2001). Furthermore, down-regulation of APP using antisense oligonucleotides also reduced 
neuronal adhesion to specific substrata, and APP over-expression in the neuronal-like B103 
cells led to more rapid cellular adhesion (Schubert and Behl, 1993). 
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Figure I.9. Glycosylation relevant APP domains. CHO, chains of N-glycans linked at Asn residues 542 (exon 
13) and 571 (exon 14) (APP770 numbering). L-APP isoforms lacking exon 15 possess a sequence for chondroitin 
sulphate chain attachment (at Ser619). Abeta sequence is indicated in red. 
 
 
Interstingly, cell surface APP has been recently reported to trans-interact with other 
APP (or APLP) molecules at the surface of adjacent cells, promoting trans-cellular adhesion 
“in vivo” (Soba et al., 2005). 
Cell motility regulation. Reports show that interaction of APP with the APP-
binding protein Fe65 (see section I.2.6) induced cell motility in wound healing assays 
(Guenette, 2002). At focal complexes, Fe65 binds to and recruits APP and additional proteins 
such as Mena (a cytoskeletal protein enriched in axonal growth cones) into a macromolecular 
complex that may be involved in microtubule assembly and promotes membrane extension 
and motility (Sabo et al., 2001). 
Neurite outgrowth, synaptogenesis and synaptic plasticity. APP has also been 
allocated roles in neurite outgrowth, synaptogenesis and synaptic plasticity (for review e.g. 
Mattson, 1997). Cell surface APP-induction of neurite outgrowth stimulation was observed in 
hippocampal neurons (Qiu et al., 1995) and in B103 cells overexpressing APP (Schubert and 
Behl, 1993). Studies using recombinant αsAPP or antibodies against it have demonstrated its 
role in regulation of neurite outgrowth and cell survival in developing hippocampal neurons 
(Mattson et al., 1993; Matson, 1994). Roles in synaptic plasticity of mature hippocampal 
neurons were also attributed to αsAPP (Furukawa et al., 1996b; Ishida et al., 1997).  
Growth-promoting and neuroprotective roles. Secreted APP containing the KPI 
insert was initially found by sequence analysis to be identical to protease nexin II (Van 
Nostrand et al., 1987). The latter is a growth regulatory molecule, produced by fibroblasts, that 
is an inhibitor of extracellular serine proteinases (Smith et al., 1990). A growth-promoting 
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effect of sAPP has been shown for fibroblasts and cultured neurons, and this activity has been 
claimed to reside in the amino acid sequence RERMS at residues 328-332 of APP695 
(Ninomiya et al., 1993; Jin et al., 1994). Secreted APP has also been reported to be 
neuroprotective (Mattson, 1997) and sAPP is capable of protecting cells against Abeta or 
glutamate-mediated neuronal damage (Mattson et al., 1993; Goodman and Mattson, 1994). 
However, not all of the neurotrophic and neuroprotective activities of sAPP can be attributed 
to the RERMS pentapeptide region (Ohsawa et al., 1997). The alpha sAPP form is 
approximately 100-fold more potent than beta sAPP (see below section I.2.4) in protecting 
hippocampal neurons against excitoxicity or Abeta mediated toxicity. The former is also the 
sAPP species involved in developmental regulation and synaptic plasticity (Furakawa et al., 
1996b), probably due to the VHHQK heparin-binding domain (residues 12-16 of Abeta), 
which is only present in the alpha sAPP form. 
Cellular toxicity and apoptosis. The physiological properties of Abeta seem to be 
critically dependent on its state of aggregation (Howlett et al., 1995; Atwood et al., 2003), with 
its dimeric or oligomeric (protofibrillar) forms possessing cytotoxic properties (Roher et al., 
1996; Mattson, 1997, Lambert et al., 1998). Hence, the endogenous APP derivatives are 
believed to oppositely modulate apoptosis through an autocrine loop. After KCl-induced 
apoptosis, incubation with antibodies against Abeta increased neuronal survival by 30% while 
antibodies against sAPP decreased it by 53% (Piccini et al., 2000). In primary neurons Abeta 
1-40 maximally activated NF-κB (an immediate-early transcriptional regulator of numerous 
proinflammatory genes) (Kaltschmidt et al., 1997). Interestingly, the neurotoxic properties of 
injected Abeta on primate brains only appeared in aged but not in young animals, suggesting 
that aged brains may be more vulnerable to Abeta-mediated toxicity (Geula et al., 1998). 
However, further complexity is added to the system being that weak neurotrophic properties 
were also attributed to the Abeta soluble form (Tanimukai et al., 2002; Atwood et al., 2003). 
Signalling cascades. αsAPP has been shown to induce alterations in various second 
messengers and effectors including cyclic GMP, protein kinase G (Barger et al., 1995; 
Furukawa and Mattson, 1998), phospholipase C, protein kinase C (Ishiguro et al., 1998), 
extracellular signal-regulated protein kinase (ERK) (Greenberg et al., 1994; Greenberg et al., 
1995) and inositol trisphosphate (Ishiguro et al., 1998; Koizumi et al., 1998). Noticeably, 
αsAPP induces membrane hypolarization in neurons and decreased intracellular Ca2+ levels, 
leading to decreased glutamate-induced neuronal excitability. Its effects on ion fluxes and 
various signalling pathways might underlie its reported physiological roles (Mattson, 1997). 
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Evidence points to cyclic GMP as the second messenger mediating its role in synaptic 
plasticity, involving neuronal excitability and calcium homeostasis (Barger et al., 1995; 
Furukawa et al., 1996a).  
Abeta may also play an important physiological role in the central nervous system at its 
physiological concentrations (picomolar to nanomolar), and in neurons the level of Abeta 
production is much higher than in non-neuronal cells (Simons et al., 1996). Physiological 
concentrations of Abeta were reported to increase tyrosine phosphorylation (Zhang et al., 
1994; Luo et al., 1996a), phosphatidylinositol 3-kinase activity in cultured cortical neurons 
(Luo et al., 1996a), and to increase PC12 cells proliferation Luo et al., 1996b). Abeta 1-42 was 
further reported to activate hydrolysis of an acidic phospholipid by phospholipase A2 (PLA2) 
(Lehtonen et al., 1996).  
APP Receptor-like activity. Being that APP resembles a type I integral membrane 
protein and binds to an heterotrimeric G protein (G0), a major GTP-binding protein in brain 
(Nishimoto et al., 1993), it has been proposed that APP functions as a cell-surface receptor 
involved in signal transduction. The cytoplasmic APP sequence His657-Lys676 shows a specific 
G0-activating function and is necessary for the complex formation (Nishimoto et al., 1993; 
Yamatsuji et al., 1996). Furthermore, fibrillar forms of Abeta were reported to bind to cell-
surface APP (Lorenzo et al., 2000), and cell surface APP751 forms complexes with protease 
nexin 2 ligands being subsequently internalized (Knauer et al., 1996). 
 
I. 2. 4 – APP PROTEOLYTIC PROCESSING 
APP metabolism is complex and can occur via several pathways (Nitsch et al., 1994; 
Checler, 1995; Buxbaum and Greengard, 1996; Selkoe et al., 1996), which have not all been 
fully elucidated. Three main proteolytic sites were first identified (Fig. I.10), with each cleavage 
being catalyzed by separate enzymes referred to as α-, β- or γ-secretases (Esler and Wolfe, 
2001). These cleavage sites were therefore named α-, β- and γ-sites. In its simplest form, APP 
proteolytic processing was described as occurring via two distinct pathways, one being non-
amyloidogenic and the other amyloidogenic. This classification arose as α- and β-cleavages 
appear to be mutually exclusive events, with one precluding and the other leading to Abeta 
production (Small and McLean, 1999; Nunan and Small, 2000). 
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Figure I.10. Proteolytic processing pathways of APP.  Top: “Non-amyloidogenic” pathway - α-secretase 
cleaves APP within the Abeta region precluding its formation and originating the fragments αsAPP and αCTF; 
Bottom: “Amyloidogenic” pathway - β-secretase cuts APP N-terminally to the Abeta region and gives rise to the 
fragments βsAPP and βCTF. The CTF fragments are further processed by γ-secretase to Abeta or p3 and the 
AICD fragments. The βCTF-derived Abeta product may potentially self-aggregate into amyloid fibrils.  
 
 
Alpha and beta-secretases cleaving APP at the beginning or in the middle of the Abeta 
sequence liberate a large fragment (sAPP) from the extracellular domain of the protein, named 
αsAPP and βsAPP, respectively. These sAPP fragments differ in size by only 17 amino acids 
at their carboxy terminus (see Fig. I.10), which belong to the Abeta sequence and are present 
in αsAPP but absent in βsAPP. The remaining portion of APP is called the α-carboxy-
terminal fragment (αCTF or C83), which is ∼10 KDa, or the β- carboxy-terminal fragment 
(βCTF or C99), which is ∼12 KDa. Subsequent to α- or β-cleavage, γ-secretase catalyzes two 
cleavages at the transmembrane (TM) sequence of the CTF product (Fig. I.11). One cleavage 
occurs in the middle of the TM (at the γ-site) and the other occurs at the end of the TM 
sequence (ε-site), near the cytoplasmic APP terminus (Fig. I.11). The former can occur at 
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several sites in close proximity, originating peptides of different lengths. βCTF is processed by 
γ-secretase (Younkin, 1998; Xu et al., 2002) to generate predominantly Abeta 1-40 (c.a. 90%) 
or 1-42 (c.a. 10%) fragments (Haass et al., 1992b; Seubert et al., 1992). Abeta species spanning 
from 1-39 to 1-43 amino acid long can also be produced, with fragments appearing to be more 
amyloidogenic with increasing length. Processing of αCTF by γ-secretase at the γ-site 
generates a short peptide termed p3 (3 KDa), which lacks the Abeta 17 N-terminal amino 
acids. Furthermore, using either α- or βCTF as a substrate, the additional product of the γ-
secretase processing is a short 59/57 amino acid long C-terminal peptide, named the APP 
Intracellular Domain (AICD or AID) or CTF gamma (for review e.g. Koo, 2002). However, 
CTF gamma is very unstable “in vivo” and difficult to be detected both in brain or cell lysates 
(Pinnix et al., 2001; Zheng et al., 2003; Kimberly et al., 2005). In fact, the CTF gamma/C59 
AICD is rapidly degraded (half-life of approximately 5 min) by a mechanism that is not 
inhibited by endosomal/lysosomal or proteasome inhibitors (Cupers et al., 2001). By sequence 
analysis of the AICD fragment, researchers have found that γ-secretase cleaves APP in an 
additional site (ε-site) (Sastre et al., 2001), a few amino acids downstream of the γ-site (Fig. 
I.11). Although both cleavages are independent of one another, they may occur nearly 
simultaneously (for review Selkoe and Kopan, 2003). This ε-site cleavage is thought to occur 
for better AICD membranar release, and as both cleavages rend a AICD peptide of 50 aa 
long, it was unknown which AICD peptide (C59/57 or C50) was physiologically functional 
(Selkoe and Kopan, 2003). Nonetheless, evidence points to the C50 AICD as the 
physiologically functional peptide (von Rotz et al., 2004). 
 
 
 
Figure I.11. APP cleavage by α-secretase precludes Abeta generation. In contrast, sequential cleavage of 
APP by β-secretase and γ-secretase results in the production of 40-43 amino acid long Abeta (in red) (depending 
on exactly where the γ-secretase cleavage occurs). The major cleavage sites of APP secretases are: Met596 for β-, 
and Lys612 for α-secretases, and Val636 (γ-site) and Leu645 (ε-site) for γ-secretase. M, cell membrane. 
     ...TEE ISEVKM DAEFRHDSGYEVHHQK  LVFFAEDVGSNKGAIIGLMVGGV V IAT VIVITLVMLK… NH2 COOH 
Abeta 40  42 
 α-secretase  
α-site (K612) β-site (M596) 
β-secretase 
ε-site (L645)  γ-site (V636) 
 γ-secretase   γ-secretase  
 M 
Chapter I - General Introduction                       - 34 - 
Sandra Vieira Guerra e Paz   CBC/UA, 2006 
Additional reports have revealed that APP can also be proteolytic processed at it C-
terminus by caspases, like caspase-3 (Gervais et al., 1999), caspase-6 and -8 (Pellegrini et al., 
1999), or caspase-9 (Lu et al., 2000). The target residue for the caspase-directed APP cleavage 
is Asp664 (Gervais et al., 1999; Weidemann et al., 1999; Zambrano et al., 2004). The resultant 
C-terminus C31 peptide is a potent inducer of apoptosis, and this cleavage was shown to 
reduce APP internalization but to have varying effects on the secreted levels of Abeta 
(Pellegrini et al., 1999; Lu et al., 2000; Soriano et al., 2001).  
α-Secretases. This protease cleaves APP within the Abeta fragment (Lys16), close to 
the APP membrane-spanning domain (APP695 Lys
612-Leu613). As mentioned above, cleavage at 
this site (the α-site, Fig. I.11) precludes Abeta generation and produces a soluble protein of 
612 aa, αsAPP (Esch et al., 1990; Busciglio et al., 1993). This cleavage is constitutive and 
therefore depends on an enzyme that has an active pool at all times but that can be further 
activated by protein kinase C (PKC) activators and other second messenger cascades (Mills 
and Reiner, 1999). Metabotropic glutamate receptor agonists and carbachol, a M1 muscarinic 
acetylcholine receptor agonist, also upregulate α-secretase activity (Kirazov et al., 1997; Nitsch 
et al., 1997). Therefore, this pathway of APP processing has been referred to as constitutive 
and regulated. The search for the α-secretase identity led to an interest in zinc-dependent 
metalloproteases (Esler and Wolfe, 2001), and three potential candidates were identified (for 
review see Hooper and Turner, 2002). The first was the tumor necrosis factor alpha 
converting enzyme (TACE-α or ADAM 17), a disintegrin and metallopreotease (Black et al., 
1997; Buxbaum et al., 1998) that releases tumor necrosis factor from its receptor form. It can 
also cleave a large number of other receptors including Notch (Brou et al., 2000) and TGF-α. 
Interestingly, TACE knockout mice showed deficiencies in αsAPP regulated but not 
constitutive secretion (Buxbaum et al., 1998; Merlos-Suarez et al., 1998), supporting the idea 
of more than one α-secretase cleavage activity. TACE ability to cleave APP constitutively was 
demonstrated in HEK293 cells, but it was one order of magnitude more sensitive to the 
inhibitor TAPI-1 than constitutive α-secretase (Slack et al., 2001). In addition, Checler et al. 
(2005) have observed that the majority (90-95%) of PKC-induced αsAPP production was due 
to TACE activity in fibroblasts, while this enzyme was only partially responsible for 
constitutive αsAPP production. Nitric oxide, a retrograde messenger in synaptic transmission, 
activates TACE “in vitro” and α-secretase “in vivo” (Zhang et al., 2000), and one can thus 
postulate that APP ectodomain shedding may be a crucial modulator of synaptic plasticity.  
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The second and third candidates are also members of the metalloproteases ADAM 
family: ADAM 10 and ADAM 9 (MDC9). Like TACE, they are initially expressed as inactive 
preproteins and their active forms can also affect αsAPP levels (Koike et al., 1999; Lammich 
et al., 1999). Co-transfection of APP with ADAM 10 or MDC9 results in increased 
(constitutive and regulated) sAPP secretion. ADAM 10 cleaves “in vitro” the Abeta peptide at 
the Lys16-Leu17 bond, and the Flemish mutation Ala21-Gly reduces this cleavage (Lammich et 
al., 1999). Of interest is the fact that the Drosophila Kuzbanian protein, an orthologue of 
ADAM 10, is involved in neurogenesis and axonal extension (Rooke et al., 1996).  
β-Secretases. The site of β cleavage (β-site) occurs between residues 596 and 597 of 
APP695, exactly at the N-terminus of Abeta (Fig. I.11), and releases βsAPP (595 aa long). The 
ubiquitous presence of constitutively secreted Abeta indicates that there is β-secretase activity 
in most cells (Haass et al., 1992b), but there is evidence that it is more active in brain than in 
peripheral tissues (Seubert et al., 1993). Furthermore, the levels and activity of β-secretases 
were found to be increased in AD (Fukumoto et al., 2002). The enzymes that cleave at the β-
site have been identified as the aspartyl proteases β-site APP cleaving enzyme 1, BACE-1 (also 
termed Asp2 or memapsin2) (Vassar et al., 1999; Yan et al., 1999a; Vassar, 2004), and β-site 
APP cleaving enzyme 2 (BACE-2) (Farzan et al., 2000). They share 64% of sequence 
homology and are both membrane-anchored enzymes that are expressed in neural tissues, 
although BACE-2 expression is lower than BACE-1 (Bennett et al., 2000). Like all aspartic 
proteinases, BACE-1 and BACE-2 are generated as proenzymes, and while the BACE-2 
activation by prodomain processing is autocatalytic, BACE-1 activation is mediated by furin or 
a furin-like enzyme (Bennett et al., 2000; Capell et al., 2000; Hussain et al., 2001). BACE-1 
cleaves APP carrying the FAD Swedish double mutation (K594M595-NL) 10-fold more 
efficiently than wild-type APP (Yan et al., 1999a). This enzyme cleaves APP at Abeta positions 
1 and 11, as cells over-expressing it had an increase in secreted levels of Abeta 1-40, 1-42, 11-
40 and 11-42 (Vassar et al., 1999). Conversely, BACE-1 knockout mice showed a decrease in 
secreted Abeta, but the mice were phenotypically normal (Cai et al., 2001; Luo et al., 2001), 
suggesting that inhibition of the β-site cleavage is not toxic and could be of therapeutic value 
(Roberds et al., 2001). BACE-1 seems responsible for the cleavage of approximately 10% of 
the APP pool that is proteolytically processed in neuronal cells. Of these 10%, roughly 90% 
give rise to Abeta 1-40 and 10% to Abeta 1-42 (Haass et al., 1992b; Seubert et al., 1992). 
BACE-2 cleaves APP at Abeta position 1 but also and more efficiently at sites within Abeta 
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(Phe19 and Phe20), after the alpha-site Lys16 (Farzan et al., 2000). Thus, BACE-2 can be 
distinguished from BACE-1 on the basis of autoprocessing of the prosegment and in APP 
processing specificity, with BACE-2 behaving more as an alpha-secretase-like APP enzyme 
(Yan et al., 2001). Cells overexpressing BACE-2 and APP with the Swedish mutation showed 
enhanced levels of the βCTF fragment. As BACE-2 maps to chromosome region 21q22.2-
22.3, it is tempting to speculate that some of the FAD cases linked to chromosome 21 may 
also be related with BACE-2 polymorphisms or overexpression (Turner et al., 2003). The 
third β-secretase candidate to be identified was Carboxypeptidase B (Matsumoto et al., 2000), 
which in contrast to BACE enzymes lacks a transmembrane domain. It is a soluble enzyme 
located in the cytosol of various neurons and some microglial cells, especially in the 
hippocampus, which “in vitro” or when overexpressed in cells also leads to an increase in 
βCTF levels (Matsumoto et al., 2000).    
γ-Secretases. βCTF and αCTF are cleaved, apparently intramembranously, by a 
multicomponent enzymatic complex called γ-secretase (reviewed in Wolfe and Haass, 2001; 
Selkoe and Kopan, 2003). This enzyme is also responsible for cleaving the Notch protein, a 
well known signal transducer, at its intramembranous sequence (Berezovska et al., 2001; 
Selkoe and Kopan, 2003). Similarly, both Notch and APP apparently need proteolytic 
trimming of their extracellular domain by TACE and α/β-secretase, respectively, to become a 
substrate for γ-secretase (De Strooper et al., 1998; Brou et al., 2000; Mumm et al., 2000; Struhl 
and Adachi, 2000). Several recent findings have broken down the γ-secretase complex into its 
constitutive parts. The two prime candidates for the γ-secretase catalytic region-containing 
protein are the previously mentioned Presenilin 1 and Presenilin 2. They were initially 
identified by genetic linkage analysis of non-APP FAD mutations that increased Abeta 1-42 in 
humans, and mapped to chromosomes 14 and 1, respectively (Cruts et al., 1995; Duff et al., 
1996; Hutton et al., 1996; Lemere et al., 1996). PS2 seems to be responsible for a smaller 
amount of CTF cleavage than PS1 (Herreman et al., 1999). PS1 knockout mice have markedly 
reduced γ-secretase activity (De Strooper et al., 1998), which is even more reduced in double 
knockout mice for PS1 and PS2 (Donoviel et al., 1999; Herreman et al., 1999). Nonetheless, 
there might be multiple γ-secretase enzymes with varying degrees of selectivity for producing 
Abeta 1-40 and Abeta 1-42 (Wolfe, 2001), as in PS1/PS2 double knockout mice there is a lack 
of Abeta 1-42 production in the early secretory pathway but not of Abeta 1-40 (Wilson et al., 
2002). The PS1 and PS2 related genes encode integral membrane proteins with at least eight 
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transmembrane domains that are initially expressed as inactive preproteins (Thinakaran et al., 
1996). Subsequent cleavage (named “PS maturation”) between transmembranar domains 6 
and 7 yields a C-terminal and an N-terminal fragments, which remain associated with each 
other in a multiprotein complex of high molecular weight (≥ 100 KDa) (Capell et al., 1998). 
PS1 maturation was observed to be necessary in order to obtain γ-secretase activity in primary 
neuronal cultures (Capell et al., 2005; Cupers et al., 2005). PS1 and PS2 are not found in the 
same complexes, but their tissue specific expression profiles can overlap (Saura et al., 1999).  
The demonstrated physical interaction between APP and Presenilins N-terminus, first 
suggested that Presenilins could in fact be the elusive γ-secretase catalytic proteins (Pradier et 
al., 1999). This supports that Abeta 1-40 and Abeta 1-42 biogenesis may be the result of 
distinct enzymatic activities. However, the subcellular compartments of APP, CTF, PS and γ-
secretase activity co-localizations argued against PS as the catalytic subunit (the “spatial 
paradox”) of this enzymatic complex (further presented in section I.2.7). One of the strongest 
arguments in favour of PS as the catalytic subunit comes from the identification of a new, 
evolutionary conserved, Presenilin homologue gene family of GxGD aspartyl proteases with 
five members (Haass et al., 2002; Ponting et al., 2002). This gene family codes for proteins 
with extensive predicted transmembrane domains and two predicted catalytic aspartyl residues, 
similar to the PS domains 6 and 7. Another strong argument comes from the observation that 
several compounds that inhibit γ-secretase bind specifically to PS (Esler et al., 2000; Li et al., 
2000; Seiffert et al., 2000).  
Another component of γ-secretase is Nicastrin, which also affects the complex’s 
enzymatic activity (Esler et al., 2000). Nicastrin is extensively glycosylated, has four conserved 
cysteine residues near its extracellular N-terminus (Leem et al., 2002) and possesses a single 
transmembrane domain (Yu et al., 2000). This protein interacts both with APP CTFs and PS1 
and PS2 (Fig. I.12). Mutations of Nicastrin in residues within a conserved region lead to 
enhanced Abeta secretion, while deletion of the same region prevents Abeta secretion (Yu et 
al., 2000). Two other proteins identified as γ-secretase subunits are APH-1 or APH-2 (with 
APH-2 being only relevant in cerebral tissues γ-secretase activity) and PEN-2 (Francis et al., 
2002; Steiner et al., 2002; for review De Strooper, 2003). Recent reports provide evidence that 
γ-secretase is indeed an aspartyl protease complex composed of the four core components 
APH-1, nicastrin, Presenilin, and PEN-2 (De Strooper, 2003; Kimberly et al., 2003; Capell et 
al., 2005). It is now believed that an APH/immature Nicastrin complex is formed at the ER, 
and matured at the Golgi. Also at the Golgi, APH/Nicastrin first bind to PS, stabilizing the 
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unstable and readily degraded PS pool, and following the binding of PEN-2, PS 
endoproteolysis is triggered and the γ-secretase complex is thought to be finally active (Kim 
and Sisodia, 2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure I.12. Presenilin structure and 
APP interaction. Presenilin (at it C-
terminus) associates with Nicastrin through 
the DYIGS motif in the extracellular 
domain, and after is cleaved (dashed line) 
into two molecules (from: Sisodia, 2000). 
The catalytic site is now believed to belong 
to Presenilin and not to Nicastrin.                                                                                   
 
 
I. 2. 5 – APP IS A RIP SIGNAL TRANSDUCTION MOLECULE  
APP has a receptor-like architecture with a conserved cytoplasmic domain, and can be 
located at the cell surface, although no receptor function has been demonstrated for APP. 
Recently, it was reported that this type I membrane spanning molecule may function as a 
signal transducer by Class 1 Regulated Intramembrane Proteolysis (RIP) (Ebinu and Yankner, 
2002; Koo, 2002). These molecules have a peptide sequence within their protein structure that 
is released after two subsequent protein cleavages (RIP proteolysis), and can be targeted to the 
nucleus, functioning as a gene transactivator. RIP proteolysis seems to occur at or near the 
plasma membrane and involves ADAMs and γ-secretase cleavages. The proteases involved in 
this process are thought to be under different regulation, with the activity of the first enzyme 
(responsible for the extramembranar substrate cleavage) being directly regulated. The activity 
of the second enzyme, responsible for the intramembranar substrate cleavage, seems to be 
directly regulated by substrate availability, which is dependent on the first and regulated 
cleavage. Several mammalian proteins are known to be processed by RIP to generate nuclear 
signalling, including APP, Notch-1, ErB-4, CD44, and p75NTR (Class 1 RIP), and SREBP-1 
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and ATF6 (Class 2 RIP) (reviewed in Ebinu and Yankner, 2002; Koo, 2002; Rawson, 2002; 
Pardossi-Piquard et al., 2005). Notch is a type I transmembrane receptor involved in cell fate 
decisions during embryogenesis and functions through cellular RIP. Upon ligand binding, 
Notch is proteolytically processed, initially by a TACE- (Brou et al., 2000) or an ADAM 10-
dependent cleavage event (Hartmann et al., 2002), followed by γ-secretase intramembrane 
cleavage (De Strooper et al., 1999). In these respects APP and Notch processing may be 
similar (reviewed in Selkoe and Kopan, 2003). PS knockout mice are remarkably similar to the 
Notch knockout mice (Conlon et al., 1995), possibly due to the involvement of Presenilin in 
the intramembrane cleavage of Notch processing. In fact, APP and Notch were proved to be 
competitive substrates for PS1-dependent γ-secretase cleavage (Berezovska et al., 2001). In 
addition, γ-secretase cleaves the CTFgamma (CTF produced after APP cleavage at the γ-site) 
at a site (ε-site) corresponding to the S3 cleavage site of Notch (Sastre et al., 2001). Both the 
Notch Intracellular Domain (NICD) and the resultant APP AICD fragment may act as 
transcription factors (Schroeter et al., 1998; Cao and Sudhof, 2001; Cupers et al., 2001; Ebinu 
and Yankner, 2002; Kim et al., 2003; von Rotz et al., 2004).  
The AICD fragment is very labile (Cupers et al., 2001), but the AICD-generating 
CTFs are very stable. This suggests that it may be necessary to further activate CTFs for the γ-
secretase cleavage to occur, in contrast to the Notch signalling. The AICD fragment is 
extremely small when compared with the NICD and lacks motifs commonly found in 
transcriptional regulators, suggesting that it may function in signalling differently from NICD. 
In fact, to function as a transactivator the AICD forms a multimeric complex composed of 
the nucleocytoplasmic adaptor Fe65 and other proteins as the nuclear histone acetyltransferase 
Tip60 (Cao and Sudhof, 2001; Baek et al., 2002; Kim et al., 2003; von Rotz et al., 2004). NICD 
is known to be targeted to the nucleus, where it exerts its physiological function, and AICD 
translocation to the nucleus has already been observed (Kimberly et al., 2001; Kinoshita et al., 
2002; von Rotz et al., 2004). Nonetheless, this model is controversial and Cao and Sudhof 
(2004) have proposed that the AICD itself is not necessarily nuclear targeted. The authors 
defend that the AICD role in the transsactivation process consists in activating Fe65, via 
conformational changes, for binding with Tip60 (Fig. I.13). Of note is that AICD half-life is 
not increased by binding Fe65 (Cupers et al., 2001). On the other hand, von Rotz and 
colleagues (2004) have observed in HEK293 and SH-5YSY differentiated cells the presence of 
AICD/Fe65/Tip60 complexes in multiple spherical nuclear coiled bodies, and 
JIP/AICD/Tip60 complexes in speckle-like structures.  
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Figure I.13. A working model for the 
function of APP in transcriptional 
activation. AICD binding to Fe65 at its 
PTB2 domain would disrupt Fe65 PTB2-
WW intradomain binding. This would in 
turn alter Fe65 initially closed conformation, 
and free the Fe65 WW domain for its 
transactivator role upon nuclear 
translocation. From: Cao and Sudhof (2004). 
 
 
 
AICD/Fe65/Tip60 complexes were reported to transactivate the kai1 gene, with the 
presence of the nucleasome assembly factor SET protein in the complex being necessary for 
maximal transactivation (Baek et al., 2002; Telese et al., 2005). KAI1 protein is involved in 
membrane receptor function regulation and in tumour cell proliferation inhibition (Baek et al., 
2002). SET protein binds Fe65 (Telese et al., 2005) and was additionally shown to bind an 
APP C-terminal fragment and to mediate its apoptotic effects (Madeira et al., 2005). The 
AICD/Fe65/Tip60 complex was also recently reported to transactivate the Abeta degrading 
enzyme Neprilysin (Pardossi-Piquard et al., 2005), and to promote the gene expression of APP 
itself, in an autostimulatory loop (von Rotz et al., 2004). A different AICD-containing 
complex, with Fe65 and the ternary complex CP2/LSF/LBP1, was found to promote the 
expression of the glycogen synthase kinase-3β (GSK-3β) (Kim et al., 2003). This gsk-3β 
transativation appears to be inhibited by AICD complexes of another AICD-interacting 
adaptor protein named X11 (Lau et al., 2003).  
Mature APP and Notch were observed to interact by two independent groups 
(Abraham et al., 2005; Fassa et al., 2005). Abraham and collaborators (2005) used a 
membrane-impermeable proteins crosslinker (DTSSP) in HEK293 and in primary neuronal 
cultures to detect this interaction. The group of S. Efthimiopoulos (Fassa et al., 2005) has 
further characterized this binding as Numb-independent, and observed that Notch 
overexpression did not significantly affect APP processing. 
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I. 2. 6 – APP C-TERMINUS DOMAINS AND APP-BINDING PROTEINS 
Several proteins interact with APP, most of them possessing multiple protein-protein 
interacting domains, which in turn form complexes with other proteins, suggesting that these 
proteins function as adaptor proteins bridging APP to specific molecular pathways. The 
number of APP binding proteins thus far identified is quite vast and can be loosely divided 
into two overlapping categories: signal transduction and subcellular localization (da Cruz e 
Silva et al., 2004a). For both there is an emerging consensus that the APP C-terminus is 
critical in these interactions. Examples of APP binding proteins involved in signal 
transduction are: Abl, Disabled-1 protein (mDab-1), Fe65 and Fe65-like proteins, SET 
protein, X11 (or MINT-1) and X11-like proteins (or MINT-2 and 3), Numb, and G0. APP 
binding-partners involved in APP targeting are fewer and include APPBP2 (or PAT1) and the 
X11 family proteins, important in microtubule association. X11 was also recently found to 
potentially function as an APP vesicle coat-protein (Hill et al., 2003). Recent findings on APP 
binding proteins have brought to light two other proteins putatively involved in APP traffic: 
the neuronal sorting receptor sorLA/LR11 (Andersen et al., 2005), and a novel sorting nexin 
(SNX30) (Lichtenthaler et al., 2005). The APP-G0 binding (Nishimoto et al., 1993) may also 
have a role in APP targeting, as G0 was found to be located at subcellular membrane domains 
specialized in the sorting of trafficking proteins (Qian et al., 2003). Other known APP binding 
proteins involved in trafficking are the Kinesin Light Chain (KLC) and JIP-1 [Jun N-terminal 
kinase (JNK) interacting protein 1]. Furthermore, examples exist where the binding to APP 
has not been clarified, as in the case of caveolin (Ikezu et al., 1998; Nishiyama et al., 1999).  
The function of all the APP binding proteins has yet to be completely elucidated, but 
considerable contributions have already been made. For review on APP binding proteins 
involved in APP signal transduction see da Cruz e Silva et al. (2004a). Several other APP 
binding proteins have been described that appear to have very diverse roles such as in Abeta 
clearance and/or aggregation, as for example ApoE.  Proteins which bind the N-terminus of 
APP have not been extensively documented, such as fibulin-1, whose binding blocks neural 
stem cells sAPP-mediated proliferation (Ohsawa et al., 2001), and F-spondin, which may 
mediate APP CAM and neurite outgrowth functions (Ho and Sudhof, 2004). In fact, almost 
all known APP binding proteins bind at its C-terminus, and specifically at one of two APP 
domains: 653YTSI656 and 682YENPTY687 (Fig. I.14 and Table I.1). A third domain 
(667VTPEER672 ) has not been implicated so far in any of the APP bindings, although it is 
included in the APP G0α- and Hsc73-binding sequences, but has a regulatory role that will be 
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discussed later (section I.3.3). These domains can be classified according to their attributed 
functions and are thought to be involved in regulating APP rate of secretion, endocytosis, and 
Abeta production (Ando et al., 1999; Iijima et al., 2000; Mueller et al., 2000; Ando et al., 2001; 
Sabo et al., 2001; Roncarati et al., 2002; da Cruz e Silva et al., 2004a).  
 
 
 
Figure I.14. APP C-terminal localization of the two sequence domains (YTSI and YENPTY) known to 
be the binding sites of several APP binding proteins. Adapted from: da Cruz e Silva et al., 2004a.  
 
 
Table I.1. Numerous APP binding proteins bind to specific APP C-terminal domains. (ND –not defined). 
Cytoplasmic 
APP-binding 
domain 
APP 
binding 
protein  
Putative Role 
Subcellular localization 
and/or co-localization 
with APP 
References 
UV-
damaged 
DNA-bp 
ND 
. Cytosolic fraction 
(PC12 cells) 
Watanabe et al., 
1999 
Abl 
. Abl active form 
phosphorylates APP at Y682  
. Forms a trimeric complex 
with APP and Fe65 
. Mediation of APP 
membrane internalization  
. Cytoplasm and 
nucleus 
Russo et al., 2001 
Tarr et al., 2002 
mDabl 
. Neuron migration (cell 
movement) 
. Links APP to signal 
transduction processes 
. Co-localizes with 
APLP1 in membrane 
ruffles and vesicular 
structures 
Homayouni et al., 
1999 
682YENPTY687 
domain 
Fe65 and 
Fe65L 
family 
. Regulation of APP secretion 
. Regulation of cell movement 
(APP-Fe65 complex)  
. Promotion of gene 
transactivation (AICD/Fe65/ 
Tip60 complex) 
. Cytoplasm and 
nucleus 
. In AD co-localizes 
with Tau protein in 
neurofibrillary tangles 
Fiore et al. 1995 
Bressler et al., 1996 
Guenette et al., 
1996 
Kimberly  et al., 
2001  
Sabo et al., 2001 
Kinoshita et al., 
2002 
KKKQYTSIHHGVVEVDAAVTPEERHLSKNQQNGYENPTYKFFEQMQN 
NH2 COOH 
653YTSI656 682YENPTY687 C-terminus domains: 
667VTPEER672 
APP 
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X11 (or 
Mint-1) 
and X11L 
family 
. APP trafficking (targeting) 
. APP coat vesicle protein 
. APP synaptic localization 
. Cytosolic/Golgi 
adaptor protein 
. APP/Mint/Cask 
complexes are localized 
in neuronal processes 
and in the Golgi 
Borg et al., 1996 
McLoughlin and 
Miller, 1996 
Sastre et al., 1998 
Mueller et al., 2000 
Hill et al., 2003 
682YENPTY687 
domain 
(cont.) 
JIP-1b 
. Scaffolds APP with c-Jun 
Kinase (JNK) 
. Links APP to stress kinase 
signalling pathways 
. Involved in APP axonal 
trafficking 
. APP and JIP-1b exhibit 
similar subcellular 
location: cytoplasmic 
significantly overlapped 
staining  
Matsuda et al., 2001 
Scheinfeld et al., 
2002 
Sisodia, 2002 
APPBP2 
(or PAT1) 
. Translocation of APP along 
microtubules toward the cell 
surface  
. Involved in nuclear gene 
transactivation/repression  
 
. Nucleus and 
cytoplasm, also found 
membrane-associated.  
. Golgi and in 
filamentous cytoplasmic 
structures emanating 
from the Golgi, where 
it co-localizes with APP 
Zheng et al., 1998 
Gao and Pimplikar, 
2001 
Richards et al., 
2003 
Zhang et al., 2004 
KLC (?) 
. Axonal transport of APP 
containing vesicles 
(anterograde and retrograde) 
. Cellular cytoskeleton/ 
Microtubules 
Kaether et al., 2000 
Kamal et al., 2000; 
Kamal et al., 2001 
653YTSI656 
domain 
SET (?) 
. Transactivation of the KAI1 
gene (AICD/SET/Fe65/ 
Tip60 complex) 
. Mediation of APP C-terminal 
fragment-induced apoptosis 
. Co-localizes with 
AICD at the nucleus 
(on the kai1 gene 
promoter) 
Madeira et al., 
2005; 
Telese et al., 2005 
657H-K676 
sequence G0(α) 
. APP cellular signalling  
. APP targeting  
. Co-localizes with APP 
at neuronal growth 
cones 
. Co-localizes with APP 
at  neuronal membrane 
microdomains 
Strittmatter and 
Fishman, 1991  
Nishimoto et al., 
1993  
Okamoto et al., 
1995  
Brouillet et al., 
1999 
Qian et al., 2003 
658H-D664 
sequence 
hARD1 ND ND Asaumi et al., 2005 
649K-S675  
sequence 
Hsc73 
. APP/AICD traffic  
. APP/AICD proteasomal or 
lysosomal degradation  
. Mainly cytosol, 
lysosomal membrabe, 
also in nucleus 
Kouchi et al., 1999 
Numb and 
Numb-like 
proteins 
. Link between APP and 
Notch signalling pathways 
. Neurons cytoplasm, 
dendritic and axonal 
processes; excluded 
from nuclei  
Roncarati et al., 
2002 
ND 
AIDA-1a 
. Modulator of APP 
processing 
. Diffuse localization 
with some nuclear 
accumulation  
Ghersi et al., 2004 
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The internalization signal YENPTY. The APP trafficking domain most widely 
studied has the amino acid sequence 682YENPTY687 and is situated at the APP C-terminus. It 
contains an NPXY element, which is a typical internalization signal for membrane-associated 
receptor proteins (Chen et al., 1990; Koo and Squazzo, 1994; Lai et al., 1995), and has the 
structure of a type I β-turn (Ramelot et al., 2000). This motif is thought to function through 
interaction with various known APP binding proteins (Table I.1) via phosphotyrosine 
interaction domains of the latter.  
The sorting signal YTSI.  The amino acid sequence 653YTSI656 forms a 4-residue 
tyrosine-based characteristic internalization and/or basolateral sorting signal (YXXI) (Hass et 
al., 1995; Lai et al., 1995; Zheng et al., 1998). When transplanted to the cytoplasmic domain of 
the transferrin receptor (TR), this sequence promoted the internalization of a TR-YTSI 
chimera in COS-1 cells and seemed to be partially responsible for its post-Golgi degradation 
(Lai et al., 1995). This domain has received less attention and until now only one protein 
(APPBP2) was shown to specifically bind to it. As the exact site of APP binding to the KLC 
protein is still unknown, the binding of KLC to the 653YTSI656 domain is speculative and 
supported only by KLC homology to APPBP2. Nonetheless, this is a domain that could 
contribute to the targeting of APP to correct plasma membrane subdomains and be involved 
in APP signalling functions. In light of APP as a RIP receptor involved in signal transduction, 
which may underlie many of the physiological roles that have been attributed to it (e.g. 
neuroprotection, cell adhesion, cell growth stimulation and synaptic plasticity), this domain 
may have a potentially important regulatory function. The characteristics of both the putative 
and known 653YTSI656 domain binding proteins are described below. 
APPBP2 (or PAT1). APPBP2 is a microtubule-interacting protein that recognizes and 
binds full length APP and its C-terminus fragments at the 653YTSI656 domain (Zheng et al., 
1998; Gao and Pimplikar, 2001). It is a nucleocytoplasmic protein of 585 amino acids (65-70 
KDa). In the cytosol it fractionates into a soluble and a membrane-associated pool, and has an 
apparent molecular weight of 160-180 KDa due to its binding to an unknown protein. 
APPBP2 is located throughout the cytoplasm in a punctuate or filamentous pattern, being 
more abundant in the perinuclear region of the cell (where microtubules are highly 
concentrated and where APP is also enriched). This protein seems to be involved in the 
translocation of APP along microtubules toward the cell surface and needs the tyrosine 
present in the YTSI sequence for efficient binding (Zheng et al., 1998). APPBP2 contains 
tandem-repeats also found in KLC (Zheng et al., 1998; Gao and Pimplikar, 2001), a protein 
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likewise known to complex with APP. Although still controversial, APPBP2 may also be 
involved in AICD traffic to the nucleus. AICD-nuclear exclusion was observed when AICD 
was co-transfected with an APPBP2 mutant carrying a deletion of its nuclear-localization 
signals (Gao and Pimplikar, 2001). Interestingly, AICD selectively caused cytoplasmic 
relocation of nuclear APPBP2 and its proteasomal degradation. APPBP2 has in its sequence 
DNA-binding and NR cyclin box-like motifs, the latter known to mediate the interaction of 
transactivators with their nuclear hormone receptors, including the retinoic acid receptor (Gao 
and Pimplikar, 2001). Also of note is that APPBP2 was found to interact with the androgen 
receptor and to inhibit its activity (Zhang et al., 2004). 
Kinesin Light Chain. Co-immunoprecipitation, sucrose gradient, and direct “in 
vitro” binding demonstrated that APP forms a complex with kinesin-I by binding directly to 
the TPR (tetratricopeptide repeat) domain of the KLC subunit (Kamal et al., 2000). The 
identity of the APP domain involved in this binding is still elusive, but due to sequence 
homology between APPBP2 and KLC it may be postulated to be the 653YTSI656 domain. 
Kinesin molecular motor proteins are responsible for many of the major microtubule-
dependent transport pathways in neuronal and non-neuronal cells (Goldstein, 2001). The 
microtubule motor complex kinesin-I has two components: a kinesin heavy chain (KHC or 
KIF5B) that has ATP- and microtubule-binding motifs essential for vesicle transport, and a 
kinesin light chain (KLC). KLC associates with KHC and tethers membrane vesicles 
containing proteins to be transported axonally from the neuronal soma to nerve terminals 
(Hirokawa, 1998). APP is axonally transported in elongated tubules that move extremely fast 
and over long distances, and antisense treatment with oligonucleotides against KHC slows 
down that movement and increases the frequency of directional changes (Kaether et al., 2000). 
BACE-1 and PS were found in membrane vesicles transported along the axons of peripheral 
and central mouse neurons, with this transport being mediated by kinesin-1 and requiring APP 
(Kamal et al., 2001). The fast anterograde axonal transport of this compartment is mediated by 
APP and kinesin-I binding, and APP proteolysis liberates kinesin-I from the membrane 
(Kamal et al., 2001). Deletion of the app-like gene (appl) in Drosophila or overexpression of 
human APP or APLP2 C-terminal caused aberrant accumulation of transported vesicles 
within axons. This phenotype is observed in flies with mutations in kinesin or in dynein, a 
microtubule-activated ATPase that transport vesicles from neuronal dendrites back to the cell 
body. Deletion of its C terminus disrupted APP axonal transport and abolished the organelle 
axonal accumulation phenotype due to APP overexpression (Gunawardena and Goldstein, 
2001). Taken together, these results suggest that one of the normal functions of APP may be 
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as a membrane cargo receptor for kinesin-I and that KLC is important for kinesin-I driven 
transport of APP into axons (Kamal et al., 2000; 2001). Interestingly, Tau protein was 
reported to inhibit the kinesin-dependent transport of Golgi-derived vesicles into neurites, and 
was also observed to exert inhibitory effects on APP transport into neurites, resulting in APP 
somatic accumulation (Stamer et al., 2002). 
SET. The SET protein, also called template-activating factor (TAF1beta) or 
phosphatase 2A inhibitor 2 [I2(PP2A)], was found to bind an APP C-terminal fragment 
involved in neuronal apoptosis and cell death induction (Madeira et al., 2005). The exact 
sequence on APP to wich SET binds has not been elucidated. However, death induction by 
the APP C-terminal is mediated by SET and lost when APP Tyr653 is mutated to an aspartate. 
These suggest that SET binds to APP at the 653YTSI656 domain or near by (Madeira et al., 
2005). Interestingly, a complex including Fe65/AICD/Tip60/SET was found to be associated 
with the kai1 gene promoter, and SET was shown to bind Fe65 at the WW transcativator 
domain and to be required for full levels of kai1 gene transcription (Telese et al., 2005). 
G0α. APP and the G0 alpha subunit were first reported to interact in a GTP-dependent 
manner (after G0-activation by GTP) by Nishimoto et al. (1993). The APP His
657-Lys676 
sequence is necessary for this complex formation (Nishimoto et al., 1993; Okamoto et al., 
1995; Yamatsuji et al., 1996). This sequence is predicted to have a stable structure starting with 
a hydrophobic pocket that can potentially be regulated by the immediately upstream 653YTSI656 
domain (Ramelot et al., 2000; Ramelot and Nicholson, 2001). G0 is a membrane-associated 
heterotrimeric GTP-binding protein (G protein), and one of the major G proteins in brain 
(Rouot et al., 1987; Spiegel, 1987). G proteins share similar or identical beta and gamma 
subunits but different alpha subunits. The 39 KDa G0α subunit is expressed at low levels in 
some peripheral tissues, but it is mainly cerebral (Rouot et al., 1987). These proteins are 
involved in many signal transduction pathways underlying systemic functions like learning and 
memory (Neves et al., 2002). G0 is a member of the G protein family that links growth-
promoting receptors and second messengers in hormone-induced cell growth (Post and 
Brown, 1996). G0 is also the major non-cytoskeletal protein in the growth cone membrane, 
where it is thought to transduce signals not only from outside the cell but also from within 
(Strittmatter et al., 1990; Strittmatter and Fishman, 1991). APP was recently observed to be 
co-localized with Fe65 in growth cones, where they concentrate in actin-rich lamellipodia 
(Sabo et al., 2003). Neuronal growth cones are specialized transduction systems that lead the 
elongating axon towards appropriate synaptic targets by altering motility in response to a 
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variety of extracellular signals or independent intrinsic cues. APP-G0 interaction in growth 
cones has not yet been reported but APP and G0α were reported to interact in cholesterol and 
sphingoglycolipid-enriched microdomains (CSEM), a caveolae-like compartment specialized in 
signal transduction (Brouillet et al., 1999). Furthermore, in total neuronal membranes and in 
CSEM, APP binding to an antibody against APP ectodomain (22C11) led to the reduction of 
the high-affinity G0 GTPase activity. This inhibition was specific for G0α and was reproduced, 
in the absence of 22C11, by the addition of the APP C-terminus (Brouillet et al., 1999). 
Two additional proteins were reported to bind APP at or near the 653YTSI656 domain, 
although little is known about the physiological consequences of these interactions. Human 
hARD1 is an N-terminal acetylltransferase that was recently shown to bind APP at His658-
Asp664, a sequence only lacking two amino acids of the APP hydrophobic pocket (Asaumi et 
al., 2005). The cytosolic chaperone Hsc73 appears to bind APP at an APP C-terminal 
sequence (K649-S675) that includes both the 653YTSI656 domain and the hydrophobic pocket, and 
maybe involved in APP/CTFs proteasomal degradation (Kouchi et al., 1999).  
  
I. 2. 7 – APP SUBCELLULAR TRAFFICKING 
APP trafficking and maturation. In neuronal and non-neuronal cells, APP is known 
to be transported via the secretory pathway, a continuum of separate membrane-enclosed 
organelles leading to the cell surface. Newly synthesized proteins that are destined for 
secretion or cell-surface expression enter this pathway at the rough endoplasmic reticulum 
(RER). APP is known to undergo posttranslational modifications that include N- and O-
linked glycosylation and tyrosine sulfation (Weidemann et al., 1989; Oltersdorf, 1990). APP N-
glycosylation starts at the ER and the carbohydrate chains are further processed in the cis-
Golgi, with immature N-glycated APP being found at both locations (Tomita et al., 1998). 
Two residues in the APP ectodomain (Asn467 and Asn496) have consensus sequences for N-
glycosylation, although only one appears to be N-glycosylated “in vivo” (Pahlsson and 
Spitalnik, 1996). APP maturation by O-glycosylation and tyrosyl-sulfation occurs while 
moving through the trans-Golgi network (TGN) (Weidemann et al., 1989). Maturation of all 
metabolic labelled APP cell-associated proteins reached maximum intensity after 30 min of 
chase (Peraus et al., 1997). O-glycosylation does not depend on correct APP N-glycosylation 
to precede it but, as it is performed at the TGN, is a subsequent process (Pahlsson and 
Spitalnik, 1996). Inhibition of APP O-glycosylation does not appear to affect APP 
biosynthesis or secretion (Pahlsson and Spitalnik, 1996). Nonetheless, the majority of APP 
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cleavage by secretases occurs after O-glycosylation, as shown by using HEK293 cells 
expressing mutant APP defective in O-glycosylation (Tomita et al., 1998). This mutant 
accumulated in subcellular reticular compartments and exhibited decreased cleavage to αCTFs 
or to Abeta 1-40/1-42. Mature APP (N-,O-glycated and sulfated) is therefore located in 
compartments from the trans-Golgi to the plasma membrane (Tomita et al., 1998). Moreover, 
most APP resides in the cell Golgi complex (Caporaso et al., 1994), but a small pool is carried 
into post-TGN secretory vesicles that carry it to the plasma membrane (Koo et al., 1996; 
Yamazaki et al., 1996; Peraus et al., 1997). In SH-SY5Y cells, the pool of TGN mature APP 
that is targeted to the plasma membrane takes 30 to 45 min to reach this cellular destination 
following APP translation (Cai et al., 2003). At the cell surface, APP can be cleaved or 
undergo re-internalization as a holoprotein via endocytosis, to be recycled back to the 
membrane, retrogradely delivered to the TGN or incorporated into secondary endosomes. 
Secondary endosomes target APP for complete degradation at the lysosomes or to be recycled 
back to the TGN/Golgi (Tagawa et al., 1993; Koo et al., 1996; Yamazaki et al., 1996). In 
central and peripheral neurons a pool of APP molecules is also transported from the cell body 
down axons by fast axonal transport (Koo et al., 1990; Ferreira et al., 1993; Kaether et al., 
2000). Presynaptically targeted full-length APP (and APLP2) occurs in its mature form 
(syalated and N- and O-glycosylated) (Lyckman et al., 1998). APP was also detected in both 
pre- and post-synaptic sites, in the axoplasm of myelinated and unmyelinated nerve fibres, 
within vesicular structures in axonal, dendritic and synaptic compartments, as well as on the 
surface of axons and dendrites (Schubert et al., 1991; Ferreira et al., 1993; Allinquant et al., 
1994; Caporaso et al., 1994; Simons et al., 1995). Of note is that APP was suggested to be up-
regulated in synapses with increased membrane activity, e.g., in synapses subject to high 
transmission rates or during synaptogenesis (Schubert et al., 1991). Figure I.15 represents 
schematically APP neuronal trafficking pathways.  
 
 
 
 
 
 
 
 
 
Figure I.15. APP trafficking through 
the cellular secretory and endocytic 
pathways. APP domains are indicated in 
colours: pink, cytoplasmic domain; violet, 
Abeta domain; green, ectodomain. From: 
Gouras, 2001.  
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In addition, pools of unprocessed synaptic APP are also transported retrogradely 
(transcytotic movement) from axonal synaptic compartments to neuronal cell bodies and 
dendrites (Simons et al., 1995; Yamazaki et al., 1995). In rat forebrain and PC12 cells, APP 
was observed in Rab5-containing endocytic organelles that derive from an endocytic pathway 
distinct from the one involved in synaptic vesicle recycling (Ikin et al., 1996; Marquez-Sterling 
et al., 1997). The latter further reported that cell-surface APP was initially internalized with 
membrane proteins of recycling synaptic vesicles, but subsequently sorted away from these 
vesicles and retrogradely transported to the soma. 
APP processing and its intracellular trafficking. Through the use of radioactivity-
based techniques, the half-life of total cellular APP was estimated to be of approximately 1 h 
(Weidemann et al., 1989; Koo et al., 1996). Nascent and immature (only N-glycosylated) APP 
can be degraded to a high extension by the proteasome, probably via the smooth ER (Yang et 
al., 1998; Kouchi et al., 1999). Additionally, immature APP may be cleaved by secretases at a 
low rate in the ER or the cis-Golgi but, as explained above, the majority of these cleavages 
occur after APP complete maturation. Mature APP is processed rapidly (turnover of 45 min) 
as it is transported to or from the cell surface via the secretory or endocytic pathways (Haass 
et al., 1992a; Sambamurti et al., 1992; Shoji et al., 1992; De Strooper et al., 1993; Kuentzel et 
al., 1993; Cook et al., 1997; Hartmann et al., 1997; Marambaud et al., 1997b). In several types 
of cultured cells a part of the TGN/Golgi APP pool was observed to be locally cleaved by the 
α-secretase. β-secretases can also cleave a fraction of Golgi APP but to a lesser extent. 
Additionally, a small percentage (1.5% in HeLa cells, Kuentzel et al., 1993) of full-length 
mature APP at the TGN is transported to the cell membrane. Approximately 30% of surface 
APP is cleaved to sAPP (Koo et al., 1996), with 20% being cleaved within 10 min (Lai et al., 
1995). The remaining full-length APP and the cleavage products (CTFs) are re-internalized via 
coated pits and vesicles by receptor-mediated endocytosis (Yamazaki et al., 1996). The net 
result of cell surface APP proteolytic cleavage and endocytosis is the rapid removal of cell 
surface APP. Indeed, the estimated half-life for surface-expressed APP is less than 10 min 
(Koo et al., 1996). Consequently, only minor amounts of APP (as compared to the total 
cellular pool) are detected at the cell surface (Kuentzel et al., 1993). The half-life of 
internalized APP was calculated to be ∼30 min (Koo et al., 1996), with a pool of endosomal 
APP being delivered into lysosomes. The remaining cell surface CTFs may be subsequentially 
cleaved by γ-secretase to AICD, at the cell surface or upon endocytosis in endosomes, or 
further degraded in lysosomes (Chen et al., 2000; Mathews et al., 2002; Kaether et al., 2006). 
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CTFs produced at the TGN/Golgi are thought to be cleaved locally or to be delivered to 
lysosomes for degradation (Chen et al., 2000). In neurons, sAPP may also be generated and 
released at the synaptic terminals via α-secretase cleavage (McLaughlin and Breen, 1999).  
During the APP secretory pathway, the majority of Abeta fragments are thought to be 
generated in the late Golgi, from where these peptides are packaged into post-TGN vesicles 
destined for extracellular secretion (Gouras, 2001; Xia, 2001). This Abeta production seems to 
occur at the TGN and does not need post-TGN vesicles formation (Xu et al., 1997). At the 
TGN, the absolute levels of both Abeta 1-40 and Abeta 1-42 are high and the ratio Abeta 1-42 
to total Abeta is 0.05-0.16 (Greenfield et al., 1999). A minority of Abeta peptides (1-40, 1-42 
and x-42) is thought to be generated in the ER (Xia et al., 1998; Greenfield et al., 1999), but 
some authors defend that the γ-secretase complex is still not formed or active at the ER 
(Kaether et al., 2006). A major portion of Abeta peptides are also generated in the endocytic 
pathway, following internalization of APP from the plasma membrane. In fact, mutations of 
the APP 682YENPTY687 domain that significantly impair APP endocytosis simultaneously 
inhibit Abeta levels (Perez et al., 1999). Recent findings locate β- and γ-secretases within the 
cholesterol-enriched plasma membrane lipid rafts, but Abeta production at the cellular 
membrane was reported to occur at lower amounts. APP was thus suggested to be potentially 
segregated from its proteases by the rafts lipid boundary (Kaether and Haass, 2004). Finally, 
Abeta production was also reported in axonal vesicular compartments (Kamal et al., 2001). 
The putative subcellular localization of APP proteolytic processing is shown in Figure I.16.  
 
  
 
 
 
 
 
 
 
 
 
Figure I.16. Putative localization of APP 
processing in neurons. α-, β- and γ-secretase 
activities are represented by labelled balls, 
which are located at the putative subcellular 
compartments where the APP proteolytic 
cleavages occur. CTFs are cleaved to release 
the AICD, which may modulate gene 
transcription in the nucleus (dashed arrows). 
Nuc., nucleus; RER, rough ER; Cis-G., cis-
Golgi; Trans-G., trans-Golgi; Secr. Ves., 
secretory vesicle; Endo., endosome; Lys., 
lysosome. From: Turner et al., 2003. 
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Intracellular Localization of Secretases. The α-, β- and γ-secretases are a 
heterogeneous group of enzymes located in various subcellular regions. The α-secretase was 
thought to reside in a late Golgi compartment (Sambamurti et al., 1992; De Strooper et al., 
1993; Kuentzel et al., 1993) and at the plasma membrane, possibly in microdomains known as 
caveolae (Ikezu et al., 1998). Subsequent studies indicate that cleavage at the α-site can occur 
within the trans-Golgi apparatus or in post-TGN vesicles, and at the plasma membrane 
(Culvenor et al., 1995; Parvathy et al., 1999; Jolly-Tornetta and Wolf, 2000). The ratio between 
plasma membrane and intracellular cleavage appears to be cell-specific. There is reasonable 
consensus that it is primarily an APP intracellular source (probably at the TGN/Golgi) that is 
cleaved in the α-secretase regulated pathway (Jolly-Tornetta and Wolf, 2000; Hooper and 
Turner, 2002). Fahrenholz et al. (2004), when studying mice memory improvement upon α-
secretase up-regulation, observed that the regulated α-secretase APP cleavage occured mainly 
during APP transport from the TGN to the plasma membrane. Intracellular APP α-secretase 
cleavage was first detected in studies using metabolic labelling approaches, where αCTFs 
products were detected intracellularly before the appearance of αsAPP in the medium 
(Sambamurti et al., 1992; De Strooper et al., 1993; Kuentzel et al., 1993). These results 
indicated that this APP cleavage also occurs during APP export through the secretory 
pathway. In fact, the majority of APP cleavage to αsAPP in N2a neuroblastoma cells (De 
Strooper et al., 1992; 1993), PC12 cells (Sambamurti et al., 1992), neuroblastoma H4 cells 
(Kuentzel et al., 1993), CHO cells (Jolly-Tornetta and Wolf, 2000), or even in an APP-
expressing yeast system (Zhang et al., 1997) was shown to occur intracellularly at the TGN or 
in post-TGN vesicles, probably just after sulfate incorporation. In addition, the pool of APP 
that reaches the cell surface as full-length mature molecules may also undergo cleavage by α-
secretase at that location. However, it is still not clear if this APP cleavage occurs at the 
plasma membrane or if it requires APP endocytosis and recycling (Sisodia, 1992; Nordstedt et 
al., 1993; Koo and Squazzo, 1994; Roberts et al., 1994; Parvathy et al., 1999). 
The three putative α-secretases (TACE, ADAM 10 and MDC9) are synthesized as 
preproteins and cleavage of their inhibitory prodomain in late Golgi compartments (Lammich 
et al., 1999) turns them into active enzymes (Haniu et al., 2000; Schlondorff et al., 2000; 
Anders et al., 2001). These data are consistent with functional cleavage of APP normally 
occurring in the later stages of APP maturation and translocation to the cell membrane 
(Turner et al., 2003). The mature, proteolytically active form of TACE has been detected both 
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intracellularly and at the cell surface, but it is predominantly localized intracellularly in a 
perinuclear compartment (for review, see Hooper and Turner, 2002). Through the use of a 
TACE inhibitor, Jolly-Tornetta and Wolf (2000) have reported that TACE was the α-secretase 
involved in PKC-induced αsAPP secretion at the cell surface of CHO cells. They have also 
observed TACE involvement in the αsAPP PKC answer at TGN/Golgi, but only at a partial 
level, indicating the existence of another PKC-sensitive α-secretase at this location. ADAM 10 
can occur at the cell surface but the majority is present in the Golgi apparatus and possibly in 
surface-destined transport vesicles (Lammich et al., 1999). Recently, this enzyme was 
discovered to be soluble and ready to be transported inside vesicles after its shedding 
maturation/activation by ADAM 9 (Tousseyn et al., 2005).  
Early studies suggested that β-cleavage events occur in an endosomal compartment 
(Haass et al., 1992a,b; Shoji et al., 1992; Peraus et al., 1997). However, subsequent studies 
included the secretory compartments ER and Golgi complex (Cook et al., 1997; Hartmann et 
al., 1997; Tomita et al., 1998). BACE-1 is expressed initially as a pro-enzyme and it is cleaved 
after exiting the ER (Vassar et al., 1999). Consistent with observed regions of Abeta 
production, BACE-1 is located intracellularly at the Golgi, TGN, and secretory vesicles. 
Furthermore, BACE-1 also exhibits cell surface and endosomal localization, but does not co-
localize with lysosomal markers (Huse et al., 2000). As noted above, BACE-1 was also found 
to localize at lipid rafts, which are membrane microdomains implicated in protein trafficking 
and proteolytic processing (Riddell et al., 2001). BACE-2 localizes in the ER, Golgi, TGN, 
endosomes, and plasma membrane, with its cellular localization patterns depending on the 
presence of its transmembrane domain. BACE-2 chimeras that increase localization of BACE-
2 in the trans-Golgi network do not alter APP processing and cleavage fragment levels.  
The resulting CTFs of APP α- or β-secretase cleavages are mainly delivered to 
lysosomes immediately after that cleavage (Kuentzel et al., 1993; Chan et al., 2002). 
Interestingly, Nicastrin has been identified as a major lysosomal membrane protein in a 
proteomic survey (Bagshaw et al., 2003). Furthermore, mature Nicastrin, PS1 and APP were 
found co-localized in the LAMP-1 positive endosomes membranes, where an acidic active γ-
secretase was also present (Pasternak et al., 2003). The main subcellular γ-secretase activity 
locations are in fact the endosomes and the plasma membrane (Weidemann et al., 1997; Xia et 
al., 1997; Kaether et al., 2006). The finding that Presenilins predominate at the ER and early 
Golgi (Kovacs et al., 1996) was unexpected as only limited amounts of γ-secretase activity has 
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been detected at those compartments. This is the basis of the so-called “spatial paradox” 
(Annaert and De Strooper, 1999). Despite the high concentration of Presenilins in the ER, 
and its ER co-localization with Nicastrin (Yu et al., 2000), only very limited γ-secretase 
processing seems to occur there, and at least one component of the γ-secretase complex must 
originate from a post-ER compartment (Cupers et al., 2001; Cupers et al., 2005). Moreover, 
Nicastrin does not have an ER retention signal and seems to bind PS at the Golgi (Capell et 
al., 2005). APP and βCTF chimeras targeted to different subcellular compartments provided 
evidence that APP or βCTFs γ-secretase cleavage occurs in a post-ER compartment (Cupers 
et al., 2005). More recently, by blocking selective transport steps along the secretory pathway 
Kaether et al. (2006) demonstrated that the main subcellular locations of AICD generation are 
the plasma membrane and endocytic compartments. In synthesis, efficient γ-secretase cleavage 
of APP seems to occur in compartments that contain small amounts of PS1, while little γ-
secretase activity is observed in compartments where abundant PS1 is residing (Cupers et al., 
2005). In fact, PS1 may have an additional role in protein trafficking, as it was found to 
interact or to affect the activity of three Rab proteins (small GTPases involved in vesicular 
transport): Rab11 (Dumanchin et al., 1999), Rab8 (leading to altered βCTF transport, 
Kametani et al., 2004), and Rab6 (Scheper et al., 2004). Additionally, Nicastrin trafficking and 
post-translational processing (as glycosylation) were affected in PSs double knockout mice 
(Sisodia et al., 2001; Leem et al., 2002). PS-induced alterations in the levels and subcellular 
location of Rab proteins also suggest that Presenilins might be involved in APP vesicular 
routing (Dumanchin et al., 1999; Kametani et al., 2004; Scheper et al., 2004). At a specific 
neuronal level, APP, BACE-1 and PS1 were found to co-localize in an axonal vesicular 
compartment (Kamal et al., 2001) moving anterogradely in a kinesin-dependent manner.  
 
 
I. 3 – PHOSPHORYLATION-DEPENDENT APP REGULATION  
I. 3. 1 –  PROTEIN PHOSPHORYLATION, PROTEIN KINASES AND PHOSPHATASES IN AD  
Brain ageing is characterized by a progressive decline in cognitive functions and 
memory loss. It is becoming increasingly clear that protein phosphorylation is a fundamental 
process associated with memory and brain function, with prominent roles in the processing of 
neuronal signals and in the short-term and long-term modulation of synaptic transmission. In 
neurodegenerative disorders, such as AD and ALS (Amyotrophic Lateral Sclerosis), there is 
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evidence for abnormal regulation of protein phosphorylation, which appears to contribute to 
the pathogenesis of such diseases (Wagey and Krieger, 1998).   
Reversible protein phosphorylation regulates most aspects of cellular processes. 
A key event in cell regulation, including signal transduction, is reversible protein 
phosphorylation. A protein kinase transfers a phosphate group from ATP to the protein, 
altering the conformation and function of the latter. A protein phosphatase removes the 
phosphate and the protein reverts to its original state (Figure I.17). 
 
 
 
 
 
 
 
 
 
Figure I.17. Schematic diagram of kinase and phosphatase 
antagonic actions on a common substrate.  
  
 
AD and phosphorylation. Of all mammalian tissues, the brain has the highest levels 
of protein kinases and phosphatases, suggesting that protein phosphorylation is particularly 
important in mammalian brain function. Impaired balance of cellular phosphorylation systems 
has been reported to occur in AD. These include abnormalities in both expression and activity 
levels of kinases, and/or phosphatases, thus leading to alterations in the processing of APP 
and Abeta production (Gandy and Greengard, 1994; da Cruz e Silva et al., 1995a; Tian and 
wang, 2002). For example, altered PKC activities and levels, decreased activity of protein 
phosphatases PP1 and PP2A, overexpression of calcineurin mRNA levels, protein Tau and 
Beta-tubulin hyperphosphorylated states (Gong et al., 1993; Matsushima et al., 1996; Bennecib 
et al., 2000; Hata et al., 2001; Vijayan et al., 2001) have all been associated with AD. 
Furthermore, many proteins that are relevant to the disease condition, including APP, Tau, 
PS1 and PS2, or BACE, are phosphorylated “in vivo” and can be regulated by 
phosphorylation. Alterations in the phosphorylation state of APP C-terminal fragments were 
reported in AD patients brains (Lee et al., 2003a). In the hippocampal pyramidal neurons of 
these brains phospho-APP was observed to accumulate inside large vesicular structures where 
it co-localized with endosome markers and BACE-1 (Lee et al., 2003a). 
Phosphatase 
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PKC levels and activity have been reported to be altered in AD brains (Cole et al., 
1988), as well as in fibroblasts derived from patients with sporadic AD, familial AD, and 
Down's syndrome (Koo, 1997; Maasch et al., 2000). A significant decrease in PKC levels and 
PKC activity was observed in the membranous fraction of AD human cortex (Cole et al., 
1988; Shimohama et al., 1993; Wang et al., 1994) and altered immunohistochemical 
distribution of some PKC isozymes in AD brain has also been reported (Masliah et al., 1990). 
Comparative studies of phosphatase activities in AD versus control brains (Gong et al., 1993) 
led to the findings that the activity of the Ser/Thr protein phosphatase PP1 and 
phosphotyrosyl-protein phosphatases in grey matter and of the Ser/Thr phosphatase PP2A in 
both grey and white matters were significantly lower in AD brains. In contrast, the mRNA of 
a PP2B catalytic subunit was found to be up-regulated in AD brain (Hata et al., 2001). The 
authors used cDNA microarray technology to study altered gene expression in an AD patient 
afflicted hippocampus. The most up-regulated gene in AD proved to be the β isoform of the 
catalytic subunit of calcineurin (PP2B Aβ). Indeed, in situ hybridization, histochemistry and 
RT-PCR analysis revealed that this PP2B Aβ was significantly up-regulated in the pyramidal 
neurons of AD hippocampus (Hata et al., 2001). Interestingly, work from Ermak et al. (2001) 
revealed that the mRNA levels of a calcineurin inhibitor (DSCR1) were also overexpressed in 
AD and Down’s syndrome patients.  
 
I. 3. 2 – PHOSPHORYLATION AND APP PROCESSING 
Although the factors regulating APP processing and Abeta production have not been 
fully elucidated, it is now widely accepted that protein phosphorylation is involved. Processing 
of APP and Abeta production were shown to be regulated by phosphorylation and 
phosphorylation-dependent events (Gillespie et al., 1992; da Cruz e Silva et al., 1995a; Ando et 
al., 2001; da Cruz e Silva et al., 2003). As APP proteolytic processing is a necessary step in 
APP RIP cellular signalling and phosphorylation is involved in signal transduction pathways, 
further elucidation on the molecular mechanisms underlying phosphorylation-dependent 
regulation of APP processing is required. 
Protein kinase C. Previous studies have revealed that APP levels and APP processing 
are under PKC regulation. Long-term exposure of a human glial cell line to PKC stimulating 
agents, such as the phorbol ester PMA (phorbol 12-myristate 13-acetate), increased APP 
mRNA levels and protein-binding activity to the APP promoter (Trejo et al., 1994; Lahiri and 
Nall, 1995). Short-term exposures to phorbol esters invariably results in a higher non-
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amyloidogenic APP processing rate. Phorbol esters such as PMA or phorbol 12,13-dibutyrate 
(PDBu) enhance α-secretase cleavage of APP and αsAPP production in several cultured cell 
lines (Buxbaum et al., 1990; Caporaso et al., 1992b; Gillespie et al., 1992; da Cruz e Silva, 1993; 
Demaerschalck et al., 1993; Gabuzda et al., 1993; Slack et al., 1993; Dyrks et al., 1994; 
Marambaud et al., 1997a,b; Mills et al., 1997). The phorbol esters-induced APP processing is 
also evident in primary cultures of rat cortical neurons (Mills and Reiner, 1996), and 
specifically in rat cortical synaptosomes (McLaughlin and Breen, 1999). Furthermore, “in 
vivo” studies using rats expressing hyperactivated PKC demonstrated enhanced synaptosomal 
sAPP production and decreased levels of synaptosomal membrane-bound APP in selected 
brain regions (cortex and hippocampus) (Caputi et al., 1997). PKC-mediated stimulation of 
sAPP has been shown to be specific insofar as down-regulation of PKC blocked the phorbol 
ester-stimulated sAPP release (Buxbaum et al., 1994). Nonetheless, there is controversy in the 
effects of this α-secretase pathway induction and the consequential decrease in Abeta 
production, raising the question of competition between α- and β- secretases for substrate. In 
fact, PKC-activators or carbachol, which are known α-secretase pathway inducers, were 
reported to decrease Abeta secretion in cultured cells transfected with APP FAD mutant 
forms (Gabudza et al., 1993; Hung et al., 1993; Felsenstein et al., 1994). Constitutive 
overactivation of PKC in guinea pig brain also enhanced cortical α-secretory APP processing 
but without decreasing Abeta generation (Rossner et al., 2001a). The mechanisms of PKC-
dependent induction of APP α-secretase cleavage are complex and still being unravelled. PKC 
is known to be involved in the process of post-TGN vesicle formation, through binding and 
activating the phospholipase involved in vesicles scission (Sabatini et al., 1996; Simon et al., 
1996). Activation of endogenous PKC by phorbol esters or addition of purified PKC 
increases formation of APP-containing secretory vesicles from the trans-Golgi network (Xu et 
al., 1995), and drastically reduces the amount of APP at the cell surface (Koo, 1997). This can 
be explained by accelerated APP trafficking through the exocytotic pathway and accelerated 
α-secretase APP cleavage intracellularly and at the plasma membrane. The hypothesis that 
PKC phosphorylation of sites within the APP intracellular carboxy terminus may change the 
conformation of its extracellular domain and make it a better substrate for the cleaving 
enzyme was recently advanced (Turner et al., 2003). Nonetheless, da Cruz e Silva et al. (1993) 
showed that cleavage of APP tailless constructs (with a stop codon at the KKK sequence) to 
yield sAPP was still stimulated by phorbol esters. Hence, PKC-dependent sAPP-induction 
may occur as a sum of indirect and direct actions.  
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Ser/Thr Protein Phosphatase 1. Okadaic acid (OA), a Ser/Thr protein phosphatases 
type 1 (PP1) and type 2A (PP2A) inhibitor, was found to stimulate APP processing to sAPP in 
COS-1 cells (da Cruz e Silva et al., 1995a). APP processing and secretion modulation by OA 
was also observed in primary guinea pig neurons (Holzer et al., 2000). Da Cruz e Silva et al 
(1995a) were able to specifically implicate PP1 in this APP regulation through the use of OA 
and other inhibitors with different inhibitory potencies against PP1/PP2A. Interestingly, PP1 
is known to be involved in long-term potentiation (LTP) and in long-term depression (LTD), 
thereby influencing learning and memory (Mulkey et al., 1994; Genoux et al., 2002; Waddell, 
2003). Furthermore, PP1 and PP2B activities are interconnected in so far as PP2B is able to 
inhibit (dephosphorylate) DARPP-32, a potent PP1 inhibitor (Mulkey et al., 1994; Yan et al., 
1999b), providing a further mechanism for PP2B modulation of APP processing. The 
mechanism by which PP1 down-regulates APP processing and/or sAPP secretion are not yet 
defined, but direct APP dephosphorylation remains a possibility (Oishi et al., 1997).  
APP secretase phosphorylation. Another potential stage for phosphorylation-
dependent regulation of APP proteolytic processing is through modulation of APP secretases. 
All three members of the ADAM family are synthesized as preproteins, so that their 
proteolytic function is regulated to prevent damage to other proteins, or the premature 
cleavage of their substrates, including APP (Turner et al., 2003). The TACE cytoplasmic 
domain contains potential phosphorylation sites, and the enzyme was reported to be 
phosphorylated at Ser819 after growth factor stimulation of the Erk/MAPK pathway or after 
PMA-induced PKC-activation (Black et al., 1997; Diaz-Rodriguez et al., 2002). PMA exposure 
did not alter TACE maturation or cellular distribution (Hooper and Turner, 2002), suggesting 
other still unknown roles for this phosphorylation that may involve its enzymatic kinetics of 
APP proteolysis (Fan et al., 2003). ADAM 10 is also stimulated after PKC activation 
(Etcheberrigaray et al., 2004). MDC9 was also phosphorylated after PMA activation of the 
PKC isozyme δ (Izumi et al., 1998; Roghani et al., 1999). The role of BACE-1 
phosphorylation on a cytoplasmic serine residue is better known and involves regulation of 
BACE-1 subcellular traffic. When phosphorylated on serine residue Ser498, this enzyme enters 
the recycling pathway of Golgi-retrieval after endocytosis (Walter et al., 2001). 
Phosphorylation at this serine, which is immediately upstream of the BACE-1 binding 
sequence for its vesicle coating protein GGA, was recently reported to enhance by three-fold 
the affinity of this binding (Shiba et al., 2004). 
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Phosphorylation may also affect γ-secretase activity. The PS2 protein can be highly 
phosphorylated, whereas little phosphorylation is observed for PS1 (Walter et al., 1996; 1998). 
Casein kinases 1 and 2 (CK1, CK2) phosphorylate PS2 at three serine residues in its N-
terminus before PS2 maturational cleavage by caspases, and after this cleavage its C-terminus 
is also phosphorylated at three serine residues, putatively by the same casein kinases (Walter et 
al., 1999). After PS1 caspase cleavage, its C-terminal is also phosphorylated at two still 
unknown residues by protein kinases A and C (Walter et al., 1996; 1998). 
 
I. 3. 3 – APP AS A PHOSPHOPROTEIN 
Direct phosphorylation of the APP molecule is potentially an important mechanism 
for regulating APP binding, traffic and processing, and therefore worthwhile pursuing. APP is 
a phosphoprotein with putative phosphorylation sites on its extracellular and intracellular 
domains. Of particular note is the finding that AD patients’ exhibit altered APP 
phosphorylation, with APP βCTFs carrying phosphorylated Thr688 being up-regulated in AD 
brains (Lee et al., 2003a). Furthermore, it was recently reported that phosphorylation of the 
APP CTFs appears to regulate the formation and/or stability of AICDs, probably by 
disrupting AICD complexes, leading to altered AICD-mediated signalling events (Zheng et al., 
2003). A Thr668 phosphorylated APP C-terminal fragment, probably AICD, was shown to be 
present in the nucleus of CAD cells (a catecholaminergic cell line), where it localizes to 
subnuclear particles that define the splicing factor compartment (SFC) [e.g. the small nuclear 
ribonucleoprotein (snRNP), U2B, and serine/arginine-rich (SR) proteins], but is excluded 
from the coiled bodies and the gems (Muresan and Muresan, 2004). This distribution of 
phospho APP (pAPP) epitopes was found in CAD cells independent of their state of 
differentiation, as well as in primary cortical neurons, epithelial cells and fibroblasts. These 
authors further showed that exogenously expressed AICD becomes phosphorylated and 
distributes throughout the cell, with a fraction being translocated into the nucleus, where it co-
localizes with endogenous pAPP epitopes and with Fe65 at intranuclear speckles. Hence, 
phosphorylation may be involved in the targeting of AICD to specific nuclear compartments. 
APP has seven potentially phosphorylatable residues, which have been shown to be 
phosphorylated “in vitro” and “in vivo” (Koo, 1997;  Oishi et al., 1997; Iijima et al., 2000; 
Walter et al., 2000, Minopoli et al., 2001; Standen et al., 2001) (Fig.  I.18). In Table I.2 a 
summary is given of these seven APP phosphorylation residues, with their putative kinases 
and functions. 
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Figure I.18. Exon localization of APP phosphorylatable residues. Extracellular (NH2-terminal) APP 
domain has two phosphorylatable residues (Ser198 and Ser206) and intracellular (COOH-terminal) APP domain 
presents five residues (Thr654, Ser655, Thr668, Tyr682, and Tyr687). Adapted from: da Cruz e Silva et al., 2004. 
 
 
Table I.2. APP phosphorylatable residues and kinases implicated. 
APP Phospho 
Residue 
Kinase Putative Role of Phosphorylation Reference 
Ser198 
. CK2 
. ecto-CK2 
. Possible involvement in LTP in 
neurons and synaptogenesis 
Hung and selkoe, 
1994 
Walter et al., 1997 
Walter et al., 2000 
Ser206 
. CK1 
. ecto-CK1 
. Possible involvement in LTP in 
neurons and synaptogenesis 
Hung and selkoe, 
1994 
Walter et al., 1997 
Walter et al., 2000 
Thr654 
. CaMKII 
(“in vitro”) 
. ND (“in vivo”) 
. Potential regulation of APP binding 
and APP secretory trafficking 
Gandy et al., 1988 
Oishi et al., 1997 
Ramelot and 
Nicholson, 2001 
Ser655 
. PKC (“in vitro” 
and “in vivo”:  
cultured cells and 
rat brain) 
. CaMKII (“in 
vitro”) 
. APP kinase I (rat 
brain) 
. Potential regulation of APP binding 
and APP secretory trafficking 
. Involvement in PKC-regulated sAPP 
processing 
Gandy et al., 1988 
Suzuki et al., 1992  
Oishi et al., 1997 
Ramelot and 
Nicholson, 2001 
Lee et al., 2003a 
 
Thr668 
. Cdk5 
. Cdc2 
. MAPKs (GSK-3 
and JNK-3) 
. Potential regulation of APP binding to 
Fe65 and JIP-1 
. Regulates neurite extension 
. Regulation of APP axonal trafficking 
. Attenuates APP cleavage by caspases 
. Down-regulates AICD-mediated 
nuclear signalling 
Suzuki et al., 1994 
Aplin et al., 1996 
Oishi et al., 1997 
Iijima et al., 2000 
Ando et al., 2001 
Ramelot and 
Nicolson, 2001 
Standen et al., 2001 
Sisodia, 2002 
Taru et al., 2004 
Kimberly et al., 2005 
 M 
198 
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654 655 
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APP Phospho 
Residue 
Kinase Putative Role of Phosphorylation Reference 
Tyr682 . Tyrosine kinase 
Abl  (active form) 
. Promotes the interaction with Shc 
proteins 
. May regulate the association of the 
cytoplasmic tail of APP with its binding 
partners 
Haass et al., 1993 
Koo and Squazzo, 
1994 
Zambrano et al., 2001 
Tarr et al., 2002 
Tyr687 ND 
. May regulate the association of the 
cytoplasmic tail of APP with its binding 
partners 
Lee et al., 2003a 
 
 
APP ectodomain phosphorylation.  In its ectodomain APP was reported to be 
phosphorylated on serine residues (Ser198 and Ser206). Phosphorylation of the two serine 
residues occurs in two distinct cellular locations: in a post-Golgi secretory compartment (most 
likely within secretory vesicles) and at the cell surface by ectoprotein kinases (Walter et al., 
1997). The authors also found that “in vivo” sAPP was detected exclusively in the double 
phosphorylated form. Subsequently, it was shown that ectocasein kinases 1 and 2 were the 
kinases involved in the “in vivo” cell surface APP phosphorylation at residues Ser198 and Ser206, 
respectively, in a process strongly inhibited by heparin (Walter et al., 2000).  
APP cytoplasmic domain phosphorylation. The Ser/Thr and Tyr cytoplasmic 
phosphorylatable residues are located within three APP functional motifs, previously 
mentioned in section I.2.6 and shown in Figure I.14: 682YENPTY687, 667VTPEER672, and 
653YTSI656. Other potentially phosphorylatable residues (Ser675, Thr686) were reported to 
undergo phosphorylation by Lee et al (2003a) but have received little attention. 
In the internalization signal domain 682YENPTY687, Tyr682 phosphorylation is a 
consensual site and in contrast Tyr687 was initially reported not to undergo phosphorylation 
(Haass et al., 1993; Koo and Squazzo, 1994; Minopoli et al., 2001). More recently, however, 
“in vivo” phosphorylation of Tyr687 was reported (Lee et al., 2003a). APP is tyrosine-
phosphorylated in cells expressing a constitutively active form of the Abl protooncogene, a 
non-receptor tyrosine kinase similar to c-Src, which can form a stable complex with APP and 
Fe65 (Zambrano et al., 2001). Abl-dependent Tyr682 phosphorylation appears to involve the 
nerve growth factor receptor TrkA, to mediate APP membrane internalization and to result in 
reduced γ-secretase APP processing (Koo and Squazzo, 1994; Lai et al., 1995; Tarr et al., 
2002).  
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The Thr668 residue of the 667VTPEER672 domain is found phosphorylated in rat brain 
and in several cell lines (Oishi et al., 1997). In PC12 cells immature APP is preferentially 
phosphorylated at this residue during the G2/M phase of the cell cycle (Suzuki et al., 1994; 
Oishi et al., 1997). At this phase total levels of holo APP do not change but the levels of 
secreted sAPP decrease and the levels of the CTFs increase (Suzuki et al., 1994). The known 
kinases involved are cyclin-dependent kinases in neurons (cdk5) and in PC12 or HeLa cells 
(cdc2) (Suzuki et al., 1994; Oishi et al., 1997; Iijima et al., 2000). GSK-3β and c-Jun protein 
kinase 3 (JNK-3) may also phosphorylate Thr668 “in vitro” (Aplin et al., 1996; Standen et al., 
2001). Mature APP phospho Thr668 (pThr668) only occurs in the brain (and not in non-neuronal 
tissues) (Ando et al., 1999; Iijima et al., 2000).  In PC12 cells (Oishi et al., 1997) and neurons 
(Ando et al., 1999) pThr668 APP and pThr668 CTFs were selectively localized in neurites, mostly 
within the growth cones, while Thr668 dephosphorylated APP is found mostly in the cell body. 
Brain mature APP Thr668 phosphorylation occurs during and after neuronal differentiation, 
and in PC12 cells regulates neurite extension, correlating with the timing of neurite outgrowth 
in differentiating cells (Oishi et al., 1997). Furthermore, pThr668 was described to selectively 
target APP for axonal transport in APP/BACE-1/PS co-localizing vesicles (Amaratunga and 
Fine, 1995). Interestingly, enhanced levels of pThr668 CTFs were reported in AD brains, along 
with enhanced and extensive co-localization of an anti-pThr668 antibody with BACE-1 (Lee et 
al., 2003a). In addition, the authors have observed that βCTFs were found to be preferentially 
phosphorylated at this residue when compared with αCTFs. In fact, the 667VTPEER672 domain 
has been the focus of intense research and Thr668 phosphorylation is now known to be 
involved in the regulation of APP protein binding at the 682YENPTY687 domain (Ando et al., 
2001). This is thought to occur through pThr668-induced alterations of the APP C-terminus 
conformational structure (Ramelot et al., 2001). Specifically, pThr668 exerts differential 
regulation of APP binding to Fe65 (down-regulated) versus X11 or mDab1 (pThr668-
insensitive) (Ando et al., 2001). For example, Wasco et al. (1993) and Ando et al (1999) have 
reported that HEK293 cells overexpressing Fe65 show inhibited secretion of Abeta 1-40 and 
1-42. This effect was further observed to be partially cancelled by a Thr668 mutation or by its 
kinases inhibitors (Lee et al., 2003a). In recent reports, Fe65 binding to APP was observed to 
enhance APP cleavage by caspases at Asn664 (Zambrano et al., 2004). In parallel, Thr668 
phosphorylation was observed to attenuate this cleavage (Taru et al., 2004). Finally, pThr668-
induced decrease in AICD-Fe65 binding affinity appears to lead to down-regulation of the 
AICD-mediated gene transactivation (Kimberly et al., 2005).  
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Phosphorylation of the YTSI domain.  The amino acid sequence 653YTSI656 that 
functions as an APP sorting signal is not as well characterized as the other two domains and is 
the object of this thesis. Central to the domain are two consensus residues for 
phosphorylation, Thr654 and Ser655, found to be phosphorylated “in vitro”and “in vivo” (see 
Table I.2 for references). The occurrence of full length APP phosphorylated at Thr654 or Ser655 
has been reported in cultured cell lines and rat cortex (Gandy et al., 1988; Oishi et al., 1997).  
However, in human hippocampus of AD patients only phospho Ser655 CTFs, and not 
phospho Thr654, was observed (Lee et al., 2003a).  
Phosphorylation of APP at its Ser655 residue can be postulated to be involved in the 
PKC and PP1 APP mediated processing (section I.3.2). In PC12 cells, phosphorylation at 
Ser655 was found to be highest in mature rather than immature APP isoforms and was 
increased more than 10-fold by treatment with okadaic acid (Oishi et al., 1997). In addition, 
Ser655 is the only APP residue that undergoes “in vitro” and “in vivo” PKC-induced 
phosphorylation (Gandy et al., 1988; Suzuki et al., 1992; Isohara et al., 1999). PKC was 
demonstrated to rapidly phosphorylate this residue on an APP C-terminal synthetic peptide 
(Gandy et al., 1988). In a semi-intact PC12 cell system, APP holoprotein and APP CTFs were 
found to be specifically phosphorylated at Ser655, after purified PKC addition or PMA 
incubation (Suzuki et al., 1992). Under these conditions, all the mature but not the immature 
major APP isoforms (695, 751 and 770) were found to be phosphorylated at Ser655, and 
phosphorylation of threonine residues was not detectable by phosphoamino acid analysis even 
after longer exposures (Suzuki et al., 1992). A putative PKC-downstream APP kinase is APP 
kinase I, a Ca2+-independent kinase of ∼43 KDa that was found to phosphorylate Ser655 in rat 
brain (Isohara et al., 1999). APP kinase I was discovered by chromatographic analysis of 
soluble cytoplasmic fractions of rat brain homogenates. In these fractions, containing APP 
Ser655 Ca2+-independent kinase activity, ∼50% of the latter was due to APP kinase I and ∼35% 
was due to a mixture of PKC and a fragment of PKC (Isohara et al., 1999).  
At a molecular level, APP phosphorylation at Ser655 may regulate APP binding to other 
proteins, as it was reported to induce “in vitro” structural alterations to the APP C-terminus 
to a higher level than phosphorylation at Thr654. While the latter affected mainly the structure 
of the threonine residue, phosphorylation at Ser655 induced significant structural alterations on 
Thr654, Ser655, and on the two downstream adjacent amino acids (I656 and H657) (Ramelot and 
Nicholson, 2001). These are the first residues of the Ile656-Val663 hydrophobic pocket, located 
immediately downstream to the 653YTSI656 domain (Ramelot et al., 2000; Ramelot and 
                      - 63 - 
Phosphorylation-dependent Alzheimer’s amyloid precursor protein (APP) targeting   
Nicholson, 2001). In fact, the chemical changes observed were up to six residues away from 
phosphorylated Ser655, suggesting induced altered conformation of residues inside the pocket 
(Ramelot and Nicholson, 2001). Thus, the binding affinities of APP binding proteins for the 
653YTSI656 domain (e.g. APPBP2) or for the downstream sequence (e.g. G0α), may be 
significantly altered upon Ser655 phosphorylation. Further support for the existence of a linkage 
between the 653YTSI656 domain and the hydrophobic pocket comes from comparison of APP 
sequences in various species. The YTSI and hydrophobic pocket domains were found to exist 
both in the same APP sequence or to be both absent. In several mammalian and fish species, 
and at least in chicken and frog, both the 653YTSI656 and the Ile656-Val663 hydrophobic pocket 
were found to be absolutely conserved. Contrarily, in Drosophila and C. elegans both motifs are 
degenerated (see Sabo and Ikin, 2002). Furthermore, Suzuki et al. (1997) demonstrated that 
APLP1 and APLP2, like APP, could both be phosphorylated “in vitro” by PKC. These 
authors highlighted the fact that Ser655 has “equivalent” serine residues in the amino acid 
sequences of APLP-1 and APLP-2 proteins (Suzuki et al., 1997). These proteins also have 
653YTSI656-like domains and Ile656-Val663 hydrophobic pocket-like sequences (Fig. I.19). 
Therefore, Ser655 is a pivotal residue whose phosphorylation may be potentially implicated in 
regulating APP interactions at these C-terminal motifs. 
 
 
 
Figure I.19. Alignment of the Ser655 APP residue with other members of the APP mammalian 
superfamily. Sequence homology between APP and APLPs. C-termini demonstrating the existence of 
653YTSI656-like YGXIS domains (blue) in APLPs and of a phosphorylatable serine residue within them (bold). The 
hydrophobic pocket (yellow) immediately downstream the YGXIS domain is also conserved. Conserved amino 
acid residues are underlined. M, cellular membrane. 
 
APLP1             ...RKKPYGAISHGVVEVDPMLTLEEQQLREL... 
APLP2             ...RKKQYGTISHGIVEVDPMLTPEERHLNK... 
 M 
APP                 ...KKKQYTSIHHGVVEVDAAVTPEERHLSK... 
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I. 4 – AIMS OF THIS THESIS 
The findings that APP cellular fate can be regulated by protein phosphorylation, a 
major mechanism regulating signal transduction pathways and protein-protein interactions, 
provide us with a strong hypothesis for APP as a signal transduction molecule. 
Phosphorylation-dependent events include APP traffic, cleavage, and protein-complex 
formation of APP and AICD, consequently affecting targeting to different intracellular 
molecular pathways. Thus, APP traffic targeting signals containing pivotal residues for 
regulatory phosphorylation mechanisms can be crucial in the disease process. APP direct 
phosphorylation studies that are now emerging focus on the phosphorylatable residues from 
the 667VTPEER672 and 682YENPTY687 motifs. The less well-studied APP 653YTSI656 motif, a 
basolateral sorting signal in MDCK cells, seems to be involved in APP secretory trafficking 
and potentially in neuronal APP polarized sorting. PKC and PP1 are two phosphorylation 
effector proteins that are both involved in the regulated α-secretase APP cleavage into the 
neuroprotector and neurite outgrowth factor αsAPP. These effectors may function directly 
through APP phosphorylation, being that they are the best candidates for “in vivo” 
phosphorylation/dephosphorylation of the 653YTSI656 serine 655 residue. Therefore, a possible 
mechanisms underlying APP α-secretase regulated cleavage may involve Ser655 
phosphorylation-induced APP targeting to subcellular compartments or specialized domains. 
To date, data strongly suggests a putative involvement of 653YTSI656 and Ser655 phosphorylation 
in the regulation of APP C-terminal fragment production, as well as in the regulation of 
APP/AICD traffic. Alterations of all these processes could have strong effects on APP 
cellular signalling and even Abeta production. Nonetheless, there is still no information about 
the physiological relevance of APP Ser655 phosphorylation including a potentially important 
role in APP signal transduction. 
The aim of this thesis is to study the role of APP phosphorylation at the Ser655 residue 
and the consequential protein’s cellular fate, both in terms of APP intracellular targeting and 
APP proteolytic processing. Understanding the underlying molecular mechanisms controlling 
APP trafficking and processing events, and their relevance to APP function as a signal 
transducer, should lead to new insights into the aetiology, pathogenesis and therapy of AD, 
shedding light onto the ongoing discussion. 
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CHAPTER II – SERINE 655 PHOSPHORYLATION-
DEPENDENT APP695 TARGETING 
 
II. 1 – INTRODUCTION 
APP is a signal transduction transmembranar protein that is processed intracellularly 
via various pathways, including the secretory and endocytic pathways. Inside a cell, neuronal 
or non-neuronal, APP is generated in the ER (where it is N-glycosylated) and transported to 
the Golgi complex (where it matures through O-glycosylation and sulfation), where a pool can 
be carried into post-TGN secretory vesicles to the plasma membrane (see Chapter I). 
Regulation of APP trafficking and subcellular targeting, as well as consequential cleavages of 
subpopulations of APP, are not fully understood. APP secretases don’t exist ubiquitously in 
the cell and their distribution seems to be restricted to specific cellular compartments. It is not 
yet clear if APP proteolytic cleavages are regulated by temporal APP substrate/enzyme co-
distribution and/or by enzyme activation. Additionally, and when required, it is possible that 
more APP substrate may be “activated” and targeted to specific subcellular microdomains to 
be cleaved. Although the factors regulating APP trafficking/processing have not been fully 
elucidated, protein phosphorylation is thought to be involved. Activation of endogenous PKC 
increases formation of APP-containing secretory vesicles from the TGN (Xu et al., 1995), 
accelerating APP trafficking in the secretory pathway (Koo, 1997). In semi-intact cell systems 
APP Ser655 was the only phosphorylatable residue found to be phosphorylated by PKC or by a 
PKC downstream kinase (Suzuki et al., 1992). Furthermore, this residue belongs to the 
653YTSI656 basolateral sorting motif (Lai et al., 1995; Zheng et al., 1998) that is the binding site 
for APPBP2, a protein thought to be involved in regulating APP in the secretory pathway. 
Hence, all the evidence implicates 653YTSI656 as a molecular targeting signal and place Ser655 at 
a pivotal regulatory position (Ando et al., 2001; Ramelot and Nicholson, 2001). APP Ser655 
phosphorylation may be a key process regulating differential binding of APP scaffolding 
proteins to the 653YTSI656 motif, with significant consequences for APP targeting. Nonetheless, 
and despite all the evidence pointing to the importance of this residue in the protein’s cellular 
fate, very few studies have focused on this APP domain and even fewer on unravelling the 
possible functions of Ser655 phosphorylation.  
In order to address this question, we first constructed a number of APP695 cDNA 
point mutations at Ser655 (from now on referred to as “S655”). This residue was mutated to 
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alanine (S655A) to mimic a constitutively dephosphorylated site, or to glutamate (S655E) to 
mimic a constitutively phosphorylated residue. These mutants, along with the parental wild-
type APP cDNA, were used in a series of assays designed to study the putative S655 
phosphorylation-dependent effects on APP trafficking and proteolytic processing. 
 
 
II. 2 – AIMS OF THIS CHAPTER 
The work presented in this chapter addressed the putative regulatory functions of APP 
phosphorylation at the 653YTSI656 basolateral sorting signal. The main objectives of this chapter 
were: 
1. To generate S655 APP phosphorylation mutants as GFP (Green Fluorescent 
Protein) fusion cDNAs in an appropriate mammalian expression vector.  
2. To develop a model system to monitor wild-type (Wt) APP-GFP subcellular 
trafficking. 
3. To apply the system developed to APP-GFP phosphorylation mutants and 
monitor intracellular protein trafficking. 
4. To study whether any observed APP trafficking differences can be coupled to  
organelle specific targeting, in a S655 phosphorylation-dependent manner. 
 
For Objective 1 APP cDNAs were engineered to be visible for epifluorescence 
microscopy when transfected into cells in culture. Hence, the APP695 S655A/E point mutants 
and parent Wt cDNAs were fused in frame with EGFP (Enhanced GFP, a fluorescent 
reporter) to render APP695-GFP fusion constructs. The second objective involved the 
development of an experimental design to follow APP-GFP protein trafficking intracellularly. 
The method developed is based on inhibiting “de novo” protein synthesis and striving for low 
levels of protein expression, being first used and optimized to monitor Wt APP traffic (da 
Cruz e Silva et al., 2004b). Thus objectives 3 and 4 were subsequently addressed. 
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II. 3 – MATERIALS AND METHODS 
A list of all solutions and protocols used, as well as other relevant information, is 
presented in Appendices I to III. All reagents were of cell culture grade or ultrapure. 
 
II. 3. 1 – ANTIBODIES 
The primary antibodies used in this study were the monoclonal antibody 22C11 
(Chemicon) directed against the APP N-terminal aa 60-100, the monoclonal antibody JL-8 
(BD Living Colours, Clontech) to detect the GFP moiety of APP-GFP proteins, polyclonal 
369 (kind gift from Dr. S. Gandy) that recognizes the APP C-terminus (last 50 aa), and the 
monoclonal 6E10 (Sigma-Aldrich) to detect Abeta residues 1-17. For the co-localization 
studies the polyclonal anti-Calnexin (StressGen Biotechnologies) antibody was used as an ER 
marker, the monoclonal anti-Syntaxin 6 (BD Biosciences) antibody was used as a TGN/Golgi 
marker, and the monoclonal anti-Cathepsin D (Transduction Laboratories) antibody was used 
as a lysosomal marker. Additional antibodies used were anti-mouse and anti-rabbit IgGs Texas 
Red-conjugated secondary antibodies (Molecular Probes), for Immunocytochemistry 
procedures, and anti-mouse IgGs horseradish peroxidase-linked whole antibody (Amersham 
Pharmacia), for enhanced chemiluminescence (Amersham Pharmacia Biosciences) detection. 
Dilutions of the antibodies used in this and following chapters are given in Table II.1. 
 
Table II.1. Antibodies, respective target proteins and specific dilutions used for the different techniques 
employed: IB., Immunoblot; ICC, Immunocytochemistry. 
Primary Antibody Secondary Antibody 
Target 
Protein/Epitope 
Assay/Dilution Assay/Dilution 
Horseradish Peroxidase conjugated α-Mouse IgG 
IB dilution:  1:5000 
APP N-terminal 
22C11 
IB dilution: 1:250 
ICC dilution: 1:50 Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
Horseradish Peroxidase conjugated α-Mouse IgG 
IB dilution:  1:5000 
APP Abeta 1-17 
6E10 
IB dilution: 1:1000 
ICC dilution: 1:200 Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
APP C-terminal 
369 
ICC dilution: 1:200 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
EGFP 
JL.8 
IB dilution: 1:1000 
Horseradish Peroxidase conjugated α-Mouse IgG 
IB dilution:  1:5000 
Calnexin 
Calnexin 
ICC dilution: 1:200 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
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Primary Antibody Secondary Antibody 
Target 
Protein/Epitope 
Assay/Dilution Assay/Dilution 
Syntaxin 6 
Syntaxin 6 
ICC dilution: 1:200 
Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
Cathepsin D 
Cathepsin D 
ICC dilution: 1:200 
Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
 
II. 3. 2 – S655A AND S655E APP695 PHOSPHORYLATION CDNA CONSTRUCTS 
Site-directed mutagenesis. The S655 human APP695 phosphorylation cDNA point 
mutants, produced by site directed mutagenesis, were already available in our laboratory (S655 
to Alanine and S655 to Glutamate). Alanine is a non-phosphorylatable and non-polar residue, 
which blocks APP phosphorylation at that residue. Glutamate is a non-phosphorylatable but 
negatively charged residue that by its size and charge mimics to some extent the presence of a 
phosphate group at that position. The nucleotide sequences of the APP S655 point mutations 
were confirmed by DNA sequencing. APP695 was the isoform used given its relevance in AD 
neuropathology. 
Vector preparation of APP-GFP fusion constructs. For the translational fusion of 
the APP cDNAs with a reporter gene coding for the GFP (Fig. II.1), the APP cDNAs were 
amplified by Polymerase Chain Reaction (PCR) using specific primers (NAPN and S1 primers, 
Appendix III). The PCR reaction was performed using Pfu DNA Polymerase (Promega) as 
indicated in Appendix II. PCR cDNA products were analysed by gel electrophoresis and 
digested with Nru I at 37 ºC and Age I at 25 ºC, for the subsequent subcloning into the GFP-
encoding mammalian expression vector (pEGFP-N1; BD Living Colours, Clontech). 
 
Figure II.1. Schematic representation of the APP-GFP fusion construct preparation. A: APP695 site-
directed mutagenesis. B: Sequencing of mutated APP cDNAs. C: Subcloning of mutated APP cDNA into EGFP 
mammalian expression vector, upstream of the EGFP-encoding sequence. 
       A.                B.                      C. 
-C 
S655A / S655E 
APP Aβ 
 
pEGFP 
N1 
STOP 
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The pEGFP-N1 mammalian expression vector was first digested with the restriction 
enzyme Sma I at 30 ºC, purified and further digested with Age I at 25 ºC, in appropriate 
buffers. The digestion products were electrophoretically resolved in 0.8% agarose gels and 
purified by means of a Gel Extraction kit (QIAgen), after which the vector was ready for 
ligation with the different APP inserts. Ligations were carried out overnight at 16 ºC using 
bacteriophage T4 DNA ligase (Promega). All subcloning procedures and DNA manipulation 
techniques used are extensively described in Appendix II, and the primers and vector 
description are presented in Appendix III.  
Transformation, mini-amplification, and plasmid DNA extraction. APP-GFP 
fusion constructs were amplified in bacterial systems. E. coli XL1-blue competent cells were 
first transformed with an aliquot of each ligation reaction (see Appendix II). Bacterial cells 
were plated on LB agar plates containing the appropriate antibiotic (100 µg/ml kanamycin) to 
select transformants, and incubated at 37 ºC for 16 hours. Colonies were picked and left to 
grow overnight with agitation in liquid LB media supplemented with the appropriate antibiotic 
at 37 ºC. Plasmid cDNAs were extracted from these bacterial cultures.  
APP-GFP cDNAs construct confirmation and mega-amplification. All putative 
APP-GFP fusion constructs-containing clones were first confirmed by plasmid DNA 
digestion with appropriate restriction enzymes (EcoR I and Pst I) and further analysed by gel 
electrophoresis. The nucleotide sequences and correct open reading frames fusions were 
confirmed by DNA sequencing. The confirmed S655A, S655E and Wt APP695-GFP cDNAs 
subcloned into the pEGFP vector were subjected to mega-prep amplification in E. coli XL-1 
Blue. A 400 µl aliquot of the resultant construct was purified by ethanol precipitation and used 
for transfection and expression in mammalian cells. 
 
II. 3. 3 – CELL CULTURE AND TRANSIENT TRANSFECTIONS 
Cell culture maintenance. A monkey kidney cell line (COS-7) was the model system 
in these studies given their low content in APP695, easiness of transfection and the large 
number of previous studies in this cell line. For experimental procedures, cells were 
maintained in DMEM medium (Dulbecco’s Modified Eagle’s Medium, Sigma-Aldrich). Prior 
to experimental conditions medium was supplemented with 10% (v/v) foetal bovine serum 
(FBS; Gibco BRL, Invitrogen) and this is termed complete DMEM. Long term maintenance 
used complete DMEM supplemented with antibiotic/antimycotic solution (see Appendices I 
and II for detailed composition). Cultures were always maintained at 37 ºC and 5% CO2 . 
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Transient transfections. COS-7 cells were transfected with pEGFP-N1, Wt, S655A 
or S655E APP-GFP cDNAs using a cationic lipid reagent-mediated method (LipofectAMINE 
2000 Reagent; Invitrogen Life Technologies. The day before transfection, cells were plated 
onto 100 mm cell culture plates with complete DMEM. Transfections were carried out 
according to the manufacter’s instructions (see Appendix II), with cells at a density around 
90%. Briefly, each cDNA and LipofectAMINE 2000 was separately diluted in DMEM 
medium (serum-free). Both solutions were mixed and left for 20 min at RT for DNA complex 
formation to occur. This mixture was then added to the medium of the respective plates of 
COS-7 cells. The plates were incubated at 37 ºC and 5% CO2 for the times indicated. Table 
II.2 presents details on the transient transfections performed for each specific assay. 
 
 
Table II.2. COS-7 cells transient transfection procedures adopted for each of the different assays. Recovery 
period: period for cell adherence and recovery upon removal of transfection medium.  
Procedure Transfected cDNAs 
Quantity / Plate 
diameter 
Transfection 
period 
Recovery 
period  
APP-GFP expression  
(Pilot experiment) 
pEGFP 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
2.0 µg / 35 mm 12 h - 
Time course of Wt 
APP-GFP levels 
pEGFP 
Wt APP-GFP 
8.0 µg / 100 mm 8 h 4 h 
Intracellular APP-
GFP tracking 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
8.0 µg / 100 mm 8 h 4 h 
Nuclear targeting 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
4.0 µg / 60 mm 8 h 4 h 
APP endocytosis 
assay 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
1.5 µg / 35 mm 8 h 4 h 
Antibody uptake 
assay 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
4.0 µg / 60 mm 8 h 4 h 
APP lysosomal 
targeting 
Wt APP-GFP 
S655A APP-GFP 
S655E APP-GFP 
1.5 µg / 35 mm 8 h 4 h 
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APP-GFP construct expression in COS-7 cells. For evaluating the expression of 
APP-GFP constructs in this mammalian cell line, COS-7 cells were grown in 35 mm six-well 
plates and transiently transfected with the APP-GFP cDNAs, along with the appropriate 
controls (non-transfected, MOCK, and pEGFP-N1 transfected cells). Cells were washed with 
PBS, harvested in 500 µl of 1% boiling SDS, and cells lysates were boiled for 10 min and 
sonicated for 30 sec. Samples aliquots were subjected to 7.5% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), and electrophoretically transferred onto nitrocellulose 
membranes. Immunoblotting of the transferred proteins was performed as described in 
Appendix II, using the primary antibodies 22C11 (anti-APP) or JL-8 (anti-GFP) in overnight 
blots incubations (antibody dilutions are specified in Table II.1). Detection was achieved using 
horseradish peroxidase-linked secondary antibodies and an enhanced chemiluminescence 
detection system (ECL kit; Amersham Pharmacia Biosciences). For analysis of the intracellular 
APP-GFP localization, another subset of cells was treated as above but grown in six-well 
plates containing 100 µg/ml poly-L-ornithine (Sigma-Aldrich) pre-coated glass coverslips and 
fixed using a 4% paraformaldehyde solution (see Appendix II).  
Time course of Wt APP-GFP levels in the presence of cycloheximide. The 
methodology here used for combined trafficking/processing studies (da Cruz e Silva et al., 
2004b) makes use of a known protein synthesis inhibitor, cycloheximide (CHX, Sigma-
Aldrich). CHX is a well known drug that reversible inhibits protein synthesis by blocking the 
mRNA translation at the level of polypeptide translocation. It has been used to study protein 
post-translational modifications and the role of protein synthesis in apoptosis, gene expression 
and steroidogenesis (Parat and Fox, 2001). In our experimental model, CHX is used to inhibit 
cellular “de novo” protein synthesis, enabling the isolation of APP-GFP protein populations, 
thus reducing the background of continuous protein synthesis and resulting in a more efficient 
tracking. The dose used (50 µg/ml) in the following assays was experimentally optimized (da 
Cruz e Silva et al., 2004b). Of note is that cells exposure to 100 µg/ml CHX for 5:30 hours 
was observed to have no effect on protein glycosylation processes (Brion et al., 1992), and still 
allowed for constitutive protein secretion from the Golgi. Hence, this reversible protein 
synthesis inhibitor enables monitoring of an APP cellular pool and the study of potential 
differences in the cDNA mutants as they are processed intracellularly. 
For a comparison of the time courses of cellular endogenous APP and transfected Wt 
APP-GFP, COS-7 cells were transfected with pEGFP vector or Wt APP-GFP (Table II.2) 
and plated on six-well plates. Cells were incubated with DMEM medium supplemented with 
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50 µg/ml CHX, for the following time periods: 0:00, 1:00, 2:00, 3:00 and 5:00 h. At each 
specific time point, cells were harvested in boiling 1% SDS solution, samples boiled and 
sonicated, and their total protein content determined using the BCA kit (Pierce), according to 
the supplier’s instructions. Mass-normalized aliquots were resolved by 6.5% SDS-PAGE and 
subjected to Immunoblot detection as described. Detection was carried out using an IgG 
horseradish peroxidase-linked secondary antibody and the ECL detection kit.  
 
II. 3. 4 – APP-GFP TRAFFICKING ASSAYS 
II. 3. 4. 1 – Intracellular APP-GFP tracking 
Transiently transfected cells were harvested and replated onto six-well plates 
containing pre-coated glass coverslips. After a recovery period of 4 hours, cells were incubated 
in 1 ml of DMEM medium supplemented with 50 µg/ml CHX. For a time-course analysis the 
six-well plates were incubated for different periods of time - 1:00, 1:30, 2:00, 2:30, 3:00, 3:30 
and 5:00 h - after which cells were fixed by means of the 4% paraformaldehyde fixation 
method. Coverslips with fixed cells were mounted with antifading reagent (FluoroGuard, Bio 
Rad) on microscope slides and analysed by epifluorescence microscopy. For co-localization 
studies of APP-GFP with specific organelles, a subset of the cells fixed at 0 h CHX was 
subject to Immunocytochemistry procedures (described below in section II.3.4.6). The anti-
Calnexin (an ER marker) and anti-Syntaxin 6 (a TGN/Golgi marker) antibodies were used. 
II. 3. 4. 2 – AICD nuclear targeting 
Cells previously transfected with the APP-GFP constructs (Table II.2) were divided 
into six-well plates containing pre-treated and pre-coated coverslips and subject to the same 
procedures as described above in section II.3.4.1. Two sets of cells were immediately fixed 
after the recovery period. (0:00 h of CHX exposure) and a third was fixed upon 5:00 h of 
CHX exposure. Coverslips containing fixed cells were mounted with antifading reagent on 
microscope slides and subjected to Immunocytochemistry analysis.  
II. 3. 4. 3 – APP endocytosis assay – APP/Transferrin co-localization 
Endocytosis of Texas Red-conjugated Transferrin (Molecular Probes) was monitored 
in APP-GFP transiently transfected cells grown on poly-L-ornithine-coated glass coverslips. 
Cells were first exposed for 2:15 h to 50 µg/ml CHX, upon what were washed with complete 
DMEM. In order to eliminate endogenous transferrin cells were further incubated for 30 min 
at 37 ºC with DMEM medium supplemented with 20 mM HEPES and 50 µg/ml CHX. 
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Medium was exchanged for 500 µl fresh medium of equal composition but containing 1 
mg/ml BSA and 100 nM Texas Red-conjugated transferrin, and cells incubated for a further 
15 min at 37 ºC. The plates were immediately cooled to 4 ºC, washed twice with ice-cold PBS, 
and cells fixed on coverslips were processed for Immunofluorescence as previously described. 
II. 3. 4. 4 – Uptake assay using an anti-APP N-terminal antibody 
Cells grown in 60 mm plates were transiently transfected with Wt or the S655 
phosphomutant APP-GFP cDNAs (Table II.2). After 8 hours of transfection cells from each 
plate were divided into 4 wells of six-well plates containing polyornithine-coated glass 
coverslips. Following a recovery period, each well was incubated with 2 ml of DMEM 
medium supplemented with 50 µg/ml CHX, for 2:30 hours. Cells were washed twice with ice-
cold PBS and incubated for 20 min on ice with 150 µl of DMEM medium containing the anti-
APP ectodomain (22C11) antibody. Cells were washed three times with ice-cold PBS and 
subsequently incubated at 37 ºC in 5 ml of complete DMEM with 50 µg/ml CHX, for the 
following time periods: 0, 15, 30 and 150 min. After two washes with PBS, cells were fixed 
with a 4% paraformaldehyde solution and processed for Immunocytochemistry with the 
Texas Red-conjugated α-mouse antibody.  
II. 3. 4. 5 – APP-GFP constructs lysosomal targeting 
COS-7 cells transfected and treated as described in Table II.2 were plated into six-well 
plates containing pre-treated coverslips. Cells were incubated with 50 µg/ml CHX for 3:00 h, 
fixed with 4% paraformaldehyde solution and processed for Immunocytochemistry with the 
anti-Cathepsin D antibody as described below. 
 II. 3. 4. 6 – Immunocytochemistry procedures 
For co-localization procedures (Intracellular tracking, Nuclear targeting, Antibody 
uptake assays and Lysosomal targeting) Immunostaining was performed after cells fixation 
with 4% paraformaldehyde. For these procedures, cells were first permeabilized with 
methanol to allow for further incubations with specific antibodies. Briefly, after 
permeabilization cells were washed with PBS and incubated at 37 ºC with the appropriate 
primary antibodies. Except when otherwise specified, primary antibodies were incubated for 2 
hours. Following three washes with PBS, 300 µl of Texas Red-conjugated secondary antibody 
were added to cells (for antibody dilutions see Table II.1). A further incubation was carried 
out in the dark for 2 h at 37 ºC to allow for labelling of antigen-primary antibody complexes. 
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Coverslips were further washed three times with PBS and mounted with the antifading reagent 
on microscope glass slides.  
For the Intracellular tracking time-course assay, APP-GFP co-localization with two 
subcellular compartment markers was performed. At 0:00 h of CHX exposure, APP-GFP 
transfected cells grown on glass coverslips were fixed, permeabilized, and subjected to 
Immunocytochemistry using anti-Calnexin (an ER marker) or anti-Syntaxin 6 (a TGN/Golgi 
marker) primary antibodies. For the nuclear co-localization studies, transfected cells were 
fixed, permeabilized, and incubated with the antibodies 22C11 (anti-APP N-terminus; 4 h of 
incubation), 369 (anti-APP C-terminus), or 6E10 (anti-APP Abeta region; 4 h of incubation). 
For the Antibody Uptake assay, the Immunocytochemistry procedure was the same but the 
primary antibody incubation step was omitted. In addition, in a control experiment for non-
endocytosed membranar APP-GFP analysis, cells were not permeabilized. For the APP-GFP 
lysosomal targeting assay, coverslips with fixed cells were incubated with the anti-Cathepsin D 
antibody. 
II. 3. 4. 7 – Data analysis 
Cells percentages (section II.4.3.1) and vesicles scored for fluorescence (sections 
II.4.3.4 and II.4.4) are expressed as mean ± SEM (standard error of the mean). Statistical 
significance analysis was conducted by one way analysis of variance (ANOVA) followed by 
the Tukey-Kramer test. Statistical significance symbols used were (*) for comparison of S655 
phosphomutant and Wt data, and (+) for S655A versus S655E data. Statistical significance 
levels are presented as (*/+), p < 0.05; (**/++), p < 0.01; and (***/+++), p < 0.001. 
 
II. 3. 5 –  MICROSCOPY TECHNICAL DATA 
Image acquisition. Cells mounted on coverslips were analysed using an Olympus 
IX-81 Motorized Inverted Epifluorescence microscope equipped with Olympus LCPlanFl 
20x/0.40 and 60x/0.70 objective lenses. Photographs were taken at 18 ºC with a Digital CCD 
monochrome camera F-View II (Soft Imaging System) and processed with the AnalySIS 
software (Soft Imaging System).  
Fluorophores and Epifluorescence Microscope filters. EGFP (Chroma 41020) 
and Texas Red (Chroma 41004) filter cubes were used for fluorophores visualization. 
Fluorescence excitation and emission spectra of the used fluorophores (EGFP, Texas Red), as 
well as the epifluorescence microscope filter cubes definitions, are presented in Appendix III. 
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II. 4 – RESULTS AND DISCUSSION  
II. 4. 1 – CONSTRUCTION OF WT AND S655A/E APP695-GFP CDNAS  
PCR amplification of Wt and S655 phosphomutants APP fragments. APP695 Wt 
and S655A/E mutated cDNAs were amplified by PCR using specifically designed primers to 
remove the APP stop codon. Analysis of 1/10 of the PCR products was performed by 
electrophoresis in a 1.2% agarose gel. A single band per reaction of 2.1 Kb was observed, the 
expected molecular weight for the APP inserts. Figure II.2 shows representative agarose gels 
with the cDNA products (arrow) of the amplifications. 
 
 
 
Figure II.2. APP products of PCR amplification. MM, molecular markers (“1Kb 
ladder”, Invitrogen).  
 
 
APP-GFP N-terminal fusion constructs. The remainder 9/10 of the PCR reaction 
products were subjected to sequential digestion with the endonucleases Nru I (that produces 
DNA blunt terminals) and Age I (cohesive DNA terminals). The vector pEGFP-N1 was also 
sequentially digested with the restriction enzymes Sma I (produces blunt terminals) and Age I. 
The pEGFP-N1 digestion product was resolved on a 0.8% agarose gel, extracted from the gel 
and purified by means of a Gel Extraction kit (QIAgen). The PCR APP resulting fragments, 
Age I/Nru I digested, were subcloned into the Age I/Sma I restriction sites of the pEGFP-N1 
vector. Ligation products (2 and 5 µl) were used to transform E. coli competent cells. 
Transformation mixes were plated on LB agar plates with kanamycin, and randomly picked 
colonies were further grown overnight in LB/kanamycin liquid medium. Minipreps of these 
liquid cultures were performed to extract the plasmid DNAs for confirmation of the APP-
GFP constructs. Extracted DNAs were digested with two endonucleases: EcoR I and Pst I. 
The strategy for a first confirmation of positive clones was based on the different number of 
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consensus sequences for EcoR I and Pst I enzymatic restriction of the pEGFP vector alone or 
the vector plus fusion construct. The restriction products were analysed by 1% agarose gel 
electrophoresis (Fig. II.3). The vector alone has only one site for EcoR I or Pst I restriction, 
and digestion yields one single band of 4.7 Kb (pEGFP expected size) corresponding to the 
linearized form of the vector. When APP is correctly inserted, the APP-GFP plasmid 
constructs have additional restriction sites for these two endonucleases: one for EcoR I and 
two for Pst I enzymatic cleavages. Hence, for these constructs, two EcoR I fragments of 5.1 
Kb and 1.8 Kb, and three detectable Pst I fragments of 5.1 Kb, 0.9 Kb and 0.2 Kb were 
expected and obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.3. Confirmation of APP695 -GFP fusions by endonuclease restriction. All APP-
GFP constructs were confirmed by EcoRI and PstI digestion. MM, molecular markers “1Kb 
ladder”. 
 
 
APP-GFP DNA fusions were confirmed by sequencing 0.1 ng of the plasmids. 
Sequencing was performed using six different primers and a personal Mastercycler Automated 
Sequencer (Eppendorf). The primers were designed to be complementary to different APP 
cDNA sequences spaced ∼500 nucleotides apart: NAPN, APP500, APP1100, APP1500, 
APP1800 and APP2000 (sequences of primers in Appendix III). The resultant sequences 
confirmed not only the point mutations at the serine 655 residue but also the correct insertion 
of APP as an APP-GFP fusion, in frame with the GFP coding sequence. Part of the 
sequences obtained with the APP2000 primer, spanning the point mutations, are presented in 
Figure II.4. 
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Figure II.4. Confirmation of APP695 -GFP mutations by DNA sequencing. APP-GFP constructs were 
sequenced using a series of appropriate primers. The sequences shown here were obtained using the “APP2000” 
primer, and display the specific point mutations at S655 (black rectangle). S655A and S655E have an additional 
but silent point mutation at Tyrosine 653 (TAC → TAT).  
 
 
II. 4. 2 –  APP-GFP EXPRESSION IN COS-7 CELLS 
APP-GFP construct expression in COS-7 cells. The extracted and ethanol purified 
APP-GFP constructs were expressed in COS-7 cells using transient transfection methodology 
(described in section II.3.3). Cells lysates collected in 1% SDS were subject to SDS-PAGE, 
along with lysates of non-transfected, MOCK and pEGFP (vector only) transfected cells, used 
as controls. Gels were used to prepare Immunoblots and the latter were developed using the 
anti-APP 22C11 (Fig. II.5, A.I) and the anti-GFP JL-8 (Fig. II.5, A.II) antibodies. Another 
subset of pEGFP and APP-GFP transfected cells were fixed and analysed by epifluorescence 
microscopy (Fig. II.5, B). 
 
 
 
S655A APP-GFP  TCC → GCT    S655 → A655 
S655A APP-GFP           TCC → GAG         S655 → E655 
Wt APP-GFP                                         TCC    -    S655 
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Figure II.5.  APP-GFP expression in COS-7 cells. A: Immunoblot analysis of APP-GFP cell lysates. NT, 
non-transfected cells; M, mock transfected cells (no cDNA); Cells transfected with: pEGFP, EGFP-Vector; Wt, 
APP-GFP wild-type cDNA; S655A, APP-GFP S655A cDNA; S655E, APP-GFP S655E cDNA. A.I and A.II: 
Immunoblots of cellular lysates probed with the 22C11 (anti-APP N-terminus) and the JL-8 (anti-GFP) 
antibodies, respectively. a and b are the transfected APP-GFP forms, immature and mature, respectively. c and d 
are COS-7 endogenous APP forms; e corresponds to APP GFP-fused C-terminus fragments; f and g correspond 
to the GFP protein, with g appearing to derive from GFP cellular degradation. The relative position of protein 
molecular weight markers is indicated. B: APP-GFP subcellular distribution (epifluorescence microscopy 
analysis). 
 
 
Detection with antibody 22C11 (Fig. II.5, A.I) revealed the COS-7 endogenous APP 
forms, immature APP695 (c, ∼108 KDa) and immature APP751/770 (d, ∼115 KDa). These forms 
are not detected by the anti-GFP antibody (Fig. II.5, A.II) and their protein levels seem to 
suffer an up-regulation when cells are transfected with plasmids encoding exogenous APP 
(‘APP-GFP’ lanes, A.I blot). Two extra bands, migrating at ∼136 (a) and ∼145 (b) KDa, 
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appear only in the APP-GFP transfected cellular lysates and not in the controls. These 
correspond to the immature (a) and the mature (b) forms of the APP695-GFP proteins, also 
positive with the anti-GFP antibody (A.II).  
Additional bands of low molecular weight (“e”, “f” and “g”) appear when detection is 
performed with the anti-GFP antibody. The ∼29 KDa band (“f”) has the molecular weight 
expected for the GFP protein alone (27-30 KDa) and is stronger in the pEGFP lane 
(transfection with vector alone). The ∼20 KDa band (“g”) appears in all lanes corresponding 
to transfections of GFP alone or fusion constructs (pEGFP and APP-GFP lanes), and 
probably corresponds to a cellular degradation fragment(s). The “e” band migrating above at 
higher molecular weight (∼34 KDa) appears only in APP-GFP transfected lysates. This band 
was further confirmed (data not shown) to contain APP-GFP derived C-terminal fragments 
(α- and βCTF-GFP).  
Subcellular localization analysis of transiently expressed APP-GFP proteins (Fig. II., 
5B) led to the observation that the three (Wt and S655 phosphomutant proteins) apparently 
had similar distribution patterns. Proteins were present mainly in the perinuclear region (ER 
and Golgi apparatus) and in cytoplasmic vesicles. Being that the 653YTSI656 domain is thought 
to be involved in the regulation of APP trafficking, a time-dependent subcellular localization 
analysis was subsequently performed under mild conditions of inhibiting ‘de novo’ protein 
synthesis.  
Time course of Wt APP-GFP levels in the presence of CHX. Preliminary studies 
with the wild-type APP-GFP and the pEGFP alone were carried out for comparative analysis 
of transfected and endogenously expressed APP turnover during CHX exposure. Procedures 
were as described in section II.3.3 and Table II.2, and the results obtained are shown in Figure 
II.6. The apparent molecular weights for the APP-GFP bands in these 6.5% gels were of 
136.1 KDa (a) and 144.9 KDa (b), and are at the expected range since the GFP protein alone 
has a molecular weight between 27-30 KDa. The use of lower amounts of DNA for 
transfection resulted in more endogenous-like levels of expression of APP-GFP, with both -
APP695-GFP and endogenous APP - disappearing with time of CHX incubation. In fact, at 5 h 
of CHX incubation most of the transfected and endogenous APP species have disappeared 
(Fig. II.6, 5 h). 
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Figure II.6. Time-dependent effect of CHX exposure on intracellular APP levels (transfected and 
endogenous).  APP expression levels were analysed by Immunoblotting with the 22C11 (anti-APP N-terminus) 
antibody.  CHX  h, period in hours of CHX exposure. a and b are the transfected APP695-GFP immature and 
mature forms, respectively. c and d are endogenous immature APP forms, mainly 695 and 751/770, respectively. 
The relative position of protein molecular weight markers is indicated. 
 
 
II. 4. 3 – INTRACELLULAR APP-GFP TRACKING 
APP-GFP co-localization with ER and Trans-Golgi Network markers. 
Identification of the APP695-GFP cellular distribution at ER and Golgi/TGN compartments 
was confirmed using specific organelle protein markers, visualized using Texas Red-linked 
secondary antibodies (Fig. II.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.7. Identification of APP-GFP localization in COS-7 cells by co-localization analysis of APP-GFP 
(green fluorescence) proteins with two subcellular compartment markers - Calnexin for the ER and Syntaxin 6 
for the Trans-Golgi network (TGN). Detected by Immunocytochemistry with specific primary and Texas Red-
linked secondary antibodies (red fluorescence). PhC, Phase Contrast. 
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 The perinuclear distribution (ring-like) of green fluorescent APP-GFP protein was 
confirmed to co-localize extensively with the ER protein marker Calnexin (Fig. II.7, panel A, 
yellow/orange staining in the overlay image). The staining of the TGN/Golgi protein marker, 
Syntaxin 6 (Fig. II.7, panel B) was mainly visible in a nuclear juxtaposed structure, in 
accordance with the expected localization of Golgi complex. Subcellular APP-GFP co-
localizes with, and is mainly concentrated at this Syntaxin 6-positive structure. 
II. 4. 3. 1 – Subcellular localization of Wt and S655 phosphomutants in a time- 
dependent manner 
The role of S655 APP phosphorylation in APP subcellular targeting and translocation 
was analysed. APP-GFP transiently transfected cells were exposed to CHX and fixed at 
different time points (see section II.3.4.1 and Table II.2). 60 cells per coverslip for each time 
point, in triplicate (three independent experiments), were scored by epifluorescence 
microscopy for the presence/absence of GFP fluorescence in specific subcellular 
compartments (ER, Golgi, cytoplasmic vesicles, nucleus and plasma membrane). This 
quantitative data (100% = 120 cells) is presented in Figure II.8. Further, the predominant 
pattern of APP695-GFP subcellular distribution at each time point was also analysed. A 
representative cell for each time point is shown in Figure II.9.  
From Figure II.8 it is evident that the trafficking of the Wt APP-GFP and S655 
phosphomutants is somewhat different. For example, for the Wt APP-GFP (Fig. II.8, A) the 
percentages of cells with fluorescent ER decreased rapidly from 59.4 ± 13.7% (1:00 h) to 16.1 
± 3.9% at 2:00 h, and to < 10% by 2:30 h and only ∼3% from 3:00 to 5:00 h. The ER 
fluorescence decrease for the S655A mutant was similar to the Wt (Fig. II.8, B). However, the 
S655E mutant had higher ER percentages at the early time points (1:00-2:30 h), although only 
significantly different from Wt at 2:30h (21.7 ± 1.7%, p < 0.01), pointing to a relatively delayed 
S655E ER exit (Fig. II.8, C).  
Scoring Golgi fluorescence in a time-dependent manner revealed that for the Wt APP-
GFP species, 97.2 ± 2.0% of the cells had fluorescent Golgi at 1:00 h, and this percentage 
decreased to 64.4 ± 2.8% by 2:00 h. At 2:30 h a small rise in the number of cells with Golgi 
fluorescence was observed (75.6 ± 5.2 %), and from that time point on it decreased to 58.3 ± 
7.7% and 33.3 ± 5.3% (3:00 and 5:00 h, respectively) (Fig. II.8, A, “G”). 
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Figure II.8. Quantitative analysis of S655 phosphorylation state-dependent APP cellular trafficking. 
After fixing at the indicated time points of CHX exposure (1:00 - 5:00 h), COS-7 cells transfected with Wt (A) or 
S655 mutants (B and C) APP-GFP were analysed for the presence/absence of green fluorescence at different 
subcellular organelles. ER, endoplasmic reticulum; G, Golgi; PM, plasma membrane; N, nucleus. Tuckey test, 
and statistical significance levels are presented as (*/+), p < 0.05; (**/++), p < 0.01; and (***/+++), p < 0.001; (*), 
S655 phosphomutants vs. Wt; (+), S655A vs. S655E. 
 
 
For the S655A mutant the percentage of Golgi-positive cells started at a slightly lower 
value (88.3 ± 3.5% at 1:00 h), but remained high and barely decreased in comparison to the 
Wt at subsequent time points (Fig. II.8, B, “G”). These values were 75.0 ± 1.0% at 2:00 h, 78.9 
± 2.4% (3:00 h), and 70.6 ± 6.5% at 5:00 h, all are significantly different from Wt. Hence, the 
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S655A mutant seemed to have impaired Golgi exit, which was pronouncedly delayed relative 
to Wt APP-GFP.  
The percentages of S655E cells with APP-GFP fluorescent-positive Golgi were closer 
to the values obtained for the Wt (Fig. II.8, C, “G”). Values at 1:00 h and 2:00 h were almost 
equal to Wt (∼93% and ∼67%). Also, as for the Wt, from 2:00 to 2:30 h the “G” percentage 
increased to ∼73%, and from 2:30 to 3:00 h decreased to ∼56%. These results indicate a 
normal pattern of APP Golgi traffic at these time points. Nonetheless, from 3:30 to 5:00 h 
there was an increase in the number of Golgi fluorescing cells (52.2 ± 4.9% and 69.4 ± 3.1%, 
respectively, compared to 35.6 ± 4.8% and 33.3 ± 5.3% for the Wt). Additionally, at 1:30 h the 
percentage of “G” fluorescing cells was higher for S655E than for Wt (∼93%, compared to 
73%). This question will be further addressed in section II.4.3.4.  
Plasma membrane (PM) fluorescence was also scored (Fig. II.8, “PM”), and both the 
S655A and S655E mutants exhibited significantly higher percentages of PM GFP-positive 
fluorescence than the Wt protein (e.g. ∼32% and ∼27% at 1:30 h, respectively, versus ∼7% for 
the Wt). Furthermore, these percentages were overall higher for the S655A mutant when 
compared with the other two species (e.g. 45.6 ± 4.7% and 47.8 ± 7.1% at 2.30 and 3:00 h, 
compared to 33.3 ± 4.8% and 27.8 ± 1.5% for S655E, and 11.7 ± 1.9 and 21.7 ± 3.8% for Wt). 
In addition, the APP-GFP species nuclear time course distribution also presented differences, 
but this will be analysed in detail in section II.4.3.2. 
Figure II.9 depicts a representative cell for each time point based on the quantitative 
data discussed above. For the Wt APP-GFP (panel A) we can observe that at 1:00 and 1:30 h 
the protein appears mainly in a typical ER “nuclear ring” distribution (arrow “ER”), with an 
intensely fluorescent Golgi complex, and in some cytoplasmic vesicles. The presence of green 
fluorescence at the plasma membrane only became significantly visible from 3:00 h on (arrow 
“PM”). The ER fluorescence almost completely disappeared for longer periods of CHX 
exposure, while Wt APP-GFP fluorescence was observed in cytoplasmic vesicles at all CHX 
incubation periods. Golgi fluorescence intensity, visibly decreased at 3:30 and 5:00 h (arrows 
“G”). In fact, upon 5:00 h of CHX exposure, fluorescence intensity was found to be 
drastically decreased overall. This faded fluorescence was distributed through the Golgi, 
cytoplasmic vesicles and PM, with the Golgi being the most intense. Of note is that due to the 
low fluorescence intensities, the CCD microphotograph camera exposure times had to be 
increased at 5.00 h.  
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Relatively to the Wt, and consistent with the quantitative data, the S655A mutant (Fig. 
II.9, B) presented a similar pattern of ER fluorescence staining, which decreased and almost 
disappeared by 1:00 to 2:00 h. More significantly for this mutant, and in agreement with the 
above mentioned findings (Fig. II.8, B), S655A has an almost non-decreasing Golgi 
fluorescence intensity. Additionally, for the first hours (1:00 to 3:00 h) this mutant was less 
visible in GFP-positive cytoplasmic vesicles, again suggesting an impairment in its Golgi exit. 
Also in agreement with the quantitative analysis, S655A-transfected cells showed plasma 
membrane fluorescence earlier than the Wt (2:30 versus 3:00 h for Wt). In fact, of the three 
APP-GFP species, S655A was the one presenting more intense fluorescence at the plasma 
membrane (arrows PM) at all time points.  
The S655E APP mutant (Fig. II.9, C) had a slight delay in its ER exit, observed as ER 
fluorescence for up to 2:00 h, contrasting with 1:30 h for Wt (arrows ER). Consistent with the 
quantitative data (Fig. II.8), the time course and intensity of S655E Golgi fluorescence was 
very similar to the Wt, with the exception of the two last time points, where S655E was more 
intense (arrows G at 3:30 and 5:00 h). In addition, this mutant appeared to result in a similar 
or even higher number of fluorescent cytoplasmic vesicles when compared to the Wt species 
(2:00 and 2:30 h). The S655E phosphomutant also resulted in slightly increased PM 
fluorescence, but this was much weaker than for S655A (arrows PM from 2:00 to 3:30 h).  
II. 4. 3. 2 –  S655 APP695 phosphorylation alters AICD nuclear targeting   
Of particular interest was the comparative fluorescence monitored in the nuclei for 
each of the species. The percentages of cells with GFP-positive nuclei and the overall nuclei 
fluorescence intensity increased with time of CHX exposure, although differences were 
observed. Two phases could be distinguished, in particular for the Wt and S655E species, a 
first accumulation ranging from 1:00 to 2:30 h and a second from 2:30 to 5:00 h (Fig. II.8, 
“N”). During the first phase both S655A and S655E transfected cells presented higher 
percentages of GFP-positive nuclei staining in comparison to the Wt. Percentages at 1:30 and 
2:30 h were ∼10 and ∼24% for the Wt, ∼16 and ∼41% for the S655A, and ∼22 and ∼43% for 
the S655E mutant. For the second phase, where more cells in general had nuclear 
fluorescence, the percentages of S655E and Wt transfected cells with nuclear fluorescence 
increased at a similar rate, while an increase was not observed for the S655A mutant. For the 
last three time points, these percentages were of ∼57/67/64% for the Wt, ∼40/48/47% for 
the S655A mutant, and ∼68/68/72% for the S655E mutant. Hence, the latter exhibited 
nuclear targeting kinetics similar to the Wt, but at all time points with slightly higher 
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population percentages. In addition, the intensity of nuclei staining was overall higher for the 
S655E protein and lower for the S655A (Fig. II.9 and Fig. II.10). 
Given that nuclear fluorescence increased with time of CHX exposure, nuclear 
targeting of GFP-linked APP fragments seemed to be occurring. In order to determine 
whether nuclear GFP fluorescence was derived from the APP-GFP full-length species or 
from its proteolytic fragments, Immunocytochemistry studies were carried out with the 22C11 
anti-APP N-terminus antibody (Fig. II.10) at 5:00 h of CHX exposure. As expected from the 
literature, no APP N-terminus nuclear presence (22C11 red fluorescence) was observed for 
any of the three species (arrows N), despite the presence of nuclear green-fluorescence.  
 
 
 
Figure II.10. Co-localization of APP-GFP and the anti-APP N-terminus 22C11 antibody (labelled with 
Texas Red-linked secondary antibody) at 5:00 h CHX. Arrows indicate: G, the Golgi region; N, the nucleus.  
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Golgi were also analysed for immunoreactivity with 22C11 (arrows G). For all the 
constructs tested the yellow/orange co-localization staining of GFP and 22C11 could always 
be observed, although to different degrees (Wt ∼ S655A < S655E) and with the highest co-
localization being observed for the S655E mutant. In fact, this construct could be singled out 
as the one with marked 22C11 Golgi staining. These results thus suggest that for the S655E 
mutant at 5:00 h there is a significant full-length APP-GFP population in the Golgi.   
In order to determine whether nuclear GFP fluorescence was mainly due to AICD 
fragments proteolytically derived from each of the APP-GFP constructs (and not from CTFs 
or from GFP alone) further co-localization studies were carried out (Fig. II.11). 
Immunocytochemistry of APP-GFP transiently transfected COS-7 cells was performed with 
two antibodies, the 369 antibody (anti-APP C-terminus; panel A) and the 6E10 antibody (anti-
Abeta 1-17; panel B), labelled with Texas Red-linked secondary antibodies. The 369 antibody 
recognizes full-length APP, both CTFs (α and β cleaved) and the AICD fragment; the 6E10 
antibody recognizes full-length APP, the βCTF and Abeta fragments but not the αCTFs and 
AICDs. Wt and S655 phosphomutant APP-GFP fluorescence co-localized with the 369 and 
the 6E10 antibodies red fluorescence at the perinuclear region (ER, Golgi), cytoplasmic 
vesicles, and plasma membrane (Fig. II.11). Significantly, however, only the 369 antibody 
(panel A) but not the 6E10 (panel B) co-localized with APP-GFP at the nucleus (full arrows). 
Cells with less or non-visible nuclear green fluorescence (panel A, dashed arrows) had a 
concordant lower level of 369 staining. Hence, the nuclear green fluorescence scored in 
section II.4.3.1 is confirmed to be due to the presence of AICDs or αCTFs APP-GFP-
derived fragments, and not βCTFs fragments or full-length APP-GFP.  Furthermore a good 
correlation was observed between GFP nuclear fluorescence and APP C-terminus (369 
antibody) red fluorescence (Fig. II.12, full arrows). Untransfected cells in the vicinity are 
indicated by dashed arrows, and these did not stain as intensely with the antibody 369. 
Consistantly all transfected cells had higher red nuclear fluorescence than non-transfected 
ones, confirming that APP-GFP-derived AICDs was being targeted to the nucleus.  
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Figure II.11. Co-localization of APP-GFP with APP C-terminal fragments. APP C-terminal fragments were 
detected with the 369 (anti APP C-terminus) (Panel A) and the 6E10 (anti APP Abeta region) (Panel B) 
antibodies, labelled with Texas Red. Full arrows indicate cells with high nuclear green fluorescence; dashed 
arrows indicate cells with very faint nuclear green fluorescence.  
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Figure II.12. Nuclear co-localization and correlation of APP-GFP and the 369 (anti-APP C-terminus) 
antibody. Dashed arrows indicate non-transfected cells. Full arrows indicate cells with green nuclear 
fluorescence; to increasing numbers correspond increasing intensities of green fluorescence at the nucleus.  
 
 
In conclusion, increasing nuclear green fluorescence intensity always correlated with 
increasing 369 nuclear red fluorescence intensity. In addition, APP-GFP transfected cells with 
green fluorescence at their nuclei always presented increased red nuclear intensity when 
compared with the red nuclear staining of non-transfected cells. This supports the notion that 
the nuclear green fluorescence was not due to a nuclear targeting of GFP alone upon APP-
GFP degradation. Furthermore, these results confirm that nuclear green fluorescence presence 
and intensity correlate well with the presence of AICD-GFP (or αCTF) at this compartment.  
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II. 4. 3. 3 – APP endocytosis assay  
The higher S655A APP-GFP membranar levels observed in the trafficking studies 
could indicate some impairment in APP internalization by endocytosis. This, in turn, could 
indirectly influence α- and β-secretase APP substrate availability at the membrane and in the 
endosomes, as well as subsequent targeting of APP and specific APP fragments. To clarify this 
question a standard assay was used to monitor APP-GFP co-endocytosis with Texas Red-
labelled transferrin molecules (Benmerah at al., 1998). The experimental procedure is 
described in section II.3.4.2 and in Table II. The CHX 2:45 - 3:00 h time period was chosen 
due to the high levels of Wt and phosphomutants APP-GFP present at the cellular membrane, 
and theoretically available for endocytosis. Results are presented in the panel below (Fig. 
II.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.13. Endocytosis studies of the APP-GFP constructs. Analysis of the co-localization of Texas Red-
conjugated Transferrin (red endocytic vesicles), with the Wt or S655 phosphomutants-containing (green) 
cytoplasmic vesicles. Co-localizing vesicles in the “Overlay” panel have yellow/orange fluorescence. 
 
Co-localization 
S655E APP-GFP 
S655A APP-GFP 
Wt APP-GFP 
60x 
Transferrin 
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All cells transfected with the different APP-GFP constructs exhibited a high number 
of APP-GFP/transferrin co-localizing endocytic vesicles per cell. As the transferrin staining 
appeared in a large number of vesicles, it was not possible to do a count of the co-localizing 
vesicles in order to identify possible differences in the ratio of co-localizing to transferrin-
positive vesicles. Nonetheless, it appears that the S655E mutant has more APP-GFP 
incorporated into endocytic vesicles. In fact, the relative rate of intensity indicating GFP 
incorporation into vesicles appeared to be: S655E > Wt > S655A. Total membrane substrate 
availability could not account for these differences since, and as previously shown, S655A has 
the highest percentage of plasma membrane fluorescence and was at its highest value at this 
time point (Fig.s II.8 and II.9, “PM”).  
II. 4. 3. 4 – APP-GFP endocytosis and Golgi retrieval – Antibody uptake assay 
As observed in the trafficking studies, there was an unexplained rise in the number of 
S655E APP-GFP transfected cells with Golgi fluorescence in the last CHX exposure periods. 
Additionally, from the transferrin assays it seemed that higher amounts of this mutant were 
undergoing endocytosis. Surface APP protein can undergo endocytosis and then be recycled 
back to the membrane, be delivered into lysosomes or retrieved to the TGN/Golgi apparatus 
(Yamazaki et al., 1996). The mechanisms regulating this sorting are not yet clear for APP, but 
the signal targeting endocytosed BACE to Golgi retrieval  was found to be BACE 
phosphorylation at its cytoplasmic residue serine 498 (Walter et al., 2001). In order to 
investigate if serine 655 APP695 phosphorylation possesses a similar targeting role, COS-7 cells 
transiently expressing Wt, S655A or S655E APP-GFP proteins were subjected to antibody 
uptake assays. The experimental procedure is described in detail in section II.3.4.4 and in 
Table II. Briefly, after a 2:30 h CHX block, cells were incubated on ice with the anti-APP 
ectodomain 22C11antibody and further incubated at 37 ºC for 0, 15, and 30 minutes. Cells 
were monitored for the kinetics of APP-GFP endocytosis and retrieval to the Golgi, by time 
course analysis of co-localization between Texas Red fluorescence (22C11 labelling) and the 
transfected APP-GFP proteins (Fig. II.14). Control cells (non-transfected, NT) were also 
treated as APP-GFP transfected cells, and were observed to have almost undetectable 22C11 
cell surface staining. 
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Figure II.14. Endocytosis and retrieval to Golgi of wild-type and S655 phosphomutant APP-GFP. Kinetic 
analysis of APP-GFP endocytic vesicles (red labelled with the N-terminal antibody 22C11) with time of 
endocytosis: 0 min (panel A), 15 min (panel B) and 30 min (panel C). Arrows indicate co-localizing vesicles 
near or at the TGN/Golgi area (yellow/orange in “Overlay”). NT, non-transfected cells. 
 
 
APP-GFP endocytosis and Golgi retrieval. At 0 min (Fig. II.14, panel A) Wt, 
S655A or S655E transfected cells all have strong antibody red staining that co-localized with 
APP-GFP fluorescence at the cell surface. Upon incubating for 15 min at 37 ºC (Fig. II.14, 
panel B), a great number of vesicles where APP-GFP and 22C11 co-localized was observed 
for the three species. Part of these vesicles was found near or at the TGN/Golgi for the Wt 
and S655E proteins. However, this was much more marked for the S655E protein, as it could 
be detected in 50% of the population, compared to only 30% of the Wt APP-GFP cells. 
Contrarily, S655A showed very poor or none co-localization at TGN/Golgi at this time point.  
In fact, in 71% of the population expressing S655A, vesicles were randomly distributed 
throughout the cytoplasm and did not appear to be targeted to the Golgi.  
At the 30 min time point, ∼70% of S655E expressing cells had co-localizing APP-GFP 
endocytotic vesicles already fused to TGN/Golgi structures, compared with 50% for Wt and 
only 40% for S655A (Fig. II.14, panel C). Furthermore, the number of co-localizing vesicles 
C. 
30 min 
Wt  APP-GFP 22C11 (APP N-term) Overlay 
S655A APP-GFP 
S655E APP-GFP 
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per cell also appears to be higher for S655E and lower for the S655A mutant. The increased 
number of Golgi co-localizing vesicles for the S655E mutant clearly supports that S655 
phosphorylation can function as a targeting signal for APP PM-to-Golgi retrograde transport.  
APP-GFP plasma membrane dynamics. To confirm that the vesicles monitored 
above resulted from endocytosis at the plasma membrane, cell surface APP was labelled for 
comparison, by omiting the cellular permeabilization step (Fig. II.15). Thus Texas Red-
conjugated secondary antibody only labels the APP population at the plasma membrane, 
enabling us to monitor the APP surface population at the same time points. 
The distribution patterns of the 22C11 red staining at 0 min of 37 ºC incubation (Fig. 
II.15, panel A) are identical to those previously observed in Figure II.14, panel A.. Upon 15 
min of incubation, the intensity of 22C11 plasma membrane staining decreased for the three 
APP-GFP species (Fig. II.15, panel B), but particularly so for the Wt and the S655E mutant. 
Similarly, further decreases were observed after 30 min of 37 ºC incubation (Fig. II.15, panel 
C). These decreases in PM 22C11 staining did not result in increased co-localization of APP-
GFP green/22C11 red fluorescence, confirming that the previously observed co-localizing 
vesicles (Fig. II.14) were indeed deriving from intracellular endocytosed APP-GFP molecules.  
 In addition, although APP-GFP PM populations decreased with time of incubation, 
this decrease was much less pronounced for the S655A mutant. These results strongly indicate 
a diminished rate of APP membranar internalization for this mutant, as already suggested in 
Figures II.8 and II.9.  
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Figure II.15. Membranar APP-GFP dynamics. Membranar APP-GFP was labelled with the N-terminal 
antibody 22C11 and monitored with time of 37 ºC incubation: 0 min (panel A), 15 min (panel B) and 30 min 
(panel C). Microphotographs of panel B and especially of panel C required higher CCD exposure times, 
relatively to the same panels in Figure II.14. 
 
 
APP-GFP S655A impaired endocytosis. From the experiments discussed above one 
is left with the suggestion that S655A does not incorporate into endocytic vesicles as well as 
S655E. Moreover, in the Antibody uptake assays (Fig. II.14) almost all 22C11-containing 
vesicles co-localized with S655E, but this was not so for the S655A mutant. In order to clarify 
whether S655 phosphorylation had an effect on APP endocytosis, 20 cells at the 15 min time 
point (as in Fig. II.14, B) were scored for red 22C11 endocytic vesicles alone and co-localizing  
yellow/orange vesicles (Fig. II.16). The percentage of non-colocalizing (red only) vesicles was 
thus calculated to be 3.4 ± 0.6% for Wt, 2.3 ± 0.4% for S655E and 9.8 ± 1.7% for S655A.  
These values for the S655A mutant were significantly different as determined by the Tukey 
test (p < 0.01 vs. Wt and p < 0.001 vs. S655E). Hence, the S655A mutant has indeed 
decreased endocytosis. Of note is that for all the APP-GFP species many of the cytoplasmic 
vesicles observed appeared to be endocytic in nature.   
 
 
C. 
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Figure II.16. Co-localization analysis of APP-GFP/22C11 endocytosed vesicles. Cells transiently 
transfected with the APP-GFP species and incubated for 2:30 h with CHX were surface labelled with the 22C11 
antibody (red labelled). Upon 15 min of 37 ºC incubation cells were processed for immunofluorescence analysis 
of the number of green/red co-localizing and non-colocalizing cytoplasmic vesicles. Arrows indicate 22C11 red-
positive vesicles that do not co-localize with APP-GFP. 
 
 
II. 4. 4 – S655 PHOSPHORYLATION RESULTS IN LESS APP LYSOSOMAL TARGETING  
Endocytosed APP can be recycled to the cell membrane, be sorted to TGN/Golgi or 
be targeted to lysosomes for complete degradation. As mimicking APP S655 constitutive 
phosphorylation-state resulted in slightly higher APP-GFP endocytosis and in its targeting at a 
higher rate to the TGN/Golgi, we analysed whether APP-GFP S655 phosphorylation could 
also affect targeting to lysosomes. APP-GFP constructs were co-localized with the enzyme 
Cathepsin D, a known lysosomal marker previously used in APP subcellular localization 
studies (Haass et al., 1992a). The experimental procedure is described in section II.3.4.5. The 
same end time point of CHX exposure used in the Antibody uptake assays (3:00 h) was used 
for a direct comparison. Results are presented in Figure II.17, the typical small dots of 
Cathepsin D subcellular distribution are stained with Texas Red-conjugated secondary 
antibody. This enzyme is reported to be mainly sorted directly from the TGN/Golgi to 
15 min 
Wt  APP-GFP 22C11 (APP N-term) 
S655E APP-GFP 
Overlay 
S655A APP-GFP 
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lysosomes but can be targeted to the plasma membrane first and then directed to lysosomes 
via the endosomal pathway (Press et al., 1998). 
Several cells were scored for the APP-GFP/Cathepsin D co-localization, in terms of 
percentage of red/green co-localizing vesicles relative to the total number of APP-GFP 
cytoplasmic vesicles (green). Of note is that the number of APP-GFP/Cathepsin D co-
localizing vesicles was low, ranging from 5 to 20 per cell, when compared with the average 
number of ∼100 APP-GFP endocytic vesicles per cell (Figure II.16). These results are in 
agreement with previous reports on APP lysosomal targeting, where APP could only be 
considerably detected in these structures when lysosomal proteolysis was inhibited with 
specific drugs (Hass et al., 1992a; Caporaso et al., 1994). Indeed, the percentage of Wt APP-
GFP/Cathepsin D co-localizing vesicles was low, 5.0 ± 0.5%. The S655A mutant had a 
significantly higher lysosomal targeting than the Wt and S655E proteins, with a percentage of 
co-localizing vesicles around 9.6 ± 0.4% (p < 0.001 vs. Wt and S655E data). In contrast, the 
values obtained for the S655E protein were 3.1 ± 0.3% (p < 0.01 vs. Wt and p < 0.001 vs. 
S655A data) indicating a lower S655E targeting to lysosomes. Of note is that the majority of 
the Golgi area was not scored given the difficulty in distinguishing vesicular structures (see 
Fig. II.17 legend). However, the S655A mutant presented higher co-localization at that region, 
and S655E protein the lowest co-localization. Hence, the S655A mutant appears to be 
comparatively more targeted for lysosomal degradation, and S655 phosphorylation could 
represent a rescue mechanism. This will be addressed in the future.  
- 101 - 
Phosphorylation-dependent Alzheimer’s amyloid precursor protein (APP) targeting 
  
 
Wt APP-GFP 
Cathepsin D (lysosomes) 
S655A APP-GFP 
Cathepsin D (lysosomes) 
Overlay 
Overlay 
S655E APP-GFP Overlay 
Cathepsin D (lysosomes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.17. Co-localization analysis of APP-GFP and the lysosomal marker Cathepsin D. Arrows 
indicate green (APP-GFP) and red (Cathepsin D) co-localizing vesicles. The majority of co-localizing vesicles 
observed at the TGN/Golgi area were not scored to not introduce errors due to the low resolution at that area.  
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II. 5 – CONCLUSIONS  
APP S655 phosphomutant and APP-GFP fusion constructs were engineered and used 
together with cell culture and epifluorescence microscopy techniques, in order to determine 
the consequence of APP S655 phosphorylation on APP targeting and subcellular localization. 
The major observations from these studies were: 
1. S655 phosphorylation-state determines the kinetics of APP traffic, with special 
relevance for the APP TGN/Golgi to PM anterograde and retrograde traffic. 
2. APP TGN/Golgi exit is delayed for the S655A mutant. In addition, it seemed to 
be less efficiently incorporated into cytoplasmic vesicles.  
3. In contrast, the S655E mutant, mimicking APP S655 constitutive phosphorylation, 
exited relatively better from the TGN/Golgi and seemed to be packaged into 
cytoplasmic vesicles more efficiently. 
4. Both S655 phosphomutants had a higher number of cells with APP-GFP at the 
plasma membrane, with the S655A mutant showing the highest intensity. The 
higher PM staining for S655A appears to correlate with decreased endocytosis, this 
was shown not to be the case for S655E and will be addressed in Chapter III. 
5. All APP-GFP proteins produced GFP-fused C-terminal fragments that were 
targeted to the cell nucleus. These fragments presented GFP intensities that 
correlated well with the intensities of nuclear 369 antibody-positive APP C-
terminal fragments. Further, they were 22C11 and 6E10-negative, strongly 
suggesting that it is the APP AICD fragment that is nuclear targeted. 
6. The nuclear targeting kinetics of APP-GFP-derived C-terminal fragments were 
observed to be very similar for the Wt and S655E proteins. Nonetheless, the 
S655E expressing cells exhibited a higher percentage of nuclei fluorescence and 
qualitatively these were more intense. Conversely, the nuclear targeting of a 
S655A-derived C-terminal fragment seemed to occur initially in a slightly faster 
manner but subsequently showed no further targeting, and overall exhibited 
relative lower nuclear staining intensity. 
7. Cell membrane endocytosis is slightly increased for the mutant mimicking S655 
phosphorylation and decreased for the S655A mutant. Moreover, the S655E and 
S655A endocytic vesicles were, respectively, more and less APP-GFP intense than 
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the Wt related ones. Hence, phosphorylated APP S655 seems to be preferentially 
endocytosed compared to the APP S655-dephosphorylated form. 
8. Endocytosed S655E APP is retrieved faster and to a higher extent to the 
TGN/Golgi, while the S655A mutant is less likely to be recycled through the PM-
to-Golgi retrograde pathway. 
9. Part of the subcellular S655A population was observed to be preferentially 
delivered for lysosomal degradation, when compared with the other two APP-
GFP proteins. This lysosomal targeting was two times higher for APP S655A, and 
slightly lower for APP S655E, relatively to Wt APP-GFP. 
10. In conclusion S655E experiences faster anterograde and retrograde traffic and is 
preferentially targeted to the nucleus, being potentially rescued from the lysosomal 
pathway. S655A does not incorporate as well into vesicular like structures, is 
delayed at the Golgi and PM and is preferentially targeted to lysosomes. 
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CHAPTER III – SERINE 655 PHOSPHORYLATION-
DEPENDENT APP695 PROCESSING 
 
III. 1 – INTRODUCTION 
Proteolytic processing of APP to sAPP and Abeta, as well as AICD fragments, have 
been implicated to be regulated by phosphorylation and phosphorylation-dependent events 
(section I.3.2). Previous reports point to the phosphorylatable APP 653YTSI656 domain as a 
molecular targeting signal, and place S655 at a pivotal regulatory position. In fact, the 
trafficking experiments performed with APP S655 phosphomutants described in Chapter II 
started to unravel that potential role. Under conditions of inhibiting “de novo” protein 
synthesis, the S655A phosphomutant, mimicking an APP S655 constitutive dephosphorylated 
state, was found to be more slowly sorted from the TGN/Golgi and packaged into 
cytoplasmic vesicles. Furthermore, under these conditions part of the S655A-GFP Golgi 
population failed to be exported and remained in the Golgi compartment. Conversely, the 
S655E mutant, mimicking a S655 constitutive phosphorylation, had no visible impairment in 
its Golgi-sorting, and upon integration at the cell membrane was endocytosed and rapidly 
recycled to the TGN compartment. In addition, the S655A mutant exhibited a down-
regulation in its rate of endocytosis and an increased targeting to lysosomes. As altered APP 
protein trafficking may potentially lead to alterations in its cellular processing, the role of APP 
S655 phosphorylation on APP proteolytic cleavage was thus addressed and is described in this 
chapter. 
 
 
III. 2 – AIMS OF THIS CHAPTER 
The putative alterations on APP proteolytic processing due to the constitutive 
phosphorylated/dephosphorylated states of APP at serine 655 were addressed. The main 
objectives of this chapter were: 
1. To monitor the levels of full-length (immature and mature forms) Wt and S655 
phosphomutants APP-GFP proteins under CHX exposure (time course analysis). 
2. To evaluate the rate of APP-GFP cellular catabolism in a S655 phosphorylation 
state-dependent manner.  
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3. To monitor the levels of medium sAPP secretion for each of the Wt and S655 
phosphomutants APP-GFP under CHX exposure (time course analysis). 
4. To assess, in a S655 phosphorylation state-dependent manner, sAPP secretion 
under basal conditions or upon blocking TGN/Golgi vesicles traffic. 
5. To compare the efficiency of PMA to stimulate sAPP secretion from the Wt and 
S655 phosphomutant APP-GFP proteins.  
6. To analyse APP S655 phosphorylation-dependent Abeta production. 
 
Hence, the processes of APP maturation, catabolism, and proteolytic cleavage by the 
different APP secretases were evaluated in a time-dependent manner. Several parameters 
described above and relative to APP processing and metabolism were monitored, namely 
intracellular immature and mature APP, as well as sAPP and Abeta levels.  
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III. 3 – MATERIALS AND METHODS 
A list of all solutions and protocols used, as well as other relevant information, is 
presented in the Appendix. All reagents were of cell culture grade or ultrapure. 
 
III. 3. 1 – ANTIBODIES 
The primary antibodies used in the following studies were the previously described 
monoclonal 22C11, to detect holo APP and all sAPP forms, and monoclonal 6E10 antibody, 
which cross-reacts with αsAPP. The anti-GFP JL-8 antibody was also used, for specific APP-
GFP detection. An anti-β-Tubulin antibody (Zymed, Portugal) was used for control of 
specific cellular alterations. For Abeta immunoprecipitation and analysis the 1E8 monoclonal 
antibody was used (Nanotools, Germany). Anti-mouse and anti-rabbit IgGs horseradish 
peroxidase-linked whole antibodies were used as secondary antibodies for ECL detection.  
 
III. 3. 2 –  CELL CULTURE AND TRANSIENT TRANSFECTIONS  
COS-7 cells were transfected with the APP-GFP constructs by means of the 
Lipofectamine reagent and as previously described in Chapter II. Further transfection details 
for each of the assays performed is outlined in Table III.1. 
 
 
Table III.1. Transient transfection procedures adopted for the assays described in this chapter. Following 
removal of transfection medium and cell division into multi-well plates cells were allowed to recover for 4 -12 h.  
General 
Procedure 
Procedure Transfected cDNAs 
Quantity / Plate 
diameter 
Transfection 
period 
APP-GFP and 
sAPP time course 
analysis 
 Wt APP-GFP 
 S655A APP-GFP 
 S655E APP-GFP 
8.0 µg / 100 mm 8 h 
CHX Time 
Course 
Experiments Abeta secretion 
analysis 
(3:00 h CHX) 
 Wt APP-GFP 
 S655A APP-GFP 
 S655E APP-GFP 
4.0 µg / 60 mm 8 h 
Point 
Experiments 
APP and sAPP 
Inhibition upon 
severe CHX block 
 Wt APP-GFP 
 S655A APP-GFP 
 S655E APP-GFP 
4.0 µg / 60 mm 8 h 
Point 
Experiments 
sAPP production 
at 20 ºC (basal and 
PMA-stimulated)  
 Wt APP-GFP 
 S655A APP-GFP 
 S655E APP-GFP 
4.0 µg / 60 mm 8 h 
Chapter III –S655 phosphorylation-dependent APP processing                                                                    - 110 - 
Sandra Vieira Guerra e Paz                                                                                                                CBC/UA, 2005 
III. 3. 3. – ANALYSIS OF S655 PHOSPHORYLATION-DEPENDENT CELLULAR APP-GFP 
LEVELS 
III. 3. 3. 1 – Time-course analysis of the cellular levels of immature and mature APP-
GFP  
COS-7 cells were transfected with the Wt and S655 phosphomutants APP695-GFP 
cDNAs and treated as described above (Table III.1). Following a recovery period of cells 
which had been split into six-well plates, the media was substituted with DMEM 
supplemented with 50 µg/ml CHX. Incubation was allowed to proceed for extending time 
periods of time (0:00, 1:00, 2:00, 3:00 and 5:00 h), after which cells were harvested into 1% 
SDS. Cells lysates aliquots, mass normalized, were subject to Western blot analysis, as 
described below in section III.3.6, to detect their intracellular levels of full-length APP-GFP. 
As specified in Chapter II, complete DMEM without serum is here referred to as DMEM. 
III. 3. 3. 2 – Comparative analysis of the Wt and S655 phosphomutants rate of cellular 
catabolism  
The rate of cellular catabolism can be evaluated by analysing the different recovery 
capacities of the levels of full-length APP-GFP following a period where protein synthesis was 
severely inhibited. An assay based on protein secretion studies described in Brakch et al. 
(2002) was adopted, and COS-7 cells were transiently transfected with the three APP-GFP 
constructs as described in Table III.1. Cells were further incubated with fresh DMEM 
supplemented with CHX at 100 µg/ml (“CHX block”). After a 2:00 h incubation period the 
medium was withdrawn, cells were washed twice with PBS, and DMEM (CHX-free) medium 
was added. Cells were incubated at 37 ºC and 5% CO2 for 3:00 h, after which cells and media 
were collected into 1% SDS. The cellular APP-GFP and medium sAPP contents were 
analyzed by Western blot.  
 
III. 3. 4. – ANALYSIS OF S655 PHOSPHORYLATION-DEPENDENT SAPP PRODUCTION  
III. 3. 4. 1 – APP-GFP-derived sAPP production in a CHX time-dependent manner    
For the time course analysis of medium sAPP secretion in a S655 phosphorylation 
state-dependent manner, the conditioned media of cells treated as above (section III.3.3.1) 
were also collected into 1% SDS following CHX exposure for increasing periods: 1:00, 2:00, 
3:00 and 5:00  h.  
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III. 3. 4. 2 –  Temperature- and PMA-dependent sAPP production 
COS-7 cells were transfected with the APP-GFP cDNAs as described in Table III.1, 
and pre-incubated for 15 min at 20 ºC, a temperature known to block APP/sAPP vesicle 
secretion from the TGN/Golgi (Kuentzel et al., 1993; Xu et al., 1995; Sabatini et al., 1996, 
Walter et al., 1997). Subsequently, APP-GFP proteins were monitored by epifluorescence 
microscopy at the following time points of further incubation at 20 ºC: 0 min, 15 min, 30 min, 
1 h, 2 h, and 4 h. For the sAPP production assays at 20 ºC, APP-GFP transfected cells were 
pre-incubated at 20 ºC for 15 min, cells medium was substituted for equal fresh medium, and 
cells further incubated for 2 h at 20 ºC. A control set of APP-GFP transfected cells was 
incubated for 2 h at 37 ºC. The 2 h cells incubation was performed with 0.5 ml DMEM (basal 
conditions) or with 0.5 ml DMEM supplemented with the phorbol ester PMA (phorbol 12-
myristate 13-acetate) (Calbiochem) at 0.5 µM (PMA-stimulation conditions). Conditioned 
media and cells were collected into a final boiling 1% SDS solution, and APP-GFP and sAPP 
levels were evaluated by Immunoblotting using the 22C11 antibody. 
 
III. 3. 5. – ABETA SECRETION ANALYSIS   
The levels of different secreted Abeta fragments were analyzed for the three APP-
GFP constructs. APP-GFP transfected cells were treated as described in Table III.1 and 
incubated for 3:00 h with 50 µg/ml CHX as for the cellular APP-GFP assays (section 
III.3.3.1). This time point was chosen, as by 3.00 h differences were already evident between 
the three APP-GFP constructs and APP depletion had not become significant. After the 
incubation period, cells and conditioned medium were collected, the latter centrifuged at 310 x 
g for 5 min, and the resultant supernatants immediately frozen in dry ice. Cell lysates in 1% 
SDS were resolved by SDS-PAGE and subjected to immunoblot detection of APP-GFP 
proteins. The Abeta detection analysis of the conditioned media was performed in 
collaboration with Dr. Hermann Esselmann and Prof. Jens Wiltfang (Neurobiology Lab, 
University of Goettingen, Germany). Briefly, immunoprecipitation of medium secreted Abeta 
fragments was accomplished using 25 µl dynabeads (Dynal, Germany) coated with the anti-
Abeta 1E8 antibody. Immunoprecipitated samples were resolved on 12% Bicine/Tris gels 
containing 8 M urea (Lewczuk et al., 2004) and different Abeta peptide forms were revealed 
by immunoblotting using the 1E8 antibody. Synthetic Abeta peptides were run in parallel for 
the identification of the different Abeta peptide species. 
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III. 3. 6 – SAMPLE PREPARATION AND PROTEIN ANALYSIS 
At the specified time points, cells and conditioned medium were harvested into 1% 
SDS final solutions, and samples were boiled for 10 min with cell lysates being further 
sonicated for 30 sec. Total protein content was determined by the BCA kit method (Pierce), 
according to the supplier’s instructions (see Appendix II). Mass-normalized aliquots were 
subjected to 6.5% (cellular holo APP-GFP) or 7.5% (medium sAPP) SDS-PAGE in Tris-
Glycine buffer. The proteins and protein fragments resolved by SDS-PAGE were 
electrophoretically transferred onto nitrocellulose membranes. Immunoblotting of the 
transferred proteins was performed with the above described antibodies (section III.3.1) and 
detection was achieved using an enhanced chemiluminescence detection system (as in Chapter 
II).  
Protein band quantification and statistical analysis.   
Immunoblots autoradiographic film exposures were scanned in a GS-710 calibrated 
imaging densitometer (Bio-Rad), and protein bands quantified using the Quantity One 
densitometry software (Bio-Rad). Data are expressed as mean ± SEM (standard error of the 
mean) of triplicate determinations from at least three independent experiments. Statistical 
significance analysis was conducted by one way analysis of variance (ANOVA) followed by 
the Tukey-Kramer test. Statistical significance symbols used were (*) for comparison of S655 
phosphomutant and Wt data, and (+) for S655A versus S655E data. Statistical significance 
levels are presented as (*/+), for p < 0.05; (**/++), for p < 0.01; and (***/+++), for p < 0.001. 
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III. 4 – RESULTS AND DISCUSSION 
III. 4. 1 – TIME-COURSE ANALYSIS OF FULL-LENGTH APP-GFP CELLULAR LEVELS 
In order to determine APP695 cellular processing in a S655 phosphorylation-state 
dependent manner, Immunoblot time course analyses of APP-GFP and derived sAPP were 
performed in parallel with the time course traffic assays of section II.3.4.1. COS-7 cells were 
transiently transfected at low levels with the fusion APP-GFP cDNAs and treated as 
described in section III.3.3.1. Mass normalized cells lysates were resolved by SDS-PAGE and  
analyzed by Immunoblotting with the anti-APP N-terminal antibody 22C11 (Fig. III.1, A). 
Relevant bands (a and b), which correspond to the transfected APP-GFP proteins, were 
quantified by densitometry and the data (Table III.2) plotted as percentages of their respective 
OD at 0:00 h. Data obtained for the levels of immature APP-GFP (band a) with time, and the 
levels of mature APP-GFP (band b), are plotted in Fig. III.1, B. The latter reflects the rate of 
cellular catabolism of mature APP-GFP, such as proteolytic cleavages and degradation.  
 
 
 
 
Figure III.1. Cellular processing of the Wt and S655 APP-GFP phosphorylation mutants. A: Immunoblot 
detection of Wt and S655 mutants (S655A and S655E) in cells lysates with time (hours) of CHX incubation. a 
and b are the transfected immature and mature APP695-GFP forms, respectively. c and d, endogenous APP 
forms, nd, non-determined band (further discussed in section III.4.3). B: Plotted data for the levels of APP-GFP 
immature (“immt”) (B.I) and mature (“mt”) (B.II) forms with time.  
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Table III.2. Comparison between immature and mature APP-GFP intracellular levels with 
time of CHX exposure, expressed as percentages of the respective initial 0:00 h level. (n), 
number of independent experiments. 
 
 APP-GFP Percentage 
APP-GFP 
Hours in 
CHX 
Wt (n=6) S655A (n=6) S655E (n=6) 
0:00 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
1:00 104.2 ± 0.7 97.5 ± 4.2 94.7 ± 0.3 
2:00 72.7 ± 3.3 65.4 ± 3.5 83.9 ± 4.1 
3:00 34.6 ± 1.4 36.0 ± 2.1 58.1 ± 2.2 
Immature  
5:00 23.6 ± 2.2 18.6 ± 4.7 24.1 ± 2.3 
0:00 100.0 ± 0.0 100.0 ± 0.0 100.0 ± 0.0 
1:00 115.5 ± 5.5 90.4 ± 8.2 131.6 ± 5.3 
2:00 55.0 ± 2.7 53.3 ± 6.8 105.2 ± 9.2 
3:00 33.2 ± 2.2 35.6 ± 0.6 92.2 ± 3.4 
Mature 
5:00 20.0 ± 2.7 12.9 ± 2.1 45.0 ± 4.3 
 
 
The depletion patterns of the immature APP-GFP forms, which are related to the 
rates of APP maturation and its degradation, were very similar for Wt and S655A APP-GFP. 
These depletions decrease to 35% by 3:00 h of CHX incubation, and stabilize to around 20-
25% thereafter (Graph III.1, B.I). However, the pattern of immature S655E depletion with 
time was slightly slower, dropping only to 58% by 3:00 h of CHX exposure, although reaching 
the same final ∼20% level at 5:00 h (Table III.2). 
From Graph B.II we can observe that the mature forms of the three APP-GFP 
species exhibited differences in their processing patterns. During the time monitored, the 
mature forms of Wt and S655A species decreased to 10-20% of their initial levels, while the 
S655E mutant only decreased to ∼45% (Fig. III.1, B.II, 5:00 h). The half-lifes of the three 
APP-GFP mature forms were calculated to be 2.46 ± 0.16 h for the Wt, 2.12 ± 0.08 h for the 
S655A, and 5.56 ± 0.41 h (p < 0.001 vs Wt and S655A data) for the S655E mutant. Hence, 
S655 constitutive phosphorylation greatly increases mature APP-GFP half-life. Interestingly, 
the mature Wt APP-GFP time course has a pattern that is similar to the S655E one initially 
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(0:00-1:00 h), from which it deviates between 1:00 to 2:00 h towards the S655A pattern. 
Indeed, from 2:00 h on, the mature Wt and S655A patterns are more alike. Graph III.1 B.II, 
shows that the levels of Wt mature APP-GFP suffered an initial increase (0:00-1:00 h), and 
although mature S655A catabolism was similar to Wt, it lacked the Wt 1:00 initial peak. This 
suggests an availability of this mutant for a faster and immediate cellular 
processing/degradation. As previously observed in Chapter II, the slightly higher S655A 
lysosomal targeting (Fig. II.17) may be one of the factors contributing to this result. As with 
the Wt, the pattern of mature S655E disappearance exhibited an initial increase although 
higher, but the mature S655E levels decreased below 100% only between 2:00-3:00 h. Thus 
one is left to conclude that the S655E mature form has a lower rate of degradation, resulting 
in a doubled half-life (5.56 h), when compared to the other two APP-GFP proteins (2.46 and 
2.12 h, Wt and S655A, respectively). Of note is that the level of APP-GFP maturation, 
calculated as the percentage of the mature form relatively to total APP-GFP levels, was found 
to be equal for the three proteins. These were calculated using the APP-GFP data in the 0:00 
h CHX lysates, and were of 36.0 ± 3.3% for the Wt, 32.8 ± 2.7% for the S655A, and 34.0 ± 
4.0% for the S655E species. 
 
III. 4. 2 – COMPARATIVE RATES OF WT AND S655A/E APP-GFP CELLULAR CATABOLISM 
Further evidences of the differential fates of the S655 mutants may be obtained by 
addressing their rate of cellular catabolism. This was evaluated by analysing the different 
recovery capacities of cellular APP-GFP levels following APP-GFP depletion (severe protein 
synthesis inhibition conditions). The correspondent medium sAPP levels were also analysed 
for comparison. For this purpose, COS-7 cells transfected with the APP-GFP cDNAs, and 
treated as described in section III.3.3.2, were first incubated for 2:00 h with a high CHX dose 
(100 µg/ml) (“CHX block” period). This CHX treatment allows for the clearance of newly 
synthesized proteins (Brion et al., 1992; Brakch et al., 2002; da Cruz e Silva et al., 2004b). The 
medium was substituted with fresh CHX-free DMEM, and cells were allowed to recover for 
3:00 h, upon which cells and conditioned medium were collected. Medium samples were 
subjected to SDS-PAGE, and Immunoblotted with the 22C11 antibody (Fig. III.2, A). The 
inhibitory effects of CHX on APP-GFP and sAPP695 levels were evaluated by densitometry 
analysis of APP-GFP and sAPP bands, and data were expressed as percentages of control 
(CHX-free) levels (Fig. III.2, B and C).  
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Figure III.2. CHX inhibitory effects on Wt and S655 phosphomutants APP-GFP and sAPP levels. A: 
APP Immunoblots of cells subject to a CHX pre-treatment (“CHX block”) and collected following a CHX-free 
recovery period. Medium was also collected at the end of that period and medium sAPP detected. a and b, 
immature and mature APP-GFP forms; h, medium sAPP695. i, endogenous sAPP751/770. B and C: Graph and 
table with the CHX-induced levels of total cellular APP-GFP (tAPP-GFP, immature plus mature forms) and 
derived medium secreted sAPP695 (sAPP).  
 
 
When comparing both S655 phosphomutants, we can see differences in the CHX-
induced decrease of their cellular APP-GFP levels. CHX induced a greater decrease in the 
cellular content of the S655A mutant (∼40%) when compared to the S655E mutant (∼25%) 
(Fig. III.2, B and C). These values are statistically significantly different by the Student’s two-
tail t test. An intermediate down-regulation by ∼34% was observed for the wild-type APP-
GFP. Thus, after cellular depletion of APP-GFP proteins, the S655A protein was the most 
affected in terms of decreased APP-GFP levels. Conversely, the levels of the APP-GFP 
S655E protein were the less affected by this treatment. This differential inhibition is also 
observed when medium sAPP levels are evaluated upon the CHX block. Of note is that, as 
already observed, COS-7 cells have low levels of endogenous APP 695 isoform, and so the 
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majority of the sAPP695 observed (Fig. III.2, A, band h) derives proteolytically from the 
transfected full-length APP695-GFP. Under basal conditions the relative levels of medium 
secreted sAPP were found to be very similar for the three APP-GFP species: 91.0 ± 5.8 % for 
S655A and 96.0 ± 5.8 % for S655E, in comparison with Wt levels (taken as 100%). After the 
CHX exposure period (Fig. III.2, B and C), the S655A mutant showed the highest decrease in 
sAPP production (∼70% decrease). The S655E-derived sAPP levels were not so affected 
(∼40% decreased), and were more similar to Wt ones (∼50% decreased). The levels of 
inhibition of medium sAPP for the three species vary accordingly to the levels of inhibition of 
intracellular full-length APP-GFP, although more pronouncedly.  
In conclusion, upon protein synthesis inhibition, the S655A cellular pool is depleted at 
higher extent and/or is more difficulty replaced. Conversely, the S655E cellular pool is more 
easily maintained or recovered in these conditions. These results point to a higher rate of 
cellular catabolism for the S655A mutant, and a lower rate for the S655E mutant.  
   
III. 4. 3 – TIME-COURSE ANALYSIS OF TOTAL AND αSAPP695 PRODUCTION 
The influence of S655 phosphorylation on the cleavage of APP-GFP to total sAPP 
and αsAPP was further analyzed in detail. The pattern of sAPP production with time of CHX 
exposure was evaluated for the Wt and mutant proteins. Conditioned media, collected at the 
same time points as the cellular lysates of the previous section III.4.1, were subjected to 
Western blot analysis. Two antibodies, 22C11, for total sAPP detection (derived from alpha 
and beta-secretase cleavages) (Fig. III.3, A and B.I), and 6E10 for specific detection of αsAPP 
(Fig. III.3, A and B.II), were used. The sAPP band deriving from APP-GFP cleavage (band h) 
was quantified by densitometry analysis for Wt and mutants, and the data plotted graphically 
as fold-increase over sAPP production at 1:00 h (Graphs III.3, B). A table with the sAPP fold-
increases is presented, to allow for a better comparison of the results (Fig. III.3, C). 
 
 
Chapter III –S655 phosphorylation-dependent APP processing                                                                    - 118 - 
Sandra Vieira Guerra e Paz                                                                                                                CBC/UA, 2005 
 
 
 
Figure III.3. S655 Phosphorylation state-dependent APP processing to secreted total sAPP and αsAPP. 
A: Immunoblot analysis of total sAPP695 (upper blot) and αsAPP695 (lower blot) secreted and accumulated into 
conditioned medium with time of CHX exposure (hours in CHX). h, sAPP695; i, sAPP751/770. B: Graphs with 
time courses of total sAPP (B.I) and αsAPP695 (B.II) levels, expressed as fold-increases over 1:00 h sAPP level. 
C: Table with the data of the APP-GFP derived total (α+β) and αsAPP secretions. 
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Comparison of Figures III.3 B.I and B.II reveals that the patterns of total (α+β) sAPP 
and αsAPP secretion are similar for each of the APP-GFP species. Thus, the majority of the 
total sAPP695 produced consists, as expected, of the αsAPP695 form. The analysis of both types 
of graphs (Fig. III.3, B.I and B.II) indicates that the time-course pattern of Wt sAPP fold-
increase is similar to the S655E pattern until 2:00 h, but at 3:00 h and 5:00 h it approaches the 
S655A pattern. Wild-type sAPP levels seemed to reach a maximum at 2:00 h (fold-increase of 
2.49 ± 0.07), to have a small decrease until 3:00 h, followed by a small increase to 5:00 h. This 
2:00 h peak does not seem to happen or is ‘masked’ in the case of the phosphomutants. The 
S655A mutant has a more linear and slower increase in its sAPP levels, which reaches its peak 
(2.80 ± 0.35) only at 5:00 h. Hence, S655A sAPP production and/or secretion are initially 
comparatively delayed, relative to the Wt. The S655E species presented the faster and higher 
total and αsAPP fold-increases, which peaked at 3:00 h (fold-increases ∼3.3) (Fig. III.3, B and 
C). Hence, a hypothesis previously formulated of S655E having an enhanced half-life due to 
being less cleaved by secretases was discarded. Taken together, the cellular APP-GFP and 
sAPP results strongly support a lower targeting of the S655E mutant to degradation pathways. 
Results also support the previous Chapter II findings of a higher rate of S655E trafficking 
between the two main subcellular sites of α-secretase cleavage: the TGN and the plasma 
membrane. The S655A pattern of delayed sAPP secretion is also consistent with this mutant 
having a delayed Golgi exit and less PM retrieval to the Golgi (Fig.s II.8 and II.9). It is 
possible that in COS-7 cells the main site of α-secretase cleavage is the TGN/Golgi. In 
several cell lines such as H4 neuroglioma cells, CHO cells or the kidney-derived HEK cells 
(Kuentzel et al., 1993; Marambaud et al., 1997; Walter et al., 1997), sAPP was observed to be 
mainly produced intracellularly at the TGN/Golgi and possibly at secretory vesicles. Of note 
is that the previously observed undefined band (band nd, ∼105 KDa) in cells lysates (Fig. III.1, 
A) could potentially correspond to intracellularly produced sAPP695. This band was observed 
to be only present at the APP-GFP transfected cells and was found to be immunonegative 
with the APP C-terminal 369 antibody (data not shown). For the Wt and S655E species, the 
patterns of variation of band “nd” with time of CHX exposure (Fig. III.1, A) were very similar 
to the medium sAPP patterns of Fig. III.3, B. For the S655A mutant, however, the pattern of 
band “nd” variation is similar to the Wt pattern and not to S655A medium sAPP (Fig. III.3, 
B). A potential explanation may reside in S655A being cleaved intracellularly to a similar 
extent as the Wt species but having a delayed TGN sAPP secretion, consistent with the 
observed slower increase in the S655A medium sAPP levels (Fig. III.3, B and C).   
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III. 4. 4 – S655 PHOSPHORYLATION-DEPENDENT APP CLEAVAGE AT THE SECRETORY 
PATHWAY 
The previous results may indicate that intracellular APP and sAPP secretions are more 
delayed for the S655A species and occurs faster for the S655E mutant. One of the major 
pathways of sAPP production and secretion is the secretory pathway, specifically the TGN, 
secretory post-TGN vesicles and PM (Khvotchev and Sudhof, 2004). The traffic analyses of 
Chapter II strongly suggest that S655E is more incorporated into vesicles and that the S655A 
mutant is less targeted for vesicle incorporation. This could result in differential rates of 
intracellular sAPP production and secretion, along with differential amounts of APP delivered 
to the PM and subsequentially cleaved to sAPP. In order to further clarify this question, the 
APP-GFP species sAPP production was evaluated at 20 ºC. Incubating cells at 20 ºC causes a 
block in post-TGN vesicles secretion (Sabatini et al., 1996), but does not inhibit ER-to-Golgi 
traffic or cellular endocytosis (Kuismanen and Saraste, 1989; Ellinger et al., 2002). This low-
temperature block also allows for the APP cleavage to sAPP within the TGN, after sulphation 
(Kuentzel et al., 1993).   
APP-GFP expressing cells were first pre-incubated for 15 min at 20 ºC, to allow 
temperature lowering and stabilization. Cells were further incubated for 4 h at 20 ºC and APP-
GFP traffic monitored at specific time points of 20 ºC incubation: 0 min, 15 min, 30 min, 1 h, 
2 h, and 4 h. Figure III.4 shows that cells incubation at 20 ºC severely reduced APP-GFP-
positive vesicles, with the few cytoplasmic vesicles still observed at 4 h most probably 
resulting from endocytosis. In addition, a gradual higher condensation of the Golgi APP-GFP 
fluorescence could also be observed. These alterations occurred in a time-dependent manner, 
and are in agreement with a block in post-TGN vesicle release and even formation at the later 
periods (Fig. III.4, 2:00 and 4:00 h). The same effects could be observed for the three APP-
GFP species, but they started at different times of 20 ºC incubation. The S655A mutant is 
apparently faster to disappear from cytoplasmic vesicles, including vesicles near or at the 
TGN/Golgi area, than the other two APP-GFP proteins. A significant decrease in the 
number of S655A-containing vesicles is already visible by 1 h of 20 ºC incubation, with this 
effect being visible for the Wt and S655E only after 2 h at 20 ºC. In fact, at 2 h the S655E 
protein is still present in a large number of cytoplasmic vesicles at the TGN/Golgi, while 
fewer TGN vesicles are observed for the Wt. In addition, the fluorescing Golgi condensation 
effect also starts sooner for the S655A mutant (1 h), followed by the Wt (2 h) and the S655E 
species (2-4 h). These observations are in agreement with higher and lower targeting to post-
TGN vesicles for the S655E and S655A mutants, respectively, and relatively to the Wt protein.                              
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Further evaluation addressed the proteolytic processing of the APP-GFP species 
under the 20 ºC temperature block. The 2 h time point was chosen due to the fact that the 
block on post-TGN vesicles release was already visible for the three APP-GFP species (Fig. 
III.4). Moreover, although at 4 h this block was more severe, sAPP was reported no longer to 
be detectable upon 4 h of cells incubation at 20 ºC (Kuentzel et al., 1993; Walter et al., 1997). 
Hence, a subset of cells expressing the APP-GFP constructs were incubated for 2 h at 37 ºC, 
and another subset was first pre-incubated for 15 min at 20 ºC for temperature stabilization, 
cells conditioned medium was exchanged, and cells were further incubated for 2 h at 20 ºC. 
After the 2 h incubation period, cells and conditioned media were collected. Cellular and 
medium samples were subject to Immunoblot analysis with the 22C11 antibody (Fig. III.5, A), 
and the relevant bands quantified by densitometry analysis. The cellular APP and medium 
secreted sAPP levels are tabulated and represented graphically in Figure III.5, B. Cellular 
tubulin was also detected and used as control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure III.5. 20 ºC temperature effects on the APP-GFP proteins processing to sAPP. A: Immunoblot 
analysis of APP-GFP in cellular lysates (A.I) and medium secreted sAPP (sAPP) (A.II) upon 2 h of cells 
incubation at 37 ºC or 20 ºC. Cells lysates were also probed for tubulin as a control (A.I). a and b, immature and 
mature APP-GFP, respectively; d, endogenous APP; h, medium secreted sAPP695. B.I and B.II: Table and 
Graphic analysis, respectively, of the percentage of sAPP levels at 20 ºC relatively to the respective 37 ºC control 
levels.  
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Figures III.5, A.II and B, show that lowering the temperature from 37 ºC to 20 ºC 
results in lower levels of medium secreted sAPP derived from the three APP-GFP proteins or 
endogenous APP. Additionally, for all APP-GFP constructs, as for endogenous APP, the 
levels of the cellular forms increase upon incubation at 20 ºC (Fig. III.5, A.I), correlating with 
a lower cleavage of APP to sAPP. This has already been reported for H4 and HEK 293 cells 
(Kuentzel et al., 1993; Walter et al., 1997). The decrease in sAPP secretion is thought to result 
from a blockage in post-TGN vesicles and most probably also from lowering the temperature 
below the APP secretases temperature optima, which results in less efficient APP cleavage. 
Interestingly, while the 20 ºC-induced inhibitions on Wt and S655A sAPP secretions 
are similar, the S655E-derived medium sAPP seems much more sensitive to the temperature 
block (Fig. III.5, B). Upon 2 h of 20 ºC incubation around 40% of Wt and S655A sAPP were 
still detected in medium, while medium secretion of S655E sAPP fell to 25% of control levels 
(incubation at 37 ºC). In fact, when sAPP data at 20 ºC is corrected for the relative APP-GFP 
transfection rates, the medium S655E sAPP level is half (56.8 ± 12.0%) of Wt levels, while the 
S655A secretes the same (97.3 ± 7.1%) as the Wt. Hence, at 20 ºC part of Wt and S655A 
cellular populations are still able to be cleaved to sAPP and secreted while S655E is less able 
to produce and/or secrete sAPP. In the 20 ºC APP-GFP traffic assay (Fig. III.4, 0 - 2 h) the 
S655E protein was observed to be apparently more trapped inside post-TGN vesicles, while 
the Wt and S655A proteins were more blocked at the TGN/Golgi apparatus. Taken these 
results in consideration, it appears that S655E is mainly cleaved at post-TGN vesicles and/or 
at the plasma membrane. These are the subcellular locations where, during 2 h of 20 ºC 
incubation, S655E APP-GFP is trapped (post-TGN vesicles) or has difficulties to reach 
(plasma membrane).  
 
III. 4. 5 – PMA-INDUCED STIMULATION OF SAPP PRODUCTION 
In order to evaluate the PMA stimulatory effects on the APP-GFP proteins processing 
to sAPP, cells expressing the APP-GFP constructs were treated as described in the previous 
section (III.4.4), and incubated for 2 h with 0.5 µM PMA at 37 ºC or 20 ºC. Detailed 
procedures are described in section III.3.4.2 and Table III.1. The 2 h cells and conditioned 
media were collected, and analyzed by Western blot using the 22C11 antibody (Fig. III.6, A.I 
and A.II, respectively). The fold-increases in medium secreted sAPP levels, after PMA 
exposure, are tabulated in Figure III.6, B.I, and represented graphically (Fig. III.6, B.II). 
Cellular tubulin was also detected in the cells lysates and used as control. 
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Figure III.6. Temperature-dependent PMA-induced stimulation of APP-GFP cleavage to sAPP. A: 
Immunoblot analysis of cellular (A.I) and medium secreted (A.II) sAPP upon cells incubation at 37 ºC or at 20 
ºC, in the presence (PMA +) or absence (PMA -) of PMA. Cells lysates were also probed for tubulin as a control 
(A.I).  a and b, immature and mature APP-GFP, respectively; h, medium secreted sAPP695. B.I and B.II: Table 
and Graphic analysis, respectively, of the PMA-induced medium secreted sAPP fold-increases for each of the 
APP-GFP constructs at 37 ºC and 20 ºC.  
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Results show that the ability of PMA to stimulate medium sAPP levels is not 
statistically significantly different for the three APP-GFP constructs. This agrees with previous 
reported work (Da Cruz e Silva, 1993; Hung and Selkoe, 1994). Nonetheless, both S655A 
phosphomutants appeared to be less sensible to the PMA-induced stimulus than the Wt 
protein, in terms of sAPP increased secretion (Fig. III.6, A.II). At 37 ºC, PMA was able to 
induce a ∼3 fold-increase in medium secreted sAPP, but this stimulation decreased markedly 
at 20 ºC (Fig. III.6, B and C). Hence, part of the cellular mechanism by which PMA stimulates 
sAPP levels seems to be blocked at 20 ºC. Of note is that, in several cultured lines, a major via 
of phorbol esters-induction of sAPP levels occurs by activation of TGN intracellular sAPP 
production and secretion (Kuentzel et al., 1993; Marambaud et al., 1997; Jolly-Tornetta et al 
Wolf, 2000). Thus, it is possible that formation and/or release of APP and sAPP-containing 
post-TGN vesicles is part of the PMA stimulatory mechanism, as it is blocked upon 2 h of 20 
ºC incubation. This will be further addressed in the following Chapter. 
 
III. 4. 6 – COMPARATIVE ANALYSIS OF ABETA SECRETION  
The different times of retention at the TGN/Golgi for the two S655 APP-GFP 
mutants may result in different extensions of cleavage in the β-secretase pathway. Thus, the 
following studies addressed the β-secretase processing of the three APP-GFP species, which 
was evaluated directly by monitoring Abeta production. For this purpose, COS-7 cells 
expressing the APP-GFP cDNAs (Table III.1 and section III.3.3.3) were incubated for 3 h in 
the absence or presence of CHX. This time point was chosen, as by 3 h differences were 
already evident between the three APP-GFP constructs and APP depletion had not become 
significant. Conditioned media were collected for analysis of Abeta fragments, by means of 
Immunoprecipitation and separation by urea gel electrophoresis. The respective Immunoblots 
were probed with an antibody against the Abeta sequence, and the various Abeta forms were 
quantified by densitometric analysis (Fig. III.7). Experiment A (Fig. III.7, A) was performed in 
the presence of CHX and experiment B shows the results of three independent experiments 
performed in the absence of CHX (Fig. III.7, B).  
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Figure III.7. Abeta secretion. Conditioned medium was collected for 3 h in the presence (A) or absence (B) of 
CHX. I: Expression of cellular APP-GFP at 0 h; II: Immunoblots of media samples detected with Abeta specific 
antibodies; ssm, synthetic standard mix; udA, undefined Abeta forms, running between the 1-40 and 1-42 forms. 
III and IV: Graphs plotted with data obtained from the Immunoblots, where Abeta OD values are expressed as 
a ratio of the Wt OD levels: for each known Abeta form (III), or total Abeta forms (IV).  
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The Immunoblots were analysed by densitometry and the S655 mutants O.D. data are 
plotted as percentages or fold-increases over Wt O.D. data. Figure III.7 A.III and B.III show 
the relative levels of each of the detected and determined Abeta species as percentages of the 
respective Wt O.D. value (taken as 100%). Figure III.7 A.IV and B.IV shows the data on total 
Abeta species (the sum of each individual species), presented as fold-increases of the Wt O.D. 
sum value (taken as 1). These O.D. data were initially corrected for the relative cellular APP-
GFP expression levels (Fig. III.7, A.I and B.I). Of note is the presence of two bands (udA 
bands) in the Immunoblots, migrating ahead the 1-40 but before the 1-42 Abeta forms, which 
seem not to correspond to the 2-40 and are still undefined. 
Upon CHX exposure (Fig.s III.7, A) both mutants exhibited differences in total Abeta 
levels, as well as individual Abeta species. Total S655A Abeta production was 1.28 fold higher 
than Wt, and total S655E Abeta was 0.91 of Wt production. Under these conditions, the 
S655E Abeta fragments that decreased most were the 1-38 and 1-39 species. For the S655A 
mutant, the Abeta species which increased more was the 1-40 (fold-increase of 1.50). 
Unfortunately, only one experiment under CHX exposure was successful, as under these 
conditions the levels of Abeta produced are low and difficult to measure. Nonetheless, a 
tendency for S655A to result in higher and S655E in lower Abeta productions could be 
observed in the absence of CHX (experiment B). In fact, the comparative levels of Abeta 
secretion for the APP-GFP proteins followed similar patterns, whether monitoring each 
Abeta species separately (Graph III.7, B.III) or total Abeta (Graph III.7, B.IV). The S655E 
mutant presented a small decrease of total Abeta production (0.83 ± 0.13 of Wt values), and a 
small increase (1.10 ± 0.17) was observed for the S655A mutant. Although not high, these 
small differences in the levels of Abeta secreted into the medium for 3 h may be 
physiologically relevant, bearing in mind that AD is a slow progressive disease. 
 
- 129 - 
Phosphorylation-dependent Alzheimer’s amyloid precursor protein targeting  
III. 5 – CONCLUSIONS 
In this chapter the cellular fate of the Wt and S655 phosphomutant APP-GFP 
proteins was analyzed in terms of the APP catabolic pathways, such as restricted cleavages to 
sAPP and Abeta (directly) and other degradation pathways (indirectly). The major 
observations taken from these studies were: 
1. Mature Wt and S655A proteins are intracellularly catabolized to the same extent, 
although the S655A mutant presents a slightly shorter half-life. In turn, the S655E 
mutant presented a longer (doubled) half-life and its catabolism was reduced. 
2. The S655E species has a higher and faster rate of αsAPP increase, while the 
S655A mutant has a slowest rate of αsAPP production and/or secretion.  
3. Under CHX exposure, the mature S655E APP-GFP form is catabolized to a lower 
extent although being highly cleaved by the α-secretase. Hence, S655E seems to 
be preferentially targeted to the α-secretase pathway. 
4. Interestingly, both the time course patterns of cellular Wt mature APP-GFP and 
Wt medium (total and α) sAPP are initially similar to those obtained for S655E. 
However, the Wt APP-GFP processing becomes more similar to the S655A 
processing at the later time points. This strongly suggests that cycles of S655 
phosphorylation and dephosphorylation - which can only occur for the Wt APP-
GFP protein - are involved in these pathways of APP cellular processing. 
5. From the 20 ºC assays, we could observe that the S655E phosphomutant is more 
committed to be intracellularly packaged into post-TGN vesicles. In parallel, the 
S655E sAPP production is more severely inhibited at this temperature than for the 
other two APP-GFP proteins. These results suggest that majority of the S655E 
proteolytic cleavage to sAPP occurs in subcellular structures involved in the 
secretory traffic, most probably at post-TGN vesicles or at the plasma membrane.  
6. The S655A mutant is apparently less targeted to post-TGN vesicles packaging, as 
observed from its faster depletion of cytoplasmic vesicles at the TGN/Golgi 
region upon the 20 ºC temperature block. 
7. All the three APP-GFP species were able to respond to the phorbol ester PMA, in 
terms of enhanced sAPP secretion, with no statistically significantly differences 
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being observed in the PMA-induced sAPP fold-increases, either at 37 ºC or at 20 
ºC. Hence, at least one of the major mechanisms of PMA-induced sAPP 
stimulation is S655-phosphorylation state independent. Nonetheless, both S655 
phosphomutants had a tendency for being less stimulated by PMA to produce 
sAPP. 
8. Additionally to their differential rates of α-secretase processing, the S655 mutants 
showed a tendency to be differentially cleaved by the β-secretase pathway. 
Although no statistically significantly differences were observed for 3 h of Abeta 
medium secretion, during this period the S655A mutant was cleaved at a slight 
higher extent to Abeta, while the S655E mutant produced slightly less Abeta 
fragments. 
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CHAPTER IV – PKC-DEPENDENT APP PROCESSING 
 
 
IV. 1 – INTRODUCTION 
Direct and indirect approaches indicate that protein kinase C and protein 
phosphatases 1 (PP1) are enzymes putatively involved in the “in vivo” 
phosphorylation/dephosphorylation of the APP S655 residue. Interestingly, these proteins 
have been also implicated in the regulation of APP proteolytic processing and in the 
production of the neuroprotective αsAPP fragment, both in cultured cells and in cortical 
neurons. To date, the intracellular mechanisms of S655 phosphorylation and the protein 
kinases and phosphatases involved have not been widely studied. Previously, in section III.4.5 
(and as reported in da Cruz e Silva et al., 1993), we observed that the αsAPP-stimulation 
induced by phorbol esters (PE) did not seem altered for the S655 phosphorylation site 
mutants. Nonetheless, the results do not rule out a physiological relevant association between 
APP S655 phosphorylation and PE-induced sAPP production.  
Several isoforms of PKC are known, some of which have been differentially 
implicated in AD or in APP proteolytic processing. APP processing by α-secretase can be 
stimulated by PEs and by intracellular diacylglycerol (DAG) generation. At the same time, 
classical (Ca2+-dependent) and novel (Ca2+-independent) PKC isozymes, which are both 
activated by DAG and PEs, have been described to regulate APP processing. For example, 
specific overexpression of PKCα or PKCε in 3Y1 fibroblast cells led to enhanced levels of 
αsAPP production (Kinouchi et al., 1995). PKC isoforms are involved in specific intracellular 
functions, but the different isoforms display little substrate specificity “in vitro”. Selective 
PKC isoform spatial and temporal targeting to subcellular compartments appears to be a 
mechanism to achieve localization-dependent specificity (Maasch et al., 2000). Translocation 
of specific PKC isoforms to subcellular membranes allows for activation of the enzyme, as 
well as for positioning of the enzyme close to its substrate. PE-dependent PKC-activation 
functions through PKC targeting, in a mechanism both isoform-specific and cell type-
dependent (Pascale et al., 1996; Cedazo-Minguez, 1999). PKCα and β1 isoforms were 
reported to be regulators of α-secretase APP processing in the neocortex with constitutive 
overactivated PKC (Rossner et al., 2001b). In this model system, both isoforms translocated 
from the cytosol to the cell membrane, both were responsible for PE-driven enhanced PKC 
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activity, and for the concomitant αsAPP increased production. Recent findings (Lanni et al., 
2004) implicate PKCα and also PKCε in the regulated secretion of αsAPP in SH-SY5Y 
neuroblastoma cells. PKCα-deficient cells exhibited impaired αsAPP stimulation by PEs, but 
still responded significantly to carbachol stimulation. For PKCε-deficient cells, the PE 
response was even more severely impaired, in terms of increased αsAPP levels, and the 
carbachol-induction of αsAPP secretion was completely blocked (Lanni et al., 2004). In fact, 
blockade of PKCε activation attenuates the PE-induced αsAPP increase (Yeon et al., 2001; 
Zhu et al., 2001). Interestingly, the PKCα and PKCε isoforms rapidly translocated to different 
intracellular compartments in response to PE treatment: PKCα to the plasma membrane and 
PKCε to the PM and Golgi-like structures (Lanni et al., 2004). These are the two subcellular 
locations implicated in the APP α-secretase cleavage and αsAPP production. In fact, PKCα 
and δ but not ε are known to regulate the release of TGN secretory vesicles by inducing 
vesicle membrane scission from the TGN membrane (Sabatini et al., 1996). PKC was already 
reported to be involved in the budding and release of post-TGN APP-containing vesicles in a 
semi-intact PC12 cell system (Xu et al., 1995). More contradictory is the question if PE-
induced PKC activation induces higher APP cell surface expression, with reports 
demonstrating opposite results (e.g., Bullido et al., 1996; Jolly-Tornetta and Wolf, 2000). 
Nonetheless, in these studies the PKC isozyme(s) involved were not addressed.  
The only candidate protein to dephosphorylate S655 is the Ser/Thr protein 
phosphatase 1, PP1. This protein belongs to the family of the Ser/Thr phosphatases PP1/PP2 
(A and B). Three genes encode the ∼37 KDa PP1 catalytic subunits (PP1α, β/δ, and γ). The 
catalytic subunits of Ser/Thr phosphatases share high amino acid sequence homology but 
exhibit little substrate specificity “in vitro”. These enzymes were found to be targeted to their 
specific “in vivo” substrates by regulatory subunits that are highly specific (for review see e.g. 
Wera and Hemmings, 1995). The potential use of Ser/Thr PP1 regulatory proteins in AD and 
other neurodegenerative disorders has been discussed in Tian and Wang (2002) and in da Cruz 
e Silva et al. (2004a). The PP1/PP2A inhibitor okadaic acid was observed to induce APP cell 
surface expression in lymphocytes (Bullido et al., 1996). In fact, PP1 was observed to be 
directly involved in a mechanism of regulation of sAPP production and/or secretion (da Cruz 
e Silva et al., 1995a). Interestingly, okadaic acid exposure resulted in a 10 fold-increase in S655 
phosphorylation levels (Oishi et al., 1997). Therefore, PP1 is of research interest when 
considering S655 dephosphorylation and its effects on APP processing. A role in APP 
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processing and Abeta generation was also attributed to another Ser/Thr protein phosphatase: 
PP2B (or calcineurin). Specific inhibitors of PP2B induce an inhibitory effect on Abeta 
production similar to PKC activators (Desdouits et al., 1996). PP2B and PKC were suggested 
to have opposite regulatory effects on a Rab protein (Rab6), which is involved in Golgi exit 
and Golgi/endosomes intertraffic (Scheper et al., 2004). Interestingly, modulation of Rab6-
mediated transport has been shown to affect APP processing (see Scheper et al., 2004). 
Moreover, PP2B is known to inhibit “in vivo” the PP1 inhibitor DARPP-32 (Mulkey et al., 
1994; Yan et al., 1999b), thus potentially leading to PP1 activation. Hence, PP2B is also of 
interest, being that PP1 and PP2B activities are interconnected.  
 
 
IV. 2 – AIMS OF THIS CHAPTER 
The Ser/Thr kinases and phosphatases involved in APP S655 
phosphorylation/dephosphorylation are still elusive, thus the main objectives of this chapter 
were: 
 
1. To evaluate the subcellular localization of various PKC isozymes and Ser/Thr 
phosphatases in COS-7 cells, and compare it with APP subcellular distribution.  
2. To differentially down-regulate PKCα and PKCε, in order to evaluate the effects 
on endogenous APP and sAPP levels. 
3. To evaluate and compare the degree of co-localization between PKCα and PKCε 
and the APP-GFP (Wt and S655 phosphomutant) proteins.  
4. To evaluate the effect of PKCα and PKCε down-regulation on the subcellular 
distribution and processing of the APP-GFP proteins.  
5. To analyse the relative abundance of PKC isozymes and Ser/Thr phosphatases in 
rat cortex lysates. 
 
The mechanism(s) by which signal transduction via protein phosphorylation can 
regulate APP metabolism may include substrate/enzyme co-distribution and phosphorylation-
dependent subcellular targeting. Thus, COS-7 cells were first characterized in terms of the 
presence and subcellular distribution of different PKC isozymes and Ser/Thr phosphatases. 
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Furthermore, PKCα and PKCε were specifically investigated. These isozymes have been 
implicated in the regulation of α-secretase APP processing as well as being candidate proteins 
involved in regulating TGN/Golgi and endocytic functions. In Chapter II we showed that 
APP TGN and endocytic traffic could be affected by S655 phosphorylation. Hence, COS-7 
cells were subject to PDBu long-term exposures for differential PKCα/PKCε down-
regulation and APP cellular processing was evaluated under these conditions. Co-localization, 
subcellular localization, and subcellular processing to sAPP were also evaluated for the APP-
GFP species. The cerebral relevance of the enzymes putatively involved in APP S655 
phosphorylation/dephosphorylation was also addressed, with the relative abundance of APP, 
PKC and Ser/Thr phosphatases being evaluated in rat cortex lysates.  
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IV. 3 – MATERIALS AND METHODS 
A list of all solutions and protocols used, as well as other relevant information, is 
presented in the Appendix. All reagents were of cell culture grade or ultrapure. 
 
IV. 3. 1 – ANTIBODIES 
Besides the previously described anti-APP 22C11 and the anti-Syntaxin 6, other 
primary antibodies used in this study were rabbit polyclonal antibodies against PKC isozymes 
α, β, γ, δ, ε and ζ (Gibco, BRL), and polyclonal antibodies against the catalytic subunits of 
PP1α, PP1γ and PP2B (da Cruz e Silva, 1995b). Anti-β-Tubulin (Zymed, Portugal) and anti-
APP KPI domain (Chemicon, PG-Hitec) primary antibodies were also used. Secondary 
antibodies used were horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgGs, and 
alkaline phosphatase-conjugated anti-rabbit IgGs (Sigma-Aldrich) for colorimetric NBT/BCIP 
detection (Promega). Texas Red- (Molecular Probes, BD Biosciences) and Fluorescein-
conjugated (Calbiochem, VWR International) anti-mouse and anti-rabbit IgGs secondary 
antibodies were also used for Immunocytochemistry. Antibody dilutions and applications are 
presented in Table IV.1. 
 
 
Table IV.1. Antibodies, respective target proteins and specific dilutions used for the different techniques 
employed: IB., immunoblot; ICC, immunocytochemistry. 
Primary Antibody Secondary Antibody 
Target 
Protein/Epitope 
Assay/Dilution Assay/Dilution 
Horseradish Peroxidase-conjugated α-Mouse IgG 
IB dilution:  1:5000 
Fluorescein-conjugated α-Mouse IgG 
ICC dilution:  1:50 
APP N-terminal 
22C11 
IB dilution: 1:250 
ICC dilution: 1:50 
Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
Horseradish Peroxidase-conjugated α-Rabbit IgG 
IB dilution:  1:5000 
Fluorescein-conjugated α-Rabbit IgG 
ICC dilution:  1:50 
PKC isozymes 
Anti-PKC x 
IB dilution: 1:2000 
ICC dilution: 1:200 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
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Primary Antibody Secondary Antibody 
Target 
Protein/Epitope 
Assay/Dilution Assay/Dilution 
Horseradish Peroxidase-conjugated α-Rabbit IgG 
IB dilution:  1:5000 
Fluorescein-conjugated α-Rabbit IgG 
ICC dilution:  1:50 
PP1α 
Anti-PP1α 
IB dilution: 1:2500 
ICC dilution: 1:50 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
Horseradish Peroxidase-conjugated α-Rabbit IgG 
IB dilution:  1:5000 
Fluorescein-conjugated α-Rabbit IgG 
ICC dilution:  1:50 
PP1γ 
Anti-PP1γ 
IB dilution:  1:2500 
ICC dilution: 1:50 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
Horseradish Peroxidase-conjugated α-Rabbit IgG 
IB dilution:  1:5000 
Fluorescein-conjugated α-Rabbit IgG 
ICC dilution:  1:50 
PP2B 
Anti-PP2B 
IB dilution:  1:2500 
ICC dilution: 1:50 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
 
 
IV. 3. 2 – SUBCELLULAR DISTRIBUTION OF APP, PROTEIN KINASE C ISOFORMS AND 
SER/THR PROTEIN PHOSPHATASES IN COS-7 CELLS 
COS-7 cells were cultured in 100 mm cell culture plates with complete DMEM at 37 
ºC and 5% CO2. For Immunocytochemistry procedures using anti-APP, PKC, or PPs 
antibodies, cells were further divided into six-well plates containing polyornithine pre-coated 
glass coverslips, and incubated until ∼ 80% confluence was reached. Cells on coverslips were 
fixed, subject to Immunocytochemistry studies as described in section II.3.4.6, and analysed 
by epifluorescence microscopy. For the co-localization studies of APP with PKCα, PKCε, 
PP1α and PP2B, the Wt APP-GFP construct was used. Wt APP-GFP cDNA was transfected 
into COS-7 cells, as described previously in section II.3.3 and Table II.2.   
 
IV. 3. 3 – APP PROCESSING UPON PKCα AND PKCε DOWN-REGULATION 
Monolayers of COS-7 cells approximately 90% confluent were incubated with 1 µM 
of the phorbol ester phorbol-dibutyrate (PDBu) in DMEM (serum-free) or complete DMEM 
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(with serum). Cells and conditioned media were collected every two hours for ten hours, into 
1% SDS solutions. Samples were further analysed by Immunobloting using the anti-PKC 
isozyme antibodies, and the 22C11 and 6E10 antibodies.  
 
IV. 3. 4 – APP SUBCELLULAR LOCALIZATION UPON MODULATION OF PKCα AND PKCε 
LEVELS 
The wild-type APP695-GFP construct was transfected into COS-7 cells, as described 
above (section IV.3.2).  Cells were divided into six-well plates containing pre-treated 
coverslips, and treated with 1 µM PDBu for 8 hours. This was performed in the absence or 
presence of serum, in order to down-regulate PKCα alone or both PKCα and PKCε, 
respectively. After this period, cells were fixed, processed for Immunocytochemistry with the 
anti-Syntaxin 6 antibody (as in section II.4.3), and analysed by epifluorescence microscopy.  
 
IV. 3. 5 – S655 PHOSPHORYLATION-DEPENDENT APP SUBCELLULAR LOCALIZATION 
AND PROCESSING UPON MODULATION OF PKCα AND PKCε LEVELS 
Co-localization of the S655 phosphomutant APP-GFP proteins with PKCα and 
PKCε under basal conditions was first analysed using the same approach described above for 
the Wt construct (section IV.3.2). Further analysis focused on S655A and S655E APP-GFP 
subcellular distribution following 8 h of PKCα down-regulation, or PKCα plus PKCε down-
regulation. The same methodology as for the Wt APP-GFP was used (section IV.3.4).  
In parallel, the subcellular processing of the APP-GFP constructs was assayed under 
these conditions. COS-7 cells transfected with the APP-GFP constructs (as in section IV.3.2) 
were divided into six-well plates and incubated with 1 µM of PDBu under the presence or 
absence of serum. Conditioned media was first collected at 2 h of PDBu exposure and 
substituted by equal PDBu-containing fresh media. Upon a total of 8 h of exposure to PDBu, 
cells and conditioned media were collected into 1% SDS solutions. Samples were further 
analysed by Immunobloting using the 22C11 antibody.  
 
IV. 3. 6 – APP, PKCS AND PPS EXPRESSSION IN RAT CORTICAL LYSATES 
To evaluate APP, PKC isozymes and PP1/PP2B expression in rat cortex, 1% SDS 
lysates from young adult male rats were comparatively analysed with mass-normalized COS 
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cells lysates by Immunoblotting. The anti-PKCs and anti-PPs primary antibodies were used in 
addition to the anti-APP N-terminal and anti-APP KPI domain antibodies.     
 
IV. 3. 7 – SDS-PAGE, IMMUNODETECTION AND DATA ANALYSIS 
Total protein concentration was determined as described previously (section III.3.6). 
Mass-normalized aliquots were subjected to 7.5% (APP and sAPP detection) or 12% (PKCs 
and PPs detection) SDS-PAGE, and to Immunoblot procedures using the primary antibodies 
specified above (described in Appendix II). Immunodetection was accomplished using 
horseradish peroxidase-conjugated secondary antibodies and the ECL detection system. For 
Tubulin detection, alkaline phosphatase-conjugated antibodies and a colorimetric system 
(NBT-BCIP) were used. Protein band quantification was performed as described previously in 
section III.3.6. Data are expressed as mean ± SEM (Standard Error of the Mean) of triplicate 
determinations from at least three independent experiments. Statistical significance analysis 
was conducted by ANOVA followed by the two-tail Student’s t test (endogenous APP assays) 
or the Tuckey test (APP-GFP proteins assays). Statistical significance symbols used were (*) 
for statistically significant differences against control determinations or against Wt APP-GFP 
data, and (+) for statistically significant differences between the two S655 APP-GFP 
phosphomutants data. Statistical significance levels are presented as (*/+), for  p < 0.05; 
(**/++), for p < 0.01; and (***/+++), for p < 0.001. 
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IV. 4 – RESULTS AND DISCUSSION 
IV. 4. 1 – SUBCELLULAR DISTRIBUTION OF APP, PROTEIN KINASE C ISOFORMS AND 
SER/THR PROTEIN PHOSPHATASES IN COS-7 CELLS  
The subcellular distributions of PKC isozymes and Ser/Thr protein phosphatases 
putatively involved in APP S655 “in vivo” phosphorylation were analysed in COS-7 cells and 
compared with endogenous APP distribution (Fig. IV.1). Cells were subject to 
Immunocytochemistry procedures using the 22C11 antibody against APP or specific 
antibodies against six different PKC isozymes [conventional (α, β, γ); novel (δ, ε); and atipical 
(ζ)], and three Ser/Thr protein phosphatases (PP1α, PP1γ and PP2B).  
The subcellular distribution of endogenous APP (Fig. IV.1, A) revealed to be similar 
to the previously observed Wt APP-GFP distribution (Chapter II), and as reported for other 
cultured cell lines (e.g. Peraus et al., 1997; Kouchi et al., 1998). APP is therefore present 
mainly at perinuclear structures, namely the Golgi (G) and the ER, and throughout the 
cytoplasm in small vesicles and in smooth ER-like tubular structures. Faded localization at the 
plasma membrane is observed only in some cells.  
For PKC isozymes, PKCα and PKCε isozymes were the most easily detected PKC 
isoforms in COS-7 cells (Fig. IV.I, B). The β and ζ isozymes were detected but at low levels, 
and the γ and δ were not detectable (Fig. IV.I, C) with these immunocytochemistry 
procedures. Of note is that these γ and δ isozymes have not been particularly associated with 
APP processing. Figure IV.I B, reveals that the PKC isozymes have isoform-specific 
distributions, but are all nuclear enriched. The PKCα and PKCε isoforms are found speckled 
in the nucleus (N), but excluded from the nucleolus (Nu), in cytoplasmic vesicular structures 
(CVS) and at the plasma membrane (PM). The β and ζ isoforms are mainly found at the 
nucleus, being concentrated at nucleolar (Nu)-like structures.  
The three Ser/Thr protein phosphatases studied are all nucleus-enriched, with PP1γ 
being the only one present at the nucleolus (Fig. IV.I, D). Of note is that PP1α and PP2B 
nuclear staining is speckled. Additionally, PPs are also found at cytoplasmic locations, with 
PP1α and PP2B being found in cytoplasmic vesicular structures. Of note is that PP2B is the 
phosphatase tested that is found in a higher number of cytoplasmic vesicles, and that it is also 
distinctly visible at cells plasma membrane. 
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Figure IV.1. Immunocytochemistry analysis of COS-7 cells endogenous subcellular distribution of A: 
APP; B: Four PKC isozymes (α, β, ε, and ζ; detectable) C: Two PKC isozymes (γ and δ; absent); D: 
Three Ser/Thr phosphatases. G, Golgi region; ER, endoplasmic reticulum; PM, plasma membrane; N, 
nucleus; Nu, nucleolus; CVS, cytoplasmic vesicular structures. C, control cells subject to Immnunocytochemistry 
procedures with secondary antibody only. PhC, Phase constrast. 
 
 
Further analysis focused on the putative co-localization of Wt APP-GFP with PKCα, 
PKCε, PP1α and PP2B (Fig. IV.2). These were the PKC and phosphatase proteins that were 
both easily detected in COS-7 cells and found to be distributed at known sites of APP 
processing: cytoplasmic vesicles and PM (Fig. IV.1). Wt APP-GFP seems to have some co-
localization (arrows in the overlay panel) with PKCα at the Golgi region and at very few 
cytoplasmic vesicles (Fig. IV.2, A). PKCε immunoreactivity was mainly observed in nuclear 
speckles, but also in small cytoplasmic vesicles, in this case concentrated at or near the Golgi 
area (Fig. IV.2, B). Wt APP-GFP and PKCε were found to co-localize in some of these Golgi 
vesicles. Figure IV.2 C shows that PP1α and Wt APP-GFP apparently only co-localize in 
some punctate structures at the PM. In addition, very few cytoplasmic vesicles were found to 
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be both positive for Wt APP-GFP and PP2B, and although some of these were found near 
the PM (Fig. IV.2, D), PP2B does not seem to co-localize with Wt APP-GFP specifically at 
the PM. 
 
 
Figure IV.2. Co-localization of Wt APP-GFP with PKCα (A), PKCε (B), PP1α (C) and PP2B (D). COS-7 
cells transfected with the Wt APP-GFP construct were subject to immunocytochemistry procedures using Texas 
Red-conjugated secondary antibody for PKCs and phosphatases detection. CVS, cytoplasmic vesicular structures; 
G, Golgi area; PM, plasma membrane; N, nucleus.  
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IV. 4. 2 – PKCα AND PKCε DIFFERENTIAL DOWN-REGULATION, AND THE EFFECT ON 
CELLULAR APP 
Previous observations from our group and others (e.g. Bourgoin et al., 1996) indicate 
that expression of different PKC isozymes, namely PKCα and PKCε, can be differentially 
modulated upon exposure to phorbol esters, such as PMA or PDBu. Thus, this approach was 
used to evaluate PKCα and PKCε involvement in APP cellular processing (see section IV.3.3 
for details). First, the expression levels of four PKC isozymes (α, β, ε and ζ) were monitored 
upon COS-7 cells treatment with 1µM PDBu, in a time-dependent manner, and both in the 
absence or presence of serum (Fig. IV.3). Cellular Tubulin levels were used as control. 
 
Figure IV.3. PKC isozyme protein expression levels upon exposure to PDBu. Immunoblot analysis of 
experiments carried out in DMEM, without serum (A.I) or in complete DMEM (A.II). Tubulin expression levels 
were monitored as a control. B: The cellular levels of PKCα and PKCε were analysed in COS-7 cells lysates 
maintained in DMEM with or without serum for 2 hours. 
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During PDBu exposure in the absence of serum the only isozyme found to be down-
regulated was PKCα, the levels of the β and ζ isozymes increased slightly, and PKCε was up-
regulated (Fig. IV.3, A.I). In contrast, PDBu addition in the presence of serum, both the 
PKCα and ε isozymes were down-regulated (Fig. IV.3, A.II). The levels of the β isozyme were 
found to be unaffected with time, and the ζ isozyme was barely detected. The main 
differences in the PKCα and ε isozymes levels were found immediately upon 2 hours of 
PDBu exposure. In minus serum conditions PKCα decreased to less than half of its initial 
levels and PKCε increased by 70%, while in plus serum conditions both isozymes decreased 
to 60 and 30%, respectively. These effects were PDBu specific as the withdrawal of serum 
alone did not result in PKC levels alterations (Fig. IV.4, B). Subsequently, the effects of these 
PKCα and PKC(α+ε) down-regulation on holo APP levels (Fig. IV.4) were analysed.  
 
 
Figure IV.4. Effect of PDBu mediated PKC alpha and epsilon down-regulation (D.R.) on intracellular 
levels of holo APP. A: Immunoblots of endogenous holo APP with time, in the absence (left panel, n=3) or 
presence (right panel, n=2) of serum in the medium. B: Graphic representation of the PDBu-dependent fold-
increase in holo APP levels, over the respective level at 0:00 h, in the absence (I) or presence (II) of serum.   
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With increasing periods of exposure to PDBu there was a significant increase in the 
intracellular levels of endogenous APP (Fig. IV.4, A - left panel - and B.I), but only in the 
absence of serum. This effect was dependent on the period of exposure and also on the 
concentration of PDBu (data not shown) with maximal levels of expression (2.33 ± 0.33 fold-
increase) for 1 µM PDBu and 10 h of exposure (Fig. IV.4, B.I). In the presence of serum, 
intracellular holo APP levels are unaffected with time, either in the absence or presence of 
PDBu (Fig. IV.4, B.II). Being that in the presence of serum PKCε levels are additionally 
down-regulated, these suggest that PKCε is implicated in the holo APP increase. Friedman et 
al (1997) have also observed a PMA dose-dependent up-regulation of APP levels in PC12 
cells, which appeared related to differential down-regulation of PKC isozymes. Up-regulation 
of the app gene may account for this up-regulation effect, as PDBu is documented to affect 
the AP-1 promoter resulting in increased APP mRNA levels (Trejo et al., 1994). In fact, both 
PKCα and PKCε have been reported to regulate transactivation of the AP-1 promoter, but 
with prevalence for the epsilon isozyme (Uberall et al., 1994; Soh et al., 2003). Hence, in the 
light of the results, PKCε may be involved in the APP mRNA up-regulation. In addition, 
PKCε may also be involved in APP recycling pathways and enhance APP half-life by 
potentially “rescuing” it from degradation. In fact, a possible route of endosomes-to-TGN 
retrieval is Rab6-dependent (Mallard et al., 2002) and, interestingly, Rab6-mediated transport is 
up-regulated by PKC and affects APP processing (Scheper et al., 2004). Furthermore, PKCε 
has been specifically implicated in the regulation of endocytic and Golgi-related processes 
(Lehel et al., 1995; Hoy et al., 2003). 
 
IV. 4. 3 – PKCα AND PKCε IN APP REGULATED CLEAVAGE TO SAPP  
Further analysis addressed the processing of endogenous APP to medium secreted 
sAPP under the conditions of differential PKC alpha and epsilon down-regulation, by means 
of Immunoblotting procedures. The accumulative secretion of sAPP under PDBu exposure 
was analysed in a time-dependent manner and compared with control secretion (Fig. IV.5). 
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Figure IV.5. Effects of PKC down-regulation (D.R.) on sAPP production in a time-dependent manner. 
A: Immunoblots of sAPP cumulative secretion in the absence or presence of PDBu and serum. B.I and II: 
Quantitative analysis of the sAPP levels with time and in the absence or presence of serum, respectively. Data are 
presented in terms of fold-increase, where control (- PDBu) sAPP levels at 2:00 h are taken as 1.   
 
 
Following exposure of cells to PDBu, the levels of medium secreted sAPP are 
increased at all time points of drug exposure, both in the absence or presence of serum (Fig. 
IV.5, A and B). These increases were confirmed to be mainly due to the αsAPP fragment, as 
observed by Immunoblot analysis with the 6E10 antibody (data not shown). For a quantitative 
analysis, O.D. data from the sAPP bands densitometric analysis were plotted in Figures IV.5 
BI and B.II, as fold-increases over the initial control sAPP levels at 2:00 h. Results following 2 
hours of PDBu exposure show that while in serum-free conditions PDBu is able to increase 
sAPP levels by three-fold (2.91 ± 0.24), when serum is present the increase is less and about 
two-fold (2.15 ± 0.15) (Fig. IV.5, B.I and B.II). Of note is that the presence of serum alone 
has an up-regulating effect on sAPP secretion (compare control 2 h sAPP levels at Fig. IV.5, 
A). Following the 2 h initial period, the PDBu-induced fold-increase in sAPP secretion (over 
control levels at the same time point) appears to slowly decrease with time of PDBu exposure. 
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In fact, at 10 hours of PDBu exposure the accumulative sAPP levels are no longer statistically 
significantly different from control levels, for both serum conditions. These results suggest 
that there is a lost of the ability of PDBu to stimulate sAPP production/secretion with time. 
Work from our lab revealed that after cells exposure to PDBu for the above time points, 
posterior additions of PDBu have gradually decreasing stimulatory effects on sAPP (da Cruz e 
Silva et al., in preparation). This study was only performed in the absence of serum. Hence, 
there is a gradual loss of further PDBu stimulation (“acute” stimulation following prolonged 
PDBu exposure) that correlates well with the decrease in PKCα levels (Fig. IV.3, A.I). PKCα 
may be involved in part of the stimulatory mechanism of PE action on sAPP levels, with this 
question being further addressed below in section IV.4.5.3. 
  
IV. 4. 4 – EFFECT OF MODULATING PKCα  AND PKCε ON APP SUBCELLULAR 
LOCALIZATION 
Along with the observed consequences that down-regulating PKCα alone or 
PKCα and PKCε had on APP cellular processing, further analysis focused on the effects that 
these down-regulations may have on APP subcellular localization. Transfection with the Wt 
APP695-GFP was thus used (method described in section IV.3.4), and its subcellular 
localization monitored following 8:00 h exposure to PDBu in the absence or presence of 
serum (Fig. IV.6). 
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Figure IV.6. Effect of PKC alpha down-regulation and PKC epsilon up- or down-regulation (D.R.) in 
the subcellular localization of Wt APP-GFP in COS-7 cells. A: in the absence (C) or presence of PDBu 
(PDBu) for 8 hours, and in the absence of serum (A.I) or in the presence of serum (A.II). G, Golgi apparatus; V, 
cytoplasmic vesicles. B: Co-localization of Wt APP-GFP with the TGN/Golgi marker Syntaxin 6. C: The 
percentages of cells with high green fluorescence intensity at the Golgi (G+++) or presenting green fluorescent 
cytoplasmic vesicles (V+) were scored in serum-free conditions (PKC alpha D.R.). 
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In the absence of serum and upon 8:00 h of exposure to PDBu, the number of 
cytoplasmic vesicles per cell decreased dramatically (Fig. IV.6, A.I). In fact, there was a drop in 
the number of cells with a significant number of fluorescent cytoplasmic vesicles from 70% to 
18% (Fig. IV.6, C). PDBu treatment also caused the number of cells with high fluorescing 
Golgi to increase marginally, and more significantly the fluorescence in the Golgi became 
more intense, rather suggesting swelling of this structure (Fig.s IV.6, A.I and C). Co-
localization of this subcellular structure with Syntaxin 6 confirmed its identity as the 
TGN/Golgi (Fig. IV.6, B). Thus, decreased APP trafficking via vesicle formation upon PDBu 
exposure and down-regulation of PKCα is evident. When this assay was performed in the 
presence of serum (Fig. IV.6, A.II), the resulting PDBu-induced phenotype was very similar in 
terms of a high decrease in the number of cytoplasmic fluorescent vesicles. Nonetheless, in 
serum-plus conditions the number of cells with intense Golgi did not appear to increase as 
much, and this structure did not swell dramatically as in the absence of serum. In fact, scoring 
the number of cells with swelled Golgi structures resulted in 67.4 ± 1.5% for the serum-free 
condition but only 22.2 ± 3.5% (p < 0.0001) for the serum-plus condition. The absence of 
Golgi swelling and the lower increase in fluorescence intensity indicates that less APP is 
trapped in this organelle.  
These results suggest the involvement of PKCα in APP TGN/Golgi exit, with its 
down-regulation leading to inhibition of APP packaging and/or export into post-TGN 
secretory vesicles. This is in agreement with previous findings indicating a central role for 
PKC in the control of constitutive and regulated APP Golgi exit (Xu et al., 1995), and a role 
for PKCα, but not ε, in the formation and budding of post-TGN vesicles (Bourgoin et al., 
1996; Sabatini et al., 1996, Singer et al., 1996). The decrease in APP cytoplasmic vesicles, 
induced by PKCα down-regulation, seems therefore to be the cause of the previously 
observed gradual loss of acute PDBu-induced sAPP stimulation with time of PDBu exposure. 
Thus, a mechanism by which phorbol esters induce sAPP levels includes stimulation of the 
budding of TGN APP-containing vesicles, in a PKCα-dependent manner.    
Additionally, the observed absence of Golgi swelling and lower Golgi intensity when 
serum and PDBu are both present (and both PKC isozymes are down-regulated), indicates a 
lower APP Golgi population under these conditions. Previously we have observed that the 
PKCε isozyme seems to be implicated in APP up-regulation (Fig. IV.4), and under conditions 
of PKCε D.R. (serum-plus) the APP levels are lower than under PKCε U.R. (serum-free) 
conditions. Furthermore, the PKCε isozyme has been implicated in positive regulation of the 
Chapter IV – PKC-dependent APP processing                                                              - 152 - 
 
Sandra Vieira Guerra e Paz                                                                                                                CBC/UA, 2005 
endocytic processing and is putatively involved in PM-to-TGN retrograde traffic (as 
previously observed in section IV.4.2). Supporting this hypothesis are the findings that upon 
phorbol ester exposure, PKCε is rapidly activated and up-regulates endocytosis, while PKCα 
is activated later and inhibits the initial PKCε effect on endocytosis (Song et al., 2002). 
Further, in response to phorbol ester treatment, PKCα was reported to translocate to the 
plasma membrane and PKCε to Golgi-like structures (Lanni et al., 2004).  
 
IV. 4. 5 – S655 PHOSPHORYLATION-DEPENDENT APP CELLULAR FATE UPON 
MODULATION OF PKCα AND PKCε LEVELS  
Further work focused on the putative involvement of S655 phosphorylation in PKC-
dependent APP cellular traffic and processing. For that, the subcellular localization and 
proteolytic processing of the S655 phosphomutants and Wt APP-GFP proteins were 
comparatively analysed under normal conditions or under conditions of PKCα specific or 
PKCα and PKCε down-regulation (see section IV.3.5 for procedure details).  
IV. 4. 5. 1 – S655 phosphomutants subcellular co-localization with PKCα and PKCε 
The subcellular co-localization of the three APP-GFP species with both PKCα and 
PKCε proteins, under normal conditions, was first addressed. For that, COS-7 cells 
transfected with the APP-GFP constructs were grown on coverslips and subject to 
Immunocytochemistry procedures using specific antibodies for PKCα and PKCε isozymes 
and Texas Red labelling (Fig. IV.7).  
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Figure IV.7. Wt and S655 phosphomutants APP-GFP subcellular co-localization with PKCα and PKCε 
(red labelled). Arrows in overlay microphotographs indicate vesicular structures with co-localization.  
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Immunocytochemistry results show that APP-GFP green and PKCα red fluorescence 
(Fig. IV.7, upper panel) seem to co-localize in few small cytoplasmic vesicles per cell, near the 
Golgi region (white arrows). Analysis of the co-localization leads to the suggestion that the 
S655A mutant might present a higher co-localization degree with this isozyme. The S655E 
protein, however, has an apparent lower degree of co-localization and is similar to the Wt 
APP-GFP. In contrast, the three APP-GFP proteins appear not to co-localize with nuclear 
PKCε speckles, and other PKCε-positive structures are difficult to visualize (Fig. IV.7, lower 
panel). As the cytoplasmic vesicles of both these PKC isozymes are very small, further co-
localization studies will be forthcoming using confocal microscopy procedures. 
IV. 4. 5. 2 – S655 phosphomutant subcellular distribution upon PKCα and PKCε D.R. 
The subcellular distribution of the S655 phosphomutants upon modulation of PKCα 
levels alone, or PKCα and PKCε down-regulation was also addressed. Briefly, cells expressing 
the APP-GFP constructs were exposed for 8 h to 1 µM PDBu, in the absence or presence of 
serum. Cells were subsequently subjected to Immunocytochemistry analysis using the anti-
APP 22C11 antibody, which allows for APP-GFP and endogenous APP detection (Fig. IV.8).  
Epifluorescence analysis revealed that for the three APP-GFP species there is a sharp 
decrease in the number of APP cytoplasmic vesicles after 8 h of PDBu exposure, similar to 
that previously observed for the Wt (Fig. IV.6). In serum-free conditions (upper panel) higher 
Golgi fluorescence intensity and Golgi swelling is observed for the three APP-GFP species. In 
serum-plus conditions (Fig. IV.8, lower panel), these Golgi PDBu-induced features appear less 
severe for the Wt and S655A species, although this is not so evident for the S655E mutant. 
Immunocytochemistry analysis (Fig. IV.8, 22C11 microphotographs) revealed an almost 
completely overlap between the subcellular distributions of endogenous APP and APP-GFP, 
although the red fluorescence was more intense. These confirmed holo APP-GFP species and 
endogenous APP Golgi retention under conditions where PKCα levels are highly decreased 
(Fig. IV.3). PKCα seems therefore to be involved in APP incorporation into TGN vesicles in 
an S655-phosphorylation independent manner. The low levels of APP-GFP and PKCα co-
localization (Fig. IV.7, overlay panel) further suggest that the mechanism of action of PKCα is 
fast and transient. Of note is that the S655A mutant has an apparent higher co-localization 
with PKCα at cytoplasmic vesicles near the Golgi, consistent with S655A impaired and 
delayed Golgi exit, and with more time spent on S655A incorporation into post-TGN vesicles.  
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Figure IV.8. Wt and S655 phosphomutants APP-GFP (green) and total cellular APP (22C11, red) 
subcellular localization upon 8 h of PDBu exposure (+ PDBu), in the absence or presence of serum. 
Control, non-PDBu exposed cells G, Golgi region. 
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A putative involvement of PKCε in APP PM-to-TGN retrograde transport still 
remains to be further elucidated, as well as if APP S655 phosphorylation may constitute part 
of the PKCε mechanism of sAPP induction. It is tempting to speculate that the S655E mutant 
may retain more the Golgi swelling and intensity in conditions of PKCε down-regulation due 
to its higher Golgi retrograde transport. Future work may focus, for example, S655 
phosphorylation state-dependent APP-GFP localization at the TGN/Golgi during the first 2 
h of PDBu exposure. This is a period where PKCε already suffers a major D.R. (Fig. IV.3), 
and where subcellular distribution differences may be more distinctly visible for the three 
APP-GFP species.  
IV. 4. 5. 3 – Wt and S655 phosphomutant processing with PKCα and PKCε D.R. 
In parallel with the subcellular assays, the processing of APP-GFP species to sAPP 
was evaluated under conditions of specific PKC isozymes down-regulation. APP-GFP 
expressing cells were exposed to PDBu for 8 h in the presence or absence of serum. Media 
samples were collected upon 2 h of PDBu exposure, media substituted for equal PDBu-
containing medium, and media was further collected upon a total of 8 h of PDBu exposure 
(Fig. IV.9). 
 
 
 
Figure IV.9. PDBu effect on APP-GFP Wt and S655 phosphomutants processing. Immunoblot analysis of 
sAPP in media collected upon 2 h and 2-8 h of PDBu exposure. Both serum-free and serum-plus conditions 
were assayed. h and i, medium secreted sAPP695 and sAPP751/770, respectively. 
 
 
Figure IV.9 shows that not only at the initial 2 h period of exposure to PDBu, but also 
in the following 6 h (“2-8 h”), the levels of sAPP are higher in the PDBu exposed cells relative 
to control determinations. This was true for the three APP-GFP species (band “h”) and for 
Wt       S655A            S655E 
PDBu:     -       +       -       +       -      +       -       +       -     +        -      + 
   h:          2             2 - 8             2             2 - 8            2             2 - 8   
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h 
i 
h 
i 
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endogenous sAPP secretion (band “i”), under both serum conditions. Of note is that upon 2 h 
of PDBu exposure, Wt sAPP levels suffered a 3.5 fold-increase in serum-free conditions and 
only a 2.5 fold-increase in serum-plus conditions, similarly to endogenous APP (section 
IV.4.3). In the subsequent exposure period (2-8 h) a robust PDBu-induced sAPP increase 
could still be observed for all species. In synthesis, enhancement of sAPP and APP-GFP 
levels seem to occur independently of the APP phosphorylation state at the S655 residue, as 
previously observed in the PMA assays (see Fig. III.7), and occur under both serum-plus and 
serum-minus conditions.  
Taken together with the observed effects of PKC isozymes D.R. in APP-GFP 
subcellular distribution (Fig. IV.8), PDBu appears to exert its long-term sAPP stimulatory 
effects in an APP population that is trapped at the TGN/Golgi and available for intracellular 
cleavage. Nonetheless, concentrating APP at the TGN/Golgi region in the absence of post-
TGN vesicles seems not, per se, a condition that leads to an enhancement in sAPP production 
(previous results of 20 ºC assays, Fig.s III.4 and III.5). Hence, it is probable that an additional 
step, as e.g. PDBu-induced PKC-activation of TGN α-secretase (Skovronsky et al., 2000), 
may be required and occurring. The S655 phosphomutations are therefore not sufficient to 
override the PKC isozymes down-regulation in terms of APP TGN vesicular exit. This points 
to more than one point of phosphorylation control, i.e., more than one event that is regulated 
by phosphorylation. 
 
IV. 4. 6 – APP AND PKCS/PPS EXPRESSION IN RAT CORTEX  
As APP S655 has been reported to occur “in vivo” in mammalian brains (Oishi et al., 
1997; Lee et al, 2003a), a neuronal system was also characterized in terms of the co-
distribution of APP and its putative S655 phosphorylation/dephosphorylation enzymes. The 
relative expression of APP, PKC isozymes and Ser/Thr phosphatases, were thus determined 
in rat cortex lysates and COS cells (Fig. IV.10).  
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Figure IV.10. Comparison of COS cells and rat cortex (Ctx) expression levels of APP (A), PKC isozymes 
(B) and Ser/Thr protein phosphatases (C). c, COS immature APP isoform 695; d, COS immature APP 
isoforms 751/770; c’, rat cortical immature APP isoform 695; d’, rat cortical immature APP isoform 751/770. 
Arrows B and C indicate the PKCs/PPs specific bands. 
 
 
 
As previously observed, COS cells present almost only KPI-positive APP isoforms 
(751 and 770, band d), and much less APP695 (Fig. IV.10, A). This was expected, as COS cells 
are derived from peripheral (kidney) cells. The rat cortical samples are in contrast enriched in 
the immature APP 695 isoform (band c’). 
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In agreement with the Immunoblot analysis (Fig. IV.3), COS-7 cells have mainly 
PKCα and PKCε isozymes, with PKCβ and ζ being barely detected and PKCγ and δ 
undetected (Fig. IV.10, B). Comparatively, rat cortex presents high expression of all PKC 
isozymes with exception of the ζ (Fig. IV.10, B). Relative to the Ser/Thr phosphatases protein 
expression (Fig. IV.10, C), COS-7 cells have significant amounts of both PP1 isoforms tested, 
but very low amounts of PP2B. In rat cortex tissue, PP1α and PP2B are highly enriched, 
especially PP2B, while PP1γ was present at considerable although lower amounts. Finally, with 
the exception of the PKCζ, both type of enzymes (PKC isozymes and Ser/Thr phosphatases) 
are more abundant in the cortical lysates than in COS cells samples.  
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IV. 5 – CONCLUSIONS 
The putative system of APP S655 cellular kinases and phosphatases was addressed in 
terms of their co-localization with APP. The roles of PKCα and PKCε in APP cellular fate 
were also analysed. The main conclusions of these studies were: 
1. In COS-7 cells the PKC isozymes which are more abundant and apparently 
present at subcellular sites of α-secretase processing (plasma membrane and 
cytoplasmic vesicles) are PKCα and PKCε.  
2. While the Ser/Thr phosphatase PP1γ is mainly nuclear, PP1α and PP2B were 
observed at the plasma membrane and cytoplasmic vesicles. Some co-localization 
with Wt APP-GFP was observed at the plasma membrane (PP1α) and at 
cytoplasmic vesicles (PP2B). 
3. In conditions of long-term exposure to PDBu in serum-free medium, which leads 
to PKCα down- and PKCε up-regulation, the levels of cellular APP suffer an up-
regulation (∼2 fold-increase). This increase seems PKCε-dependent as 
demonstrated by its absence when both PKC isozymes are down-regulated.  
4. PKCα seems to contribute more for the phorbol ester sAPP stimulation than 
PKCε. In a simplistic way we could say that the first seems to contribute for 2/3 
and the latter for 1/3 of the PDBu-induced sAPP stimulation.  
5. PKCα down-regulation leads to a loss of APP-containing cytoplasmic vesicles, 
indicating a role for this PKC isozyme in APP TGN/Golgi secretion, specifically 
in the post-TGN vesicle formation.  
6. This PKCα-dependent mechanism is independent of the APP S655 
phosphorylation state. Nonetheless, results do not eliminate that S655 
phosphorylation up-regulates sAPP vesicle incorporation at the TGN. In fact, an 
apparent higher degree of S655A and PKCα co-localization supports this mutant 
being slowly packaged into post-TGN vesicles. 
7. Under prolonged PKCα down-regulation, PKCε up-regulation seems to lead to a 
higher APP Golgi retention. A working hypothesis comprehends the involvement 
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of PKCε in the up-regulation of APP endocytosis and consequently APP PM-to-
Golgi retrograde transport.  
8. Long-term exposure to PDBu results in the inhibition of APP-containing post-
TGN vesicles formation and higher APP Golgi retention. This is accompanied 
with higher sAPP production. Hence, the induction of APP cleavage to sAPP 
under long-term PDBu exposure appears to correlate with the amounts of APP 
available at the Golgi.  
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CHAPTER V – S655 PHOSPHORYLATION-DEPENDENT 
APP695 NEURONAL TARGETING 
 
V. 1 – INTRODUCTION 
The physiological role of APP in normal brains and in AD is the focus of considerable 
research. Full-length APP and its longer proteolytic product sAPP (soluble APP) have 
neuroprotective, neuritogenic and synaptogenic properties (Furukawa et al., 1996a,b; Ando et 
al., 1999; Torroja et al., 1999b, Cai et al., 2006). Several other functions have been attributed to 
APP that include roles in substrate-cell and cell-cell adhesion (Kusiak et al., 2001, Soba et al., 
2005), as a gene expression transactivator by RIP signalling (Cao and Sudhof, 2001; Baek et 
al., 2002; Koo, 2002; Cao and Sudhof, 2004), and in vesicular traffic through neuronal 
terminals (Torroja et al., 1999a; Kamal et al., 2001; Muller and Kins, 2002; Sisodia, 2002; 
Satpute-Krishnan et al., 2003; Cottrell et al., 2005; Cai et al., 2006). Missorting of APP and 
accumulation of APP in neurons may contribute to some forms of AD and correlates with 
mild neuronal damage and impairment of axonal transport (L’Hernault and Arduengo, 1992; 
Tomimoto et al., 1995; Ahlgren et al., 1996; Praprotnik et al., 1996; Tienari et al., 1996a; 
Torroja et al., 1999a; Kamal et al., 2001; Muller and Kins, 2002; Pigino et al., 2003). In fact, 
APP binds the axonal motor protein kinesin, putatively via binding to KLC (Kamal et al., 
2000; 2001), and during its axonal transport APP may generate Abeta peptides (Amaratunga 
and Fine, 1995; Kamal et al., 2001; Muller and Kins, 2002; Yoon et al., 2006).  
Neurons have a highly polarized structure that includes specialized terminals, and APP 
undergoes neuronal sorting and polarized transport. While intraneuronal APP is localized both 
at the axonal and somatodendritic domains, plasma membranar APP is almost exclusively 
found at the soma and axonal surfaces (Simons et al., 1995; Yamazaki et al., 1995). 
Furthermore, the intraneuronal APP pool is also subjected to polarized transport (Allinquant 
et al., 1994). Intracellular APP is described to first travel from the Golgi towards the axon 
terminal by fast anterograde transport (Koo et al., 1990; Ferreira et al., 1993; Simons et al., 
1995; Yamazaki et al, 1995; Lyckman et al., 1998; Kaether et al., 2000). Consequently, axonal 
full-length APP can be transcitotically transported back to the neuronal cell body (the “soma”) 
and from there to dendrites (retrograde transport) (Simons et al., 1995; Yamazaki et al., 1995; 
Kaether et al., 2000). APP can also be cleaved during its subcellular transport, where it can 
generate Abeta peptides, but APP proteolytic cleavages appear to be highly regulated in 
neurons (Hung et al., 1992). 
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In hippocampal neurons in culture the Abeta sequence and APP N-glycosylation, in 
this order of importance, were found to participate in intraneuronal APP sorting to the axon 
(Tienari et al., 1996b). Furthermore, the use of C-terminus deletion mutants prevented APP 
from being directed to the axon, indicating the existence of axonal targeting domains in the 
APP cytoplasmic tail (Tienari et al., 1996b). In the polarized Madin-Darby canine kidney 
(MDCK) cells, APP is sorted basolaterally in a process involving two distinct sorting signals. 
These are the APP 653YTSI656 cytoplasmic signal and an undetermined signal in its ectodomain 
near the Abeta sequence (De Strooper et al., 1993; Haass et al., 1995). Hence, phosphorylation 
at the APP sorting domain 653YTSI656 has a potential role in regulating APP neuronal traffic. 
Furthermore, the fact that the 653YTSI656 motif is the binding sequence to the KLC-
homologous APPBP2 protein (Lai et al., 1995; Zheng et al., 1998) also suggests a putative role 
for 653YTSI656 in APP traffic to and through neurites, the neuronal processes. This hypothesis 
is also attractive as APP phosphorylation at other cytoplasmic residue, Thr668, enhances its 
localization within neuronal growth cones and neurites (Ando et al., 1999; Iijima et al., 2000; 
Muresan and Muresan, 2005). Thr668 phosphorylation also appears to enhance APP interaction 
with axonal KLC (Inomata et al., 2003; Muresan and Muresan, 2005), and to lead to higher 
Abeta production (Ando et al., 1999). The previously observed S655 phosphorylation state-
dependent effects in APP subcellular traffic (non-neuronal COS-7 cells, Chapters II and III) 
also suggest a possible role for S655 phosphorylation in APP neuronal traffic. Additionally, 
S655 was found to be phosphorylated in adult rat brain (Suzuki et al., 1992; Oishi et al., 1997; 
Isohara et al., 1999), and in human AD brains (Lee et al., 2003a). Hence, this chapter focuses 
on putative S655 phosphorylation state-dependent APP neuronal targeting.  
 
 
V. 2 – AIMS OF THIS CHAPTER 
This chapter focussed on APP phosphorylation dependent targeting using primary 
neuronal cultures as a model system, in order to analyse the “in vivo” relevance of APP 
phosphorylation. The main objectives of this chapter were: 
1. To compare APP distribution during neuronal “in vitro” development, in a S655 
phosphorylation state-dependent manner. 
2. To analyse the effect of APP S655 phosphorylation on the APP distribution in 
axonal and dendritic neurites of mature neurons. 
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3. To distinguish whether APP phosphorylation state affects APP targeting and/or 
neuritic outgrowth upon 24 h period of APP-GFP expression. 
4. To address if APP phosphorylation can affect the nuclear targeting of APP-GFP 
derived C-terminal fragments in neuronal cultures. 
5. To analyse possible effects of S655 phosphorylation on the intracellular level of 
the pre-synaptic protein GAP-43. 
 
For Objective 1 rat cortical primary neurons were prepared and transfected with the 
APP-GFP Wt and S655 phosphomutants cDNAs at several days “in vitro” (DIV). APP-GFP 
distribution at the soma and dendrites were further analysed by epifluorescence microscopy. 
For an evaluation of the neuritic (axonal and dendrites) extension of APP-GFP distribution 
two parameters were used: distal versus proximal categories, and comparison with the MAP-2 
(microtubule-associated protein 2) dendritic staining. The presence, intensity and identity of 
GFP nuclear fluorescence was also addressed in a phospho state-dependent manner. 
Subsequently, the putative APP S655 phosphorylation-dependent effects on the protein level 
of the axonal protein GAP-43 were addressed.   
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V. 3 – MATERIALS AND METHODS 
A list of all solutions and protocols used, as well as other relevant information, is 
presented in Appendices I to III. All reagents were of cell culture grade or ultrapure. 
 
V. 3. 1 – ANTIBODIES 
The primary antibodies used in this study were the previously described anti-APP N-
terminus monoclonal antibody 22C11, the anti-GFP monoclonal antibody JL-8, and the anti-
APP C-terminus polyclonal 369 and anti-APP Abeta region monoclonal 6E10 antibodies. For 
the co-localization studies the monoclonal anti-microtubule associated protein 2 (MAP-2) 
antibody (Calbiochem, VWR International) was used. For the protein expression studies the 
polyclonal anti-growth associated protein-43 (GAP-43) antibody (Chemicon, PG-Hitec) was 
used. Additional antibodies used were anti-mouse and anti-rabbit IgGs Texas Red-conjugated 
secondary antibodies (Molecular Probes), and anti-mouse IgGs Alexa 350-conjugated 
secondary antibody (Molecular Probes) for Immunocytochemistry procedures, and anti-mouse 
and anti-rabbit IgGs horseradish peroxidase-linked whole antibody (Amersham Pharmacia), 
for enhanced chemiluminescence (Amersham Pharmacia Biosciences) detection. Dilutions of 
the antibodies used in this Chapter are given in Table V.1. 
 
 
Table V.1. Antibodies, respective target proteins and specific dilutions used for the different techniques 
employed: IB., Immunoblot; ICC, Immunocytochemistry. 
Primary Antibody Secondary Antibody 
Target 
Protein/Epitope 
Assay/Dilution Assay/Dilution 
APP N-terminal 
22C11 
IB dilution: 1:250 
Horseradish Peroxidase conjugated α-Mouse IgG 
IB dilution:  1:5000 
APP C-terminal 
369 
ICC dilution: 1:200 
Texas Red-conjugated α-Rabbit IgG 
ICC dilution: 1:300 
APP Abeta 1-17 
6E10 
ICC dilution: 1:200 
Alexa 350-conjugated α-Mouse IgG 
ICC dilution: 1:100 
EGFP 
JL.8 
IB dilution: 1:1000 
Horseradish Peroxidase conjugated α-Mouse IgG 
IB dilution:  1:5000 
MAP-2 
anti-MAP-2 
ICC dilution: 1:1000 
Texas Red-conjugated α-Mouse IgG 
ICC dilution: 1:300 
GAP-43 
anti-GAP-43 
IB dilution: 1:1000 
Horseradish Peroxidase conjugated α- Rabbit IgG 
ICC dilution: 1:5000 
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V. 3. 2 – PRIMARY NEURONAL CULTURE AND TRANSIENT TRANSFECTIONS 
Rat cortical primary neuronal culture. Cortical neuronal cultures were prepared 
from cortex of Wistar Hannover 18 days rat embryos as described in detail in Appendix II. 
Neuronal cultures were plated on 0.1 mg/ml poly-D-lysine (Sigma Aldrich, Portugal) pre-
coated glass coverslips (epifluorescence microscopy) or plates (Immunoblot analysis) at 9.0 x 
104 cells/cm2. Cells were maintained in complete Neurobasal medium (composition in 
Appendix I) in a humidified incubator at 37 ºC, 5% CO2. Cells conditioned medium was 
partially substituted with fresh equivalent medium when required.  
Transient transfections. Transient transfections with the APP-GFP constructs were 
performed at 0, 3, 10 and 13 DIV using LipofectAMINE 2000 (Invitrogen Life Technologies) 
and as described in the literature (Dalby et al., 2004; see Appendix II). Upon 24 h of 
transfection, cells were collected into 1% SDS boiling solutions (Immunoblotting analysis), or 
fixed with the 4% paraformaldehyde fixative solution for Immunocytochemistry and 
epifluorescence microscopy analyses.  
APP-GFP and GAP-43 protein expression in neuronal cells. For evaluating the 
expression of APP-GFP constructs in neuronal cells at 14 DIV, cells lysates were prepared as 
described in Chapter III (section III.3.6). Briefly, cells transfected at 13 DIV with the APP-
GFP constructs were harvested in 1% SDS solution. Mass-normalized aliquots were subject to 
Immunoblot analysis in 6.5% SDS-PAGE gels followed by APP-GFP immunodetection using 
the 22C11 (APP) and JL-8 (GFP) antibodies. The relative expression level of the growth- 
associated protein GAP-43 was also assessed in these cellular lysates. 
 
V. 3. 3 – APP-GFP NEURONAL TRAFFICKING 
Intraneuronal APP-GFP trafficking with time of “in vitro” culture. Cells 
processed as described above were fixed and mounted with FluoroGuard antifading reagent 
(BioRad) on microscope slides (Immunocytochemistry procedures are described in section 
II.3.4.6 and Appendix II). The APP-GFP intraneuronal distribution was further analysed by 
epifluorescence microscopy at 1, 4, 11, and 14 DIV. 11 and 14 DIV APP-GFP transfected 
neurons were monitored in more detail in terms of their number of APP-GFP-positive 
neurites and neuritic terminals. Neurites were scored as “proximal” and “distal” (Hill et al., 
1994; Silverman et al., 2001). Proximal neurites were considered to have lengths equal or 
inferior to two neuronal soma diameters (17.1 ± 0.4 µm in average), and distal neurites had 
lengths superior to two soma diameters.  
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MAP-2 co-localization studies in 14 DIV APP-GFP expressing neurons. Fixed 
neuronal cells, transfected with the APP-GFP constructs for 24 h at 13 DIV, were processed 
for Immunocytochemistry with the anti-MAP-2 antibody, a dendritic marker. Cells were first 
incubated for 2 h with MAP-2 antibody diluted 1:1000 in PBS with 3% BSA, washed three 
times with PBS, and anti-mouse IgG Texas Red-conjugated antibody was added to cells. A 
further incubation was carried out in the dark for 2 hours to allow for labelling of antigen-
primary antibody complexes. Coverslips were further washed with PBS and mounted with the 
antifading reagent on microscope slides. Fixed cells were analysed by epifluorescence 
microscopy for the presence of APP-GFP in dendrites (MAP-2-positive) and axon (MAP-2-
negative) and for the number of APP-GFP growth cones. Additionally, the length of APP-
GFP dendritic distribution was compared with the one of MAP-2. The presence and intensity 
of APP-GFP-derived C-terminal fragments at neurons nuclei was also qualitatively addressed.  
Identification of the nuclear targeted S655E APP-GFP-derived C-terminal 
fragment. Fixed neuronal cells, transfected with the S655E APP-GFP construct at 13 DIV 
and expressing the APP-GFP protein for 24 h, were processed for Immunocytochemistry 
with the anti-APP C-terminus 369 antibody and the anti-APP Abeta domain 6E10 antibody. 
Cells were first incubated with these two antibodies for 2 h upon permeabilization with 
methanol, washed with PBS, and further incubated for 2 h with the anti-rabbit IgG Texas 
Red-conjugated antibody and the anti-mouse IgG Alexa 350-conjugated antibody. Coverslips 
were further washed with PBS and mounted with the antifading reagent on microscope slides. 
Cells were analysed by epifluorescence microscopy for nuclear co-localization. 
 
V. 3. 4 – DATA ANALYSIS 
Immunoblots autoradiographic film exposures were scanned in densitometer and 
protein bands quantified by densitometry. Data on neuritic APP-GFP targeting, and protein 
expression levels, are expressed as mean ± SEM (standard error of the mean). Statistical 
significance analysis was conducted by ANOVA, with a level of statistical significance being 
considered p < 0.05, followed by the Tukey-Kramer test. Statistical significance symbols used 
were (*) for comparison between the S655 phosphomutants and the Wt data, and (+) for 
S655A versus S655E data. Statistical significance levels are presented as (*/+), p < 0.05; 
(**/++), p < 0.01; and (***/+++), p < 0.001.  
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V. 4 – RESULTS AND DISCUSSION 
V. 4. 1 – APP-GFP NEURONAL TRAFFICKING WITH TIME OF “IN VITRO” CULTURE 
APP targeting in immature neurons. In order to address the role of APP S655-
phosphorylation in neuronal APP targeting, rat primary cortical neurons were transfected with 
the APP695-GFP Wt and S655 phosphomutants as described above (sections V.3.2 and V.3.3). 
Cells were fixed and analysed at several stages of neuronal “in vitro” development and 
maturation (Dotti et al., 1988; Goslin and Banker, 1989). Figure V.1 shows that at 1 DIV the 
somatic body was the only structure clearly visible with GFP fluorescence, reflecting an initial 
stage of neuronal development before neurites protruding. A speckled pattern of APP-GFP 
somatic fluorescence could be observed for the three APP-GFP constructs (Fig. V.1, A). With 
time in culture, neurons start to develop neurites and to become polarized. 4 DIV neurons 
presented several short neurites and an obviously more developed neurite (Fig. V.1, B). At this 
stage the latter has been reported to be the cell axon, which grows at a faster rate than 
dendrites (Dotti et al., 1988; Goslin and Banker, 1989). By epifluorescence microscopy 
analysis, the presence of Wt APP-GFP fluorescence was observed at 4 DIV in neuronal 
locations where endogenous APP has been described. Wt APP-GFP was found both at the 
small somatic body and at the long neuritic processes, being enriched in the neuronal soma at 
the perinuclear region (Fig. V.1, B). Both type of neuritic processes, axons and dendrites, 
presented a discontinuous pattern of green fluorescence. In the cells expressing the S655 
phosphomutants the soma did not suffer any visible alteration in terms of fluorescence 
distribution or intensity. This is similar to COS-7 cells when “de novo” protein synthesis is 
not inhibited (Chapter II, Fig. II.5). APP-GFP fluorescent cells were further monitored for 
the characteristics of the GFP-positive neurites, such as the branching and fluorescence 
intensity of the axon. For all constructs, ∼80% of the APP-GFP expressing cells had a more 
elongated and ramified neuritic process that should correspond to the axon (arrows), and 
smaller neuritic processes corresponding to dendrites (Fig. V.1, B). The majority of dendrites 
were small, and cells mainly presented a long putative axon with ∼3 terminals, arriving from 
axonal branching. In fact, the ramification of the putative GFP-positive axon was found to be 
equal between cells expressing the S655 APP-GFP phosphomutants: 3.5 ± 0.6 for S655A and 
3.4 ± 0.6 for the S655E mutant. Furthermore, in terms of fluorescence intensity or GFP-
visible length, no detectable differences were observed in “axonal” staining for the three APP-
GFP species.     
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Figure V.1. Neuronal APP S655 phosphomutants distribution. The subcellular localization of APP Wt, 
S655A or S655E GFP-labelled fusion proteins was analysed by epifluorescence microscopy at 1, 4, 11 and 14-d-
old rat cortical neurons. Arrows at 4 DIV indicate putative axons as the longest neurite. At all days in culture the 
pattern of APP-GFP labelling at the cells soma was virtually identical for the three APP-GFP species. However, 
differences were found in the APP-GFP neuritic distribution at 14 DIV, a time when the S655E mutant was 
observed in more distal neurites than the Wt or S655A APP-GFP proteins. DIV, days “in vitro”. Bar, 10µm. 
A. 1 DIV 
Wt APP-GFP              S655E                   S655A               
B. 4 DIV 
Wt APP-GFP
  
 S655E                
S655A               
Wt APP-GFP                     S655E                                            S655A  
C. 11 DIV 
D. 14 DIV 
Wt APP-GFP                     S655E                                            S655A  
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S655-dependent APP distribution in polarized maturing neurons. APP-GFP 
proteins localization was further monitored at 11 DIV, as dendrites are reported to continue 
to develop with time in culture, and at 11 DIV the process of establishment of polarization is 
almost or totally completed (Dotti et al., 1988; Goslin and Banker, 1989). At this stage the 
pattern of APP-GFP somatic staining was maintained as for immature neurons, and no 
differences were observed between the three constructs (Fig. V.1, C). In a large number of 
cells the axon could still be distinguished and, when comparing with 4 DIV neurons, appeared 
to be slightly more branched. Furthermore, and as expected from the literature, some (up to 
two) fluorescing dendrites were longer than at 4 DIV (Fig. V.1, B and C).  
Fluorescing neurites of 11 DIV transfected neurons were scored as proximal or distal 
(depending on their length, see section V.3.3) and scored. Hence, distal neurites include both 
axon and long dendrites. Other parameters monitored included the level of GFP-visible 
neuritic ramification (Table V.2). The number of proximal neurites and proximal terminals 
was similar for the three APP-GFP proteins at 11 DIV, but the level of proximal neurites 
ramification was lower for S655A (1.6, p < 0.05) than for the Wt or S655E proteins (1.9). 
Axonal ramifications were also scored when possible and found to be equal between the Wt 
and S655 phosphomutants (4.3 - 4.5). Overall, at 11 DIV all APP species behave similarly 
although the S655E mutant seemed to be slightly more targeted to distal neurites and the 
opposite could be occurring for the S655A protein. In line with this observation, the ratio 
between distal terminals and visible protruding processes (GFP-positive processes that 
protrude from the neuronal soma) was slightly lower for the S655A protein (1.0), and the ratio 
between distal and proximal neurites was slightly higher for the S655E mutant (1.2).  
S655 phosphorylation increases APP targeting to mature neurites. Upon two 
weeks of “in vitro” culture, neurons are reported to be fully mature and the majority of their 
synapses fully functional (Dotti et al., 1988; Goslin and Banker, 1989). Microphotographs of 
APP-GFP 14 DIV expressing cells (Fig. V.1, D) show no visible alterations in APP-GFP 
intracellular somatic staining for the three proteins. This was as discussed above for 1, 4 and 
11 DIV. In terms of neurites fluorescing pattern, at 14 DIV the number of protruding 
processes (∼7) and the number of proximal (∼6) and distal (∼3) neurites were found to be 
equal for the three proteins (Table V.2). Strikingly, at 14 DIV, S655E was found more 
abundant in distal terminals when compared to the other two APP-GFP proteins, with the 
number of these terminals being almost the double than for S655A (13.4 ± 0.9 vs. 7.0 ± 0.6, 
respectively). These numbers were more similar between the S655A and Wt proteins, with the 
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latter exhibiting 8.9 ± 0.6 distal terminals per cell. Visually, the S655A APP-GFP-containing 
distal neurites were in general shorter and/or less ramified and, in contrast, S655E expressing 
cells visually appear with longer and/or more branched distal neurites (Fig. V.1, D). In fact, in 
this neuronal culture the S655E mutant presented the highest level of fluorescent neuritic 
ramification (Table V.2), either distal [(S655E) 4.2 > (Wt) 3.0 > (S655A) 2.4)] or proximal 
[(S655E) 2.1 > (Wt) 1.8 > (S655A) 1.7)]. This had consequences in the total number of APP-
GFP-positive terminals: S655E (25.7 ± 1.1; p < 0.01 vs. Wt, and p < 0.001 vs. S655A) > Wt 
(20.9 ± 1.1) > S655A (16.1 ± 0.8; p < 0.05 vs. Wt, and p < 0.001 vs. S655E). 
 
 
Table V.2. Characteristics of APP-GFP distribution in the neurites of 11 and 14 DIV cortical neurons. (n), 
number of cells scored. 
 11 DIV 14 DIV 
Scores and Ratios 
Wt 
(n=50) 
S655E 
(n=45) 
S655A 
(n=67) 
Wt 
(n=60) 
S655E 
(n=85) 
S655A 
(n=40) 
 PP1 7.3 ± 0.3 5.6 ± 0.3*** 6.4 ± 0.3 7..3 ± 0.4 7.6 ± 0.2 6.9 ± 0.4 
 Proximal2 5.7 ± 0.3 4.7 ± 0.4 5.3 ± 0.3 6.4 ± 0.4 5.9 ± 0.3 5.3 ± 0.4 
Neurites per 
cell  
 Distal3 2.7 ± 0.5 2.0 ± 0.2** 1.8 ± 0.1*** 3.1 ± 0.2 3.4 ± 0.2 3.1 ± 0.3 
 Proximal 11.0 ± 0.8 9.1 ± 0.9 8.8 ± 0.6 11.6 ± 0.9 12.3 ± 0.7+ 9.1 ± 0.7 Neuritic 
Terminals  
per cell   Distal 8.2 ± 0.6 6.4 ± 0.6* 6.1 ± 0.5* 8.9 ± 0.6 13.4 ± 0.9***/+++ 7.0 ± 0.6 
 Proximal 1.9 ± 0.1 1.9 ± 0.1+ 1.6 ± 0.1*/+ 1.8 ± 0.1 2.1 ± 0.1+ 1.7 ± 0.1+ 
Neuritic 
Ramification 
 Distal 3.2 ± 0.2 3.4 ± 0.2 3.4 ± 0.2 3.0 ± 0.2 4.2 ± 0.3**/+++ 2.4 ± 0.2+++ 
/ PP  1.2 ± 0.1 1.2 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 2.0 ± 0.1**/+++ 1.0 ± 0.1+++ Ratio 
Distal 
terminals /  / Proximal 
terminals  
0.9 ± 0.1 1.2 ± 0.2 0.9 ± 0.1 1.2 ± 0.1 2.2 ± 0.4*/+ 0.9 ± 0.1+ 
1 Protruding processes from the soma. Some of these processes show immediate ramification by bifurcation, but were 
considered just one process coming out of the somatic body. 
2 , 3 Processes with terminal tips distant from the neuronal soma by ≤ 2 and  > 2 somatic diameters, respectively. 
 
 
Potentially, it appears that S655E has a higher transport into distal processes and this 
is also reflected in the ratio between distal terminals and the number of GFP-visible 
protruding processes: S655E (2.0 ± 0.1; p < 0.01 and p < 0.001 vs. Wt and S655A, 
respectively) > Wt (1.3 ± 0.1) ≥ S655A (1.0 ± 0.1). In addition, the ratio between distal 
terminals and the number of proximal terminals showed the same relationship: S655E (2.2 ± 
0.4; p < 0.05 vs. Wt or S655A) > Wt (1.2 ± 0.1) ≥ S655A (0.9 ± 0.1; p < 0.05 vs. S655E).  
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To analyse whether the neuritic traffic differences may be due to varying expression 
levels of the APP-GFP constructs, these were evaluated in a subset of 14 DIV neurons by 
Immunoblot analysis (see section V.3.2). Figure V.2 shows that in the cells lysates three bands 
appeared when probing with the anti-APP 22C11 antibody (Fig. V.2, left panel). Of these, two 
bands (bands b and c) were not visible with the anti-GFP antibody (Fig. V.2, right panel), and 
had similar apparent molecular weights as COS-7 cells endogenous APP forms. This is as 
expected for neuronal endogenous APP proteins (Selkoe et al., 1988). The APP-GFP band 
“a”, the only band visible either with the anti-GFP or the 22C11 antibody, migrated at ∼133 
KDa. This is a molecular weight expected for the immature form of the APP695-GFP fusion 
protein, when compared with band “a” obtained in COS-7 cells transfections (Fig. II.5). 
Bands analysis revealed that the Wt and S655E APP-GFP proteins were expressed at similar 
levels, while the S655A mutant was expressed at slightly higher levels (1.3 fold higher). Hence, 
the higher S655E neuritic targeting its not an artefact of a higher S655E APP-GFP expression.   
 
 
 
Figure V.2. APP-GFP expression in 14 DIV neuronal cells. Immunoblot analysis of APP-GFP expressing 14 
DIV neuronal lysates, using antibodies against APP N-terminus (22C11) and against GFP (JL-8) for APP-GFP 
detection. a, APP695-GFP, probably immature; c’ and d’, endogenous neuronal APP proteins. 
 
 
V. 4. 2 – APP-GFP NEURITIC TARGETING – CO-LOCALIZATION WITH MAP-2 
APP-GFP distribution in axons and dendrites of 14 DIV neurons. In order to 
characterize the nature of the APP-GFP positive neurites and neuritic terminals at 14 DIV, 
co-localization studies of the APP-GFP proteins and the dendritic marker MAP-2 were 
performed (Fig. V.3). The latter is a protein that, at this developmental stage, is widely 
reported to be restricted to the cell soma and dendrites, being absent from axonal processes or 
only present at their “basis” (most proximal portion) (Caceres et al., 1986).     
14 DIV lysates 
APP (Ab 22C11) 
120  
KDa 
99  
APP-GFP (Ab JL-8) 
a 
b 
Wt         S655A      S655E                      Wt         S655A      S655E 
 
c 
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Figure V.3. Dendritic and axonal distribution of Wt and S655 phosphomutants in 14 DIV cortical 
neurons. Co-localization analysis of neuronal APP-GFP and the dendritic marker MAP-2 (Texas-red). Soma: 
The majority of APP-GFP-positive neurites were observed to be dendrites, where MAP-2 and APP-GFP co-
localize (yellow labelling in the overlay). Arrows indicate the cells axon, as defined by the almost absence of 
MAP-2 labelling, which exhibit a much fainter APP-GFP fluorescence than dendrites. Neurites: Cells dendritic 
trees (asterisk) were monitored for the extent of APP-GFP and MAP-2 staining. At the dendritic terminals 
(arrowheads), Wt and S655A APP-GFP green fluorescence were observed to mainly match in length the red 
MAP-2 immunostaining. Conversely, the S655E dendritic green fluorescence usually surpassed MAP-2 labelling. 
Distal portions or terminals of the APP-GFP-positive axon could also be observed (arrows); in the S655A photo 
the axon makes a contact with a dendritic terminal of an adjacent non-transfected neuron. Bar, 10µm. 
Wt  
* 
S655A  
S655E  
* 
soma 
neurites 
* 
* 
soma 
neurites 
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* 
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As can be observed in the “soma” panels of Fig. V.3, axonal processes are APP-GFP-
positive (arrows) for all APP species, but did not stain for MAP-2 (red fluorescence), thus 
facilitating their identification. The axonal GFP fluorescence intensity is fainter than in 
dendrites, with the axon being more difficult to identify and to follow. Nonetheless, and 
correlating with an increased S655E axonal transport, the axon had generally a higher intensity 
and was more easily detected in the S655E expressing neurons. Co-localization analysis 
showed that the S655E-positive neurites and neuritic terminals corresponded both to axonal 
and dendritic branches. Again, the S655E mutant was found more abundantly in longer 
neuritic processes, both when axonal or dendritic in origin, and these were typically more 
intense than for the other two APP-GFP proteins. The S655A fluorescence generally 
decreased with increasing neuritic length, while S655E fluorescence intensity was maintained 
with distance from the soma. In some neuritic terminals, APP-GFP could be observed to be 
concentrated at growth cones, which when of dendritic nature had also a concentration of 
MAP-2. This has already been described for APP (Ando et al., 1999; Sabo et al., 2003). GFP-
visible dendritic and axonal growth cones were additionally scored in 20 cells per APP-GFP 
protein type. The S655E protein was present in a higher number of growth cones (GC) of 
both kinds - axonal (Ax) and dendritic (Dt). Average values obtained were of: 4 Dt GC and 3 
Ax GC for S655E > 1.7 Dt GC and 0.7 Ax GC for Wt ≥ 2 Dt GC and 0.4 Ax GC for S655A.  
S655 phosphorylation increases APP targeting to mature neurites. Visually, the 
S655E APP-GFP also appeared to be more distally transported in neurites (as in Fig. V.1). In 
order to confirm the existence of a S655 phosphorylation-dependent APP neuritic trafficking, 
these 14 DIV neurons were monitor using two independent parameters. The first was the 
proximal/distal parameter used above in section V.4.1, and a small set of APP-GFP 
expressing cells (around 15) was scored. Noteworthy is the fact that this data was collected 
blind. The second evaluation made use of the length of MAP-2 staining as an internal control 
of the APP-GFP length of transport.  
Using the distal/proximal parameters, the S655E protein was found in 26 ± 3 distal 
neuritic terminals, a number significantly higher than the Wt and S655A values (18 ± 2; p < 
0.05). Of note is that these neurons (Fig. V.3) had longer neurites than the previous 14 DIV 
neurons of section V.4.1. In fact, there was a decreased number of proximal neurites and a 
higher number of distal neurites. The same parameter (two-soma diameters) was used, and 
values still confirmed an increased S655E distal transport, with the number of S655E distal 
terminals being ∼1.5 fold higher than of S655A.   
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The lengths of APP-GFP and MAP-2 dendritic staining were also compared. In the 
majority of Wt and S655A-positive dendrites, the extension of APP-GFP green and MAP-2 
red dendritic fluorescences matched in length (Fig. V.3, Wt and S655A “neurites”). This was 
true for 56% of Wt cells and 76% of S655A cells. For the S655E protein, the APP-GFP green 
fluorescence went beyond the red MAP-2 staining. This is clear in Fig. V.3 S655E 
microphotographs (arrowheads in the “neurites” panel), where the green APP-GFP 
fluorescence was distally maintained in dendritic terminals that were no longer positive for 
MAP-2. Indeed, S655E staining at neuritic terminals was observed to largely surpass in length 
the MAP-2 staining in the majority of the dendrites of all (100%) cells monitored. Again, this 
confirms an increased S655E neuritic terminal targeting. 
APP-GFP expression has no apparent effect on MAP-2 length of staining. The 
length of the MAP-2-positive dendritic portions was also addressed in the 14 DIV neurons 
expressing the APP-GFP constructs. This study aimed to clarify whether APP S655 
phosphorylation was affecting both the APP neuritic traffic dynamics and the MAP-2-positive 
dendritic length. For that, the length of MAP-2 staining was measured on the three longer 
dendrites of 20 APP-GFP expressing cells. In addition, control determinations were taken by 
measuring MAP-2 dendritic length in various non-transfected cells in the vicinity of APP-GFP 
expressing neurons (Table V.3). No alterations in this parameter could be observed for any of 
the APP-GFP species, with MAP-2 length of staining being in average of 150µm per dendrite, 
either in APP-GFP transfected or non-transfected neurons.  
 
Table V.3. MAP-2 dendritic staining in APP-GFP transfected (n=60 
dendrites) and control (neighbour non-transfected) cells (n=30 dendrites). 
MAP-2 staining (µm) 
 
Wt S655A S655E 
APP-GFP cells 154 ± 6 147 ± 6 149 ± 5 
Control cells 155 ± 9 142 ± 7 149 ± 7 
 
 
V. 4. 3 – NUCLEAR TARGETING OF APP-GFP-DERIVED C-TERMINAL FRAGMENTS  
When performing the above described co-localization studies of APP-GFP proteins 
with MAP-2, differences were detected in terms of the presence and intensity of green 
fluorescence at cells nuclei. The nuclear targeting of APP-GFP derived C-terminal fragments 
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in 14 DIV APP-GFP expressing neurons was particularly addressed. Hence, 20-35 cells per 
APP-GFP construct were monitored for the presence or absence of GFP green fluorescence 
in their nuclei. Additionally, when the green nuclear fluorescence was detected, its intensity 
was further characterized as “medium” or “intense” (Fig. V.4). This evaluation was performed 
not only by analysis of APP-GFP nuclear labelling, but also by comparison with the MAP-2 
immunostaining, which was used as a negative control as MAP-2 is a nuclear excluded protein. 
 
 
Figure V.4. Characterization of Wt and S655 phosphomutants APP-GFP-derived nuclear green 
fluorescence in 14 DIV neurons. The absence (w/o) or presence of green fluorescence at the nuclei of APP-
GFP 14 DIV cortical neurons was scored, with green fluorescence intensity being divided into medium or 
intense. Data is presented as percentage of the number of cells evaluated (Wt: 20; S655A: 33; S655E: 35).  
 
 
In Wt APP-GFP expressing neurons, only 10% of the cells did not have visible 
nuclear green fluorescence (Fig. V.4). Moreover, the majority of cells presented nuclear green 
fluorescence of medium intensity (70% of cells). For the S655A mutant, although the majority 
of the population (∼60%) presented green nuclear fluorescence of medium intensity, there was 
a higher number of cells where nuclear labelling was absent (∼20%, double than for Wt). The 
S655E mutant however, presented nuclear GFP staining in virtually all neurons (∼94%) and 
this staining was more intense than for the other two APP-GFP species. In fact, two thirds of 
the population (∼66%) had intense nuclear green fluorescence, and this can be denoted from 
the S655E “soma” panel of Fig. V.3. Noteworthy is that a higher nuclear GFP labelling in 
S655E expressing cells was also previously observed for COS-7 cells (Chapter II, section 
II.4.3.2). These suggest a higher targeting of APP-GFP-derived C-terminal fragments bearing 
the S655E phosphomimicking mutation. Hence, in an independent experiment, the co-
localization of nuclear S655E APP-GFP fluorescence with the anti-APP 369 (APP C-
terminus) and 6E10 (APP Abeta region) antibodies was performed (details in section V.3.3). 
Nuclear GFP labelling  
S655E
 w /o
medium
 intense
S655AWt
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As in Chapter II (Fig. II.11), this aimed to further characterize the APP-GFP fragments 
nuclear targeted. Cells were analysed by epifluorescence microscopy for the nuclear presence 
of the GFP and the antibodies specific fluorescences, and their nuclear co-localization (Fig. 
V.5, arrows). 
 
 
 
Figure V.5. Co-localization of neuronal somatic APP-GFP with APP C-terminal fragments. APP C-
terminal fragments were detected with the anti-APP C-terminus 369 antibody, labelled with Texas Red-
conjugated antibody, and the anti-APP Abeta region 6E10 antibody, labelled with the blue fluorescing Alexa 350-
conjugated antibody. Arrows indicate the cell nucleus.  
 
 
Figure V.5 shows that while the green (APP-GFP) and red (Ab 369, APP C-terminal 
fragments) nuclear fluorescences could be readily visible, the blue (Ab 6E10, APP Abeta 
region) fluorescence was apparently absent from the nucleus. A good correlation can be 
observed between GFP nuclear fluorescence and APP C-terminus red fluorescence (Fig. V.5, 
Overlay APP-GFP + Ab 369, arrow), that is less evident between the nuclear staining of the 
369 and 6E10 antibodies (Fig. V.5, overlay Ab 369 + Ab 6E10, arrow). As observed in 
Chapter II, the 369 antibody recognizes full-length APP, both α- and βCTFs, and the AICD 
fragment. The 6E10 antibody recognizes full-length APP, the βCTF and Abeta fragments, but 
not the αCTFs and AICDs. Hence, the nuclear green fluorescence previously scored (Fig. 
V.4) seems to be due to the presence of AICDs or αCTFs APP-GFP-derived fragments, and 
not full-length APP-GFP, APP βCTFs fragments, or GFP alone. 
       S655E APP-GFP               Ab 369 – Texas Red           Overlay GFP+369  
       S655E APP-GFP                Ab 6E10 – Alexa 350         Overlay GFP+6E10 
       Ab 369 – Texas Red           Ab 6E10 – Alexa 350         Overlay 369+6E10 
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V. 4. 4 – S655 PHOSPHORYLATION STATE-DEPENDENT GAP-43 NEURONAL EXPRESSION  
The putative effects of the S655 phosphomutants neuronal expression on the levels of 
some proteins of interest are focus of current analysis. APP has been shown to possess 
synaptotrophic effects, and transgenic mice with neuronal APP overexpression were observed 
to present increased number of synaptophysin immunoreactive presynaptic terminals and 
increased expression of the growth-associated marker GAP-43 (Mucke et al., 1994). Here we 
present an Immunoblot analysis, performed in the neuronal lysates of Fig. V.2, where the 
effects of the expression of the different APP-GFP species on the protein levels of GAP-43 
were evaluated (Fig. V.6).  
 
 
 
Figure V.6. APP S655 phosphorylation state-dependent GAP-43 
expression in 14 DIV neuronal cells. Immunoblot analysis of GAP-43 
expression in APP-GFP expressing 14 DIV neuronal lysates. 
 
 
 
The relative levels of protein expression of the axonal GAP-43 protein were calculated 
by densitometry and found to be ∼0.9 for the S655A and ∼1.5 for the S655E phosphomutants 
(taken Wt O.D. data as 1). More striking differences in the GAP-43 levels arise when the 
neuronal APP-GFP expression levels (Fig. V.2) are taken into account: ∼0.7 for S655A and 
∼1.7 for S655E. Hence, in comparison with the Wt species, the S655A neuronal expression 
had a down-regulation effect on GAP-43, while the expression of S655E in mature 14 DIV 
neurons seems to up-regulate the levels of this pre-synaptic and growth-cone enriched protein.  
 
14 DIV lysates 
(Ab anti-GAP-43) 
54  
KDa 
Wt          S655A      S655E  
GAP-43 
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V. 5 – CONCLUSIONS  
The S655 phosphomutant APP-GFP fusion constructs were used to determine 
putative regulatory functions of S655 phosphorylation in APP neuronal targeting. The major 
observations from these studies were:  
1. The APP S655 phosphorylation-state is involved in the APP traffic in neuritic 
processes. This regulatory role seems to be dependent on the level of neuronal 
maturation. 
2. In mature neurons, the S655A APP-GFP protein had a neuritic targeting that was 
slightly decreased or equal to the Wt protein. Conversely, the S655E protein, 
mimicking an APP S655 constitutive phosphorylated state, presented an increased 
neuritic targeting. Indeed, this phosphomutant was found present at higher 
amounts in neuritic portions and terminals more distal to the cell body. 
3. S655 phosphorylation or dephosphorylation does not impair APP targeting to 
axonal or dendritic domains, with the S655 phosphomutants being found 
distributed through all neuronal domains. In fact, S655 phosphorylation appears to 
increase both axonal and dendritic APP transport. 
4. In parallel with its higher length of distal transport, the S655E protein was present 
in a higher number of axonal and dendritic growth cones, labile zones at the tips 
of the neuritic terminals, related with neuritic outgrowth and signal transduction.  
5. In agreement with the previous COS-7 cells results, the nuclear targeting of APP-
GFP-derived AICD-GFP (or αCTF) was found increased for the S655E protein. 
In fact, there was a higher number of cells with nuclear S655E GFP fluorescence 
and, especially, these presented a higher nuclear GFP intensity.  
6. APP S655 phosphorylation appears to have an important neuronal physiological 
role, not only in targeting, but also in signal transduction, as demonstrated by the 
alterations on the neuronal GAP-43 protein levels.  
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CHAPTER VI – DISCUSSION 
 
VI. 1 – OVERVIEW 
AD is multifactorial in its aetiology and the complex cause-consequence mechanisms 
are still not completely understood. In the last few years the cellular mechanisms by which 
cellular APP is regulated have started to be unravelled. Related research has characterized APP 
binding proteins, identified some of the domains involved in these interactions, as well as the 
physiological relevance of these complexes. APP is a transmembranar protein processed via 
the secretory and endocytic pathways (see Chapter I) and, as part of its population is cleaved 
during its subcellular translocation, regulation of APP trafficking is thus of singular 
importance. APP proteolytic cleavages may be regulated by temporal APP substrate/enzyme 
co-distribution, and by substrate and enzyme activation. A possible scenario would involve 
APP substrate targeting to specific subcellular microdomains in order to perform a specific 
cellular function, for example activation of gene expression. Several factors have been 
described to regulate APP trafficking and proteolysis, among them protein phosphorylation. 
Moreover, APP phosphorylation and APP protein-protein interactions are found to be 
intimately related (Ando et al., 2001; Scheinfeld et al., 2002; Taru et al., 2004), with APP 
phosphorylation now emerging as a regulatory mechanism of APP binding to other proteins. 
Interestingly, in AD patients not only an impairment in the cellular phosphorylation system 
balance was detected, but alterations of the APP phosphorylation state were also found (Lee 
et al., 2003a). Additionally, Abeta phosphorylated at its serine residue 26 was reported in AD 
brains and this phosphorylation putatively implicated in Abeta toxicity (Milton, 2005). 
Nonetheless, little is known regarding the role of APP phosphoresidues, and even less 
regarding its 653YTSI656 domain. In order to determine the consequence of APP S655 site 
specific phosphorylation in the dynamic process of APP targeting and processing, APP S655 
phosphomutants and APP-GFP fusion constructs were engineered and used together with 
cellular biology, epifluorescence microscopy and proteomic techniques. The results obtained 
in the separate experiments discussed in the previous chapters are now object of an integrative 
analysis. 
 
Chapter VI – Discussion                - 186 - 
Sandra Vieira Guerra e Paz   CBC/UA, 2006 
VI. 1. 1 –  S655 PHOSPHORYLATION-DEPENDENT APP SORTING  
ER exit. As a secretory protein, APP is synthesized in the ER, where it suffers its first 
maturation process, and it translocates to the cis-Golgi. The ER to Golgi translocation of the 
S655E mutant appeared to be slightly delayed relative to the other two APP-GFP species 
(Fig.s II.8, C and II.9, C). In parallel, the rate of disappearance of its immature form was 
slightly slower (Fig. III.1 B.I), with S655E having a half-life of 3 h, while the Wt and S655A 
have half-lives of 2.5-2.7 h. Different maturation rates are dismissed, as they were found to be 
identical for the three APP-GFP species. Immature APP was previously observed not to be 
phosphorylated at S655 (Suzuki et al., 1992; Oishi et al, 1997), and newly-synthesized and 
immature APP S655E passes the ER, a site where usually APP is not phosphorylated at S655. 
Hence, it is expected that immature S655E behaves slightly different from the other two 
immature APP-GFP species, which are much more alike in their behaviour.  
TGN/Golgi sorting. In the assays monitoring APP trafficking (Fig.s II.8 and II.9), 
the S655A mutant exhibited slower packaging into post-TGN vesicles, which was further 
supported by the traffic assays at 20 ºC (Fig. III.5). In addition, part of its Golgi population 
remained at that organelle even after 5:00 h of monitoring (Fig.s II.8 and II.9), indicating a 
partial block in S655A Golgi exit. The S655E mutant presented an apparently normal 
TGN/Golgi exit (Fig.s II.8, II.9) and appeared to be preferentially targeted for post-TGN 
vesicle packaging (Fig. III.5). Figure VI.1 shows the percentage of GFP-positive Golgi for the 
three species, allowing for a better comparison of Golgi exit patterns. The high S655A Golgi 
percentages decrease little with time, suggesting Golgi retention for this mutant (Fig. VI.1). 
The number of cells with GFP-positive Golgi oscillated similarly for the Wt and the S655E 
species, especially between 1:30 and 3:00 h (Fig. VI.1). From 3.00 h on these patterns diverge 
significantly, and these will be discussed later.  
 
 
 
    
Figure VI.1. Time course 
analysis of APP-GFP-positive 
Golgi cell percentages (data 
derived from Fig. II.8). 
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Cell surface endocytosis. The differences observed in increased GFP fluorescence 
and increased APP retention for the S655A mutant at the plasma membrane, suggested that 
S655A was less endocytosed (Fig.s II.8, II.9, and II.15). The APP-GFP/transferrin co-
localization assay (Fig. II.13) also indicated a decreased S655A incorporation into endocytic 
vesicles. Further support was obtained from the antibody uptake assays, either from visual 
analysis of the differential cell surface APP turnovers (Fig. II.15), or by directly scoring the 
number of APP-GFP-positive vesicles that resulted from surface APP being internalized (Fig. 
II.16). In summary, this significant novel finding shows that the S655 phosphorylation state is 
important in APP endocytosis, and is consistent with the APP 653YTSI656 sequence being a 
consensus signal for internalization. In addition, Lai et al. (1995) had reported that the 
presence of the APP 653YTSI656 sequence at the cytoplasmic domain of the transferrin receptor 
(TR) induces its partial internalization (∼50% of Wt TR). The S655E mutant, however, also 
exhibited a slightly higher surface APP-GFP staining (Fig.s II.8 and II.9). Nonetheless, its 
slightly higher rate of membranar endocytosis and turnover (Fig. II.15) strongly suggests that 
this is not a resting population. Thus, the higher PM staining for both mutants seems to have 
different origins, which include higher rate of traffic between the TGN and the PM for 
S655E, and a lower rate of PM internalization for S655A. In conclusion, S655 
phosphorylation seems to promote APP cell surface internalization by increasing APP 
endocytosis. Nonetheless, we can not exclude the possibility that the rates of cell surface APP 
recycling (back to the PM) may also be altered for the phosphomutants.  
PM-to-TGN retrograde transport. Detailed analysis of Figure VI.1 reveals that 
although similar to the Wt, the S655E Golgi fluorescence pattern suffers more pronounced 
variations with time. These could reflect a higher income of APP-GFP to the Golgi, coming 
from the PM-to-TGN retrograde route at, e.g., 2:00-2:30 and 3.00-5:00 h of CHX exposure. 
This S655E APP Golgi population appears to be full-length, given the high Golgi co-
localization of S655E APP-GFP with the APP N-terminal antibody 22C11 at 5:00 h (Fig. 
II.10). Further analysis using the antibody uptake assay confirmed that S655 phosphorylation 
also plays a role in APP sorting at endosomes. Co-localization of S655E-containing endocytic 
vesicles with the TGN/Golgi was faster and apparently higher (Fig. II.14). Indeed, retrograde 
transport of endocytosed APP to the TGN was found to be enhanced for S655E and 
impaired for the S655A mutant. Phosphorylation of the APP at S655 appears to function as a 
signal for endocytosed APP retrieval to the trans-Golgi network. This stimulation of the PM-
to-TGN retrograde transport is most likely to be the cause of the cyclic point increases in 
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S655E Golgi fluorescence (Fig. VI.1 and Fig. II.8: 1:30, 3:30 and 5:00 h). The decreased 
S655A retrograde transport from the PM-to-TGN, along with its impaired Golgi exit, may 
explain the more constant pattern of S655A Golgi fluorescence with time (Fig. VI.1). 
Lysosomal delivery. Further results indicated the three APP-GFP proteins also 
varied in their post-endocytic fate in terms of lysosomal delivery. A fraction of re-internalized 
APP is known to be targeted to lysosomes for complete degradation. For example, Haass et al. 
(1992a) observed that re-internalized APP partially co-distributes with Cathepsin D at 
lysosomes, using epifluorescence microscopy or lysosomal purification approaches. In 
agreement with this, APP-GFP fluorescence was also observed to partially co-localize with the 
lysosomal protein Cathepsin D. In COS-1 cells, a role for the APP 653YTSI656 sequence in 
targeting to a cellular degradation pathway had already been described (Lai et al, 1995). In line 
with these findings, our results implicate S655 phosphorylation in APP lysosomal delivery. A 
higher targeting, almost double, of S655A APP-containing vesicles towards lysosomes was 
observed (Fig. II.17). In contrast, S655E was slightly less targeted to lysosomes. Furthermore, 
the half-lives and patterns of mature APP-GFP cellular catabolism support the existence of a 
S655 phosphorylation-dependent APP lysosomal targeting. First, the mature S655E form has 
a doubled half-life (5.56 ± 0.41 h) compared to mature Wt (2.46 ± 0.16 h) or mature S655A 
(2.12 ± 0.08 h) APP-GFP. Furthermore, mature Wt APP-GFP has a pattern of cellular 
catabolism that is initially similar to S655E, but approaches the S655A pattern in the later time 
points (Fig. III.1). This strongly suggests that there is a S655 phospho-dephospho event, only 
possible to occur for the Wt species, that affects the APP degradation rate. In addition, there 
was no direct correspondence between the S655E lower turnover rate and decreased sAPP 
production, or between the initially higher S655A turnover rate and enhanced sAPP 
production (Fig. III.3). In fact, at earlier time points, sAPP from S655A origin was the lowest 
(Fig. III.3). A higher targeting of this mutant to cellular degradation could also be denoted 
from its higher decreased cellular levels upon severe protein synthesis inhibition (Fig. III.2). 
Conversely, under these latter conditions, the S655E APP-GFP cellular and sAPP medium 
levels were less affected. Hence, part of the APP cellular catabolism is under the control of the 
S655 phosphorylation state, with phosphorylation rescuing APP from degradation.  
Further support for a role of S655 phosphorylation in APP lysosomal targeting and 
degradation comes from comparison of the APP-GFP catabolism with previously reported 
work on APP lysosomal degradation. Interestingly, the pattern of mature S655E APP-GFP 
catabolism has close similarities with the pattern of mature APP catabolism upon inhibition of 
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lysosomal activity (Caporaso et al., 1992a). These authors observed that chloroquine-induced 
inhibition of lysosomal activity rendered no effect on immature APP processing but led to an 
enhancement of the mature APP half-life. Their time course analysis of endogenous mature 
APP (time of chase up to 8 h), and the results of CHX time course of mature Wt and S655E 
APP-GFP (adapted from Fig. III.1 B.II) are compared (Fig. VI.2).  
 
 
Figure VI.2. Comparison between the effects of lysosomal inhibition and S655 phosphorylation in APP 
mature levels. A: 8:00 h chase of endogenous radiolabelled APP mature levels in the presence (+) or absence (-) 
of chloroquine, a lysosomal activity inhibitor (Caporaso et al., 1992a); and B: 5:00 h time course of Wt and 
S655E APP-GFP mature levels in the presence of CHX .  
 
 
Indeed, similarities can be draw between the metabolic degradation patterns of 
endogenous mature APP in the presence of the lysosomal inhibitor chloroquine (Fig. VI.2A), 
and of the mature S655E APP-GFP proteins (Fig. VI.2B). For example, chloroquine induced 
a significant effect on the mature APP turnover mature, with APP levels roughly duplicating 
in the presence of this drug. In the results presented here, the S655E APP-GFP mutant also 
exhibited a doubled half-life, relatively to the Wt or S655A species. 
The YTSI Sorting signal and the Regulatory role of S655 Phosphorylation. A 
detailed search of the literature for traffic sorting motifs similar to the 653YTSI656 domain 
provides further support for a S655 phosphorylation role in APP traffic sorting. For example, 
the YXXI motif present in the cytoplasmic terminus of lysosome membrane-associated 
glycoproteins (LAMPs), was found to be both necessary and sufficient for the targeting of 
these proteins or chimeric proteins to lysosomes (Williams and Fukuda, 1990; Rohrer et al., 
1996). This motif also functions as a signal for protein sorting at several cellular sorting 
stations, and the surrounding amino acid sequence may also play an important role. At the 
TGN level, the presence of a glycine residue immediately upstream (GYQTI) targets proteins 
like LAMP-1 and Lgp120 from the TGN to lysosomal delivery through endosomes (Williams 
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and Fukuda, 1990; Harter and Mellman, 1992; Guarnieri et al., 1993; Honing and Hunziker, 
1995). In addition, a small part of LAMP-1 and Lgp120 populations are, also due to the 
presence of the YXXI motif, sorted from the TGN to the PM. In the case of APP, the 
653YTSI656 is preceded by a glutamine (Q) residue, and so it is most probable that it is mainly 
sorted to the cell surface. At the PM, the YXXI motif is also responsible for the rapid 
internalization of proteins into clathrin-coated pits (Lai et al., 1995; Rohrer et al., 1996). For 
APP, there are two signals for PM endocytosis: the YNPTY and the YTSI motifs. Alone, 
these two motifs were similarly efficient (∼50% of Wt TR) in the process of internalization of 
the transferrin receptor, together they appear to function in synergy (∼80% of Wt TR) (Lai et 
al., 1995). A further step of sorting occurs at the early endosomes, to sort proteins to the late 
endosomes (and subsequently to lysosomes) or to recycle back to the plasma membrane in 
what is considered the default mechanism (Mayor et al., 1993). While proteins with an YTRF 
cytoplasmic motif, such as the TR receptor protein, are mainly early endosome residents 
(Mayor et al., 1993), the YXXI motif is responsible for protein sorting to late endosomes 
(Honing and Hunziker, 1995; Rohrer et al., 1996). Further protein sorting occurs to lysosomes 
or to the TGN/Golgi retrograde transport route, and in some cases such as for the cation-
dependent mannose 6-phosphate receptor (CD-MPR), these are two competing routes 
(Rohrer et al., 1995). While sorting to lysosomes occurs at the late endosomes (Rohrer et al., 
1995), sorting to TGN/Golgi may occur at the early/sorting endosome (Mallard et al, 1998; 
Mallard et al., 2002; Saint-Pol et al., 2004) or at the late endosome (Rohrer et al., 1995; Nair et 
al., 2003). In both sorting decisions the YXXI/L/V motifs may function as targeting signals. 
For example, the YQTI LAMP-1 motif targets the protein for lysosomal targeting (Rohrer et 
al., 1996), and the YQRL TGN38 motif regulates this protein’s PM-to-TGN recycling (Reaves 
et al., 1993). Both of these are “four charged/polar residues Tyr-based motifs”, but the latter 
has a higher charge due to the presence of the Arg residue (YQRL) instead of the Thr one 
(YQTI) at the third aa position. Interestingly, S655 phosphorylation at the APP 653YTSI656 
motif results in a similar effect of polar-to-charge substitution at the third aa position. Of note 
is that BACE-1 phosphorylation at a cytoplasmic serine residue, belonging to a sorting motif 
different to the YXXI one, targets the protein to TGN retrograde traffic and rescues it from 
lysosomal delivery (Walter et al., 2001; Wahle et al., 2005). It is possible that APP S655 
phosphorylation, as BACE-1 S498 phosphorylation, enhances specific protein-protein 
binding, resulting in a higher PM-to-TGN retrograde transport, but further work has to be 
performed in this respect. 
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From the analysis of the APP-GFP trafficking and catabolism results, we conclude 
that the APP 653YTSI656 domain must be involved in the targeting of APP at several sorting 
stations, and that S655 phosphorylation has an important regulatory role. At the TGN and cell 
surface, S655 phosphorylation seems to lead to higher transport efficiencies, as for example, a 
preference in S655 APP to be vesicle-incorporated. Upon internalization, two scenarios are 
possible depending where APP sorting towards the TGN occurs. If it occurs at the 
early/sorting endosomes, S655 dephosphorylation would be decisive for APP late endosomes 
delivery (S655A), and the phosphorylated form (S655E) directed for TGN recycling. If this 
sorting decision occurs at late endosomes, phospho S655 APP would be rescued from 
lysosomal degradation and targeted to be TGN delivered. It is of note that these targeting 
signals are not omnipotent, with proteins being preferentially but not exclusively target to one 
of these sorting pathways (Rohrer et al., 1996; Walter et al., 2001).   
 
VI. 1. 2 – CONSEQUENCES OF S655 PHOSPHORYLATION-DEPENDENT SORTING ON THE 
APP PROTEOLYTIC PROCESSING 
The different subcellular targeting of the APP-GFP phosphomutants in COS-7 cells 
had important effects on the rate of APP-GFP cleavage by α- and β-secretases. Indeed, APP 
proteolytic cleavages seem not to be directly dependent on the APP S655-phosphorylation 
state, but as the latter influences APP subcellular targeting, it has consequences on APP 
availability for subsequent cleavages. In addition, the results obtained also support the findings 
of the phosphomutants differential subcellular targeting. 
α-secretase processing. S655 phosphorylation was found to increase APP 
processing by the α-secretase pathway. In fact, the S655E mutant presented a slightly faster 
rate and a higher fold-increase in αsAPP secretion (3.36 ± 0.14, Fig. III.3). Relatively to the 
Wt species, the S655A mutant had a slower rate of αsAPP secretion, although presenting a 
similar final fold-increase. The fact that the three APP-GFP species present similar basal levels 
of sAPP production and secretion (sections III.4.2 and III.4.3), may be explained by their 
subcellular distribution. The traffic assays (Fig.s II.8, II.9, and III.5) confirm that the S655E 
mutant has a higher and faster incorporation into post-TGN vesicles, while the opposite 
seems to occur for the S655A mutant. Nonetheless, the final net result must be similar for the 
two S665 phosphomutants in terms of availability to be cleaved by α-secretase: higher APP-
GFP population at the main sites of α-secretase cleavage (TGN and PM), either dynamic (for 
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the S655E mutant) or resting (for the S655A mutant). Indeed, it seems that although not being 
preferentially targeted for TGN secretion, the higher retention time of the S655A mutant at 
the Golgi permits its cleavage by TGN α-secretases, as suggested by the sAPP assays at 20 ºC 
(Fig. III.5). Nonetheless, this S655A cleavage to sAPP or this latter subsequent secretion seem 
to occur slower than for the S655E mutant (Fig. III.3). Finally, considering the similar basal 
sAPP levels for the three APP-GFP species, the differences observed in the final levels of 
αsAPP production under CHX exposure must be related to the different mature APP-GFP 
half-lives. This is also indicated by the lower recovery of both S655A APP-GFP and sAPP 
levels after a period of severe protein synthesis inhibition (Fig. III.2).  
β-secretase processing. Further characterization on the APP S655-phosphorylation 
state-dependent processing also revealed marginal differences on the S655 phosphomutants 
cleavage to Abeta. Although the S655A mutant had a higher percentage of cells with 
fluorescent Golgi with time (Fig.s II.8 and 9), the lower 22C11 Golgi staining at 5:00 h 
suggested that this pool had contributions from cleaved APP molecules lacking the N-
terminal epitope (Fig. II.10). As the S655A α-secretase cleavage was not found to be 
increased, its rate of β-secretase cleavage was addressed, and the S655A-derived Abeta levels 
were observed to be slightly increased. Work from Hung and Selkoe (1994) on APP basal and 
regulated cleavage by secretases, suggested that the APP S655A mutant is more cleaved to 
Abeta. Under the presence of CHX, the cleavage of S655A by β- and γ-secretases to yield total 
Abeta was found to be increased by ∼30% (Graph III.7, A.IV), although this increased was 
smaller (∼10%) in the absence of CHX. In contrast but physiologically consistent, the S655E-
derived Abeta production decreased by ∼10% both in the presence or absence of CHX (Fig. 
III.7, A.IV and B.IV). The two reported main subcellular locations of Abeta production are 
the TGN and the endosomes, subcellular organelles enriched in β-secretase and γ-secretase. 
Although both S655 phosphomutants result in intense fluorescence of these subcellular 
compartments, the S655A has a higher time of residence at the Golgi, and this may be 
necessary and sufficient to be cleaved by the β-secretase at slightly higher rates. In addition, 
some competition between the S655 phosphorylation-dependent sorting/α-secretase and the 
β-secretase cleavage may exist. One hypothesis involves the preference of TGN phospho 
S655 APP to be vesicle incorporated and α-secretase cleaved, while dephospho S655 APP 
would have delayed vesicle incorporation and could be more available for β-secretase 
cleavage. 
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VI. 1. 3 – S655 PHOSPHORYLATION IN AICD NUCLEAR TARGETING 
In agreement with previous direct visualizations of AICD nuclear targeting (Kinoshita 
et al., 2002; Muresan and Muresan, 2004, von Rotz et al., 2004), APP-GFP C-terminal 
fragments were also observed at the cells nuclei. These fragments most likely correspond to 
the expected AICD (although the αCTFs were not ruled out), as observed using 
Immunocytochemistry assays (Fig. II.11). Indeed, the APP-GFP-derived nuclear fluorescence 
co-localized and correlated with the staining of the anti-APP C-terminal antibody, but not 
with the staining of antibodies directed against the APP N-terminus or Abeta region. In 
addition to a S655 phosphorylation role in APP subcellular targeting and proteolytic 
processing, we could also observe alterations in the fate of the generated AICD peptides. 
Time-course analysis of the AICD-GFP nuclear localization led to the observation that 
S655E-derived AICD-GFP had slightly increased nuclear targeting kinetics, when compared 
with the Wt (Fig. II.8 and II.9). The S655A AICD-GFP, although initially having similar 
nuclear fluorescence percentages as the S655E mutant, failed to be highly nuclear targeted in 
the later time points, as observed to occur for the Wt and S655E species. In addition, the 
S655E AICD-GFP nuclear intensity was also overall higher than for Wt, and the S655A 
AICD-GFP nuclear fluorescence was overall less intense. Of note is that nuclear fluorescence 
intensity seems to reflect AICD-GFP abundance and provides a good visual correlation 
between the amounts of nuclear AICD and GFP intensity (Fig. II.12). These results are in 
agreement with the above mentioned higher processing of S655E APP by the α-secretase and 
consequently higher amounts of AICD generation. Hence, S655-phosphorylation may lead to 
a higher AICD generation through the α-secretase pathway, and to a higher AICD nuclear 
targeting. Taken together, these two facts support the hypothesis of APP as a RIP signalling 
molecule, and this is further discussed below.  
 
VI. 1. 4 – SCHEMATIC REPRESENTATION OF S655 PHOSPHORYLATION-DEPENDENT APP 
CELLULAR PROCESSING  
A schematic summary of the results obtained for the cellular fate of S655 
phosphomutants in COS-7 cells, is presented in Figure VI.3, A. These schemes represents the 
main subcellular compartments for both the S655A and S655E mutants, and the observed 
alterations in terms of their cellular traffic sorting, proteolytic processing, and targeting of the 
generated AICD fragment. A synthesis of the main consequences of APP S655 
phosphorylation in its cellular fate is presented in Figure VI.3., B.  
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Figure VI.3. Schematic representation of S655 phosphorylated state-dependent APP cellular traffic and 
proteolytic processing in COS-7 cells. A: Summary of APP S655 phosphomutants (A.I: S655A; A.II: S655E) 
subcellular traffic and processing. B: S655 phosphorylation induces APP to circulate in a close circuit where it is 
mainly cleaved by the α-secretase. The generated AICD is nuclear targeted, where it may function as a gene 
transactivator. Orange arrows indicate direction of S655-induced APP/AICD traffic. RER, rough endoplasmic 
reticulum; TGN, trans-Golgi network; pTGNV, post-TGN vesicle (secretory vesicle); PM, plasma membrane; 
EE, early endosome; LE, late endosome; Lys, lysosome; N, nucleus. E, endosome. Note: in this scheme the 
early endosome was arbitrary taken as the sorting station where sorting and targeting of proteins to the 
retrograde TGN transport occurs.  
 
 
Taken together, the results point to S655 phosphorylation as a cellular mechanism for 
activating the APP molecule to be preferentially cleaved through the α-secretase pathway and 
to generate its derived physiological active fragments: αsAPP and AICD. This is accomplished 
by decreasing mature APP degradation and targeting it to the subcellular compartments where 
α-secretase cleaves APP. Specifically, S655 phosphorylation “traps” APP, trafficking it 
between the trans-Golgi network and the plasma membrane. The generated AICD is, in 
addition, highly targeted to the cell nucleus, where it may form protein complexes with gene 
promoting activity.  
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VI. 1. 5 – S655 PHOSPHORYLATION-DEPENDENT APP NEURONAL TARGETING 
In primary neurons of rat cortical origin, the APP S655 phosphorylation-state also 
influenced APP subcellular targeting. The S655E APP-GFP protein was observed to be 
targeted to more distal neuritic terminals than the other two APP-GFP species, in an apparent 
neuronal maturity-dependent manner (Fig. V.I). In turn, the S655A APP-GFP protein had a 
neuritic targeting that was slightly decreased and more resembling the Wt protein. The S655 
phosphorylation state appeared not to influence the polarized intraneuronal APP targeting in 
terms of sorting into the axonal and somatodendritic domains (Fig. V.3, MAP-2 co-
localization assays) but time-lapse experiments will be necessary to analyse this issue in more 
detail. In fact, it is possible that the S655E mutant is initially more targeted to the axon and 
subsequently endocytosed, and retrogradely transported back to the soma and dendritic 
compartments. The initial observations of S655E higher cell surface endocytosis and higher 
retrograde PM-to-TGN targeting in COS-7 cells support this hypothesis. As neuronal APP 
retrograde transport may occur via secondary endosomes, it is possible that the observed 
lower S655E lysosomal targeting in COS-7 cells may have a parallel in neurons. In a 
speculative hypothesis, S655E APP proteins arriving at the soma via retrograde axonal 
transport may be rescued from lysosomal delivery and degradation, being delivered instead to 
the dendrites. The net result of these hypotheses would still be the observed increase in both 
axonal and dendritic S655E APP-GFP transport. Interestingly from a signal transduction 
perspective, was the observation that the S655E protein was present in a higher number of 
axonal and dendritic growth cones. Axonal growth cones are specialized transduction systems 
involved in neuritic outgrowth and motility, which guide the elongating axon towards 
appropriate synaptic targets in response to extracellular signals or intrinsic cues. Two major 
proteins found in axonal growth cones are the APP-binding protein G0α and its binding 
protein GAP-43 (Strittmatter et al., 1990; Strittmatter and Fishman, 1991), whose expression 
is up-regulated by APP (Mucke et al., 1994). The APP His657-Lys676 hydrophobic pocket is 
necessary for APP-G0α binding, and S655 phosphorylation may potentially regulate protein 
binding at this downstream region (see Chapter I). The finding that APP increases GAP-43 
levels in a S655 phosphorylation state-dependent manner (Fig. V.6) suggests a role for S655 
phosphorylation in neuronal APP RIP signalling, especially at neuritic growth cones. Further 
results supporting this hypothesis concern the observed higher targeting of nuclear S655E C-
terminal fragments (Fig.s V.4 and V.5). This is in agreement with the previously observed 
higher nuclear targeting of S655E C-terminal fragments in COS-7 cells (Fig. II.8 and II.9). 
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VI. 2 – S655 PHOSPHORYLATION IN APP RIP SIGNALLING  
Recent finding that APP has a physiological role as a nuclear gene transactivator have 
brought even more complexity to the putative APP functions and its mode of action. Only 
recently some of the physiological functions of AICD are being unravelled. AICD-containing 
nuclear complexes were observed to promote expression of genes such as app itself, gsk-3β, 
tip60, bace (Kim et al., 2003; von Rotz et al., 2004), neprelysin (Pardossi-Piquard et al., 2005), 
kai1 (Baek et al., 2002; von Rotz et al., 2004; Telese et al., 2005). The first four seem to 
implicate AICD in an auto-positive feedback mechanism by the β-secretase (BACE) pathway, 
as GSK-3β was observed to phosphorylate APP at T668 (Aplin et al., 1996), apparently 
targeting APP to the β-secretase pathway. Tip60 is a nuclear histone acetylase involved in 
DNA binding and gene expression activation, which forms transactivation complexes with 
AICD and other proteins (Cao and Sudhof, 2001; von Rotz et al., 2004; Telese et al., 2005). 
The fifth gene (neprelysin) codes for an enzyme (Neprelysin, NEP), known to be involved in 
Abeta degradation. The sixth gene codes for KAI1, a tetraspanin protein involved in cell 
proliferation as a metastasis suppressor (reviewed in Jackson et al., 2005), and indicates a 
mechanism by which full-length APP may auto-regulate part of its functions (Qiu et al., 1995). 
Additionally, AICD was found to be involved in cellular Ca2+ signalling, and a mechanism of 
action was postulated involving transactivation of genes with kai1 promoter elements, such as 
the gene coding for an ER Ca2+ ATPase (Leissring et al., 2002). This may also present a 
mechanism of APP involvement in cellular Ca2+-dependent processes such as cellular 
differentiation, neurite outgrowth, and synaptic plasticity. Promoting APP expression may 
ultimately function to restore the cellular APP pool, but the fact that AICD up-regulates both 
BACE and NEP expression (with simultaneous enhancement of NEP activity) is intriguing. In 
fact, it seems that the generation of more AICD without possible pathogenic Abeta side-
effects, would be more easily accomplished by up-regulation of app and adamX (X = 9, 10 or 
17) genes. Nonetheless, AICD was not observed to induce adam10 expression (von Rotz et al., 
2004). Also intriguing is the finding that transfected AICD C59 inhibits, in a dose-dependent 
manner, the retinoic-acid (RA)-induced gene transactivation (Gao and Pimplikar, 2001). 
Retinoic acid is known to increase APP and BACE expressions (König et al., 1990; Lahiri and 
Nall, 1995; Beckman and Iverfeldt, 1997; Satoh and Kuroda, 2000), and recently it was 
observed to also induce adam10 expression. APP/AICD and RA have some opposing effects 
in cells growth and differentiation, and APP/AICD antagonize RA-mediated responses 
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(Yoshikawa et al., 1992; Honda et al., 1998; Goodman and Pardee, 2003; Ono et al., 2004). 
Therefore, app expression and/or APP RIP signalling seem to set an end-point in RA-induced 
response. Hence, AICD signalling seems far more complex than expected, and may involve 
antagonistic effects (gene transcription inhibition or activation) under different physiological 
scenarios.  
 
VI. 2. 1 –  S655 PHOSPHORYLATION TRIGGERS APP RIP SIGNALLING 
Kume et al. (2004) have shown that elevated β-secretase levels induce an increase in 
βCTF and Abeta generation, but led to a reduction of αCTF and AICD C50 generation. 
Furthermore, elevated α-secretase levels induced an increase of AICD C50. The generation of 
AICD C50 by epsilon-cleavage seems therefore to depend on αCTF, from which it seems to 
be more efficiently generated. This observation of gamma- and epsilon-cleavages being 
differentially regulated, is supported by findings of uncorrelated Abeta and AICD generation 
that will be discussed later (section VI.4). All these observations suggest that AICD C50 is 
mainly generated via the α-secretase pathway, as already expected from its much higher rate of 
APP cleavage. In addition, the α-secretase-triggered AICD generation was observed to be of 
central importance for APP nuclear signalling. Khvotchev and Sudhof (2004) have 
demonstrated that in COS, HEK 293, and PC12 cells, APP is cleaved at a high extent by the 
α-secretase at TGN and/or secretory vesicles. Disruption of the Golgi apparatus led to a 
severe inhibition of APP cleavage by the α-secretase, while inhibition of cellular exocytosis 
(but not of TGN and post-TGN vesicle release) did not inhibited APP cleavage although it 
did inhibit sAPP and Abeta secretions. Significantly, the authors observed that inhibition of 
APP processing by the α-secretase led to a severe down-regulation of AICD-induced 
transactivation, while sole inhibition of APP exocytosis did not render such an effect. Hence, 
the major route of physiological active AICD generation involves the APP α-secretase 
cleavage, which in COS-7 cells appears to occur to a higher extent at TGN and/or secretory 
vesicles. Our work supports the hypothesis that the main physiologically active AICD arrives 
from APP that is initially cleaved by the α-secretase, and that S655 phosphorylation regulates 
APP targeting to this pathway. As observed for the S655E mutant, S655 phosphorylation 
appears to mark the protein as a functional molecule and to lead to it’s α-secretase cleavage 
and consequent AICD generation. Of note is that it is still unknown if the AICD generated 
from α- and β-secretase cleavages possess the same transactivation roles. In fact, although 
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being virtually identical, they may form different protein complexes due to being generated in 
different subcellular compartments, and thus induce different downstream effects. For 
example, phospho T668 APP is preferentially cleaved by the β-secretase and simultaneously 
interacts more loosely with one of the major AICD-binding protein (Fe65), which participates 
in most of the known AICD signalling complexes.  
Protein phosphorylation is a well known strategy employed by the cells to regulate 
gene transactivation, including activation of latent transcription factors to perform their 
nuclear function. This may be accomplished by direct activation of the signalling protein (e.g. 
the signal transducers and activators of transcription - STAT - factors), or by inactivating its 
constitutive inhibitors (e.g for the transcription factor NF-κB; Rawson, 2002). In the APP RIP 
signalling context, “direct activation of the signalling molecule” may involve proteolytic 
activation of its precursor (APP) and/or of AICD itself. The first mechanism seems to occur 
after APP S655 phosphorylation and additionally, phospho S655 AICD appears to be in an 
activated “signalling mode”, as it is highly targeted to the cells nuclei. One of the possible 
mechanisms involved in S655-induced AICD nuclear targeting is AICD stabilization. After 
being released from membranes to the cytoplasm, AICD is known to be rapidly degraded 
(Cupers et al., 2001; Kimberly et al., 2001), partially by the insulin degrading enzyme (Edbauer 
et al., 2002; Farris et al., 2003). AICD stabilization and nuclear targeting may be accomplished 
through AICD complex formation with specific proteins. In fact, AICD phosphorylation 
state-dependent formation of protein complexes seems the most attractive mechanism of 
modulating AICD effects on target genes.  
 
 
VI. 3 – PUTATIVE MOLECULAR BASIS OF S655 PHOSPHORYLATION ACTION 
Phosphorylation of APP at its C-terminus is believed to regulate binding of APP to 
other cellular proteins that participate and mediate APP cellular processing and function. 
Ando et al (2001) showed that the phosphorylation state of T668 regulates APP interactions at 
the 682YENPTY687 motif.  XL11 and mDab1 bind APP regardless of the phosphorylation state 
of APP T668, while Fe65 interaction with the APP recognition motif is weaker upon T668 
phosphorylation. In addition, phosphorylation at this residue is associated with a preference 
for APP to be cleaved in the β-secretase pathway (Lee et al., 2003a; Muresan and Muresan, 
2005). Nonetheless, it is still a matter of controversy if T668 phosphorylation results in higher 
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or decreased AICD nuclear targeting and transactivation (Zheng et al., 2003; Muresan and 
Muresan, 2004; Kimberly et al., 2005).  
The targeting of APP to the α-secretase pathway by APP direct phosphorylation had 
not yet been observed.  Our results implicate APP S655 phosphorylation in this targeting and 
strongly suggest its involvement in AICD nuclear signalling. The mechanisms by which S655 
phosphorylation acts most probably include regulation of APP binding to specific proteins. 
For example, S655 phosphorylation may induce alterations in the APP affinity for specific 
APP binding proteins with roles as coat proteins or carrier microtubule-associated proteins, 
resulting in enhanced APP targeting to post-TGN, endocytic or specific neuronal vesicles. For 
example, BACE-1 S498 phosphorylation enhances its binding, through the S498-containing 
sorting motif, to the adaptor protein GGA (Shiba et al., 2004). This protein is involved in 
TGN anterograde transport and GGA-BACE-1 binding was later shown to be responsible for 
the phosphorylation-dependent BACE-1 retrograde transport (Wahle et al., 2005). A similar 
mechanism, involving a serine residue immediately upstream a sorting motif, occurs for the 
cation-independent MRP protein (Kato et al., 2002). APP S655 phosphorylation may 
therefore in this way accelerate specific vesicle traffic stages, such as APP cargo packaging, 
vesicle release, or vesicle targeting. Strong support for a regulatory role of S655 
phosphorylation in APP binding comes from the reported effects of S655 phosphorylation on 
the APP molecule backbone. As indicated in Chapter I, characterization of APP phospho 
S655 molecules by multidimensional NMR spectroscopy points to S655 phosphorylation-
induced structural changes in the 653YTSI656 domain and in the downstream hydrophobic 
pocket (Ramelot and Nicholson, 2001). These alterations were also of higher range than T654 
phosphorylation, with this latter only affecting the conformation of the 653YTSI656 domain 
(Ramelot and Nicholson, 2001). The proteins that interact with these domains/sequences are 
the best candidates to bind APP in a S655 phosphorylation-dependent manner. These 
candidates include: APPBP2 (or PAT1), the alpha subunit of the G0 protein, the Hsc73 (or 
Hsc70) chaperone, and an N-terminal acetyl-transferase protein (hARD1). This latter has not 
been well characterized and the only phenotype observed as a consequence of its binding to 
APP was a decreased Abeta generation, in an acetyl-transferase activity-dependent manner 
(Asaumi et al., 2005). The APP recognition sequence for the SET protein binding is still 
elusive, although it is thought to be at or near the 653YTSI656 domain (Madeira et al., 2005). 
This protein appears to be involved in a Fe65/AICD/Tip60/SET protein complex, and to 
participate in AICD-mediated kai1 gene transcription (Telese et al., 2005). 
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 APPBP2 (“PAT1”). APPBP2 is a microtubule-interacting protein whose interaction 
with APP/AICD YXXI motif requires the Y653 integrity (Zheng et al., 1998). This binding 
leads to enhanced sAPP secretion into the medium (Zheng et al., 1998) and AICD nuclear 
targeting (Gao and Pimplikar, 2001). It is thought to increase sAPP secretion by increasing 
APP traffic to the secretory pathway. This protein has in its sequence four tandem repeats 
(TPR) conserved in all species of kinesin light chains (KLC). As the latter, APPBP2 binds to 
microtubules in an ATP-dependent manner (Zheng et al., 1998), and thus it may function as a 
motor protein, tracking vesicles along microtubules. Interestingly, APPBP2 is localized to the 
Golgi area, the cytoplasm and the nucleus, and it has been implicated in the neuronal 
anterograde transport and nuclear export of a herpes virus protein (Benboudjema et al., 2003). 
Hence, we postulate that APP phosphorylation at S655 enhances APP binding to APPBP2, 
thus leading to APP higher and faster vesicle trafficking.  
The APP-APPBP2 binding may also be maintained after APP γ-secretase cleavage and 
play a role in APP nuclear targeting and nuclear function (Gao and Pimplikar, 2001). Co-
transfection of MDCK cells with APPBP2 and AICD C59 or C57 lead to a higher AICD 
nuclear localization that was dependent on the presence of the APPBP2 nuclear localization 
signals (Gao and Pimplikar, 2001). This seems to implicate APPBP2-AICD binding in AICD 
stabilization and nuclear targeting, but a possible direct role for the APPBP2-AICD complex 
in transcription regulation is now emerging. Overexpression of APP or CTFs was reported to 
antagonize the RA-mediated responses, along with interfering with RA-induced mouse P19 
stem cell differentiation. Furthermore, AICD was found to be a dose-dependent inhibitor of 
the retinoid pathway (see Gao and Pimplikar, 2001). As RA and AICD both promote app 
expression, the AICD may also have nuclear functions that are a part of an inhibitory 
mechanism of RA-mediated responses. In this transcription repression, the AICD may use 
APPBP2 DNA-binding motifs and its NR cyclin binding motif, which is commonly present in 
transcription corregulators. For instance, this NR cyclin motif is known to mediate the 
interaction of transactivators with their nuclear hormone receptors, such as the retinoid acid 
receptor (RAR). Interestingly, APPBP2 was found to form complexes with and to inhibit the 
action of the androgen receptor (Zhang et al., 2004), and of a strong inducer of the retinoid 
pathway, termed R3, that interferes with RAR function (Richards et al., 2003). Of note is that 
the sole co-expression of APPBP2 and AICD does not reverse the AICD-induced inhibition 
of the RA pathway (Gao and Pimplikar, 2001). AICD may also further inhibit its AICD-
APPBP2 complex formation, as AICD C59 was reported to induce APPBP2 nuclear export 
along with its cytoplasmic proteasomal degradation (Gao and Pimplikar, 2001).  
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G0α. Beyond its known role in cell signalling as a subunit of G-proteins, G0α was 
found to play a regulatory role in the process of cell secretion, including vesicle exocytosis 
(Lang et al., 1995). Interestingly, G0α was observed to be present in cellular microdomains 
specialized in sorting, both secretory or endocytic in nature (Qian et al., 2003). In particular 
G0α was detected in neuronal regulated vesicles: large dense core and small synaptic vesicles 
(Ahnert-Hilger et al., 1994). This G0 subunit was also observed at the membrane of immature 
and mature vesicle granules of endocrine cells, and after a rapid carbachol-stimulus a part of 
this G0α pool redistributes itself to the cytosol. As carbachol and other cholinergic-receptors 
agonists function as αsAPP inducers (Qiu et al., 2003), and carbachol enhances the secretion 
of APP-containing regulated vesicles (Efthimiopoulos et al., 1996), carbachol may function 
through G0α traffic-regulation. G0α has GTPase activity and Nishimoto and colleagues have 
demonstrated that an Ile656-Lys676 hydrophobic pocket-containing APP sequence binds G0α in 
a GTPγS-inhibitable manner (Nishimoto et al., 1993). Interestingly, the two types of 
molecules, along with cargo proteins, that are necessary for vesicle formation are: a small 
GTPase molecule and a coat protein, the latter necessary for cargo-recognition and 
destinations targeting. GTPases functions in traffic through coat-proteins activation and 
target, and in the vesicle uncoating for vesicle fusion with the acceptor membrane. G0α 
GTPase activity and interaction with APP C-terminus (“cargo recognition”) suggests that G0α 
may function as an APP coat-protein in APP traffic. In total neuronal membranes and in 
CSEM, APP binding to an antibody against APP ectodomain (22C11) led to the reduction of 
the high-affinity G0 GTPase activity. This inhibition was specific for G0α and is reproduced 
by the addition of APP CTFs (Brouillet et al., 1999). Speculatively, S655 phosphorylation may 
direct APP to bind G0α, and in this way promote specific APP sorting at subcellular sorting 
stations and/or enhance APP packaging into specialized vesicles. This is important in 
neurons, with G0α being potentially involved in APP neuritic traffic and signal transduction. 
In speculative terms, S655 phosphorylation may result in a more functional APP-mediated 
signalling at neuritic growth cones, by e.g. leading to more stable APP-G0α-GAP43 complexes 
and in that way stabilizing the neuronal GAP-43 pool. Furthermore, APP-G0α binding may 
also be involved in AICD signalling after APP RIP cleavage, as evidences suggest that G0α 
GTPase activity functions after γ-secretase cleavage of CTFs at the ε-site (AICD formation), 
and that AICD-G0α may be involved in the AICD signalling (Yamatsuji et al., 1996; reviewed 
in Neve et al., 2001).  
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Hsc73. Hsc73 (or Hsc70), a nucleocytoplasmic chaperone with functions in protein 
traffic and protein degradation, was found to bind APP at the APP C-terminal sequence 
Q652-S675 (Kouchi et al., 1999). This sequence includes both the 653YTSI656 and the 
hydrophobic pocket domains. Hsc73 is constitutively expressed in cells and is highly abundant 
in brain (Mathur et al., 1994). It may target proteins to proteasomal degradation, as a 
constituent of the 20S proteasome (Schmidt et al., 1997), or to lysosomal degradation 
(Agarraberes et al., 1997). Nonetheless, the proteasome has only been associated with 
immature and not mature APP degradation (Hare, 2001; Chen et al., 2005), and Hsc73 directs 
cytosolic but not membranar proteins to specific lysosomes and under stress conditions. As 
AICD degradation seems not to be dependent on lysosomal or proteasomal activity (Fadeeva 
et al., 2003), this will not be further discussed. Other important cellular processes in which 
Hsc73 is involved include cellular endocytosis, where it functions as an uncoating ATPase that 
selectively removes clathrin from brain coated vesicles (Honing et al., 1994; Buxbaum and 
Woodman, 1994), and nuclear protein import (Shi and Thomas, 1992), as is the case of 
nuclear hormone receptors (Hache et al., 1999; Krebs et al., 1999). Hence, Hsc73 binding to 
APP may be involved in its cell surface endocytosis and a putative Hsc73-AICD interaction 
may be involved in AICD nuclear inport. Thus, S655 phosphorylation may regulate APP RIP 
signalling by increasing APP endocytosis and/or AICD nuclear targeting through induction of 
APP/AICD binding to this cytosolic chaperone.  
 Figure VI.4 presents putative S655 phosphorylation-dependent binding of APP C-
terminus to proteins with which it may form signalling complexes physiologically relevant in 
the APP cellular fate and RIP signalling contexts.  
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Figure VI.4. Schematic representation of putative S655 phosphorylated state-dependent APP 
interactions with proteins known to bind APP at its 653YTSI656 domain, at the Ile656-Val663 hydrophobic 
pocket, or at APP C-terminus sequence that includes both motifs.  
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VI. 4 – S655 PHOSPHORYLATION IN AD PATHOPHYSIOLOGY AND THERAPY 
The importance of AD therapy can be outlined by the high number of reviews on this 
matter (200) just for the year 2005, and the over 200 different compounds that are at various 
stages of development for AD treatment. One of the main goals in AD therapy is to lower 
brain amyloid burden, with this being expected to be accomplished by 1) inhibition of Abeta 
production, 2) removal of amyloid plaques, and/or 3) inhibition of potential amyloidotrophic 
factors. Altogether, a minimum of six classes of compounds already exist, all of which are 
approved for clinical use and are either already being tested or ready for phase III clinical trials 
for the treatment of AD. These include: cholinesterase inhibitors, blockers of the NMDA 
receptor, antioxidants or blockers of oxidative deamination, anti-inflammatory agents, 
neurotrophic factors, and antiamyloid agents (including immunization, inhibition of the 
interaction between Abeta and its pathological chaperones, and cholesterol-lowering therapy) 
(reviewed in Schmitt et al., 2004). A GABA(B) antagonist is also being developed to be used 
in AD treatment (Ebert and Svendensen, 2005; Bullock, 2005). Nonetheless, no effective cure 
is yet available, and some of the trials in humans revealed to be disappointing. This is the case 
of Abeta immunization, for which the cognitive benefits of active immunization were difficult 
to show, and side effects were evident (high ventricular volumetry, acute autoimmune 
meningoencephalities, microhemorrhages within the brain vasculature) (Gandy and Heppner, 
2005; Wisniewski and Frangione, 2005). The use of hormone replacement therapy has also 
generated controversy, as it leads to downstream effects in humans that include both 
decreased and increased dementia risk, with the latter being prevalent (Almeida and Flicker, 
2005; Baum, 2005). Hence, adequate treatment strategies are still being actively pursued. A 
major field in new target molecules for anti-AD drugs concerns the finding of anti β- and γ-
secretase inhibitors for lowering Abeta production (Thompson et al., 2005; Churcher and 
Beher, 2005). However, this is a challenging route, as γ-secretase is a promiscuous enzyme that 
is also responsible for intramembranous cleavage of a growing list of transmembrane proteins, 
which includes Notch (reviewed in Pollack and Lewis, 2005). In addition, γ-secretase is also 
needed for the APP RIP signalling process. BACE, on the other hand, seems to have fewer 
substrates, but care is needed as low levels of Abeta may possess normal cellular functions, 
such as neurite outgrowth. Hence, such β- and γ-secretase blocks over chronic periods of time 
may be deleterious, due to interference in other cell signalling pathways. Furthermore, the 
Abeta peptide is probably not the only causative agent of AD. AD patients of the Swedish 
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FAD type possess an abnormally low ratio of APP processing via the α-secretase pathway 
relative to the Abeta-generating one (Citron et al., 1992; Felsenstein et al., 1994). Transgenic 
mice with defective APP α-secretase processing show a severe phenotype of premature death, 
behavioural abnormalities, hippocampal and cortical neurodegeneration, and apoptosis 
(reviewed in Bayer et al., 2001). Recently, double-transgenic mouse studies have shown that 
increased activity of ADAM 10 can prevent plaque formation (Postina et al., 2004). These 
findings stress the importance of altered non-amyloidogenic cleavage in the disease process. 
Furthermore, several drugs with brain protective effects and that lower Abeta production, 
such as NSAIDs, statins and flavonoids, were recently found to channel APP to non-
amyloidogenic processing (reviewed in Tang, 2005). Anti-AChE drugs, which increase 
acetylcholine brain levels, also lead to an increase in the αsAPP processing through m1 
receptors. The benefit of neurotrophic factors in dementia has been highlighted (for example, 
Levy et al., 2005), and αsAPP is one such factor. Besides having synaptogenic properties, this 
APP fragment counteracts Abeta toxicity and glutamate-induced excitotoxicity and dendrite 
outgrowth inhibition, through modulation of cGMP and intracellular calcium levels (reviewed 
in Mattson, 2004). Inhibition of Abeta overproduction and stimulation of APP α-secretase 
processing are therefore part of the rationale strategies when AD prevention or progression 
reversion are considered. Another factor that may be contributing for AD development is 
impaired APP trafficking, which is also tightly interconnected with APP proteolytic processing 
(see Chapter V). For example, a major FAD gene (Barinaga, 1995) encodes a protein 
homologous to the C. elegans Spe4, a protein that plays a role in membrane sorting (L´Hernault 
and Arduengo, 1992). Furthermore, Abeta peptides may inhibit cellular secretion pathways, 
and thus impair APP trafficking. This may be accomplished through Abeta interaction with 
PKC, with this interaction provoking a decrease in the levels of activated cellular PKCα and 
PKCε and to decrease their translocation (Lee et al., 2003b). Hence, the high Abeta levels 
observed in AD patients may lead to altered protein traffic. Many authors now defend APP 
missorting and impaired APP secretory traffic as possible mechanisms contributing to some 
forms of AD. A more complete understanding of the normal physiological functions of APP 
and Abeta, and of the molecules that control APP trafficking and processing events, is 
therefore necessary if we are aiming to prevent AD and not only alleviate the disease 
symptoms. 
The characteristics of APP as a signalling molecule and the involvement of APP RIP 
in AD onset and/or development are also the focus of interest in a large area of research. 
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Recent reports on AD, FAD mutations and APP RIP signalling dissociate the APP γ-secretase 
cleavages at the γ- and ε-sites, and thus the generation of Abeta and AICD. Several FAD 
mutations lead to Abeta enhanced production, but not all FAD mutations affect AICD C50 
generation (Hecimovic et al., 2004). Furthermore, these authors observed that changes in total 
AICD C50 levels do not correlate with either an increase or a decrease of any Abeta species. 
This was also shown through pharmacological studies, using a compound (NSAIDs) that is 
being tested for lowering Abeta. This compound was able to decrease the Abeta levels without 
affecting the γ-secretase generation of AICD C50, AICD-Fe65 complex formation, or AICD-
induced transcription (Weggen et al., 2003). Hence, a possible correlation between APP 
signalling and Abeta levels has still not been observed but, and as previously observed in 
section VI.2, APP RIP signalling may potentially alter Abeta production. In addition, the 
normal signalling mechanisms of AICD fragments may be are altered in an AD background. 
In many AD forms, especially the late-onset sporadic cases, defective degradation of Abeta 
and/or decreased APP α-secretase processing may be central to the disease process (Iwata et 
al., 2001; Leissring et al., 2003). Altered APP α-secretase processing potentially leads to down-
regulated AICD production and function (Zheng et al., 2003; Khvotchev and Sudhof, 2004; 
Kume et al., 2004; Kimberly et al., 2005). Bergman et al. (2003) have also shown that FAD-
carrying αCTF fragments are equally able to generate AICD C50 with signalling properties. 
Other possible contribution of APP C-terminal fragments in the AD disease is as cellular 
apoptotic inductors (reviewed in Neve et al., 2001). APP C-terminal fragments with or 
without the Abeta sequence were observed to be equally cytotoxic in differentiated PC12 cells 
and cortical neurons (Lee et al, 2000), directly implicating the AICD fragment as the active 
fragment. In this line, altered signalling properties of protein complexes formed by APP C-
terminal fragments and G0α, may also be involved in AD. Some evidences indicate that G0α-
APP/AICD altered binding leads to DNA fragmentation (reviewed in Neve et al., 2001). In 
fact, the APP London FAD mutation V642I causes neuronal DNA fragmentation in an APP-
G0α binding-dependent manner. This DNA fragmentation was prevented either by deletion 
of the APP hydrophobic pocket, by using a G0α -inhibitor, or by expressing a G0α dominant-
negative mutant (Yamatsuji et al., 1996). Interestingly, this FAD mutation occurs in the APP 
sequence between the two AICD-generating γ-secretase cleavages, near the γ-secretase ε-site 
(L645), and inhibition of γ-secretase activity prevented DNA-fragmentation (Yamatsuji et al., 
1996). Thus, a V642I AICD-G0α protein complex appears to be the active complex involved 
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in the observed DNA fragmentation, and deregulated AICD-G0α-downstream signalling may 
be occurring (Giambarella et al., 1997). Hence, the mechanisms controlling APP RIP 
signalling are of growing interest as they may be involved in AD pathogenesis, and APP S655 
phosphorylation may play an important role, as for example in regulating APP- G0α binding.  
S655 Phosphorylation in AD Pathophysiology and Therapy. From a therapeutic 
perspective, it appears desirable to aim for a situation where APP could still perform its 
nuclear signalling, but where Abeta levels would not be enhanced and APP traffic would not 
be inhibited. Our findings suggest that APP S655 phosphorylation may be suitable for all 
these purposes, with the benefit of being a post-translation modification that may be 
transiently modulated. In speculative terms, favouring the cerebral production of the 
neuroprotective αsAPP through S655 phosphorylation looks appealing, as it could also 
potentially maintain the Abeta levels low. S655 phosphorylation seems to “activate” the APP 
molecule to be targeted to subcellular sites of α-secretase processing. In addition, the S655A 
mutant is less efficiently sorted from the TGN, with consequences for increased cleavage by 
β-secretase. This slightly higher Abeta production, may have long-term effects on cells 
homeostasis. The observed higher S655E APP neuritic traffic has potential implications in its 
cleavage to the neurotrophic αsAPP (Parvathy et al., 1999), a hypothesis further supported by 
its higher nuclear targeting. Further work is therefore needed in clarifying the mechanisms of 
S655 phosphorylation action, and care must also be taken in developing treatment strategies. 
For example, although PKC is thought to induce APP S655 phosphorylation, long-term use of 
PKC drug activators was observed to decrease APP traffic, and to induce higher APP 
concentration at a cellular location where β-secretase is present. In fact, under these 
conditions, the Abeta levels were observed to be significantly increased (da Cruz e Silva et al., 
in preparation). Hence, long term use of PKC activators in AD therapy may potentially have 
an adverse effect and increase the Abeta burden. Additionally, adverse effects may occur 
resulting from the phosphorylation of other undetermined proteins. The development of 
therapeutic drugs targeting APP S655 phosphorylation may involve instead protein 
phosphatases or their binding proteins, which can provide tissue specificity (da Cruz e Silva et 
al., 2003 and 2004a). 
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VI. 5 – FINAL REMARKS 
These APP phosphoresidue mutant studies represent a comprehensive analysis of 
APP trafficking and processing from a phosphorylation-dependent perspective and under a 
signal transduction AD therapeutic perspective. Analysis of the S655 phosphomutants 
trafficking reveals a role of S655 APP phosphorylation in the regulation of APP695 intracellular 
traffic between the TGN and the plasma membrane (COS-7 cells), and in the neuronal 
targeting of APP to functional neuritic terminals. These alterations in the APP molecule 
subcellular trafficking had consequences in its RIP processing. In COS-7 cells, mimicking 
constitutive S655 phosphorylation lead to an enhancement of the protein’s half-life and to its 
increased α-secretase cleavage. The final objective of this APP activation and targeting to the 
α-secretase cleavage pathway strengthens the role of APP as a signalling molecule, as it leads 
to an enhancement in AICD nuclear targeting. A higher nuclear targeting of S655E APP C-
terminal fragments was also observed in neurons. APP direct phosphorylation at its S655 
residue may play important roles in regulating cerebral APP functions and neuronal signalling, 
an hypothesis supported by the higher expression of the growth associated protein 43 in 
S655E overexpressing cells.  
The results here described help to unravel the key points of S655 phosphorylation-
dependent non-pathogenic processing of APP, and to elucidate how pathological 
phosphorylation conditions maybe affecting cellular APP and amyloidogenic Abeta 
production. It is also worthwhile reinforcing that neuropathology has been associated with 
altered protein phosphorylation. Further characterization of S655 phosphorylation-dependent 
APP protein interactions and downstream effects will hopefully shed new light into these 
matters. Therefore, future research will focus on detailed characterization of key control 
points regulated by S655 phosphorylation, and in the identification of the underlying signal 
transduction cascades. The identity of target genes whose transcription may be regulated by 
S655 phosphorylation will also be addressed. Finally, the putative contributions of these 
interactions and downstream signalling to the AD pathogenesis will continue to be analysed.  
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APP Serine 655 mutated to glutamate 
Threonine amino acid residue at position XXX 
Tumor Necrosis Factor-α Converting Enzime 
Tris Buffered Saline 
TBS supplemented with Tween detergent 
N,N,N’,N’-Tetramethylethylenediamine 
Trans-Golgi Network 
Tat interactive protein, 60 kDa 
Tandem Protein Repeats  
Transferrin Receptor 
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Tris-HCl 
UV 
Vs. 
WR 
Wt 
Y/Tyr 
Tris (hydroxymethyl)-aminoethane Chloride  
Ultraviolet Light  
Versus 
Working Reagent 
Wild-type 
Tyrosine amino acid residue 
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APPENDIX I – SOLUTIONS 
 
DNA Manipulation 
 Solutions for bacterial cultures, transformation and DNA extraction: 
- SOB (Fluka)      25.5 g/L 
- SOC 
- SOB      49 ml 
- 1 M Glucose stock solution   1 ml  
- Competent cells solutions 
Solution I (1 L): 
- MnCl2.4H2O      9.9 g  
- CaCl2.2H2O      1.5 g  
- Glycerol       150 g   
- KHAc       30 ml (1 M) 
adjust pH to 5.8 with HAc, filter through a 0.2 µm filter and store at 4 ºC. 
Solution II (1 L): 
- MOPS (0.5 M, pH 6.8)     20 ml  
- RbCl       1.2 g  
- CaCl2.2H2O      11 g  
- Glycerol       150 g 
filter through a 0.2 µm filter and store at 4 ºC.   
- LB (Luria-Broth) medium (Sigma)  20 g/L 
- LB agar plates 
For a final volume of 1 L, to 950 ml of LB medium add 12 g of agar. Mix until the 
solutes have dissolved. Adjust the volume of the solution to 1 litre with LB medium and 
sterilize by autoclaving. When at cooling pour into bacterial culture plates (∼ 20 ml/ 100 
mm plate). After solidify store inverted at 4 ºC. 
- 100 mg/ml Antibiotics stock solutions (Ampicilin or Kanamycin) (1000x)  
Dissolve 1 g of the antibiotic in 10 ml of deionized H2O. Mix until the solutes 
have dissolved, filter through a 0.2 µm filter, aliquot and store at -20 ºC. 
- DNA extraction (‘mini and maxi preps’) 
Solution I (‘resuspension’):  
- Glucose      50 mM 
- Tris.Cl (pH 8.0)    25 mM 
- EDTA (pH 8.0)    10 mM 
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Solution II (‘alkaline lysis’): 
- NaOH     0.2 N 
- SDS     1% 
Solution III (‘neutralization’): 
- 5 M Potassium acetate   3 M 
- Glacial acetic acid   2 M 
- 50X TAE solution (1 L) 
- Tris base     242 g 
- Glacial acetic acid    57.1 ml 
- EDTA (pH 8.0)     100 ml  
- TE buffer, pH 7.5 
- Tris-HCl (pH 7.5)    10 mM 
- EDTA (pH 8.0)     1 mM 
- RNase stock solution    10 mg/ml 
- 10 mM dNTPs solution (100 µl) 
- dATP      10 µl 
- dTTP      10 µl 
- dCTP      10 µl 
- dGTP      10 µl 
- H2O         60 µl 
aliquot and keep at -20 ºC. 
 
Cell Culture and Rat Cortex Samples 
 Cells seeding, maintenance and experiments: 
- DMEM medium (COS-7 cells) 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine 
and 4500 mg glucose/L, Sigma Aldrich) in deionised H2O and add: 
- NaHCO3 (Sigma-Aldrich)    3.7 g 
adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC.  
- Complete DMEM (COS-7 cells) 
For a final volume of 1 L, when preparing DMEM medium adjust to pH 7.4 and 
before sterilizing add: 
- Fetal Bovine Serum (FBS) (Gibco BRL, Invitrogen) 100 ml (10% v/v) 
Notes: FBS is heat-inactivated for 30 min at 45 ºC. For cells maintenance, prior to 
pH adjustment add 100 U/ml penicillin and 100 mg/ml streptomycin [10 ml 
Streptomycin/ Penicilin/ Amphotericin solution (Gibco BRL, Invitrogen)]. 
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DMEM Components:     (g/L) 
L-Arginine•HCl      0.084 
L-Cystine•2HCl      0.0626 
L-Glutamine      0.584 
Glycine       0.03 
L-Histidine•HCl• H2O     0.042 
L-Isoleucine      0.105 
L-Leucine       0.105 
L-Lysine•HCl      0.146 
L-Methionine      0.03 
L-Phenylalanine      0.066 
L-Serine       0.042 
L-Threonine      0.095 
L-Tryptophan      0.016 
L-Tyrosine 2Na•2H2O     0.10379 
L-Valine       0.094 
Choline Chloride      0.004 
Folic Acid      0.004 
myo-Inositol      0.0072 
Niacinamide      0.004 
D-Pantothenic Acid hemicalcium   0.004 
Pyridoxal•HCl      0.004 
Riboflavin      0.0004 
Thiamine•HCl      0.004 
Calcium Chloride [Anhydrous]    0.2 
Ferric Nitrate•9H2O     0.0001 
Magnesium Sulfate [Anhydrous]    0.09767 
Potassium Chloride     0.4 
Sodium Chloride      6.4 
Sodium Phosphate Monobasic [Anhydrous]  0.109 
Glucose       4.5 
Phenol Red•Na      0.0159 
- PBS (1x) 
For a final volume of 500 ml, dissolve one pack of BupH Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
- Sodium Phosphate     8 mM 
- Potassium Phosphate    2 mM 
- NaCl      140 mM 
- KCl      10 mM 
Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
- Complete Neurobasal medium (primary neuronal cultures) 
This serum-free medium (Neurobasal; Gibco, BRL) is supplemented with: 
- B27 supplement (Gibco, BRL)    2% 
- L-glutamine (Gibco, BRL)    0.5 mM  
- Gentamicine (Gibco, BRL)    60 µg/ml  
- Phenol Red (Sigma Aldrich, Portugal)   0.001% 
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adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
- Hank’s balanced salt solution (primary neuronal cultures) 
This salt solution is prepared with deionised H2O. Final composition: 
- NaCl       137 mM  
- KCl       5.36 mM  
- KH2PO4        0.44 mM 
- Na2HPO42H2O       0.34 mM 
- NaHCO3       4.16 mM 
- Glucose       5 mM 
- Sodium pyruvate      1 mM 
- HEPES       10 mM 
adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
 
 Cells fixation and Imunocytochemistry: 
- 1 mg/ml Poly-L-ornithine solution (10x) (COS-7 cells) 
To a final volume of 100 ml, dissolve in deionised H2O 100 mg of poly-L-
ornithine (Sigma-Aldrich, Portugal).  
- 10 mg/ml Poly-D-lysine stock (100x) (neuronal cells) 
To a final volume of 10 ml, dissolve in deionised H2O 100 mg of poly-D-lysine 
(Sigma-Aldrich).  
- Borate buffer (neuronal cells) 
To a final volume of 1 L, dissolve in deionised H2O 9.28 g of boric acid (Sigma-
Aldrich). Adjust to pH 8.2, sterilize by filtering through a 0.2 µm filter, and store at 4 ºC. 
- Poly-D-lysine solution (neuronal cells) 
To a final volume of 100 ml, dilute 1 ml of the 10 mg/ml poly-D-lysine stock 
solution in borate buffer.  
- 4% Paraformaldehyde Fixative solution 
To a final volume of 100 ml, to 25 ml deionised H2O add 4 g of 
paraformaldehyde. Dissolve by heating the mixture at 58 ºC while stirring. Add 1-2 drops 
of 1 M NaOH to clarify the solution and filter (0.2 µm). Add 50 ml of 2X PBS and adjust 
the volume to 100 ml with deionised H2O. 
 
 Rat Cortex Lysates: 
- 0.32 M sucrose and 10 mM HEPES solution (rat cortex lysates) 
For a final volume of 1 L, dissolve in deionised H2O: 
- Sucrose       109.54 g  
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- HEPES      2.60 g  
adjust to pH 7.4. Sterilize by filtering through a 0.2 µm filter and store at 4 ºC. 
                             
Proteins Manipulation 
 SDS-PAGE: 
- LGB (Lower gel buffer) (4x) (1 L) 
- Tris       181.65 g 
- SDS       4 g 
Shake until the solutes have dissolved. Adjust the pH to 8.9 with HCl and adjust 
the volume to 1 L with deionised H2O. 
- UGB (Upper gel buffer) (5x) 
Per litre, to 900 ml of deionised H2O add 75.7 g of Tris base. Shake until the solute 
has dissolved. Adjust the pH to 6.8 with HCl and adjust the volume to 1 L with deionised 
H2O. 
- 30% Acrylamide / 0.8% Bisacrylamide solution 
Per 100 ml, to 70 ml of deionised H2O add: 
- Acrylamide      29.2 g  
- Bisacrylamide      0.8 g 
Shake until the solutes have dissolved. Adjust the volume to 100 ml with deionised 
H2O. Filter through a 0.2 µm filter and store at 4 ºC. 
- 10% APS (ammonium persulfate) 
In 10 ml of deionised H2O dissolve 1 g of APS. Note: prepare fresh before use. 
- 10% SDS (sodium dodecilsulfate) 
In 10 ml of deionised H2O dissolve 1 g of SDS. 
- Loading (sample) gel buffer (4x) (10 ml) 
- 1M Tris  solution (pH 6.8)   2.5 ml (250 mM) 
- SDS      0.8 g (8%) 
- Glicerol      4 ml (40%) 
- β-Mercaptoetanol    2 ml (2%) 
- Bromofenol blue     1 mg (0.01%) 
Adjust the volume to 10 ml with deionised H2O. Store in darkness at RT. 
- 1 M Tris (pH 6.8) solution 
For a final volume of 250 ml, dissolve 30.3 g of Tris base in 150 ml of deionised 
H2O, adjust pH to 6.8, and adjust final volume to 250 ml.  
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- Running buffer (10x) (1 L) 
- Tris      30.3 g (250 mM) 
- Glycine      144.2 g (2.5 M) 
- SDS      10 g (1%) 
Dissolve in deionised H2O, adjust pH to 8.3, and adjust volume to 1 litre.  
15 cm gels: 
- Resolving (lower) gel solution (60 ml) 7.5%  12%  6.5% 
- H2O     29.25 ml 20.7 ml 31.25 ml 
- 30% Acryl/0.8% Bisacryl solution 15.0 ml 24.0 ml 13.0 ml 
- LGB (4x)    15.0 ml 15.0 ml 15.0 ml 
- 10% APS    300 µl  300 µl  300 µl 
- TEMED     30 µl  30 µl  30 µl 
- Stacking (upper) gel solution (20 ml) 3.5% 
- H2O     13.2 ml 
- 30% Acryl/0.8% Bisacryl solution 2.4 ml   
- UGB (5x)    4.0 ml 
- 10% SDS    200 µl 
- 10% APS    200 µl 
- TEMED     20 µl 
 
 Immunoblotting solutions: 
- Electrotransfer buffer (1x) 
Per litre, to 700 ml of deionised H2O add:  
- Tris      3.03 g (25 mM) 
- Glycine       14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume 
to 800 ml with deionised H2O. Just prior to use add 200 ml of methanol (20%). 
- TBS (Tris Buffered Saline) (10x) 
Per litre, to 700 ml of deionised H2O add  
- Tris      12.11 g (10 mM) 
- NaCl       87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
- TBS-T (Tris Buffered Saline + Tween) (10x) 
For a final volume of 1 L, to 700 ml of deionised H2O add  
- Tris      12.11 g (10 mM) 
- NaCl       87.66 g (150 mM) 
- Tween 20      5 ml (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O. 
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- Blocking solution (100 ml) 
- TBS-T stock solution (10x)   10 ml 
- non-fat milk (dry powder)   5 g 
Dissolve in deionised H2O and adjust volume to 100 ml.  
- Antibody solution (25 ml) 
- TBS-T stock solution (10x)   2.5 ml 
- non-fat milk (dry powder)   0.75 g 
Dissolve in deionised H2O and adjust volume to 25 ml. Add antibody, mix gently 
without vortex, and store at -20 ºC. 
- Alkaline Phosphatase (AP) Reaction Solution (1 L) 
- Tris-HCl (pH 9.5)     12.11 g (100 mM) 
- NaCl       5.85 g (100 mM) 
- MgCl2       1.02 g (5 mM) 
Dissolve Tris base in deionised H2O and adjust solution to pH 9.5 with HCl. 
Dissolve the other solutes and adjust volume to 1 L. 
- AP Stop Solution (1 L) 
- Tris-HCl (pH 9.5)    2.42 g (20 mM) 
- EDTA      1.86 g (5 mM)   
Dissolve Tris in deionised H2O and adjust with HCl to pH 9.5. Add EDTA after 
and adjust volume to 1000 ml. 
- Membranes Stripping Solution (500 ml) 
- Tris-Cl (pH 6.7)     3.76 g (62.5 mM) 
- SDS      10 g (2%) 
- β-mercaptoethanol    3.5 ml (100 mM)  
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 ml.       
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APPENDIX II – KITS AND METHODS 
 
DNA Manipulation 
 PCR (polymerase chain reaction) for mutant and wt APP cDNAs 
amplification: 
PCR was performed using Pfu DNA polymerase (Promega), and the amplification 
reactions were set up according to the manufacturer instructions. The standard amplification 
reactions were performed in 0.2 ml microtubes as follows (Table A.1): 
    
Table A.1. Reagents mixtures used in APP isoform 695 cDNAs PCR amplification. Total volume: 50 µl 
Tube 
Template 
0.1 ng 
Template 
1.0 ng 
Negative Control  
1 (w/primers, w/o 
template 
Negative Control  
2 (w/o primers, w/ 
template) 
10x Pfu buffer 5 µl 5 µl 5 µl 5 µl 
dNTPs (10 mM) 1.5 µl 1.5 µl 1.5 µl 1.5 µl 
Primer NAPN 1.5 µl (10 pmol) 1.5 µl (10 pmol) 1.5 µl (10 pmol) - 
Primer S1 1.5 µl  (10 pmol) 1.5 µl  (10 pmol) 1.5 µl  (10 pmol) - 
APP cDNA 
(template) 
1 µl 10 µl - 1 µl  Wt APP 
cDNA 
Pfu polymerase 1 µl 1 µl 1 µl 1 µl 
H2O 38.5 µl 29.5 µl 39.5 µl 41.5 µl 
 
 
- PCR amplification program   
 1 min 94 ºC   1x (Denaturation) 
30 sec 94 ºC       
30 sec 67 ºC   5x   (Denaturation, Annealing, Polymerization)  
1 min 72 ºC      
30 sec 94 ºC   25x (Denaturation, Polymerization)   
3 min 72 ºC  
7 min 72 ºC   1x (Polymerization; “Extension” step)    
The annealing temperature depends on the primers melting temperatures (Tm) and it 
should usually be =(Tm – 8) ºC.  For some reactions it was necessary to undergo further 
amplification cycles: more 20 cycles (30 sec 94 ºC, 3 min 72 ºC) followed by another extension 
step of 1x 7 min 72 ºC. Amplification was confirmed by resolving a PCR reaction aliquot (10 
µl) in a 1.2% agarose gel electrophoresis. 
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 PCR cDNA products digestion with restriction enzymes: 
The amplified APP cDNA fragments were sequentially digested with the restriction 
endonucleases Nru I and Age I to allow further insertion into the EGFP-N1 plasmid. APP 
cDNAs were inserted between the Sma I and Age I sites of the pEGFP-N1 vector, upstream 
of the enhanced green fluorescent protein (EGFP) cassette and in the correct open reading 
frame. For a typical DNA digestion, the following components were added to the following 
concentrations: 
- 100 µg/ml cDNA 
- 1X reaction buffer (specific for each restriction enzyme)  
- 1U restriction enzyme /µg cDNA 
The mixture was incubated at the appropriate temperature for a few hours (or 
overnight if convenient). When sequential digestions with different enzymes were carried out 
the DNA was purified between the two reactions (see below). Table A.2 presents the 
restriction enzymes and specific mixtures used in the APP-GFP translational fusions 
production and previous confirmation before sequencing. Prior to sequencing, the plasmid 
DNA extracted from transformants and the EGFP-N1 vector (for control), were sequentially 
digested with Xba I, EcoR I, and Pst I.  
 
Table A.2. Mixtures used in APP695 and EGFP vector cDNAs digestion with restriction enxymes. Restriction 
enzymes: Nru I and Age I (NEB); Sma I, Xba I and EcoR I (Fermentas). 
Objective: APP subcloning into the EGFP vector Confirmation of APP-GFP fusion  
Restriction 
Enzyme / 
Mixture 
Components 
Nru I 
(APP 
cDNAs, 
PCR 
products) 
Age I 
(APP 
cDNAs, 
PCR 
products) 
Sma I 
(N1 vector) 
Age I 
(N1 vector) 
Xba I 
(putative 
APP-GFP 
clones) 
EcoR I 
(putative 
APP-GFP 
clones, after 
Xba I 
confirmation) 
Pst I 
(putative 
APP-GFP 
clones, after 
Xba I 
confirmation) 
Buffer 10x 10 µl 5 µl 10 µl 10 µl 1 µl 1 µl 1 µl 
Enzyme 2 µl 1 µl 3.5 µl 3.5 µl 1 µl 1 µl 1 µl 
DNA 
40 µl of 
PCR 
product 
Pellet of 
purified 
cDNA 
pre-cuted 
with NruI  
20 µl 
(± 12 µg) 
of gel 
extracted 
N1 vector 
Pellet of 
purified 
cDNA 
pre-cuted 
with SmaI 
3 µl of the 
clone 
miniprep 
3 µl of the 
clone 
miniprep 
3 µl of the 
clone 
miniprep 
H2O 48 µl 44 µl 66.5 µl 86.5 µl 5 µl 5 µl 5 µl 
Final 
Volume 
100 µl 50 µl 100 µl 100 µl 10 µl 10 µl 10 µl 
Temperature  37 ºC  25 ºC  30 ºC  25 ºC  37 ºC  37 ºC 37 ºC 
Reaction 
Time 
4 h Overnight 4 h Overnight 2 h 4 h 4 h 
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 DNA purification: 
- Method 1: QIAquick PCR Purification Kit Protocol (QIAgen # 28706) 
This kit was used to purify DNA fragments from PCR and other enzymatic reactions. 
It allowed purification from primers, nucleotides, DNA polymerases and salts by using 
QIAquick spin columns in a microfuge tube. The manufacturer’s protocol was used as follows: 
5 volumes of buffer PB were added to 1 volume of the reaction to be purified, and mixed. The 
QIAquick spin column was placed in a provided 2 ml collection tube and the sample was 
applied to the column and centrifuged for 1 min at 14,000 rpm to allow for DNA binding. The 
first flow-through was discarded and the column washed with 0.75 ml of buffer PE and 
centrifuged for 1 min at 14,000 rpm. The second flow-through was discarded, the column 
placed back in the same tube and centrifuged again to remove traces of washing buffer. The 
column was finally placed in a clean microtube, 50 µl of H2O were added and let to stand for 1 
min. To elute the DNA, the column was centrifuged for 1 min at 14,000 rpm.  
 
- Method 2: DNA precipitation with ethanol 
 This method was used to concentrate nucleic acids as well as to purify them (e.g. for 
cell culture transfection). Approximately 1/10 volume of 3 M sodium acetate (pH 5.2) was 
added to the DNA solution to adjust the salt concentration, followed by 2 volumes of ice-cold 
ethanol. The solution was mixed thoroughly and stored at –20 ºC for 30 min to allow the 
DNA precipitate to form. DNA was recovered by centrifugation at 4 ºC for 15 min at 14,000 
rpm. The supernatant was carefully removed without disturbing the pellet. The microtube was 
half filled with ice-cold 70% ethanol and re-centrifuged using the same conditions as above for 
5 min. The supernatant was again removed and the pellet allowed to dry before being 
resuspended in sterile water. 
 
 Electrophoretic analysis of DNA: 
An electrophoresis apparatus was prepared and the electrophoresis tank was filled with 
enough 1X TAE to cover the agarose gel. The appropriate amount of agarose (to a final 
percentage of 0.8 – 1.2%) was transferred to an Erlenmeyer with 50 ml 1X TAE, and this 
slurry was heated until agarose dissolution and allowed to cool to 60 ºC before adding 
ethidium bromide to a final concentration of 0.5 µg/ml. The agarose solution was poured into 
the tray and a comb was positioned on it. After the gel was completely set, the comb was 
carefully removed and the gel mounted in the tank. DNA samples were mixed with the 6X 
DNA loading buffer (DNA LB) (0.25% bromophenol blue/30% glycerol in water) and the 
mixture was loaded into the slots of the submerged gel. Marker DNA (λ-Hind III fragments or 
Invitrogen 1 Kb ladder) of known size was also loaded into the gel. The lid of the gel tank was 
closed and the electrical leads were attached so that the DNA migrated towards the anode. 
The gel was run at 100 V, and finally examined by UV light and photographed, or analysed on 
a Molecular Imager (Biorad).   
 
- DNA Gel Extraction kit (QIAgen) 
For the EGFP-N1 cDNA extraction, 0.8% gels were set as described above with some 
differences. 10 µl of non-cutted and 90 µl of Sma I/Age I cutted EGFP-N1 vector cDNA 
were loaded and resolved. The DNA standard and 10 µl lanes were UV exposed and the 
migration distance of the digested cDNA band registered. The 90 µl band was finally 
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extracted from the gel (without being exposed to UV light) with a clean spatula. The 
destination microtube was weighted, before and after receiving the extracted band, to calculate 
the cDNA weight. EGFP-N1 cDNA was further purified by using the QIAquick Gel 
Extraction Kit protocol. Briefly, 3 volumes of Buffer QG were added to 1 volume of gel (100 
mg ∼100 µl). This mixture was incubated at 50 ºC for 10 min (or until the gel slice was 
completely dissolved), while inverting the microtube every when. After the gel slice complete 
dissolution, pH was confirmed to be ≤ 7.5, and 1 gel volume of isopropanol was added to the 
sample and mixed. This sample was applied to a QIAquick spin column, previously placed in a 
2 ml collection tube, and the tube centrifuged at 10,000 x g or 1 min. The flow-through was 
discarded, 0.5 ml of Buffer QG were applied to the column and a further 1 min centrifugation 
was performed. 0.75 ml of Buffer PE were used to wash the column by two sequential 
centrifugations at 10,000 x g, and the flow-through discarded. The column was placed in a 
clean 1.5 ml tube and the DNA eluted with 50 µl of deionised H20 after 1 min standing in the 
column and a last 1 min centrifugation. 
 
 Ligation of cohesive termini and blunt ended DNA 
Digested fragments (Sma I/Age I EGFP-N1 plasmid and the Nru I/Age I APP-GFP 
cDNA fragment to be inserted) were separated by gel electrophoresis and purified. 0.1 µg of 
vector DNA were transferred to a microtube with an equimolar amount (or more) of insert 
DNA. Ligations were performed using the bacteriophage T4 DNA ligase (Promega), in a total 
volume mixture of 20 µl, and were carried out for 4 h at room temperature or overnight at 16 
ºC. Additional control reactions were also set up (Table A.3). 
 
Table A.3 – APP/GFP bacteriophage T4 DNA Ligations. 
 Ligations Ligations Controls 
Tube 
1 
(2 µl of Nru I/Age 
I PCR product) 
2 
(6 µl of Nru I/Age 
I PCR product) 
Control  1 
(w/o cDNA) 
Control  2 
(non-cutted 
EGFP vector ) 
Control  3 
(cutted EGFP 
vector ) 
10x T4 ligase 
buffer 
2 µl 2 µl 2 µl 2 µl 2 µl 
EGFP vector 
cDNA 
3.5 µl 
(100 ng) 
3.5 µl 
(100 ng) 
- 
1 µl 
(1 ng) 
3.5 µl 
(100 ng) 
APP PCR 
products 
2.5 µl 
(± 20 ng) 
6.0 µl 
(± 50 ng) - - - 
T4 DNA 
ligase 
1.0 µl 1.0 µl 1.0 µl 1.0 µl 1.0 µl 
H2O 13.5 µl 11 µl 17 µl 16 µl 14.5 µl 
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 Bacteria Transformation: 
- Preparation of competent cells 
 A single colony of E. coli XL1-Blue was incubated overnight in 10 ml SOB medium at 
37 ºC. 1 ml of this overnight culture was used to incubate 50 ml SOB until OD550= 0.3. This 
culture was incubated on ice for 15 min and centrifuged at 4,000 rpm (4 ºC) for 5 min. The 
supernatant was discarded and 15 ml of Solution I were added. After allowing standing on ice 
for 15 min, cells were centrifuged at 4,000 rpm (5 min, 4 ºC) and 3 ml of Solution II were 
added to the pellet. Cells were immediately divided in 0.1 ml aliquots and stored at -80 ºC. 
 
- Bacteria transformation with plasmid DNA 
Competent cells (50 µl) were thawed on ice and 2 or 5 µl of each ligation product (0.1 
- 50 ng of DNA) were added to the cells with gentle swirling. The microtubes were incubated 
on ice for 20 min and heat shocked at 42 ºC for 60 sec. Further incubation on ice for 2 min 
was performed, and 0.9 ml of SOC medium was added. The tubes were incubated at 37 ºC for 
1 hour with shaking at 225 rpm. 1/10 and 9/10 of this cells solution were plated on the 
appropriate antibiotic (100 µg/ml kanamycin) agar medium plates (pre-heated) and incubated 
at 37 ºC for ∼16 h until colonies appeared. Control transformations were also performed in 
parallel, which always included a negative control transformation without DNA and a positive 
control transformation with 0.1 ng of the control plasmid.  
 
 Amplification and isolation of plasmid DNA from bacteria: 
- Alkaline lysis mini-prep 
This method was used to screen the bacterial plates for transformant colonies. A single 
positive (transformant) bacterial colony was transferred to a tube containing 5 ml of LB plus 
antibiotic medium and incubated overnight at 37 ºC with vigorous shaking. After overnight 
culture growth, 1 ml of the 5 ml culture was centrifuged at 14,000 rpm and 4 ºC for 1 min. 
The medium was removed by aspiration and the bacterial pellet ressuspended in 100 µl of ice-
cold solution I (‘ressuspension’ solution) by vigorous vortexing. Afterwards, 200 µl of 
Solution II was added (‘alkaline lysis’), and the content of the tube mixed by inverting it 
several times. The microtube was placed on ice, 150 µl of ice-cold solution III (‘neutralization’ 
solution) was added and the tube gently vortexed. After standing on ice for 5 min, a 10 min 
centrifuge at 14,000 x g and 4 ºC was performed, and the supernatant transferred to a clean 
microtube. The DNA was precipitated with 2 volumes of ethanol at RT and this mixture was 
allowed to stand for 10 min at RT. After this period, the microtube was centrifuged at 14,000 
x g and 4 ºC for 5 min. The supernatant was completely removed and the pellet washed with 
70% ethanol and allowed to air-dry for 10 min. Purified DNA was dissolved in 20 µl H2O 
containing DNAse-free pancreatic RNAse (20 µg/ml) and stored at -20 ºC. 
 
- Mega-prep (Promega)  
 The Promega kit WizardTM Plus Megapreps DNA purification System # A7300 was 
used in this procedure. One litre of a single-transformant cell culture was pelleted by 
centrifugation at 1,500 x g for 20 min at RT. The cell pellet was resuspended in 30 ml of cell 
resuspension solution [50 mM Tris-HCl (pH 7.5)/10 mM EDTA/100 µg/ml RNAase A] by 
manually disrupting the pellet with a pipette. Afterwards, 30 ml of cell lyses solution (0.2 M 
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NaOH/ 1% SDS) were added to the cells and the solution mixed gently by tube inversion 
until it became clear and viscous. 30 ml of neutralization solution [1.32 M potassium acetate 
(pH 4.8)] were added and the tube immediately mixed by inversion. After centrifugation at 
14,000 x g for 15 min at RT the clear supernatant was transferred by filtering it through gauze 
swabs into a new tube, and the supernatant volume was measured. At this stage 0.5 volumes of 
RT isopropanol were added and the solution mixed by inversion. This solution was 
centrifuged at 14,000 x g for 15 min at RT, the supernatant discarded and the pellet 
resuspended in 4 ml of TE buffer. 20 ml of Wizard TM Megapreps DNA purification Resin 
were added to the DNA and mixed by swirl. A Wizard TM Megacolumn was inserted into the 
vacuum manifold port and the DNA/resin mix was transferred onto the Megacolumn. 
Vacuum was applied to pull the mix into the Megacolumn. Two washes with 25 ml of column 
wash solution (80 mM potassium acetate/8.3 mM Tris-HCl/40 µM EDTA/55% ethanol) 
were performed and the resin was rinsed with 10 ml of 80% ethanol. The Megacolumn was 
inserted into a 50 ml screw cap tube and centrifuged at 2,500 rpm for 5 min using a swinging 
bucket rotor centrifuge. The Megacolumn was removed from the tube and placed in a clean 
tube, and 3 ml of pre-heated water (70 ºC) were added to the column. After 1 min standing, 
the DNA was eluted by centrifugation at 2,500 rpm for 5 min. The DNA was stored at –20 
ºC, and a 400 µl DNA aliquot was purified by ethanol (and kept sterile) and its concentration 
and 260/280 nm purity ratio calculated by densitometry measurements at the indicated 
wavelengths. 
  
 APP-GFP DNA sequencing 
 All the DNA samples to be sequenced followed the same protocol. In a microtube the 
following components were added: 
- 1 ng dsDNA (column purified) 
- 4 µl of Ready Reaction Mix* 
- 15 pmol primer (1.5 µl  of 10 pmol/µl) 
- H2O to a final volume of 20 µl 
* Ready Reaction Mix is composed of: dye terminators, deoxynucleoside triphosphates, AmpliTaq DNA 
polymerase, FS, rTth pyrophosphatase, magnesium chloride and buffer (Applied Biosystems).  
 
This reaction mixture was vortexed and spun down for a few seconds. PCR was then 
performed using the following conditions: 
 
 96 ºC 30 sec 
 42 ºC 15 sec           25 cycles 
 60 ºC   4 min 
Afterwards, samples were purified by ethanol precipitation (as described above). 
Briefly, 2.0 µl of 3 M sodium acetate (pH 5.2) and 50 µl of 95% ethanol were added to the 
reaction microtube. The microtube was vortexed and incubated at RT for 15 min to 
precipitate the extension products. The microtube was then centrifuged at 14,000 rpm for 20 
min at RT. After discarding the supernatant, 250 µl of 70% ethanol were added, the microtube 
was briefly vortexed and re-centrifuged for 5 min at 14,000 rpm at RT. The supernatant was 
again discarded and the pellet dried. After this procedure the samples were loaded in the 
ABIPRISM (Applied Biosystems) Automated DNA Sequencer.    
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Cell Culture and Rat Cortex Samples 
 COS-7 cell culture maintenance: 
COS-7 cells were grown in complete DMEM medium (DMEM medium 
supplemented with 10% FBS) to which 100 U/ml penicillin and 100 mg/ml streptomycin 
(Gibco BRL, Invitrogen) were added. Cells were plated in 100 mm diameter plates or 6-well 
plates (35 mm diameter), and grown in a humidified incubator at 37 ºC and 5% CO2. Cells 
were subcultured whenever ∼95% confluence was reached.  
 
 Rat cortical primary cultures: 
Rat cortical neurons were isolated from cortex of Wistar Hannover 18 days rat 
embryos whose mother was killed by rapid cervical dislocation. After cortex dissection, tissues 
were treated for 10 min at 37 ºC with a 0.45 mg/ml trypsin/0.18 mg/ml deoxyribonuclease 
solution in Ca2+- and Mg2+-free HBSS (Gibco, BRL), supplemented with BSA (Merck, VWR 
International). Cells were washed with HBSS supplemented with 10% FBS to stop 
trypsinization, centrifuged at 1,000 rpm for 3 min, and further washed and centrifuged with 
HBSS for serum withdraw. Cells pellet was ressuspended in complete Neurobasal medium, 
which is supplemented with 2% B27. Viability and cellular concentration were assessed by 
using the Trypan Blue excluding dye [0.4% Trypan Blue solution (Sigma)], and cells with 
(dead) or without (living) intracellular blue staining were counted in a hemocytometer 
chamber. Cellular viability was calculated and normally higher than 95%. These neuronal cells 
were plated at 9.0 x 104 cells/cm2 on 100 µg/ml poly-D-lysine pre-coated glass coverslips that 
were placed in six-well plates. Cells were maintained in 2 ml of complete Neurobasal medium 
in a humidified incubator at 37 ºC and 5% CO2. Three and seven days after plating, 500 µl of 
cultured medium was replaced with 750 µl of gentamicine-free complete Neurobasal medium.  
 
 Rat cortex isolation: 
Young (1-2 month old) adult male rats were sacrificed by cervical dislocation and 
decapitation. Cerebral cortex was rapidly dissected on ice-cold 0.32 M sucrose/10 mM 
HEPES (pH 7.4) solution and weighted. Boiling SDS was added to a final 1% SDS solution 
(at ∼ 10% w/v solution), samples were homogenised with a Potter-Elvehjem type 
homogenizer and further boiled for 10 min. 
 
 Cells cDNA Transfection with Lipofectamine 2000: 
Lipofectamine 2000 (Invitrogen) is a cationic liposome formulation that functions by 
complexing with nucleic acid molecules, allowing them to overcome the electrostatic repulsion 
of the cell membrane and to be taken by the cell. The method of DNA delivery in culture cell 
lines and primary neurons is well described in Dalby et al. (2004), from where the following 
protocols were based: 
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- COS-7 cell line (Table A.4) 
Cells were grown in complete DMEM until 85 - 95% confluence and at the 
transfection day the culture medium was replaced for complete medium 
(antibiotic/antymicotic-free). The appropriate amount of DNA for each plate/well was 
diluted in DMEM (serum- and antibiotic/antymicotic-free). The Lipofectamine 2000 
reagent was diluted at the appropriated amount in the same medium, and the tubes were 
left to rest for 5 min. The DNA solution was added to the Lipofectamine solution drop by 
drop, and the solution was mixed by gentle bubbling with the pipette. In order to form the 
DNA-lipid complexes, the tube was left to rest at for 25 - 30 min RT, after what the 
complexes solution was directly added onto the cells medium, drop by drop and with 
gentle rocking of the plate. The cells were further incubated at 37 ºC/5% CO2 for the 
indicated transfection time prior to cell collection or fixation. 
 
Table A.4 – COS-7 cells transfection reagents  
Culture Plates 
Medium w/ 
serum (plate) 
DNA (µg) 
Lipofectamine 
2000 (µl) 
Medium w/o 
serum (per tube) 
100 mm plate  15 ml 8 50 1500 µl 
60 mm plate  5.0 ml 4 15 500 µl 
35 mm 6-wells  2.0 ml 2 10 250 µl 
 
- Primary Neuronal cultures  
Replace the culture medium in each 35 mm well for 0.8 ml of fresh gentamicine-
free complete Neurobasal medium. Per each 35 mm well to transfect, 8 µl of 
Lipofectamine 2000 were diluted in 100 µl of DMEM, and the microtube was left to rest 
at RT for 5 min. 2 µg of APP-GFP cDNA were also diluted in 100 µl of DMEM, and this 
solution was added drop by drop to the Lipofectamine solution. The final solution was 
mixed by gentle bubbling with the pipette, and left to rest for 25 - 30 min at RT in order 
to form the DNA-lipid complexes. This 200 µl DMEM complexes solution was directly 
added onto the cells medium, drop by drop and with gentle rocking of the plate. Neuronal 
cells were further incubated at 37 ºC/5% CO2 for 5 h, after what medium was substituted 
by fresh complete neurobasal medium and left for 24 h prior to cell collection or fixation. 
 
 Culture cells Fixation and Immunocytochemistry: 
COS-7 and neuronal primary cells were grown in 1M HCL pre-treated glass coverslips 
pre-coated with 100 µg/ml poly-L-ornithine or poly-D-lysine, respectively. After the 
experimental procedures, cells were washed three times with 1 ml of the serum-free DMEM, 
after which 1 ml of a 1:1 DMEM/4% paraformaldehyde fixative solution was gently added 
and allowed to stand for 1-2 min. Subsequently, 1 ml of fixative solution was gently added for 
25 minutes. Finally, cells were washed 3 times with PBS for 10 min, being ready for 
Immunocytochemistry procedures or to be directly mounted with 1 drop of anti-fading 
reagent (Fluoroguard, BioRad) on glass microscope slides for epifluorescence microscopy 
analysis. For Immunocytochemistry procedures, a permeabilization step with methanol was 
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taken (2 min at RT) and cells were immediately washed four times with PBS. Afterward, cells 
were incubated with primary antibody diluted in 3% BSA in PBS for 2-4 h at RT. The primary 
antibody was removed by washing the coverslips 3 times with PBS and a secondary antibody 
(also diluted in 3% BSA in PBS) was added for 2 h at RT. After washing three times with PBS 
the coverslips were mounted with one drop of the antifading reagent on a glass slide.  
 
Proteins Manipulation 
 Protein Assay kit (BCA, Pierce): 
Samples total protein measurements were performed with Pierce’s BCA protein assay 
kit, following the manufacturer’s instructions. The method combines the reduction of Cu2+ to 
Cu+ by protein in an alkaline medium (the biuret reaction) with a sensitive colorimetric 
detection of the Cu+ cation using a reagent containing bicinchoninic acid (BCA). The purple-
coloured reaction product of this assay is formed by the chelation of two molecules of BCA 
with one Cu+ ion. This water-soluble complex exhibits a strong absorbance at 562 nm that is 
linear with increasing protein concentration over a working range of 20 µg/ml to 2000 µg/ml.  
- Working Reagent (W.R.) 
The W.R. was prepared by mixing X ml of BCA reagent A with Y ml of BCA 
reagent B in the proportion of 50:1.  
- Samples preparation 
A microtube per sample was prepared to be assayed with 25 µl of each sample 
plus 25 µl of the solution in which the sample was collected (1% SDS).  
- Standard curve 
Microtubes with standard protein concentrations were prepared as described 
below (Table A.5).  
 
 
Table A.5 – Standards used in the BCA protein assay method. BSA, Bovine serum albumin solution (2 mg/ml). 
Standard BSA (µl) 10% SDS (µl) H2O (µl) Protein mass (µg) W.R. (ml) 
P0 - 5 45 0 1 
P1 1 5 44 2 1 
P2 2 5 43 4 1 
P3 5 5 40 10 1 
P4 10 5 35 20 1 
P5 20 5 25 40 1 
P6 40 5 5 80 1 
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- Incubation and absorbance measurement 
1 ml of W.R. was rapidly added to each microtube (standards and samples) and the 
microtubes were incubated at 37 ºC exactly for 30 min. Tubes cool to RT and immediately 
measure their absorbance at 562 nm.  
- Samples concentration 
A standard curve is prepared by plotting BSA standard absorbance vs. BSA 
concentration, and used to determine the total protein concentration of each sample. 
 
 SDS-PAGE (for Western blotting):  
SDS polyacrylamide gel electrophoresis (SDS-PAGE) separations were carried out 
using well established methods (Laemmli, 1970), where proteins are separated by their 
molecular weight and negative net charge due to SDS-amino acid binding. The gels percentage 
and size chosen depend on the molecular weight of the proteins to be separated in the gel. 
Gels were prepared by mixing several components (Appendix I). The resolving gel solution 
was immediately and carefully pipetted down the spacer into the gel sandwich, leaving free 
space for the stacking gel. Water was carefully added to cover the top of the gel and the gel 
was allowed to polymerize for 1 h. Stacking gel solution was prepared according to Appendix 
I. The water was poured out and the stacking gel was added to the gel sandwich; a comb was 
inserted and the gel allowed to polymerize for 1 h. In parallel, samples were prepared by 
adding to the protein sample solution ¼ volume of 4X LB (Loading Buffer). Samples 
microtubes were boiled and spinned down, the combs removed and the gels wells filled with 
Tris-Glycine running buffer. The samples were carefully loaded into the wells, and 
electrophoretically separated using a 90 mA electric current. Molecular weight markers 
(Kaleidoscope Prestained Standards or Prestained SDS-PAGE Standards – Broad Range, Bio 
Rad) were also loaded and resolved side-by-side with the samples. 
 
 Proteins Electrotransfer: 
Through the Western Blotting technique, proteins that were electrophoretically 
separated by SDS-PAGE can be transferred to membranes (nitrocellulose membranes, for 
instance), while keeping their positions. 3MM blotter papers and a nitrocellulose membrane 
were used to build up the transfer sandwich. The gel was removed from the electrophoresis 
device and the stacking gel discarded. A transfer sandwich was assembled under transfer 
buffer, in the following order: sponge, 3MM blotter paper, gel, nitrocellulose membrane, 3MM 
paper, sponge. The cassette was placed in the transfer device, previously filled with transfer 
buffer, oriented so that the negatively charged proteins migrate towards the anode. 
Electrotransfer was allowed to proceed for 18 h at 200 mA, after what the membrane was 
allowed to dry on a clean paper. 
 
 Immunoblot analysis: 
After proteins electrotransfer, the nitrocellulose membranes could be used 
immediately, and membranes were initially soaped in 1X TBS for 10 min. Blocking of possible 
non-specific binding sites of the primary antibody was performed by immersing the 
membrane in 5% (w/v) non-fat dry milk in 1X TBST solution for 1 - 4 h. Further incubation 
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with primary antibody was carried out for the specified times, ranging from 2 h to overnight 
incubation at 4 ºC with agitation. After three washes with 1X TBS-T, of 10 min each, the 
membrane was further incubated with the appropriate secondary antibody for 2 h with 
agitation. All primary and secondary antibodies used were diluted in 1X TBS-T/non-fat dry 
milk (3% w/v) at the dilutions specified in Chapters II, IV and V (Table II.1, IV.1 and V.1). 
Membranes were additional washed three times with 1X TBST, before being submitted to one 
of the following detection methods: 
- Colorimetric detection (NBT/BCIP, Pierce) 
Each 15 cm membrane was developed by adding to it a solution of 66 µl NBT and 
33 µl BCIP in 10 ml Alkaline Phosphatase reaction buffer. When a coloured signal was 
achieved, the developing reaction was stopped by adding 20 ml of AP stop solution. 
Membrane was washed twice with deionised water and air dried at RT. 
 - Enhanced chemiluminescence detection (ECL and ECL+ Kits, Amersham 
Pharmacia) 
ECLTM Western blotting from Amersham Pharmacia Biotech is a light emitting 
non-radioactive method for detection of immobilised specific antigens, conjugated directly 
or indirectly with horseradish peroxidase-labelled antibodies (Fig. A.II.1). 
 
 
 
Figure A.II.1. The ECL analysis system detects the presence of an antibody labelled with horseradish peroxidase 
by catalysing the oxidation of luminol, leading to the emission of light, which can be detected by an 
autoradiography film (From the manufacturer datasheet). 
 
The membrane was incubated for 1 min at RT with the ECL detection solution or for 
5 min with the ECL+ detection solution. These solutions were prepared fresh following the 
manufacturer’s instructions. ECL/ECL+ detection solution in excess was drained by touching 
the edge of the membrane against tissue paper and the membrane was gently wrapped in cling-
film, eliminating all the air bubbles. In a dark room, an autoradiography film (XAR-5 film, 
Kodak, Sigma Aldich) was placed on the top of the membrane, inside a film cassette. The 
cassette was closed and the blot exposed for an appropriate period of time. The film was then 
removed and developed in a developing solution (Kodak, Sigma Aldrich), washed in water, 
and fixed in a fixing solution (Kodak, Sigma Aldrich).               
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APPENDIX III – SEQUENCES AND TECHNICAL DATA 
 
 APP695 sequences (GenBank Acession NM_201414):     
- cDNA sequence
   1 atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta cccactgatg 
  71 gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga ctgaacatgc acatgaatgt 
 141 ccagaatggg aagtgggatt cagatccatc agggaccaaa acctgcattg ataccaagga aggcatcctg 
 211 cagtattgcc aagaagtcta ccctgaactg cagatcacca atgtggtaga agccaaccaa ccagtgacca 
 281 tccagaactg gtgcaagcgg ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg 
 351 cttagttggt gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 
 421 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag aagagtacca 
 491 acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga ggggtagagt ttgtgtgttg 
 561 cccactggct gaagaaagtg acaatgtgga ttctgctgat gcggaggagg atgactcgga tgtctggtgg 
 631 ggcggagcag acacagacta tgcagatggg agtgaagaca aagtagtaga agtagcagag gaggaagaag 
 701 tggctgaggt ggaagaagaa gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga 
 771 ggctgaggaa ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 
 841 gagtctgtgg aagaggtggt tcgagaggtg tgctctgaac aagccgagac ggggccgtgc cgagcaatga 
 911 tctcccgctg gtactttgat gtgactgaag ggaagtgtgc cccattcttt tacggcggat gtggcggcaa 
 981 ccggaacaac tttgacacag aagagtactg catggccgtg tgtggcagcg ccatgtccca aagtttactc 
1051 aagactaccc aggaacctct tgcccgagat cctgttaaac ttcctacaac agcagccagt acccctgatg 
1121 ccgttgacaa gtatctcgag acacctgggg atgagaatga acatgcccat ttccagaaag ccaaagagag 
1191 gcttgaggcc aagcaccgag agagaatgtc ccaggtcatg agagaatggg aagaggcaga acgtcaagca 
1261 aagaacttgc ctaaagctga taagaaggca gttatccagc atttccagga gaaagtggaa tctttggaac 
1331 aggaagcagc caacgagaga cagcagctgg tggagacaca catggccaga gtggaagcca tgctcaatga 
1401 ccgccgccgc ctggccctgg agaactacat caccgctctg caggctgttc ctcctcggcc tcgtcacgtg 
1471 ttcaatatgc taaagaagta tgtccgcgca gaacagaagg acagacagca caccctaaag catttcgagc 
1541 atgtgcgcat ggtggatccc aagaaagccg ctcagatccg gtcccaggtt atgacacacc tccgtgtgat 
1611 ttatgagcgc atgaatcagt ctctctccct gctctacaac gtgcctgcag tggccgagga gattcaggat 
1681 gaagttgatg agctgcttca gaaagagcaa aactattcag atgacgtctt ggccaacatg attagtgaac 
1751 caaggatcag ttacggaaac gatgctctca tgccatcttt gaccgaaacg aaaaccaccg tggagctcct 
1821 tcccgtgaat ggagagttca gcctggacga tctccagccg tggcattctt ttggggctga ctctgtgcca 
1891 gccaacacag aaaacgaagt tgagcctgtt gatgcccgcc ctgctgccga ccgaggactg accactcgac 
1961 caggttctgg gttgacaaat atcaagacgg aggagatctc tgaagtgaag atggatgcag aattccgaca 
2031 tgactcagga tatgaagttc atcatcaaaa attggtgttc tttgcagaag atgtgggttc aaacaaaggt 
2101 gcaatcattg gactcatggt gggcggtgtt gtcatagcga cagtgatcgt catcaccttg gtgatgctga 
2171 agaagaaaca gtacacatcc attcatcatg gtgtggtgga ggttgacgcc gctgtcaccc cagaggagcg 
2241 ccacctgtcc aagatgcagc agaacggcta cgaaaatcca acctacaagt tctttgagca gatgcagaac 
2311 tag 
 
- Amino acid sequence 
M L P G L A L L L L A A W T A R A L E V P T D G N A G L L A E P Q I A M F C G R L N M H M N V Q N G K W 
D S D P S G T K T C I D T K E G I L Q Y C Q E V Y P E L Q I T N V V E A N Q P V T I Q N W C K R G R K Q C K 
T H P H F V I P Y R C L V G E F V S D A L L V P D K C K F L H Q E R M D V C E T H L H W H T V A K E T C S E 
K S T N L H D Y G M L L P C G I D K F R G V E F V C C P L A E E S D N V D S A D A E E D D S D V W W G G A 
D T D Y A D G S E D K V V E V A E E E E V A E V E E E E A D D D E D D E D G D E V E E E A E E P Y E E A 
T E R T T S A I T T T T T T T E S V E E V V R V P T T A A S T PD AV D K Y L E T P G D E N E H A H F Q K A K 
E R L E A K H R E R M S Q V M R E W E E A E R Q A K N L P K A D K K A V I Q H F Q E K V E S L E Q E A A 
N E R Q Q L V E T H M A R V E A M L N D R R R L A L E N Y I T A L Q A V P P R P R H V F N M L K K Y V R A 
E Q K D R Q H T L K H F E H V R M V D P K K A A Q I R S Q V M T H L R V I Y E R M N Q S L S L L Y N V P A 
V A E E I Q D E V D E L L Q K E Q N Y S D D V L A N M I S E P R I S Y G N D A L M P S L T E T K T T V E L L 
P V N G E F S L D D L Q P W H S F G A D S V P A N T E N E V E P V D A R P A A D R G L T T R P G S G L T N I 
K T E E I S E V K M D A E F R H D S G Y E V H H Q K L V F F A E D V G S N K G A I I G L M V G G V V I A T 
V I V I T L V M L K K K Q 653Y T S I656 H H G V V E V D A A V T P E E R H L S K M Q Q N G Y E N P T Y K F 
F E Q M Q N 
Legend:   
Italic – Abeta sequence 
Bold – Cytoplasmic sequence  
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 Oligonucleotides:     
- Primers used for APP-GFP constructs engineering 
NAPN (N-terminal APP primer with NruI consensus sequence). Length: 32 nts; Melting 
Temperature: 102 ºC. 
5’ – CTT AAG CTT CGC GAT GCT GCC CGG TTT GGC AC – 3’ 
S1 (C-terminal APP primer without STOP codon and with AgeI consensus sequence). 
Length: 38 nts; Melting Temperature: 114 ºC. 
5’ – ATG GTA CCG GTG GGT TCT GCA TCT GCT CAA AGA ACT TG – 3’ 
- Primers used for APP-GFP constructs sequencing 
NAPN (above). 
APP 500 (at the beginning of APP exon 5, nucleotide 478 - APP695 numbering). Length: 
24 nts; Melting Temperature: 70 ºC. 
5’ – GAG AAG AGT ACC AAC TTG CAT GAC – 3’     
APP 1100 (at the beginning of APP exon 9, nucleotide 866 - APP695 numbering). Length: 
14 nts; Melting Temperature: 42 ºC. 
5’ – TCC TAC AAC AGC AG – 3’     
APP 1500 (at the end of APP exon 11, nucleotide 1204 - APP695 numbering). Length: 14 
nts; Melting Temperature: 44 ºC. 
5’ – ATC ACC GCT CTG CA – 3’     
APP 1800 (at the beginning of APP exon 14, nucleotide 1507 - APP695 numbering). 
Length: 16 nts; Melting Temperature: 46 ºC. 
5’ – GCC AAC ATG ATT AGT G – 3’    
APP 2000 (at the end of APP exon 16, nucleotide 1806 - APP695 numbering). Length: 22 
nts; Melting Temperature: 60 ºC. 
5’ – TGA CTC AGG ATA TGA AGT TCA T – 3’  
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 pEGFP-N1 Plasmid:     
- pEGFP-N1 (Clontech, BD Biosciences; GenBank Accession #U55762 ) 
 
 MCS: 
  
Restriction Map and Multiple Cloning Site of pEGFP-N1. (Unique restriction sites are in color or 
bold.) The Not I site follows the EGFP stop codon. The Xba I site (*) is methylated in the DNA provided 
by CLONTECH. If you wish to digest the vector with this enzyme, you will need to transform the vector 
into a dam- host and make fresh DNA.  
Description: pEGFP-N1 encodes a red-shifted variant of wild-type GFP (1-3) which has been optimized 
for brighter fluorescence and higher expression in mammalian cells. (Excitation maximum = 488 nm; 
emission maximum = 507 nm.) The MCS in pEGFP-N1 is between the immediate early promoter of 
CMV (PCMV IE) and the EGFP coding sequences. Genes cloned into the MCS will be expressed as fusions 
to the N-terminus of EGFP if they are in the same reading frame as EGFP and there are no intervening 
stop codons. SV40 polyadenylation signals downstream of the EGFP gene direct proper processing of the 
3' end of the EGFP mRNA. A bacterial promoter upstream of this cassette (Pamp) expresses kanamycin 
resistance in E. coli. The pEGFP-N1 backbone also provides a pUC19 origin of replication for propagation 
in E. coli and an f1 origin for single-stranded DNA production.  
Use: Fusions to the N-terminus of EGFP retain the fluorescent properties of the native protein allowing 
the localization of the fusion protein in vivo. The target gene should be cloned into pEGFP-N1 so that it is 
in frame with the EGFP coding sequences, with no intervening in-frame stop codons. The inserted gene 
should include the initiating ATG codon. The recombinant EGFP vector can be transfected into 
mammalian cells using any standard transfection method. If required, stable transformants can be selected 
using G418 (7). pEGFP-N1 can also be used simply to express EGFP in a cell line of interest (e.g., as a 
transfection marker).  
(From: http://www.bdbiosciences.com/clontech/techinfo/vectors/vectorsE/pEGFP-N1.shtml) 
 
 
 
- Bacteria strain (plasmid DNA amplification) 
E. coli XL1- blue:  
recA endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F’ proAB lacZ∆M15 Tn10(Tetr)] 
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 Protein Markers of Subcellular Compartments:     
 - Monoclonal Antibody anti-Syntaxin 6 (BD Transduction Laboratories) 
Syntaxin 6 is a 255 amino acid member of the Syntaxin family. It contains a C-terminal 
transmembrane domain and is located at the Golgi apparatus. 
- Policlonal Antibody Anti-Calnexin (StressGen Biotechnologies) 
Calnexin is a ∼90 KDa unglycosylated molecular chaperone and a resident ER 
transmembrane protein.  
 
 Fluorophores Excitation and Emission Spectra:     
- EGFP-N1 (pEGFP encoded) (Clontech, BD Biosciences). Excitation and Emission 
Spectra for BD Living Colors™ Fluorescent Proteins: 
 
 
 
- Secondary Fluorescent Antibodies:  
A. Fluorescein goat anti–mouse IgG antibody/pH 8.0 (Molecular Probes) (fluorescence 
absorption and emission spectra in pH 8.0 buffer) 
B. Texas Red-X goat anti–mouse IgG antibody/pH 7.2 (Molecular Probes) 
(fluorescence excitation and emission spectra in pH 7.2 buffer) 
 
 
 
A.                                        B.  
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Phosphorylation-dependent Alzheimer’s amyloid precursor protein targeting  
 Epifluorescence Microscope filter cubes (Chroma):     
  
Set ID: 41020                             
Fluorophore: EGFP. Narrow-band GFP for eliminating auto-fluorescence 
 
 Exciter 
 HQ480/20x 
 Dichroic  
 Q495LP 
 Emitter  
 HQ510/20m 
 
      
Set ID: 41004  
Fluors: Texas Red. Other: Alexa 568™ Alexa 594™ Bodipy TR Calcium Crimson™ 
Cy3.5™ DsRed  Rhodamine Mitotracker Red 580 Mitottracker Red Mitottracker Red 580 
Rhodamine Red Tetramethylrhodamine Texas Red™ X-Rhodamine 
 
Exciter 
HQ560/55x  
Dichroic  
Q595LP  
Emitter 
 
HQ645/75m  
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Phosphorylation-dependent Alzheimer’s amyloid precursor protein targeting  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Do men quest the Line of Truth or the mere control of it? 
and is it reasonable to draw parallels, when 
tangency is, at minimum, uncertain?  
 
 
(though, what a trilling path, 
what a privilege,  
as Truth is, by intangibleness,  
such a necessary desire) 
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